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Abstract 
I 
 
Abstract 
Papillomaviruses (PV) are epithelium specific DNA viruses that can cause health problems 
ranging from harmless warts to invasive cancer. Papillomavirus induced tumours most 
often arise in the cervix where human papillomavirus (HPV) infections were shown to cause 
99.7 % of all malignancies.  
This study aims to map binding sites of the multifunctional host protein CCCTC binding 
factor (CTCF) to the papillomavirus genome, validate them and determine the function of 
CTCF in the papillomavirus life cycle. Computer predictions of CTCF binding sites in the 
sequence of 8 different PV revealed a CTCF binding pattern including a conserved high-
affinity binding site around nucleotide 3000 in high risk HPV and around nucleotide 5400 in 
low risk HPV. This binding pattern was experimentally confirmed using electrophoretic 
mobility shift assays (EMSA). The binding site around nucleotide 3000 in HPV18 was 
mutated and human foreskin keratinocytes (HFK) were transfected with mutant and wild 
type HPV18 to analyse the effect of the mutation on viral gene expression and life cycle. 
Western blotting of methylcellulose differentiated HFK revealed earlier expression of E2 
and decreased expression of E1^E4 in the mutant compared to the wild type. 
Immunostaining of organotypic raft cultures grown from the mutant maintaining cells 
showed a significant increase in proliferating cells compared to the HFK maintaining the 
wild type. This was accompanied by pseudo-differentiation of keratinocytes since the cells 
of the granular layer of the raft expressed the terminal differentiation marker loricrin but 
maintained the morphology of undifferentiated cells. Thus CTCF was shown to have a major 
impact on the HPV life cycle and it may play a role in HPV induced carcinogenesis. 
Furthermore a function of CTCF in long term maintenance of the viral episome was 
revealed as cells maintaining the CTCF mutant were shown to lose episomes more quickly 
compared to wild type maintaining cells. 
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1 Introduction  
1.1 Papillomavirus types and their potential of causing disease 
Papillomaviruses (PV) are small epithelium specific DNA viruses that are able to infect a 
wide range of hosts ranging from reptiles to birds and mammals. The evolutionary origin of 
these viruses can be traced back to the emergence of amniotes (Garcia-Vallve et al., 2005). 
As a result of co-evolution with their hosts, papillomavirus infections are very common and 
often exhibit little or no symptoms (Bottalico et al., 2011, Ekstrom et al., 2010, Ekstrom et 
al., 2011, Forslund, 2007). However chronic infections with certain papillomavirus types 
over long periods of time have been shown to drastically increase the risk of certain types 
of cancer, most notably cervical cancer.  
Infections with human papillomaviruses (HPV) are of high prevalence in the general 
population and some HPV types are able to cause disease ranging from harmless warts to 
invasive cancer. The standard method of testing for cancer and pre-cancerous lesions in the 
cervix is the Papanicolaou test, better known as Pap smear or Pap test (Saslow et al., 2012, 
Papanicolaou, 1948). For this test cell samples are taken and analysed using light 
microscopy to check for abnormal cell morphology of cervical keratinocytes. Since HPV is a 
common cause of these abnormalities the test result is also used as an indicator for an HPV 
infection. To confirm an HPV infection, cell samples can be tested for HPV DNA or RNA 
(Saslow et al., 2012, Baker, 2013). 
There are more than 150 different HPV types identified so far, infecting cutaneous as well 
as mucosal epithelium (reviewed by Van Doorslaer et al., 2013, Bernard et al., 2010). The 
worldwide prevalence of HPV infections in sexually active women is between 20 % and 40 
% depending on geographical location (Richardson et al., 2003, Clifford et al., 2003). Young 
women are the part of the population where HPV infections are most common and it is 
estimated that 80 % of all women acquire a high risk HPV infection during their lives 
(Baseman and Koutsky, 2005, Bekkers et al., 2004). The majority of these infections are 
cleared by the immune system within 18 months and re-infection with the same HPV types 
is considered uncommon (Xi et al., 1995, Bosch et al., 2008, Schiffman et al., 2007, 
Baseman and Koutsky, 2005, Xie et al., 2007). However, the individuals who fail to clear the 
infection can maintain the virus over decades. Also clearance is not always 100 % complete 
and latency of HPV infections has been suggested (Maglennon et al., 2011). The factors that 
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enable an HPV infection to be maintained over extended periods of time are low antigen 
presentation on the cell surface, evasion of the innate immune system by inhibiting the 
interferon response and interference with chemokine signalling for attracting dendritic cells 
and macrophages (Nees et al., 2001, Perea et al., 2000, Kanodia et al., 2007). Secondary 
factors that increase the risk of cervical cancer in HPV infected individuals include smoking 
and the long-term use of oral contraceptives (Haverkos, 2004, Castle, 2004, Moodley, 
2004).  
The largest proportion of all HPV types (90 %) belongs to the alpha and beta genera. Alpha 
viruses target mucosal and/or cutaneous epithelium and can be classified as low risk or high 
risk types according to their association with malignancies (Bernard, 2005, Middleton et al., 
2003). Beta papillomaviruses are specialised solely on cutaneous epithelium (Bernard, 
2005, Middleton et al., 2003). The low risk types, such as HPV6 and HPV11, are the most 
common causative agents of genital warts and rarely promote severe disease. However one 
of the few serious diseases caused by low risk HPV is respiratory papillomatosis (RRP) 
(Donne and Clarke, 2010). This condition is usually found in juveniles and causes neoplasms 
in the lung that need to be treated with repeated surgery. Eventually this disease results in 
lung cancer in 5 % of cases (Derkay, 1995, Hsueh, 2009). However the overall incidence of 
RRP is low with 4 cases in 100,000 (Gerein et al., 2005, Donne and Clarke, 2010). Low risk 
HPV infections can also be associated with non-melanoma skin cancer, especially in patients 
with epidermodysplasia verruciformis (Pisani et al., 2002). The HPV-mediated impairment 
of DNA damage repair in response to UV light and the inhibition of apoptosis are thought to 
be the underlying factors for this outcome (Jackson and Storey, 2000, Underbrink et al., 
2008). Also the involvement of low risk HPV in some cases of non-melanoma skin cancer 
has been confirmed (Nindl et al., 2007). 
The HPV types classified as high risk types according to the World Health Organisation 
(WHO) are 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 (Bouvard et al., 2009, Munoz et 
al., 2006, Schiffman et al., 2009). A recent meta-analysis using data from around the world 
revealed that the most common high HPV types are HPV16, 18, 52, 31, and 58 (Bruni et al., 
2010). However, the prevalence of a particular HPV type does not always correlate with the 
degree to which that type contributes to the emergence of invasive cancer. HPV16 and 18 
are the most prevalent types and the most common causative agents of HPV induced 
cancers, but HPV45 is the third most common cancer causing HPV and this virus is not 
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among the most commonly found HPV (Bruni et al., 2010). Thus there is variation in the 
carcinogenic potential among different high risk HPV types.  
HPV induced carcinomas can be found in a range of tissues. However the most common 
HPV induced cancer arises at the cervix, in particular in the junction between endo- and 
exocervix (Herfs et al., 2012). HPV DNA is found in 99.7 % of all cervical carcinomas and an 
HPV infection is therefore the most important cancer promoting factor in this disease 
(Walboomers et al., 1999). The carcinomas themselves can be classified again into 
squamous cell carcinomas (SCC) and adenocarcinomas (AC). HPV16 is the virus that causes 
62 % of all SCC of the cervix. HPV18 on the other hand is only connected to 8 % of all 
cervical SSC. However, type 18 has a more significant contribution to AC since it is involved 
in the generation of 32 % of all adenocarcinomas in the cervix (de Sanjose et al., 2010). 
These percentages vary slightly from study to study (Munoz et al., 2003, Munoz et al., 2004, 
Geraets et al., 2012). 
With 530,000 new cases each year worldwide, cervical cancer is the second most common 
cancer in women after breast cancer (reviewed by de Martel et al., 2012). Accordingly, 0.03 
% of the female population are affected by it and about one third of all cervical carcinomas 
are lethal (Parkin et al., 2005, reviewed by Yugawa and Kiyono, 2009).  
The other sites of HPV induced tumours that are commonly found include vulva, vagina, 
anus, penis and oropharynx including tonsils and base of the tongue (reviewed by Doorbar 
et al., 2012, zur Hausen, 2009). The site of infection is closely associated with sexual 
activity. Oral, vaginal and anal intercourse with an infected individual favours an HPV 
infection at the site of sexual contact (Machalek et al., 2012, Gillison et al., 2012). A 
prevalence similar to the one of HPV-induced cervical cancer is only observed with HPV-
induced anal carcinomas in men who have sex with men (Bosch and de Sanjose, 2003). 
However, the absolute number of cervical cancer cases outnumbers the amount of HPV 
induced anal carcinomas greatly (reviewed by de Martel et al., 2012). In contrast to many 
other sexually transmitted diseases, condoms do not offer sufficient protection against a 
HPV infection (Cottler et al., 2006, Winer et al., 2006, Baldwin et al., 2004). In a study with a 
sample size of 82 sexually active female university students the prevalence of genital HPV 
infection among students who consistently used condoms was found to be 37.8 % 
compared to 89.3 % in non-condom users (Cottler et al., 2006). However these results are 
debatable due to the small sample size. 
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Figure 1) Cancer cases attributable to 
infection in 2008 
HPV is one of the three infectious agents 
causing the majority of infection related 
cancer. The other two are Hepatitis B/C and 
Helicobacter pylori. Figure of de Martel et 
al., reproduced with permission (de Martel 
et al., 2012). 
Research in recent years has shown that HPV involvement in cancer of the head and neck 
causes between 13 % and 56 % of malignancies depending on the region of the world 
(Forman et al., 2012). This cancer is of high prevalence and affects males three times more 
often than females (Gillison et al., 2012). The predominant HPV type involved in head and 
neck cancer is HPV16. This type is covered by the vaccines that are currently used for 
vaccination against cervical cancer. Thus men would benefit from the vaccination as well 
but the only part of the population frequently vaccinated in western countries is young 
women.  
 
 
1.2 Epidemiology of HPV 
Cancer is one of the major health burdens world-wide and a significant proportion of this 
disease is caused by infectious agents. This opens up the potential to prevent cancer by 
preventing or treating the underlying 
infection. From the 12.7 million new 
cancer cases in 2008, about 2 million were 
caused by infectious disease as illustrated 
in Figure 1 (reviewed by de Martel et al., 
2012, Parkin, 2011). In turn, 610,000 out 
of these 2 million cases were caused by 
HPV resulting in an overall contribution of 
HPV to the global cancer burden of 4.8 % 
(reviewed by de Martel et al., 2012). The 
less developed world has the highest 
incidence of HPV induced cancer with 
490,000 cases. However the proportion of 
HPV-induced cancer among all infection 
related cancers is higher in more 
developed countries. 
Figure 2 shows the global incidence of 
cervical cancer in form of a world map 
(Forman et al., 2012).  
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Figure 3) Percentage of asymptomatic 
HPV infections 
Percentage of the female population 
carrying a high risk HPV infection 
without showing pathological 
symptoms. This percentage is highest in 
the Caribbean and Africa. It mostly 
correlates with the development level 
of a country. Figure of Forman et al., 
reproduced with permission (Forman et 
al., 2012). 
 
Hot spots with the highest incidence with over 30 cases per 100,000 per annum are found 
in South America and Sub-Saharan Africa. On 
the other hand the incidence is lowest in 
North America, Western Europe, North 
Africa, China and Australia with less than 6.6 
cases per 100.000 inhabitants. Parts of the 
population of every country are carriers of a 
high risk HPV infection without showing any 
pathological symptoms (Forman et al., 2012).  
The percentage of these asymptomatic 
infections varies greatly among different 
regions of the world and this percentage does 
not always correlate to the incidence of 
cervical cancer as seen in Figure 2 and Figure 
3. The incidence of cervical cancer in Eastern 
Europe is on an intermediate level even 
though this region has one of the highest 
percentages of carriers of asymptomatic high 
risk HPV infections. The reason for a higher 
 
Figure 2) Global incidence of cervical cancer per 100,000 
Hot spots for a high incidence of cervical cancer are less developed regions of the world, 
for example Sub-Saharan Africa and South America. Figure of Forman et al., reproduced 
with permission (Forman et al., 2012). 
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number of cases in some regions can be diverse. 
However one of the main factors to consider is the age of the population. Whereas 
European and North American countries have a relatively high incidence of HPV infections 
in young women, this incidence declines with increasing age due to clearance of the 
infection (Franceschi et al., 2006). This decline is not seen in less developed countries. Also 
the fact that the percentage of infected young women in less developed countries is higher 
results in an even higher proportion of HPV infected females.  
The estimated number of patients per year with HPV-induced cancer from all over the 
world can be found in Table 1 (reviewed by de Martel et al., 2012). The number of cervical 
cancer cases dominates the other types of HPV induced cancer with 530,000 cases every 
year. 
 
Site of tumour 
No. of 
cases 
Cancer cases with HPV involvement 
Percentage 
of total 
Absolute 
number 
In less 
developed 
world 
In more 
developed 
world 
Cervix uteri 
carcinoma 
530,000 100 % 530,000 450,000 77,000 
Penile carcinoma 22,000 50 % 11,000 7600 3200 
Anal carcinoma 27,000 88 % 24,000 12000 12000 
Vulva carcinoma 27,000 43 % 12,000 4100 7500 
Vaginal carcinoma 13,000 70 % 9,000 5700 3400 
Oropharyngeal 
carcinoma including 
tonsils and base of 
tongue 
85,000 25.6 % 22,000 6400 15000 
Table 1) The contribution of HPV to the global cancer burden in 2008 
This is the most recent estimation to date, published in October 2012. Table modified from 
de Martel et al. (de Martel et al., 2012). 
 
The absolute number of patients with anal cancer is the same in the developed as well as 
the developing world. The fact that there are many more people living in the developing 
world than in the developed world indicates that people living in the developed world have 
a higher chance of developing anal cancer (reviewed by de Martel et al., 2012). This shift 
towards a higher chance of developing cancer is even more obvious with oropharyngeal 
carcinomas which already occur twice as much in the developed world despite the lower 
overall population (reviewed by de Martel et al., 2012).  
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For the United Kingdom, as a part of the developed world, infection related cancer makes 
up a smaller proportion of the overall cancer burden compared to the world average of 16. 
1 % (Parkin, 2011). The total incidence of infection related cancer in the UK was recently 
estimated to be 3. 1 % (Parkin, 2011). About half of that, 1.6 %, is attributed to HPV. This 
percentage is significantly lower than the estimated average of developed countries of 7.4 
% (reviewed by de Martel et al., 2012, Parkin, 2011). However, the contribution of HPV in 
particular cancers in the UK is still significant as seen in Table 2. In total 5088 cases of HPV-
induced cancers were recorded in the UK in 2010 (Parkin, 2011). The contribution of HPV in 
these cancers was determined by the presence of high risk HPV DNA in tumour tissue from 
all sites with the exception of the oropharynx. Here expression of E6 and E7 needed to be 
confirmed in addition to the presence of HPV DNA (Parkin, 2011). 
 
Site 
Overall cases of cancer Cases accountable to HPV 
Male Female Male Female Proportion of total cases 
Cervix uteri NA 2691 NA 2691 2691 (100 %) 
Oral cavity 2284 1421 183 114 296 (8.0 %) 
Oropharynx 981 323 138 45 184 (14. 1 %) 
Larynx 1803 386 191 40 232 (10.6 %) 
Anus 364 621 328 559 887 (90.0 % 
Vulva NA 1128 NA 451 451 (40.0 %) 
Vagina NA 251 NA 157 157 (62.5 %) 
Penis 475 NA 190 NA 190 (40.5 %) 
Total: 5907 6821 1030 4058 5088 (40 %) 
Table 2) Incidence of HPV induced cancer in the United Kingdom in 2010 
Table of Parkin et al., reproduced with permission (Parkin, 2011). 
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1.3 Vaccination 
In 2006, the first vaccine against HPV, Gardasil, was approved by the Food and Drug 
Administration of the USA and the approval for Europe and Australia followed the year 
after. This vaccine is manufactured by Merck & Co. and immunises against four HPV types, 
the high risk types HPV16/18 and the low risk types HPV6/11 (Siddiqui and Perry, 2006). In 
2007 a second HPV vaccine, Cervarix, was approved in the European Union which 
immunises against the high risk types HPV16/18 only (Crosbie and Kitchener, 2007). The 
manufacturer of this vaccine is GlaxoSmithKline. Both vaccines have been shown to be safe 
with only minor side effects (Bayas et al., 2008). Klein et al. conducted a study in which the 
side effects of the quadrivalent HPV vaccine with a sample size of 189,629 females were 
assessed (Klein et al., 2012). They concluded that the only side effects found were 
occasional syncope on the day of vaccination and a slightly increased chance of acquiring a 
skin infection within two weeks following vaccination (Klein et al., 2012). 
Virus-like particles containing the HPV protein L1 are the basis for both vaccines (Crosbie 
and Kitchener, 2007, Siddiqui and Perry, 2006). This protein is only found in mature viral 
particles and the uppermost layer of infected epithelium. Since the majority of cells of 
already infected epithelium do not express L1, those cells are not affected by the immune 
response induced by the vaccine. Thus the vaccine is thought to only protect from new 
infections caused by L1-coated mature viral particles (Markowitz, 2011). Immunisation 
against the two most common high risk types before the first contact with the virus is 
predicted to result in the reduction of the overall risk of developing cervical cancer by 
about 70 % since the two high risk types covered by the vaccine cause 70 % of cervical 
cancer (reviewed by Yugawa and Kiyono, 2009, de Sanjose et al., 2010). Considering that 
there is a degree of antibody cross-reactivity to other HPV types, the remaining risk of 
acquiring HPV-associated cervical carcinoma may in fact be lower than 30 % (Harper et al., 
2006, Cutts et al., 2007, Paavonen et al., 2007). However HPV infections from HPV types 
not covered by the vaccine, for example HPV45 and HPV31, will continue to cause cervical 
cancer (Paavonen et al., 2009). Hence regular pap smears are still being recommended to 
vaccinated women (Siddiqui and Perry, 2006).  
In addition to the protection against two high risk types, Gardasil also grants protection 
against HPV6 and HPV11 which are responsible for more than 80 % of all genital warts 
(Schmiedeskamp and Kockler, 2006, Winer et al., 2005). These warts are found in about 1 % 
Introduction 
9 
 
of sexually active adults and impose a £16.8 million burden on the NHS annually from cases 
in England only (Koutsky, 1997, Desai et al., 2011).  
Cervarix was shown to have a good long-term safety profile (Harper et al., 2006). More than 
98 % seropositivity for HPV16/18 antibodies was observed 4.5 years after vaccination 
(Harper et al., 2006). Thus it is expected that no follow-up vaccination is needed. In a study 
conducted over 4 years with more than 10,000 females, Lethinen et al. confirmed a 100 % 
protection against high grade cervical intraepithelial neoplasm and adenocarcinoma in situ 
caused by HPV16 and 18 in vaccinated individuals who had received the HPV vaccine prior 
to their first contact with the virus (Lehtinen et al., 2012). Additionally, it is worth noting 
that this study was funded by one of the vaccine manufacturers, GlaxoSmithKline. Although 
a review of various trials for both vaccines confirmed the efficacy of the vaccines against 
HPV infection by the HPV types covered (Schiller et al., 2012). No therapeutic efficacy of the 
vaccine in already infected individuals could be confirmed (Schiller et al., 2012).  
In most countries with a HPV vaccination program only females are vaccinated. However 
due to the existing evidence for HPV-induced cancer in other tissues, and the transmission 
via males, it would be beneficial to extend the vaccination programme to the general 
population to reduce the overall incidence of HPV-induced cancer. The chance of a male 
developing HPV-induced cancer is lower compared to a female so vaccinating males comes 
down to a matter of cost (Russell et al., 2013). Males are mainly perceived as carriers of 
HPV who less often progress to severe disease and therefore do not qualify for the expense 
needed for vaccination.  
The search for HPV vaccines targeting a wider spectrum of HPV types continues and a phase 
3 clinical trial of a third HPV vaccine called V503 (Merck) will be completed in 2013. If this 
vaccine should become available it will cover 9 HPV types and therefore provide a higher 
degree of protection than currently available vaccines. The 9 HPV types covered cause 87 % 
of cervical cancer (de Sanjose et al., 2010). In conclusion, vaccination will reduce the 
incidence of HPV induced cancer in the general population but the need for further 
research remains due to the limitations of the vaccine in terms of type specificity, the 
restriction to prophylactic use and high vaccination costs. 
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Figure 4) The HPV16 genome 
Early genes are shown in red 
(oncoproteins) and green (other early 
proteins). Late genes are coloured 
orange. All these genes are regulated 
via the long control region (LCR). Figure 
from Doorbar et al., reproduced with 
permission (Doorbar et al., 2012). 
1.4 Papillomavirus genetics and transcriptional regulation 
The HPV genome (Figure 4) consists of approximately 8kb of double stranded, circular DNA 
and encodes 6 early and 2 late open reading frames (ORFs). The early ORFs encode for E1, 
E2, E1^E4, E5, E6 and E7 whereas the late ORFs encode for L1 and L2.  
The majority of viral gene expression as well as the replication of the viral genome is 
controlled by a single long control region 
(LCR) (reviewed by Graham, 2010). This LCR 
contains the origin of replication as well as 
binding sites for various transcription factors 
including the viral regulatory protein E2, the 
viral helicase E1, the host transcription factors 
SP1, TBP, MYC and others (Steger and 
Corbach, 1997, Sichero et al., 2012). Another 
feature of the LCR is an oestrogen-triggered 
hormone response element that was shown 
to be involved in carcinogenesis (Gariglio et 
al., 2009, Arbeit et al., 1996).  
Methylation of transcription factor binding 
sites in the LCR plays a major role in viral gene 
regulation. This methylation pattern changes 
when the host cell differentiates or when it 
progresses through the different stages of 
carcinogenesis (reviewed by Johannsen and Lambert, 2013). Methylation in the LCR mostly 
affects the major viral transcription factor E2. Dimers of this protein recognise and bind 
palindromic DNA sequences (AACCg(N4)cGGTT) and regulate gene expression throughout 
all stages of the viral life cycle (Dell et al., 2003). Methylation of E2 binding site abrogates 
E2 binding and methylation of particular E2 binding sites has been linked to hyperactive 
transcription of viral oncogenes (Vinokurova and von Knebel Doeberitz, 2011, Kim et al., 
2003, Thain et al., 1996).  
In the early stages of the viral life cycle, low levels of E2 enhance transcription of the early 
genes (Steger and Corbach, 1997). This action is reversed at the later stages of the viral life 
cycle where E2 protein accumulates and triggers downregulation of the viral oncogenes E6 
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and E7 by displacing SP1 from the LCR, causing proliferation arrest while promoting 
differentiation of the host cell (Steger and Corbach, 1997).  
Next to its role in gene regulation E2 is an important factor in the amplification of the viral 
genome since it has been shown to recruit E1 to the origin of replication (Masterson et al., 
1998). This mechanism is important for the initial amplification of viral genomes upon 
infection and for the amplification of viral genomes for the assembly of viral particles (Mohr 
et al., 1990, reviewed by Doorbar et al., 2012). However, it is suggested that E2 can ensure 
maintenance of viral genomes independently of E1 (Egawa et al., 2012). 
In all papillomaviruses at least one inhibitory variant of E2 exists (reviewed by McBride, 
2013). This variant includes a part of the otherwise untranslated E8 ORF on its N-terminus 
and is therefore called E8^E2 (Hubbert et al., 1988). E8^E2 competes for E2 binding sites 
and can form heterodimers with full length E2. These heterodimers are negative regulators 
of transcription and are insufficient for long term maintenance of HPV episomes (Kurg et 
al., 2010, Stubenrauch et al., 2000). 
In papillomavirus genetics the position given in the promoter name refers to the actual 
start site of the mRNA regulated by this promoter. The promoter sequences of the two 
major promoters of PV are situated in the LCR but the only mRNA start site in the LCR 
belongs to the early promoter (PE) (reviewed by Van Doorslaer et al., 2013). In HPV16 the 
start site of the early promoter is located at nucleotide 97 and the transcription start site of 
the late promoter is at nucleotide 670 as seen in Figure 4.  
Other important features of HPV genomes are the two polyadenylation sites which are 
named early and late polyadenylation site. Promoter choice, splicing and the choice of the 
polyadenylation site determine which transcript is produced (reviewed by Graham, 2010, 
Florin et al., 2002, Johansson et al., 2012). Most HPV mRNAs are polycistronic, thus splicing 
is crucial (Stacey et al., 2000).  
Transcripts from the early promoter using the early polyadenylation signal can encode for 
the viral oncoproteins E6 and E7 (Stacey et al., 2000). These proteins immortalise the host 
cell, drive cell proliferation and inhibit apoptosis (reviewed by Yugawa and Kiyono, 2009).  
Transcripts from the late promoter using the early polyadenylation site can encode for the 
proteins needed to amplify the viral genome. These are E1, E2, E1^E4 and E5 (Bodily and 
Laimins, 2011). On the other hand transcripts from the late promoter that use the late 
polyadenylation signal encode for the proteins necessary for virus assembly and release of 
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mature viruses (Day et al., 1998, Wang et al., 2004). These proteins are E1^E4, L2 and L1 
(Bodily and Laimins, 2011).  
More specific gene regulation from either of these polycistronic transcripts is achieved by 
splicing. For example the splice variant encoding L2 is favoured first until enough L2 is 
generated. Subsequently the splice variant encoding L1 is favoured (Florin et al., 2002).  
 
 
1.5 Papillomavirus life cycle 
The entry point of a papillomavirus infection is suggested to be a microlesion in the host’s 
epithelium that enables the virus to reach the basal epithelial cells (Schiller et al., 2010). 
Upon infection of a basal cell, the viral DNA migrates into the nucleus where the HPV 
genome is initially amplified prior to being maintained as a stable episome of about 200 
copies per cell (Pyeon et al., 2009, reviewed by McBride, 2008). With each cell division, the 
amount of viral episomes is split equally between both daughter cells. An E2-mediated 
tethering mechanism to host chromosomes involving the host helicase ChlR1 is crucial for 
this event and also insures correct partitioning of viral episomes to daughter cells (McBride 
et al., 2006, Van Tine et al., 2004a, Dao et al., 2006, Parish et al., 2006, reviewed by 
McBride, 2008). One of the daughter cells resides in the basal layer whereas the second 
daughter cell migrates towards the epithelial surface, differentiating on its way (reviewed 
by Herrington, 2009). This differentiation process triggers viral maturation and results in the 
production of infective viral particles which are shed off at the surface of the epithelium. 
Hence an HPV infection is not accompanied by premature host cell death or cell lysis, so 
release of inflammatory cytokines or viremia do not occur (Stanley, 2006). Healthy cells 
only divide in the basal layer of the epithelium whereas HPV infected cells also undergo 
mitosis in the suprabasal layer (reviewed by Doorbar et al., 2012). In both layers the viral 
oncogenes E6 and E7 are expressed which promotes cell proliferation while inhibiting 
apoptosis. They push the cells in the suprabasal layer into an S-like phase followed by a G2-
like phase (Banerjee et al., 2011). However particular functions of these early proteins 
differ in high risk and low risk HPV (reviewed by Klingelhutz and Roman, 2012).  
In the mid-epithelial layers the amplification of viral episomes takes place (reviewed by 
Klingelhutz and Roman, 2012, Felsani et al., 2006). To facilitate this, the viral proteins E1, 
E2, E1^E4 and E5 are expressed. E2 is needed to recruit the viral helicase E1 to the origin of 
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replication which is crucial for initial amplification of the genome and enabling the virus to 
replicate efficiently in the later stages of the viral life cycle (Bodily and Laimins, 2011, Kim 
and Lambert, 2002, Angeletti et al., 2002). E1 may enable the viral episome to be replicated 
independently from the host genome leading to an increase in viral genomes of at least 2 
log in animal models (Banerjee et al., 2011, Wang et al., 2009, Blakaj et al., 2009, reviewed 
by Doorbar, 2006). Despite its role in viral genome amplification at advanced stages of the 
life cycle, E1 is suggested to be dispensable for episome maintenance in basal cells (Egawa 
et al., 2012). The E5 protein is involved in enhancing genome amplification by promoting 
koilocyte formation and activating the nuclear localisation signal of E1 which is in turn 
needed for genome amplification (Crusius et al., 2000, Crusius et al., 1998, Krawczyk et al., 
2008). E5 is a pore-forming transmembrane protein with a cytoplasmic C-terminus and is 
known to interfere with apoptosis and the trafficking of vesicles (Krawczyk et al., 2011, 
Kabsch et al., 2004). Another protein involved in the amplification of viral genomes is 
E1^E4. The abundant expression of E1^E4 causes growth arrest of the host cell and aides 
amplification of viral genomes (Wilson et al., 2005, Wilson et al., 2007, Peh et al., 2004). 
In one of the uppermost layers of the epithelium, the granular layer, the late genes L2 and 
L1 are expressed in consecutive order. When the cells of the granular layer exit the cell 
cycle the minor capsid protein L2 is expressed (Day et al., 1998). L2 is recruited to the 
already amplified viral genomes prior to the expression of L1. When the major capsid 
protein L1 is expressed it assembles with the complex of viral DNA and L2 to form a 
complete early virion (Day et al., 1998, Holmgren et al., 2005). The absence of 
mitochondrial activity in the granular layer of the epithelium causes a switch in the 
environmental condition from a reducing environment to an oxidising environment, thus 
enabling the formation of disulphide bonds between L1 protein resulting in the completion 
of the viral particle (Buck et al., 2005, Finnen et al., 2003). The mature viral particle consists 
of pentameric capsomeres which are formed by 360 L1 proteins and a smaller and variable 
number of L2 proteins (Buck et al., 2008).  
Additionally, E1^E4 is also expressed in the uppermost layer of the epithelium which is 
thought to have a role in the release of mature viral particles by disrupting the keratinous 
layer of the skin due to amyloid formation (McIntosh et al., 2008, Doorbar et al., 1997). 
Accordingly, loss of E1^E4 interferes with late events in the viral life cycle (Wilson et al., 
2005, Nakahara et al., 2005). The viral gene expression in each layer of the epithelium is 
illustrated in Figure 5.  
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1.6 Mechanisms of HPV induced carcinogenesis 
1.6.1 Progression from healthy epithelium to invasive cancer 
HPV can infect various kinds of epithelium; however HPV-induced tumours most commonly 
arise in the cervix, in particular at the junction between endo- and exocervix (Herfs et al., 
2012). Progression through the precancerous states to a tumour mostly occurs if a high risk 
HPV infection is maintained over many years or decades. The average time of persistence 
differs with HPV type and HPV16 has an especially long time of persistence (Koshiol et al., 
2006, Schiffman et al., 2010).  
Efficient evasion of the immune system is the key to long term persistence of an HPV 
infection. Thus HPV has evolved strategies to evade the host immune system in order to 
prevent clearance of the infection. These include limited gene expression in the basal layer 
of the epithelium which results in low immunogenicity (Hibma, 2012, Stanley, 2009). In 
 
Figure 5) HPV gene expression in mucosal epithelium 
A microlesion is shown that serves as point of entry for an HPV infection. HPV infected, 
actively dividing cells are marked with a red nucleus. Viral gene expression is closely 
connected to the differentiation state of the host cell. In different layers of the skin, all 
cells are at a defined stage of the differentiation process. The early genes are expressed in 
the basal and suprabasal layers and induce mitosis in these layers. In the mid layers of the 
epithelium E1, E2, E1^E4 and E5 are expressed, each playing a role in the amplification of 
the genome. In the top layers the late genes L1 and L2 are expressed simultaneously with 
E1^E4. These proteins are needed for virus assembly and release. HPV can also infect cells 
adjacent to the epithelium in the squamocolumnar junction of the cervix. Here the viral 
life cycle may be inefficiently supported but the risk for developing cancer as a result of 
an HPV infection is high (Herfs et al., 2012). Figure from Doorbar et al., reproduced with 
permission (Doorbar et al., 2012). 
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Figure 6) Histology of HPV induced carcinogenesis 
Histology of HPV infected epithelium through the pre-
cancerous stages to invasive carcinoma. In mild dysplasia 
the virus is able to complete its whole life cycle. This 
ability is lost with further progression of the dysplasia. 
The expression of the viral oncogenes E6 and E7 usually 
increases during the progression and the final emergence 
of a tumour often involves semi-random integration of 
the viral episome into the host genome. Figure from 
Lowry and Schiller, reproduced with permission (Lowy 
and Schiller, 2006). 
suprabasal layers expression of E5-results in the degradation of MHC class I molecules 
which leads to decreased display of viral peptides on the cell surface (Campo et al., 2010). 
Also the viral oncoproteins E6 and E7 have been shown to play a role in evasion of the 
immune system as they suppress the interferon response and downregulate other 
cytokines such as interleukins (Stanley, 2012, Kanodia et al., 2007, Karim et al., 2011). 
The most common cancer occurring in the cervix is squamous cell carcinoma (SCC), a 
tumour of cutaneous or mucosal epithelium. Various HPV types are involved in the 
emergence of SSC and the 
contribution of particular 
HPV types to SCC varies. 
The majority of SCC is 
caused by HPV16 (62 %), 18 
(8 %), 45 (5 %), 31 (4 %) 
and 33 (4 %) (de Sanjose et 
al., 2010). There are more 
HPV types associated with 
SCC but their contribution 
to the overall cases of SCC 
is below 4 % (de Sanjose et 
al., 2010). 
Another kind of malignancy 
commonly caused by HPV 
is adenocarcinoma (AC), a 
tumour of glandular origin. 
Here the group of HPV 
types causing this cancer 
includes less HPV types. The types associated with 94 % of AC are HPV16 (50 %), 18 (32 %) 
and 45 (12 %) (de Sanjose et al., 2010). All other HPV types have a contribution to AC of less 
than 1 % (de Sanjose et al., 2010). There are two different nomenclatures frequently used 
for describing the different histological stages caused by an HPV infection that ultimately 
lead to invasive carcinoma. These stages are illustrated in Figure 6. The first nomenclature 
uses the acronyms LSIL and HSIL, referring to a low or high grade squamous intraepithelial 
lesion. A mild epithelial dysplasia is referred to as LSIL whereas moderate and severe 
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dysplasia together with carcinoma in situ are referred to as HSIL. The second nomenclature 
for describing the severity of HPV induced lesions includes the terms cervical intraepithelial 
neoplasm of the grades 1 to 3 (CIN1-3). CIN1 refers to mild dysplasia, CIN2 to moderate 
dysplasia and the term CIN3 covers severe dysplasia and carcinoma in situ. Progression past 
HSIL or CIN3 results in invasive carcinoma (Lowy and Schiller, 2006). However this only 
happens in the minority of cases. Typically, progression through the stages of 
carcinogenesis takes many years and the stages CIN1 and CIN2 are completely reversible to 
healthy epithelium.  
Figure 7 illustrates the time course of HPV infections. Even though high grade dysplasia is 
mostly seen when the infection is maintained over decades, occasionally young women 
progress to CIN2+ shortly after infection (Paavonen et al., 2007, Paavonen et al., 2009, 
Szarewski et al., 2012, Quint et al., 2012). This is suggested to be caused by hormonal 
changes or epigenetic modification of the HPV DNA (Peh et al., 2004).  
 
Carcinogenesis is a process involving many molecular changes in the cell such as inhibition 
of apoptosis pathways, upregulation of growth factors and immortalisation of the cell. All 
these changes need to accumulate in a single cell to enable it to uncontrollably proliferate. 
The papillomavirus oncoproteins E6 and E7 facilitate many of these changes as shown in 
Figure 8 and Figure 9. Thus, only minor additional alterations are needed to push HPV 
 
Figure 7) Time course of high risk HPV infections 
The pre-cancerous histological stages CIN1 and CIN2 are reversible. However if the pre-
cancerous stages are maintained over many years the likelihood of progression to 
invasive cancer increases. Figure from Lowy and Schiller, reproduced with permission 
(Lowy and Schiller, 2006).  
Introduction 
17 
 
infected cells into a cancerous state. When dysplasia increases in severity, typically the 
amount of E6 and E7 expressed increases (Melsheimer et al., 2004).  
This in turn goes along with decreased host genome stability and an increased chance of 
integration of the viral genome into the host genome at common fragile sites (Van Tine et 
al., 2004b, Ziegert et al., 2003, Thorland et al., 2003). However the cancer promoting 
functions of E6 and E7 vary among HPV types. Accordingly, the oncoproteins of high risk 
HPV are more potent in promoting cancer compared to the ones from low risk HPV (White 
et al., 2012). In the majority of carcinoma in situ and invasive carcinomas of the cervix the 
HPV genome was found to be integrated into the host genome (Badaracco et al., 2002). 
Whereas HPV18 DNA is integrated in nearly all HPV18 induced carcinomas, around 30 % of 
all HPV16 induced carcinomas show no integration of the HPV16 genome (reviewed by 
Doorbar et al., 2012, Badaracco et al., 2002, Woodman et al., 2003). However, this 
percentage varies greatly from study to study (Pett and Coleman, 2007, Vinokurova et al., 
2008, Matsukura et al., 1989). Integration usually happens after the HPV infection was 
maintained over an extended period of time. In this case the viral oncogenes are often 
already de-regulated in the episomes and the integration event de-regulates these 
oncogenes even further (Melsheimer et al., 2004).  
The way the viral genome integrates into the host genome is crucial for progression to 
cancer. Integrated viral DNA must contain the LCR and the early genes E6 and E7 in addition 
to the 5’ portion of the E1 gene, but the E2 reading frame must be either disturbed or 
silenced (Pett and Coleman, 2007). Since E2 is the negative regulator protein of the viral 
oncogenes, the lack of E2 leads to overexpression of these genes (Jeon et al., 1995, Jeon 
and Lambert, 1995, Pett and Coleman, 2007). Also, E2 is able to inhibit E6 and E7 function 
by direct protein-protein interactions (Gammoh et al., 2006, Grm et al., 2005, Smal et al., 
2009). Thus loss of E2 expression is an important factor in HPV-induced carcinogenesis. 
Most viral genomes found in tumours integrated within the E1 or L1 reading frame (Xu et 
al., 2013, Theelen et al., 2013, Wang et al., 2013, Dall et al., 2008). Integration in E1 results 
in loss of E2 whereas integration in L1 leaves the E2 reading frame intact which makes 
silencing of E2 necessary for cancer progression. 
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1.6.2 Functions of high risk HPV oncoproteins 
The differences in the viral oncoproteins E6 and E7 among various HPV types determine the 
carcinogenic potential of each HPV type (Pim and Banks, 2010, reviewed by Klingelhutz and 
Roman, 2012). HPV induced carcinogenesis works via multiple molecular mechanisms, one 
of which is the ubiquitin dependent degradation of tumour suppressor genes. Ubiquitin is a 
small protein that can be attached to target proteins as a posttranslational modification 
called ubiquitination. This modification can influence protein localisation, activity or 
mediate the degradation of the target protein by the proteasome (reviewed by Glickman 
and Ciechanover, 2002, reviewed by Mukhopadhyay and Riezman, 2007, Shih et al., 2000). 
A single ubiquitin or chains of ubiquitin can be attached to lysines or the N-terminus of the 
target protein in a three-step process consisting of activation, conjugation and ligation 
(Bloom et al., 2003, reviewed by Pickart and Eddins, 2004, Flick et al., 2004). Firstly, an 
ubiquitin-activating enzyme (E1) catalyses the acyl-adenylation of the C-terminus of the 
ubiquitin molecule (reviewed by Schulman and Harper, 2009, reviewed by Komander and 
Rape, 2012). This results in a thioester linkage between the C-terminal carboxyl group of 
ubiquitin and the E1 cysteine sulfhydryl group. Secondly, an ubiquitin-conjugation enzyme 
mediates the transfer of ubiquitin from the activating enzyme to a cysteine of the 
conjugation enzyme (reviewed by van Wijk and Timmers, 2010). Thirdly an ubiquitin ligase 
forms an isopeptide bond between the C-terminal glycine of the ubiquitin and a lysine of 
the target protein (reviewed by Metzger et al., 2012). Ubiquitin ligases can have two 
different domains that can catalyse the reaction. The homologous to the E6AP carboxyl 
terminus (HECT) domain binds ubiquitin transiently whereas the really interesting new gene 
(RING) domain mediates the transfer of ubiquitin from the conjugation enzyme to the 
target protein (reviewed by Metzger et al., 2012). A chain of at least 4 ubiquitin proteins 
attached by lysine 48 to one another mediates degradation by the proteasome, cutting the 
target protein into small polypeptides (Thrower et al., 2000).  
E6 is able to form complexes with the ubiquitin ligase E6-associated protein (E6AP) and 
alter its specificity (Gewin et al., 2004, Tomaic et al., 2009). In this mechanism E6 seems to 
work like an adapter protein for E6AP, enabling E6AP to target various tumour suppressor 
genes like p53, ∆N63α and others, facilitating their degradation by the proteasome (Figure 
8) (Xu et al., 2008, Sherman et al., 2002, Senoo et al., 2007). Degradation of the major 
tumour suppressor protein p53 through this pathway is considered as the most important 
carcinogenic function of E6. Other proteins that are degraded include ∆N63α which is a 
Introduction 
19 
 
 
Figure 8) Cancer promoting functions of high risk HPV E6 
and E7 
E6 and E7 mediated degradation of cellular factors that 
contribute to tumour formation. E6 modifies the specificity 
of the host ubiquitin ligase E6-AP so that it ubiquitinates 
p53, NFX1-91 and proteins containing PDZ domains. This 
results in the degradation of these proteins and therefore 
promotes cancer formation. E7 binds and deactivates p600, 
resulting in reduced anchorage dependency. Additionally E7 
mediates calpain-dependent degradation of pRb, enabling 
the cell cycle to continue in presence of DNA damage. Figure 
from Yugawa and Kiyono, reproduced with permission 
(Yugawa and Kiyono, 2009). 
splice variant of p63 that 
plays a role in the 
regulation of cell 
proliferation. Its 
degradation favours cell 
proliferation (Patturajan 
et al., 2002). 
E6 is also able to target 
host PDZ domain 
proteins for degradation 
via its PDZ binding 
domain. This function 
was shown to be critical 
for the transformation 
ability of E6 (Kiyono et 
al., 1997, Watson et al., 
2003). Proteins 
deactivated due to their 
PDZ domain include 
various tumour 
suppressor proteins like hDLG, hScribble, MUPP1, MAGI-1 and others. Particularly the 
downregulation of the tight junction protein MUPP1 contributes to anchorage 
independency in cancer development (Kiyono et al., 1997, Lee et al., 1997, Nakagawa and 
Huibregtse, 2000, Lee et al., 2000). Additionally E6 is able to induce and activate the 
catalytic subunit of human telomerase, hTERT. This, in combination with the deactivation of 
the Rb pathways mediated by E7, is sufficient to immortalise cells (Kiyono et al., 1998, Haga 
et al., 2007). E6 mediated hTERT activation was shown to work via ubiquitination and 
degradation of a newly discovered transcriptional repressor of the hTERT promoter called 
NFX1-91 (Xu et al., 2008). Removal of NFX1-91 allows c-myc binding to the hTERT-promoter 
resulting in induction of hTERT expression. Furthermore E6 upregulates c-myc expression 
which enhances hTERT expression even further (McMurray and McCance, 2003).  
The downregulation of pro-inflammatory cytokines like type I interferons and various 
interleukins is another cancer promoting function of E6 and E7 since this contributes to the 
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ability to evade the immune system (Kanodia et al., 2007, Karim et al., 2011). The lack of 
pro-inflammatory cytokines prevents the recruitment of Langerhans cells and dendritic cells 
to the site of infection (Stanley, 2012). 
The inhibition of the differentiation of basal cells into keratinocytes was also found to be 
critical for the formation of a tumour. Differentiation of epithelial cells in tissue culture can 
be induced by exposure to serum and calcium and it was shown that E6 is able to suppress 
the differentiation induced by these stimuli (Sherman et al., 2002). Another important 
factor in the differentiation of keratinocytes is the Notch homolog 1 (NOTCH1) pathway 
(Nicolas et al., 2003, Proweller et al., 2006). The downregulation of this pathway is 
important for sustained E6 and E7 expression and tumour development in late CIN stages 
(Talora et al., 2002). Ectopic expression of NOTCH1 in the HPV-transformed cell lines HeLa 
and CaSki caused growth suppression, providing further evidence of a role of this pathway 
in cervical carcinogenesis (Talora et al., 2002). However, publications about NOTCH1 are 
partly contradictive, and it has also been shown that enhanced NOTCH1 expression can 
promote cervical carcinogenesis (Veeraraghavalu et al., 2005, Rangarajan et al., 2001, Nair 
et al., 2003).  
The second viral oncoprotein, E7, contains two conserved regions (CR1 and CR2) at its N-
terminus, which serve various cancer promoting functions. The domain CR1 plays a role in 
transformation and has been shown to bind and deactivate p600 and loss of p600 activity 
induces anchorage independency (Huh et al., 2005, DeMasi et al., 2005). Also the proteins 
p105, p107 and p130 are degraded by E7, enabling the cell to re-enter the cell cycle in the 
suprabasal layer of the epithelium (Barrow-Laing et al., 2010, Roman, 2006). Furthermore, 
CR1 interacts with P/CAF and reduces its acetyltransferase ability (Avvakumov et al., 2003). 
Acetylation of pRb was shown to be needed for exiting the cell cycle and the acetylation of 
pRb is lowered upon P/CAF deactivation (Nguyen et al., 2004, Nguyen and McCance, 2005). 
However this is not the only way for E7 to deactivate pRb. Via CR2, high risk E7 is able to 
bind pRb and promote degradation by the calcium activated cysteine protease calpain 
(Darnell et al., 2007). Retinoblastoma protein prevents cell cycle progression when DNA 
damage is detected. The degradation of this protein combined with the accumulation of 
DNA damage seen in high grade CIN contributes to cancer development.  
Also epigenetic changes are thought to be caused by E7 mediated upregulation of de-
methylating enzymes like KDM6A and KDM6B to alter the gene expression of the host cell 
(McLaughlin-Drubin et al., 2011, Laurson et al., 2010, Hyland et al., 2011). However the 
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Figure 9) Cellular level of HPV induced carcinogenesis 
The contribution of the viral oncoproteins in the acquisition of 
cancer specific traits is shown. The possible clearance of 
infection by the host immune system is shown on the left side 
of the figure. Figure of Yugawa and Kiyono, reproduced with 
permission (Yugawa and Kiyono, 2009). 
alteration of the 
methylation pattern 
caused by an HPV 
infection is diverse 
since the host 
methyltransferase 
DNMT1 was also 
shown to be 
overexpressed in 
infected human 
foreskin keratinocytes 
(HFK) as well as in 
cervical carcinomas 
(Au Yeung et al., 2010, 
Leonard et al., 2012). However this does not only affect the host DNA since the methylation 
pattern of the HPV LCR changes when a lesion progresses through the stages of CIN 
(Vinokurova and von Knebel Doeberitz, 2011).  
Other functions of E7 include the upregulation of the proto-oncogene DEK (and others) and 
the circumvention of promyelocytic leukaemia protein (PML)-induced senescence (Wise-
Draper et al., 2005, Wise-Draper et al., 2006, Bischof et al., 2005). The mechanism how the 
viral oncoproteins promote carcinogenesis is summarised in Figure 9. 
Nevertheless the host cell is not defenceless towards E7 since it has mechanisms to inhibit 
E7. The host proteins p21 and p27 are able to bind E7 with the effect of impairing its 
function (Noya et al., 2001). Accordingly, cells containing high levels of p21 and p27 are not 
pushed into S-phase via E7, in contrast to cells containing low levels of p21 and p27 (Noya 
et al., 2001).  
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1.6.3 Functions of E6 and E7 from low risk HPV 
The overall incidence of cancer caused by low risk HPV types is substantially lower 
compared to the cancers caused by high risk HPV types. The reasons for this mostly lie 
within the functional differences of the early proteins E6 and E7. The low risk E6 protein 
also binds p53 but does not target it for degradation (Zanier et al., 2012). Also the binding 
of PDZ-domain proteins and the degradation of those proteins does not occur with low risk 
E6 protein (Fu et al., 2010, Pim and Banks, 2010).  
Furthermore the oncogenic functions of low risk E7 are significantly reduced. The binding of 
pRb, p105 and p107 is weaker and no degradation of those proteins takes place (reviewed 
by Klingelhutz and Roman, 2012, reviewed by Doorbar et al., 2012). However low risk E7 is 
still able to bind and degrade p130 and thus enables re-entry in the cell cycle in mid-
epithelial layers (reviewed by Klingelhutz and Roman, 2012, Roman, 2006).  
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1.7 The host protein CTCF – properties and functions 
The CCCTC binding factor, also known as CTCF, is an essential eukaryotic protein with a 
large variety of functions (Heath et al., 2008). It was first discovered as a transcriptional 
repressor of the chicken Myc and lysozyme genes (Baniahmad et al., 1990, Lobanenkov et 
al., 1990). At this time CTCF was also called transcriptional repressor negative protein 1 
(NeP1) until it was proven that CTCF and NeP1 were identical (Burcin et al., 1997). CTCF is 
most known for being a genomic insulator and its binding sites are often located at either 
side of a gene cluster where CTCF separates heterochromatin from euchromatin (Palstra et 
al., 2003, reviewed by Wallace and Felsenfeld, 2007). In this position CTCF prevents the 
spread of heterochromatin into euchromatin, thus maintaining transcriptionally active and 
inactive regions (reviewed by Ohlsson et al., 2010, Probst et al., 2009). Also, CTCF was 
found to bind in the spacer region between nucleosomes and it was suggested that it might 
play a role in nucleosome positioning (Kanduri et al., 2002). This role seems to be locus 
specific since for the Igf2/H19 locus it was shown that nucleosome positioning did not 
depend on CTCF whereas CTCF dependent nucleosome positioning was observed in 
Kaposi’s sarcoma associated herpes virus (KSHV) (Kanduri et al., 2002, Kang et al., 2013).  
Binding sites for CTCF in mammalian DNA are abundant and binding sites of high occupancy 
are often conserved between tissues and species whereas low occupancy sites more likely 
to be tissue specific (Essien et al., 2009). The human genome is suggested to contain 
between 15000 and 40000 CTCF binding sites based on computer predictions of which tens 
of thousands have been confirmed by ChIP experiments (Xie et al., 2007, Kim et al., 2007, 
Shen et al., 2012, Barski et al., 2007). The presence of CTCF binding sites on 
retrotransposons has been found to be an important factor in evolution (Schmidt et al., 
2012). Due to this feature the translocation of retrotransposons can form new boundaries 
between transcriptionally active and inactive chromatin which potentially lead to the 
activation or deactivation of whole gene clusters (Schmidt et al., 2012).  
CTCF has uncommon features like aberrant mobility on PAGE and the unusually high 
amount of 11 zinc fingers that enable it to bind large motifs (Filippova et al., 1996). Even 
though the CTCF gene encodes for a product of 82 kDa, the CTCF protein migrates at 130 
kDa or 70 kDa on a denaturing polyacrylamide gel. Further investigation revealed that the 
130 kDa band seen on denaturing polyacrylamide gel was in fact the full length 82 kDa 
protein which inherently migrates aberrantly (Klenova et al., 1997). The 70 kDa band is a C-
terminally truncated version of the full length CTCF protein. This truncation was shown to 
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be mediated by the interaction of a sequence in the UTR with a sequence in the coding 
region of the CTCF mRNA (Klenova et al., 1997). The 70 kDa isoform of CTCF is expressed in 
some cell lines and is able to interact with the 130 kDa form of CTCF, resulting in enhanced 
transactivation (Klenova et al., 1997, Klenova et al., 1993). However full length CTCF (130 
kDa) is present in all cells and therefore the term CTCF, if not defined otherwise, refers to 
the full length variant of CTCF that migrates at 130 kDa. Furthermore dimerisation and 
oligomerisation of CTCF proteins has been observed in vitro and in vivo which have been 
suggested to be involved in DNA looping (Yusufzai et al., 2004, Phillips and Corces, 2009, 
MacPherson and Sadowski, 2010).  
Also a paralog of CTCF exists that shares the same DNA binding motif with CTCF but 
antagonises its function (Loukinov et al., 2002). This paralog is called CCCTC-binding factor-
like (CTCFL) or Brother of the Regulator of Imprinted Sites (BORIS) and was found to play a 
role in germ line cells and embryogenesis. Additionally low levels of BORIS expression were 
found in some tissues in adults, including the skin, testis and cervix (Rosa-Garrido et al., 
2012). 
Full length CTCF consists of 3 major functional parts: an N-terminal region that can be post-
translationally modified, the DNA binding middle region and the C-terminal region that can 
also be modified. Post-translational modifications include phosphorylation at the N-
terminus and poly-(ADP)-ribosylation at the C-terminus. Phosphorylation of the N-terminus 
has been shown to switch the function of CTCF from a transcriptional repressor to a 
transcriptional activator (El-Kady and Klenova, 2005, Klenova et al., 2001). Conversely a 
mutant in which phosphorylation was disturbed showed more efficient repression of 
transcription at CTCF binding sites (El-Kady and Klenova, 2005). Poly-(ADP)-ribosylation of 
CTCF has been shown to be essential for its function as an insulator. The lack of this 
modification caused abrogation of  the barrier function at the chicken HS4 β-globin FII 
insulator element (Aker et al., 2010). Additionally CTCF can be modified by the small 
ubiquitin like protein SUMO at either terminus (MacPherson et al., 2009). This modification 
does not interfere with the DNA binding capability of CTCF but it enhances the repressor 
function of CTCF at the c-myc P2 promoter (MacPherson et al., 2009). 
The 11 zinc fingers of the DNA binding region recognize a primary and a secondary motif, 
both of which are present at a single CTCF binding site. In some locations the primary 
binding motif is able to define a CTCF binding site on its own but the presence of the 
secondary binding motif enhances binding and is sometimes required to facilitate CTCF 
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binding (Schmidt et al., 2012). The primary motif is very large and consists of 20 bases. The 
secondary motif starts about 5 nucleotides downstream of the primary motif and consists 
of 9 bases. Also additional bases adjacent to the motifs are necessary for CTCF binding 
(Nakahashi et al., 2013). Accordingly, CTCF binding sites are remarkably large and a DNAse 
footprint of CTCF was shown to cover about 50 nucleotides (Chau et al., 2006). The 11 zinc 
fingers of the DNA binding region of CTCF do not all contribute equally to DNA binding as 
seen in Figure 10 
(Nakahashi et al., 2013). 
Zinc fingers 4-7 target the 
most important base pairs 
of the binding motif and 
bind to 80 % of CTCF 
binding sites. Zinc fingers 1-
2 and 8-11 stabilise CTCF 
binding by targeting non-
conserved flanking 
sequences if only the 
primary motif is present at 
the CTCF binding site in 
question. If a secondary 
motif is present zinc fingers 
9-11 bind to this secondary 
motif (Nakahashi et al., 
2013). Conversely the 
existence of a tertiary motif 
in the vicinity of a CTCF 
binding site has been 
suggested that is able to 
destabilise CTCF binding (Nakahashi et al., 2013). In this case zinc fingers 1-2 lose their 
affinity for DNA or get outcompeted by an unknown factor. In response to this, zinc finger 8 
clusters with zinc fingers 9-11 at the secondary motif. If the secondary motif is absent, zinc 
finger 3 binds to the core motif and becomes essential for binding. CTCF has been shown to 
be an important protein in the control of DNA methylation and genomic imprinting since it 
  
Figure 10) Saddle-model of CTCF multivalency 
Left: Core motif with secondary motif. Strong binding of 
zinc fingers 4-7 to the core motif (seat of the saddle). The 
upstream motif is recognised by zinc fingers 9-11 and 
stabilises overall binding (strong grip). Zinc fingers 1-2 
associate with DNA sequences that lack a consensus 
motif and stabilise binding to a lesser extend (loose grip). 
Right: Core motif without secondary motif but with 
suggested factor X. Zinc fingers 1-2 lose affinity for DNA 
or get outcompeted by an unknown factor (X). This 
results in the clustering of zinc finger 8 with zinc fingers 9-
11. If the secondary motif is absent, zinc finger 3 binds to 
the core motif and becomes essential for binding. 
The Figure was modified from Nakahashi et al. with 
permission from the copyright holder (Nakahashi et al., 
2013). 
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protects a region of at least 2 kbp in its vicinity from de novo methylation (Fedoriw et al., 
2004, reviewed by Klenova and Ohlsson, 2005). The methylation protection function of 
CTCF is facilitated via the protein poly (ADP-ribose) polymerase 1 (PARP1). This protein is 
able to regulate the activity of other proteins, like the methyltransferase DNMT1, by the 
addition of poly (ADP-ribose). CTCF forms a complex with PARP1 and the methylating 
enzyme DNMT1 which triggers PARP1-mediated poly-(ADP)-ribosylation of Conversely CTCF 
binding was shown to be 
prevented by methylation of 
the CTCF binding site (Singh 
et al., 2012, Fedoriw et al., 
2004). However methylation 
based abrogation of CTCF 
binding may be locus specific 
since it was shown that CTCF 
can also bind to its binding 
site regardless of the fact 
that it is methylated or not 
(Salamon et al., 2009). The 
methylation specific gene 
expression mediated by CTCF 
is especially important for 
imprinted loci and was first 
discovered at the mouse 
Igf2/H19 locus (Bell and 
Felsenfeld, 2000, Hark et al., 
2000, Kanduri et al., 2000). 
Methylation on the paternal 
imprinting control region 
(ICR) blocks CTCF binding with the result of silencing the H19 gene while activating 
transcription from the Igf2 gene (Figure 11). On the maternal allele the ICR is not 
methylated so CTCF can bind and activate H19 while simultaneously repressing Igf2 
(Banerjee et al., 2001). This transcription regulation was shown to be a result of enhancer 
blocking. If CTCF is present in between an enhancer and a promoter it is able to block the 
 
 
Spatial arrangement: 
 
Figure 11) CTCF function in the Igf2/H19 locus 
CTCF regulates gender specific transcription at the 
Igf2/H19 locus. CTCF binding at the internal control 
region (ICR) at the maternal locus blocks enhancers 
from the Igf2 promoter, resulting in H19 transcription. 
On the paternal locus the ICR is methylated so CTCF 
cannot bind. The enhancers are not blocked and act on 
the Igf2 promoter instead of the H19 promoter. CTCF-
mediated looping is the basis of this mechanism. Figure 
from Wallace and Felsenfeld, reproduced with 
permission (Wallace and Felsenfeld, 2007). 
Introduction 
27 
 
enhancers from acting on the promoter (Bell et al., 1999, Hark et al., 2000, Recillas-Targa et 
al., 2002). In this case the enhancers are free to target a secondary promoter. With the use 
of novel techniques for investigating the spatial arrangement of DNA it was found that CTCF 
is a major factor in the 3 dimensional structuring of DNA that was found to have an impact 
on gene regulation (Phillips and Corces, 2009). Forming 3-dimensional DNA conformations 
may be a result of the interaction of CTCF with structural nuclear proteins like 
nucleophosmin/B23 and the nuclear matrix (Dunn et al., 2003, Torrano et al., 2006). CTCF is 
able to bring two distant DNA loci in close proximity. This works in the form of a loop if the 
loci are on the same chromosome 
or in form of a bridge if the loci are 
on different chromosomes (Botta et 
al., 2010). Chromatin interaction 
analysis with paired end tag 
sequencing (ChIA-PET) revealed 
1500 intrachromosomal and 300 
interchromosomal connections 
mediated by CTCF, all of which are 
non-random (Handoko et al., 2011, 
Ling et al., 2006). Furthermore, a 
genome wide DNA interaction map 
was created using the method Hi-C 
(Lieberman-Aiden et al., 2009). Via 
intrachromosomal connections 
(loops) CTCF is able to separate 
active from inactive chromatin, to 
trap enhancers together with promoters in a loop or insulate genes by preventing a spatial 
connection of enhancer and promoter (Handoko et al., 2011, Comet et al., 2011).  
The positioning and partitioning of DNA inside the nucleus is also suggested to be mediated 
by CTCF as illustrated in Figure 12. The nuclear lamina is situated at the inside of the 
nuclear envelope and DNA in this region has been found to be of little transcriptional 
activity and CTCF is often flanking lamina associated domains (LAD) (Guelen et al., 2008). 
LAD change dynamically during differentiation which is potentially mediated by CTCF (Peric-
Hupkes et al., 2010). Furthermore it was shown that small and gene rich chromosomes tend 
 
Figure 12) CTCF-mediated chromatin 
positioning in the nucleus 
CTCF forms non-random interchromosomal 
connections of particular loci in the 
transcriptionally active centre of the nucleus. 
Additionally CTCF binds at the borders of 
transcriptionally silent lamina associated 
domains (LADs). Figure from Zlatanova and 
Caiafa, reproduced with permission (Zlatanova 
and Caiafa, 2009b). 
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to be situated more centrally in the nucleus which might be important for papillomavirus 
genome maintenance (Bolzer et al., 2005, reviewed by Cremer and Cremer, 2001).  
The co-localisation of CTCF and cohesin is important for connecting distant DNA loci 
(Stedman et al., 2008, Xiao et al., 2011, Wendt et al., 2008, Rubio et al., 2008, Parelho et 
al., 2008). Cohesin is a protein complex involved in sister chromatid cohesin during mitosis 
where it forms a ring structure around two DNA helices (Nasmyth and Haering, 2005, 
Wendt et al., 2008). In post-mitotic cells cohesin still binds to DNA and half of its binding 
sites overlap with CTCF (Wendt et al., 2008, Rubio et al., 2008, Parelho et al., 2008). CTCF-
cohesin mediated DNA looping was shown to be essential for the transcriptional regulation 
of a variety of loci including the loci for Igf2, β-globin, T cell receptor α and interferon ɣ 
(Nativio et al., 2009, Hadjur et al., 2009, Chien et al., 2011, Seitan et al., 2011).  
CTCF binding has been shown to be important in the regulation of RNA polymerase II 
progression during gene transcription. When the RNA polymerase II moves a long a 
template strand and encounters a CTCF-cohesin complex the transcription process is stalled 
until the CTCF-cohesin complex is dislocated. This stalling favours the assembly of a splicing 
complex resulting in the inclusion of exons with weak splice sites upstream of the CTCF 
binding site (Wada et al., 2009, Shukla et al., 2011).  
The function of CTCF at particular binding site has been shown to depend on factors bound 
in the close vicinity of CTCF (reviewed by Wallace and Felsenfeld, 2007, reviewed by 
Zlatanova and Caiafa, 2009b). For example the estrogen receptor co-occupies some CTCF 
binding sites. For these loci it was shown that the binding of CTCF is needed to facilitate 
transcriptional activation by the estrogen receptor (Ross-Innes et al., 2011). Other factors 
that can influence the function of CTCF when bound in its close vicinity include RNA 
polymerase I II and III, VEZF1, YY1, SMAD, FOXA1 and Oct4 (reviewed by Weth and 
Renkawitz, 2011).  
In conclusion, it is challenging to determine what purpose CTCF serves at particular binding 
sites considering the vast variety of mechanisms in which CTCF is involved. 
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1.8 The role of CTCF in the life cycle of other DNA viruses  
1.8.1 Epstein - Barr virus 
Epstein-Barr virus (EBV) belongs to the herpesviridae which are large DNA viruses. It is 
maintained episomally and can establish various types of latency, each with different 
properties in terms of growth and transformation of the host cell.  
Screening the EBV genome for CTCF binding sites resulted in the discovery of CTCF binding 
sites upstream of the promoters Cp, Qp, Wp, and the transcription start site of two latency 
specific small nuclear RNAs called EBER1 and EBER2 (Day et al., 2007, Tempera et al., 2010). 
At the binding site close to Cp, CTCF was shown to activate transcription by interacting with 
the viral protein EBNA1. Also the transcription start site Qp is regulated by EBNA1 and 
CTCF. At this locus, CTCF binds 40bp upstream of the EBNA1 binding site which is in turn 
located 10bp upstream of the transcription start site. Mutation of this CTCF binding site 
resulted in decreased maintenance of EBV genomes (Tempera et al., 2010). The decline in 
genome maintenance was suggested to be due to decreased transcription from Qp and was 
accompanied by a much delayed increase in transcription from the promoters Cp and Fp. 
This increase occurred after 8 weeks of culturing and was accompanied by a further 
decrease in transcription from Qp. After 16 weeks there was no detectable transcriptional 
activity of the Qp promoter and the promoter sequence was highly methylated. Thus CTCF 
was shown to prevent epigenetic silencing of Qp and prevent promiscuous transcription 
from certain promoters (Tempera et al., 2010).  
Furthermore CTCF has been shown to be an important factor involved in the regulation of 
latency-specific transcripts in the latency types I and III (Chau et al., 2006). Epstein-Barr 
nuclear antigen 2 (EBNA2) is one of the EBV latency proteins that are involved in 
transformation of the host cell (Zimber-Strobl et al., 1994). Deletion of a CTCF binding site 
between the origin of replication and the Cp promoter resulted in elevated EBNA2 mRNA 
levels of 3.5 fold in the latency types I and III (Chau et al., 2006). Conversely, overexpression 
of CTCF in latency type III cells decreased EBNA2 mRNA levels. In contrast to the Igf2/H19 
locus, CTCF binding in this particular region of the EBV genome is not affected by CpG 
methylation of the CTCF binding site (Salamon et al., 2009).  
Interestingly, EBV episomes inside the nucleus have been found to pair up like sister 
chromatids (Nanbo et al., 2007, Kanda et al., 2007). This mechanism was shown to depend 
on cohesin which is known to interact with CTCF. Thus CTCF may be involved. During 
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mitosis EBV genomes were found to attach to host chromosomes, presumably to ensure 
equal segregation of genomes in daughter cells (Kanda et al., 2007). EBNA1 was shown to 
be crucial for this interaction which, again, interacts with CTCF. 
 
1.8.2 Herpes Simplex Virus 
Like in EBV, the episome of herpes simplex virus type 1 (HSV1) is stably maintained in its 
host cell and can transition between a latent or lytic stage. CTCF has been shown to be 
involved in the regulation of those two stages. The HSV1 genome is subdivided into regions 
of predominantly hyperacetylated or hypoacetylated histone H3. During latency the region 
containing latency associated genes is hyperacetylated whereas the region containing lytic 
genes is hypoacetylated (Kubat et al., 2004a, Kubat et al., 2004b). CTCF is important for 
maintaining this pattern and clusters of CTCF binding sites for maintaining the histone 
acetylation pattern are located in the gene for the latency associated transcript (LAT) and 
some repeat regions of the HSV1 genome. Dissociation of CTCF from its binding site in LAT 
is accompanied by hyperacetylation of the lytic genes and reactivation of the virus from 
latency (Ertel et al., 2012). Additionally the CTCF binding sites situated upstream of the 
promoters ICP0 and ICP4 promoters were shown to block the LAT enhancer from acting on 
its target (Amelio et al., 2006, Ertel et al., 2012).  
 
1.8.3 Herpesvirus Saimiri (HVS) 
Herpesvirus Saimiri (HVS) is a primate gamma-2 herpesvirus that has been shown to use 
CTCF for episome maintenance and gene regulation during latency (Zielke et al., 2012). A 
CTCF binding map of the 155 kilobasepairs HVS episome was created and two particular 
binding sites within the promoter region of the latency-specific transcript orf73/LANA were 
mutated. The CTCF mutants showed a reduction in expression of the orf73/LANA transcript 
and impaired proliferation of the host cell (Zielke et al., 2012). Additionally episome loss 
was observed in the mutants which could be a response to the reduction in oerf73/LANA 
transcript as LANA is important for viral maintenance in dividing T-cells. It was suggested 
that CTCF is vital for maintaining the epigenetic state of this virus and the loss of epigenetic 
maintenance may have caused the change in gene expression. The lytic cycle was not 
impaired in either of the CTCF mutants (Zielke et al., 2012).  
 
Introduction 
31 
 
1.8.4 Kaposi’s Sarcoma Associated Herpes Virus (KSHV) 
Just like the previous viruses, KSHV is maintained as a stable episome and is able to 
physically attach to mitotic chromosomes to ensure equal segregation of viral episomes to 
the daughter cells (Kanda et al., 2007).  
The latent and lytic genes in Kaposi’s sarcoma associated herpesvirus (KSHV) are in close 
proximity to one another which makes the tight regulation of chromatin modification and 
enhancer targeting necessary. Co-localisation of three CTCF-cohesin complexes in the 
latency control region of KSHV was observed during latent infection (Stedman et al., 2008). 
The binding of CTCF in this particular region is involved in maintaining latency since the 
induction of the lytic cycle coincides with the loss of CTCF binding in this region (Stedman et 
al., 2008). This is confirmed by the fact that deletion of a CTCF binding site in in the latency 
control region resulted in the re-activation of the lytic genes (Stedman et al., 2008).  
There are multiple putative causes for the changes in viral gene expression observed. For 
example, the altered ratios of various splice variants of mRNA transcripts in the CTCF 
mutants (Kang et al., 2013). Next to this CTCF is necessary for the initiation of transcription 
by recruiting the RNA polymerase II to KSHV promoters in the latency control region (Kang 
et al., 2013, Chernukhin et al., 2007). However CTCF was also shown to be necessary for 
repression of the viral lytic genes since dissociation of CTCF resulted in the induction of the 
lytic genes (Chen et al., 2012b). In this mechanism CTCF is suggested to position cohesin at 
gene promoters, resulting in inhibition of RNA pol II engagement (Chen et al., 2012b). 
Furthermore, nucleosome positioning in KSHV is determined by CTCF which is in contrast to 
the Igf2/H19 locus where nucleosome positioning has been shown to be due to underlying 
sequence rather than CTCF binding (Kang et al., 2013, Kanduri et al., 2002). Apart from 
nucleosome positioning the maintenance of histone modifications in the LCR could be 
attributed to CTCF (Kang et al., 2013). 
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1.9 Hypothesis and objectives 
The goal of this study was to characterise a potential CTCF binding pattern in 
papillomaviruses and to investigate the function of CTCF in the papillomavirus (PV) life 
cycle. Many of the various functions CTCF can provide have been shown to be used by 
various large episomally maintained DNA viruses (Kang et al., 2013, Zielke et al., 2012, 
Tempera et al., 2010, Ertel et al., 2012, Chen et al., 2012b). Even though CTCF is often 
involved in the regulation of large scale genomic interactions there are still many functions 
of CTCF that have the potential to play a role in small DNA viruses like HPV. For example the 
regulation of transcription, epigenetics, methylation and the alteration of splicing mediated 
by the stalling of RNA pol II at CTCF binding sites. Thus I hypothesise that CTCF plays a role 
in the papillomavirus gene regulation. 
To investigate this hypothesis, the first objective was to create binding maps for CTCF of 
various PV genomes. Computer predictions of CTCF binding sites in 8 different PV were 
made using 3 different prediction tools. The binding sites found were confirmed by 
electrophoretic mobility shift assays (EMSA) and binding maps of 7 out of the 8 PV tested 
were created.  
The second objective was to create a CTCF mutant of a particular binding site and to create 
a cell line maintaining this mutant. The mutant was created by site directed mutagenesis 
and the abrogation of CTCF binding was confirmed by EMSA. Mutant and wild type HPV18 
were transfected into human foreskin keratinocytes (HFK) to create a cell line model of HFK 
maintaining wild type or mutant HPV18.  
The third objective was to elucidate CTCF function by comparing the life cycle of wild type 
and mutant HPV18. For this purpose the HFK cell lines were differentiated using 
methylcellulose and gene expression throughout the differentiation process was monitored 
using western blotting. Furthermore organotypic raft cultures were grown from the HFK cell 
lines and gene expression throughout the whole raft was analysed by 
immunohistochemistry.  
As a fourth objective the capability of episomal maintenance in mutant and wild type 
HPV18 was investigated. To facilitate this, the copy number of episomes against the copy 
number of host DNA was compared using qPCR. DNA extracted from cell samples taken 
over a time course served as a template for this analysis. 
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2 Materials and Methods 
2.1 Computer predictions of CTCF binding sites 
The DNA sequences for each papillomavirus screened were obtained from the PubMed 
database and the accession number for each sequence is given in Table 3. Predictions with 
the tool provided by the CTCF binding site database (CTCFBSDB) were processed using the 
website at http://insulatordb.uthsc.edu/. If the tool identified overlapping motifs only the 
motif with the highest score was recorded in the tables of the results section. The screening 
results from version 1.0 and 2.0 of the CTCFBDB tool are limited because only the best 
match to each position weight matrix (PWM) in an input sequence was given. All lesser 
matches were neglected. Also, CTCFBSDB tool version 1.0 was unable to handle line breaks 
in an input sequences. Each line break was accounted as a spacer which led to flawed 
results in some occasions. This bug was fixed in a patch of version 2.0 but the problem of 
neglecting other matches than the best to each PWM remained. Screenings with Storm did 
not have this problem. The Storm screenings were done in collaboration with Dr. Jesse 
Ziebarth from the University of Tennessee Health Science Centre, USA. The PWM and tools 
used in the screening are shown in Table 4. 
The Essex tool did no use any PWM. Instead it screened an input sequence for matches to 
EMSA confirmed CTCF binding sites from a database. This tool is available online at 
http://bsproteomics.essex.ac.uk:8080/bioinformatics/ctcfbind.htm. The locations of 
binding sites found on the antisense strand of the input sequence are given in 5’ to 3’ 
direction of the antisense strand. This can be confusing because one expects the locations 
of the binding sites to be given relative to the 5’ to 3’ direction of the sense strand. Thus the 
locations of binding sites found on the antisense strand are corrected in order to give their 
position relative to the sense strand.  
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Class Papillomavirus type Accession Number 
Bovine PV BPV1 AB626705.1 
High risk HPV 
HPV16 NC_001526.2 
HPV16 114/K EU118173.1 
HPV18 AY262282.1 
HPV31 J04353.1 
Low risk HPV 
HPV6b NC_001355.1 
HPV11 FR872717.1 
Beta HPV 
HPV8 M12737.1 
HPV38 U31787.1 
Table 3) Accession numbers of FASTA sequences for 
the prediction of CTCF binding sites 
 
 
PWM Name in 
tables 
Name in 
tools 
Publishe
d by 
Used by 
CTCFBSDB 
1.0 
Used by 
CTCFBSDB 
2.0 
Used 
by 
Storm 
 
1.PWM 
AC  
EMBL_M1 
Schmidt 
et al., 
2012 
no yes yes 
 
2.PWM 
AC  
EMBL_M2 
Schmidt 
et al., 
2012 
no yes yes 
 
3.PWM 
AC  
REN_20 
Kim et 
al., 2007 
yes yes yes 
 
4.PWM 
AC  
MIT_LM2 
Xie et al., 
2007 
yes yes yes 
 
5.PWM 
AC  
MIT_LM7 
Xie et al., 
2007 
yes yes yes 
AGCACCACCTGGTGGTA 6.PWM 
AC  
MIT_LM2
3 
Xie et al., 
2007 
yes yes yes 
Table 4) PWM used to screen all PV sequences for CTCF binding sites 
The figures of each PWM were reproduced with permission from the copyright holders 
(Schmidt et al., 2012, Kim et al., 2007, Xie et al., 2007). 
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2.2 Generation of fluorescein amidite (FAM)-labelled DNA 
fragments for EMSA  
The generation of FAM-labelled fragments containing the CTCF binding site of interest was 
done in a two-step PCR reaction. In step one a fragment of approximately 200 bp was 
amplified from template plasmids containing the PV genome of interested (Table 5). The 
forward primer for this reaction had the M13-overhang added to its 5’ end (sequence: 
5’TGTAAAACGACGGCCAGT3’). In the second step this fragment was used as a template in a 
PCR reaction together with a FAM-labelled primer that was complementary to the M13 
overhang. In this second reaction the same reverse primer as in the first reaction was used. 
This resulted in FAM-labelled fragments ready for use in EMSA. All PCR reactions were done 
using Master Mix S from Peqlab. Labelled fragments generated this way were used 
immediately or stored at -20°C and protected from light. The PCR reactions were carried 
out using the thermocycler T Personal from Biometra. Reaction details and temperature 
cycles are given below. The details of the primers used to generate the control fragments 
can be found in Table 6. All other primers are listed in the appendix in Table 38 to 47. 
 
 
First PCR reaction (fragment generation): 
Reaction components: 
20.5 µl H2O 
2 µl FW primer (10 µM) 
2 µl RV primer (10 µM) 
0.5 µl template plasmid 
25 µl Master Mix S from Peqlab 
 
Cycles: 
 
94 °C 5 min 
94 °C 30 s 
59 °C 45 s  30 cycles 
72 °C 45 s 
72 °C 10 min 
 
 
 
 
 
Second PCR reaction (labelling): 
Reaction components: 
45.5 µl H2O 
2 µl FAM primer (10 µM) 
2 µl RV primer (10 µM) 
0.5 µl template from first PCR 
50 µl Master Mix S from Peqlab 
 
Cycles: 
 
94 °C 5 min 
94 °C 30 s 
56 °C 45 s  30 cycles 
72 °C 45 s 
72 °C 10 min 
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HPV Type Vector Cloning site Obtained from 
HPV16 pBR322 BamHI Prof. Ethel-Michelle de Villiers 
HPV16 L1 pUF3 N/A Prof. Martin Muller 
HPV16 114/K puC19 BamHI Prof. Ethel-Michelle de Villiers 
HPV18 pGEM2 EcoRI Dr. Frank Stubenrauch 
HPV31 pBR322 BamHI Prof. Lou Laimins 
HPV6b pUC19 BamHI/EcoRI Prof. Ethel-Michelle de Villiers 
HPV11 pBR322 BamHI Prof. Ethel-Michelle de Villiers 
HPV38 pUC19 EcoRI Prof. Massimo Tommasino 
BPV1 pBR322 BamHI Prof. Elliot Androphy 
Table 5) Template plasmids for the amplification of DNA fragments 
 
 
Primer name Template 
Fragment 
start 
Fragment 
end 
Fragment 
length 
Primer sequence (5’-3’) Tm 
Neg. control FW BPV1 AB626705.1 4910 5051 160 
TGTAAAACGACGGCCAGT 
CCCGCAGTATTGCCTCTAAA 
60.2 
Neg. control RV BPV1 AB626705.1 4910 5051 160 AGCACAGCTGGTTCTGCTTC 60.7 
Pos. control FW Human C-myc promoter 41894249 41894403 173 
TGTAAAACGACGGCCAGT 
GGGATCGCGCTGAGTATAAA 
58.7 
Pos. control RV Human C-myc promoter 41894249 41894403 173 GGATCTCCCTTCCCAGGAC 59.2 
FAM-M13(-21) All forward primers N/A N/A N/A FAM-TGTAAAACGACGGCCAGT 57.7 
Table 6) Primers for generating EMSA control fragments 
The M13-tag at the 5’ position of the forward primers is shown in bold. 
 
 
2.3 Generation of CTCF protein  
The in vitro expression of CTCF for EMSA was carried out using 3 different kits from 
Promega according to the manufacturer’s manual, the TnT® T7 Rabbit Reticulocyte lysate 
(RRL) System, the TnT® T7 Coupled Wheat Germ Extract (WGE) System and the TnT® SP6 
High-Yield Wheat Germ Protein Expression System. These kits combine transcription of 
mRNA from template DNA with subsequent translation of this mRNA in a single reaction. 
Best results were achieved with the TnT® SP6 High-Yield Wheat Germ Protein Expression 
System. The T7 polymerase kits used a template of full length human CTCF protein with a 
10xhistidine (HIS)-tag at the N-terminus which was inserted in the plasmid pCi. In this 
plasmid the transcription of CTCF mRNA was controlled by the T7 initiation site (Farrar et 
al., 2010). The same CTCF sequence inserted into the plasmid pDrive served as a template 
when using the TnT® SP6 High-Yield Wheat Germ Protein Expression System. Both 
templates were kindly provided by Dr. Dawn Farrar from the University of Essex (Figure 13). 
The DNA sequence of each plasmid and the amino acid sequence of the translation product 
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can be found in the appendix (page 203). The reaction mix and the incubation conditions 
for each kit are given in Table 7. The presence of CTCF translated with all kits was confirmed 
using western blotting with the anti-CTCF antibody from Abcam (ab70303) at a dilution of 
1:3333. As a negative control for EMSA, luciferase was translated and the presence of 
luciferase was confirmed using the luminometer FLUOstar OPTIMA (BMG Labtech).  
 
 
TnT® T7 Rabbit 
Reticulocyte lysate 
(RRL) 
TnT® T7 Wheat 
Germ Extract 
(WGE) 
TnT® SP6 Wheat 
Germ Extract (WGE) 
Translation mix 25 µl RRL 25 µl WGE 30 µl WGE 
Kit buffer 2 µl 2 µl none 
Template 1 µg pCi T7 construct 
1 µg pCi T7 
construct 
5 µg pDrive SP6 
construct 
RNAsin 1 µl 1 µl none 
T7 polymerase 1 µl 1 µl none 
Amino acids minus 
leucine 
0.5 µl 0.5 µl none 
Amino acids minus 
methionine 
0.5 µl 0.5 µl none 
ddH2O filled up to 50 µl filled up to 50 µl filled up to 50 µl 
Incubation 
temperature 
30°C 30°C 25°C 
Incubation time 90 minutes 90 minutes 120 minutes 
Table 7) In vitro generation of CTCF protein using 3 different kits from Promega 
Two different amino acid master mixes were used in a single reaction, each lacking a 
particular amino acid. This was done to have all amino acids available in the reaction mix. 
No radiolabelled amino acids were needed since the DNA fragments used in EMSA were 
already FAM-labelled. CTCF expression worked best with the SP6 WGE kit. 
 
 
A)      B) 
   
Figure 13) Plasmid maps of both vectors used for in-vitro expression of CTCF protein 
These figures were reproduced with kind permission from Promega (A) and Qiagen (B). 
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2.4 Electrophoretic mobility shift assays 
To facilitate binding of CTCF to its binding site, the previously generated FAM-labelled DNA 
fragments were incubated together with CTCF-containing WGE in a binding buffer. Two 
different binding buffers were used. Both giving the same results but one of them produced 
more defined bands. The first buffer was prepared as described in Sambrook et al. 
(Sambrook and Russell, 2006). The buffer that improved banding was a modified version of 
the buffer used by Zielke et al. (Zielke et al., 2012). Both binding buffers consisted of a stock 
master mix and several other components that were added shortly before use. The 
composition of the stock master mixes are given in Table 8 and the composition of the final 
binding buffers are given in in Table 9. 
 
20x Stock master mix defined by 
Sambrook et al. 
Modified 10x stock master mix defined by 
Zielke et al. 
1 M KCL 5 % Nonidet P40 
400 mM HEPES-KOH pH 7.9 500 mM KCl 
40 mM MgCl2 100 mM Tris-HCl pH 7.5 
0.4 mM Zn(O2CCH3)2 (zinc acetate)  
10 mM DTT  
Table 8) Stock master mixes used in EMSA 
The master mix of Sambrook et al. was stored at 20°C whereas the modified 10x stock 
master mix from Zielke et al. was stored at room temperature 
 
Complete binding buffer defined by 
Sambrook et al. 
Complete modified binding buffer defined 
by Zielke et al. 
1 µl of the 20x stock master mix (Sambrook 
and Russell, 2006) 
1 µl of the modified 10x stock master mix 
(Zielke et al., 2012) 
0.4 µl of 1 µg/µl poly(deoxyinosinic-
deoxycytidylic) acid sodium salt 
1 µl of 1 µg/µl poly(deoxyinosinic-
deoxycytidylic) acid sodium salt 
4 µl of 50 % glycerol 1 µl of 50 % glycerol  
2 µl of 20 % ficol 400 2.5ul of 20 % ficol 400 
2 µl of labelled DNA fragment 2 µl of labelled DNA fragment 
2 µl of CTCF containing T7 WGE 1 µl of CTCF containing SP6 WGE 
8.6 µl ddH2O 4 µl ddH2O 
 0.4 µl protease inhibitor cocktail 
 0.1 µl of 100 mM PMSF 
 0.01 µl of 100 mM DTT 
Overall volume: 20 µl Overall volume: 10 µl 
Incubation time: 90 minutes Incubation time: 60 minutes 
Incubation temperature: 4°C  Incubation temperature: room temperature 
Table 9) Reaction mixes and incubation conditions of both EMSA setups 
The setup using modified buffer defined by Zielke et al. gave the highest quality data.  
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After incubation of the binding reactions the samples were loaded on 4.5 % native 
polyacrylamide gel. When preparing the gels it was made sure that all traces of ionic 
detergent were removed from the glass plates to avoid interference with the gel shift 
reaction. The gels were 1.5 mm thick and had 15 wells. Using a thick gel improved banding 
because the lack of a stacking gel caused the band to be as thick as the filling level of the 
well. A low filling level therefore resulted in sharper bands. When the gel had settled, the 
wells were labelled with a permanent marker. This was important since the samples did not 
contain any loading dye and it was therefore difficult to distinguish filled from empty wells. 
The gel casting and running equipment was the Mini-PROTEAN® Tetra Cell from BioRad 
with its accessories. The details of the gel composition as well as the running conditions can 
be found in Table 10.  
Each fragment was incubated in 3 different conditions. The first condition included no WGE 
at all to ensure that the fragment showed a single band. The second condition included 
WGE in which luciferase was expressed. This ensured that no shift resulted from the 
components of the WGE. The third conditions contained WGE in which CTCF was 
expressed. Hence testing a single fragment occupied 3 wells of the gel. Each gel was loaded 
with two control fragments. The first was a positive control fragment of the C-myc 
promoter that was previously used in CTCF EMSA (Vetchinova et al., 2006, Filippova et al., 
1996). The second was a fragment of the BPV1 genome containing no predicted CTCF 
binding site. Thus 6 out of the 15 wells of the gel were occupied with controls, leaving 9 
wells which were sufficient to test 3 fragments. The gels were run in 0.5x TBE (1x TBE 
buffer: 89 mM Tris, 89 mM boric acid and 2 mM EDTA). The running conditions were 
different for the two experimental setups and can be found in Table 10. When the run was 
finished the gels were taken out of the glass plates and FAM fluorescence at 520 nm was 
detected directly from the gels using a Typhoon FLA 7000 (GE Healthcare Life Sciences). 
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Components and specifications Volume and details 
40 % polyacrylamide with a ratio of acrylamide to 
bisacrylamide of 29 to 1. 
1.4 ml 
5x Tris-borate-EDTA buffer (TBE) 1.25 ml 
10 % ammoniumpersulfate (APS) 75 µl 
TEMED 12.5 µl 
ddH2O 9.6 ml 
Thickness 1.5 mm 
Comb 15 wells 
Running buffer 0.5x TBE 
Running conditions for the buffer defined by Sambrook 
et al. 
45 minutes at 150 V, on ice 
Running conditions for the modified binding buffer 
defined by Zielke et al. 
35 minutes at 150 V, room 
temperature 
Table 10) Composition and specifications of native polyacrylamide gels used for EMSA 
The volumes given are for a single BioRad mini-gel of 1.5mm thickness. The gels needed to 
be prepared fresh to ensure good EMSA quality. 
 
 
2.5 Investigation of HPV18 mutations using a 60 bp probe 
The FAM-labelled probes were delivered in the form of two complementary 
oligonucleotides that needed to be annealed before use. This was done by adding 
equimolar amounts of each oligonucleotide to a binding buffer consisting of 10 mM Tris-HCl 
pH8, 50mM NaCl and 1mM EDTA. This reaction mix was placed into a water bath of 98°C 
which was switched off and cooled down slowly overnight. The next morning the probes 
were ready for use. The EMSA using the probe was done as described the EMSA section 
with a few alterations. For the binding reaction 400 fmol of the probe was added to the 
binding reaction mix for each well. The native acrylamide gel was run at 150 V for 20 
minutes. The positive control probe had been used in EMSA before (Bell et al., 1999) and 
the sequences of both probes are shown below 
 
Positive control probe: 
5’-AGGCGCGCCCCCAGGGATGTAATTACGTCCCTCCCCCGCTAGGGGGCAGCGGCGCGCCT-3’ 
 
HPV18 binding site 2990 probe: 
5’-GGCATACAGACATTAAACCACCAGGTGGTGCCAGCCTATAACATTTCAAAAAGTAAAGCA-3’ 
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2.6 Bradford assay 
Bradford assays were used to quantify the protein concentration of lysed human foreskin 
keratinocyte (HFK) samples in order to normalise the loading of polyacrylamide gels for 
western blotting. A 96 well plate setup was used and a standard curve was created using 
solutions of Bovine Serum Albumin (BSA) protein in concentrations of 0.9 mg/ml to 0.2 
mg/ml in steps of 0.1 mg/ml. The Bradford reagent was prepared by mixing 1 part Bradford 
reagent with 4 parts ddH2O. Each cell lysate was diluted 1:10. From the diluted lysates and 
the standard curve samples, 10 µl were pipetted into a well and 200 µl of Bradford reagent 
were added. All samples used were loaded in duplicate. Bradford reagent and samples 
were mixed by pipetting up and down. Subsequently this mixture was incubated at room 
temperature for 20 minutes and then analysed using a spectrophotometer at 595nm 
(BioRad). If a sample was outside the range of the standard curve the experiment was 
repeated using a more suitable dilution of this sample. 
 
2.7 Western blotting 
Western blotting was used to confirm the presence of in vitro generated CTCF and to 
compare gene expression in methylcellulose differentiated keratinocytes. Before the cell 
samples could be loaded on a gel they were lysed 300 µl of either SDS lysis buffer or urea 
lysis buffer (Table 11). The protein content of methylcellulose differentiated cells was 
determined by a Bradford assay according to the manufacturer’s instructions. A normalised 
amount of cell lysate (40 µg) was mixed with loading buffer (Table 11) and heated to 99°C 
for 5 minutes. After the heat-denaturation the samples were loaded on a denaturing 
polyacrylamide gel. The samples of in vitro generated CTCF did not contain any cells and 
could therefore be directly mixed with SDS loading buffer, heated and loaded on the gel. 
The percentage of the gel used was depending on the protein to be analysed. The gel 
compositions can be found in Table 12. The gel apparatus used was the Mini-PROTEAN® 
Tetra Cell from BioRad and the gels were run for 25 to 60 minutes at 150 V depending on 
the percentage of the gel. The pre-stained protein markers used were Protein Marker IV 
and V from Peqlab. After running, the proteins in the gels were transferred to a PVDF 
membrane. This procedure was done using the Mini Trans-Blot® Module from BioRad at 
400 mA for 90 minutes. The composition of the transfer buffer used is shown in Table 13. 
Afterwards the membrane was briefly washed in TBS/T before it was blocked with 5 % milk 
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dissolved in TBS/T for 45 minutes. Subsequently the appropriate amount of primary 
antibody (Table 14) in 10 ml of 5 % milk was applied to the membrane over a 1 hour 
incubation while shaking. The primary antibody was poured off and the membrane was 
washed in TBS/T 5 times for 7 minutes each. Afterwards the secondary antibody (in 10 ml 
of 5 % milk) was applied. Subsequently the blots were washed 5 times with TBS/T, each 
wash taking about 7 minutes. After washing the detection reagent SuperSignal West Dura 
Chemiluminescent Substrate (GE Healthcare Life Sciences) was used according to the 
manufacturer’s instructions. Afterwards the membrane was analysed using a LAS 3000 
(Fujifilm). Exposure time was chosen according to the strength of the signal and 
normalisation of protein content was confirmed by Ponceau staining after the transfer step 
and western blotting for Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
 
SDS lysis buffer Urea lysis buffer Loading buffer 
1 % SDS 9 M Urea 32.9 mM Tris-HCl, pH 6.8 
50 mM Tris-HCl, pH 7.4 50 mM Tris-HCl, pH 7.4 1.05 % SDS 
5 mM DTT 5 mM DTT 13.15 % glycerol 
1:50 protease inhibitor 
cocktail (PIC) added before 
use (Sigma-Aldrich, P8340) 
1:50 protease inhibitor 
cocktail (PIC) added before 
use (Sigma-Aldrich, P8340) 
0.005 % bromophenol blue 
Table 11) Part 1 of buffers used for western blotting 
The buffers are given in the concentrations at which they were used. 
 
Components Stacking gel Resolving gel [8 %] 
30 % polyacrylamide-bisacrylamide 
mixture in a ratio of 37.5 to 1. 
500 µl 2.65 ml* 
Tris-HCl 375 µl (1 M, pH 6.8) 2.5 ml (1.5 M, pH 8.8) 
10 % SDS (sodium dodecylsulfate) 30 µl 100 µl 
10 % APS (ammoniumpersulfate) 30 µl 100 µl 
TEMED (N,N,N′,N′-
Tetramethylethylenediamine) 
3 µl 10 µl 
ddH2O 2.05 ml 4.65 ml 
Table 12) Composition of denaturing polyacrylamide gels 
*The amount of ddH2O and polyacrylamide-bisacrylamide mixture was adjusted to produce 
the desired percentage of the gel. 
 
SDS running buffer Transfer buffer TBS/T 
25 mM Tris-HCl, pH 8.3 25 mM Tris-HCl, pH 8.3 50 mM Tris-HCl, pH 7.6 
192 mM glycine 192 mM glycine 150 mM NaCl 
0.1 % SDS 5 % methanol 0.05 % Tween 20 
Table 13) Part 2 of buffers used for western blotting 
The buffers are given in the concentrations at which they were used. 
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Antibody Supplier Dilution 
Secondary 
antibody 
Protein 
MW [kDa] 
Percentage 
acrylamide-
bisacrylamide [%] 
CTCF Abcam (#ab70303) 1:1000 rabbit 82 (130)* 8 
E2 Thierry Lab 1:1000 rabbit 42 10 
E1^E4 r424** 1:3000 rabbit 10 15 
E6 
Santa Cruz  
(#sc-365089) 
1:200 mouse 18 12 
E7 Abcam (#ab100953) 1:100 mouse 12 15 
Loricrin Covance (#AF 62) 1:2000 rabbit 26 12 
p53 D01** 1:100 mouse 53 10 
GAPDH Santa Cruz (#32233) 1:3000 mouse 37 12 
Table 14) Antibodies used for western blotting 
*CTCF is a protein of 82 kDa but migrates at 130 kDa. **Produced in the University of 
Birmingham. 
 
 
2.8 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to analyse the DNA fragments used for EMSA, to 
confirm the template plasmids for fragment generation, to analyse the single steps of the 
site-directed mutagenesis procedure and to confirm DNA shearing of ChIP samples. Agarose 
was dissolved in TBE buffer (89 mM Tris-HCl, 89 mM boric acid and 2 mM EDTA. Final pH: 
8.3) using a microwave. The percentage of an agarose gel was dependent on the size of the 
fragment to be analysed. Small fragments of 200bp required about 1.6 % agarose whereas 
plasmid-sized DNA was analysed on a 0.6 % gel. Ethidium bromide in the concentration of 
0.8 µg per millilitre of gel was added to the solution after it had partly cooled down. 
Subsequently the gel was poured in a cast and left to set. Before loading the gel the DNA 
samples were mixed with 6x loading buffer containing 30 % glycerol and 0.25 % 
bromophenol blue. The gels were then inserted in an Agagel Mini Apparatus from Biometra 
and run at 120 V for 1 hour. DNA ladders used include Hyperladder II, IV and V (Bioline) as 
well as lambda HindIII ladder (Thermo Scientific).  
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2.9 Transformation and amplification of plasmids 
Commercially available Escherichia coli (E.coli) JM109 were used for the transformation of 
plasmids. 33 µl of the chemically competent E.coli suspension was supplemented with 0.5 
µl of plasmid solution (50-300 µg/ml) prior to incubating the mixture on ice for 20 minutes. 
Subsequently the samples were heated to 42 °C for 45 seconds and then chilled on ice for 5 
minutes. To the chilled cells 100ul of Luria Bertani broth (LB) were added followed by 
incubation of the samples at 37 °C while shaking for 1 hour. The incubated samples were 
spread on agar plates containing the appropriate antibiotic for selection of the plasmid and 
incubated at 37 °C overnight. Single colonies were picked the next morning to inoculate 5 
ml of LB medium to grow the culture overnight at 37 °C while shaking. Subsequently 
glycerol stocks were prepared by mixing 0.75 ml of the culture with 0.75 ml of 50 % glycerol 
solution before freezing the cells at -80 °C. The remaining culture was used to extract the 
plasmids using the QIAprep Spin Miniprep or Maxiprep kit from Qiagen according to the 
manufacturer’s instructions. The plasmids purified this way were checked for sequence by 
restriction digests or direct sequencing. Throughout the transformation procedure a 
negative and a positive control was used. No plasmid was added to the negative control 
cells so these cells had no antibiotic resistance. The positive control cells were transformed 
with a known functional plasmid. Luria Bertani broth was composed of 10 g/L Tryptone, 5 
g/L Yeast Extract and 5 g/L NaCl. 
 
2.10 Chromatin immunoprecipitation 
The ChIP-IT® Express Enzymatic kit from Active Motif was used according to the 
manufacturer’s instructions with small deviations. In brief, un-differentiated HFK containing 
wild type and HPV18 genomes were grown to 70-80 % confluency, crosslinked for 3 
minutes with 1 % formaldehyde diluted in culture medium, quenched with glycine for 5 
minutes and harvested by scraping in 2ml PBS. The cells were then pelleted by gentle 
centrifugation (720 RCF at 4°C), supplemented with 1 µl PMSF (100 mM) and frozen at -
80°C. The cells were thawed on ice and incubated in 1 ml lysis buffer for 45 minutes before 
douncing them on ice 270 times. The douncer used was the Kimble-Kontes part no. 885302-
0002 with pestle B. The release of nuclei during the douncing process was monitored 
microscopically. After douncing the nuclei were pelleted (2,400 RCF, 10 minutes at 4°C) and 
resuspended in 350 µl digestion buffer. After 5 minutes of incubation at 37°C, 17 µl of 
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restriction enzyme solution (200 U/ml) were added to randomly cut the exposed DNA in-
between nucleosomes. The digestion reaction was stopped after 10 minutes by adding 7 µl 
EDTA (0.5 M). This way the majority of the DNA fragments generated were between 150 
and 450 bp in size. The debris in this chromatin sample was removed by centrifugation 
(18,000 RCF, 10 minutes at 4°C) and the chromatin-containing supernatant was used for 
ChIP. A sample of this chromatin served as input sample and for determination of the 
chromatin concentration. 
To determine shearing efficiency and chromatin concentration the DNA had to be purified. 
The crosslinks between proteins were reversed by incubating 50 µl of the chromatin sample 
(supplemented with 150 µl ddH2O and 10 µl 5 M NaCl) at 65°C overnight. RNA was removed 
from the sample using 1 µl RNase A (15 min at 37°C) and proteins were removed using 10 µl 
of Proteinase K solution (42°C for 1.5 hours). The DNA was purified using 200 µl phenol 
chloroform solution followed by centrifuging the sample for 5 minutes at 18,000 RCF (room 
temperature). The supernatant was taken off and supplemented with 20 µl sodium acetate 
(3 M, pH 5.2) and 500 µl ethanol (100 %) before incubating the sample at -80°C for at least 
1 hour. Subsequently the sample was spun (4°C) at 18,000 RCF and the pellet was air dried 
before it was dissolved in 30ul ddH2O. The DNA concentration was assessed using the 
Nanovue (GE Healthcare Life Sciences) and the shearing efficiency was assessed by agarose 
gel electrophoresis. 
For the ChIP reaction, 15 µg of chromatin was supplemented with protease inhibitors (1 µl), 
protein G coated magnetic beads (25 µl), ChIP buffer 1 (10 µl), antibody suitable for ChIP (3 
µl) and ddH2O (filled up to 100 µl) followed by incubation overnight at 4°C on a rotator 
(Voss Model 4400). The beads were then washed once with 800 µl ChIP buffer 1 and twice 
with 800 µl ChIP buffer 2 followed by elution using 50 µl elusion buffer AM2. After 15 
minutes of incubation on an end-to-end rotator, 50 µl reverse crosslinking buffer were 
added to the samples and the beads were removed. At this point the input samples (10 µl 
chromatin samples) were supplemented with 2ul NaCl and 88 µl ChIP buffer 2. ChIP 
samples and input samples were heated to 95°C for 15 minutes using the thermocycler T 
personal from Biometra. Subsequently 2 µl of proteinase K were added followed by 
incubation at 37°C for 1 hour to digest remaining proteins in the sample. Proteinase K was 
then deactivated using 2 µl Proteinase K stop solution and the samples were cleaned up 
using the GenElute™ PCR Clean-Up kit (Sigma-Aldrich). In the final step of the clean-up 
process, the ChIP samples were eluted with 300 µl of ddH2O. At this stage the cleaned up 
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qPCR reaction mix per well (10 µl) 
5 µl SsoFast EvaGreen supermix (BioRad) 
0.25 µl forward primer (10 pmol/µl) 
0.25 µl reverse primer (10 pmol/µl) 
2 µl ddH2O 
2 µl template 
Table 15) qPCR reaction mix 
samples were ready for ChIP analysis. The polyclonal anti-CTCF antibody (pAb) was 
purchased from Active Motif, catalogue number 61311. The control antibody used was anti-
FLAG antibody (FLAG M2 monoclonal, Sigma-Aldrich, F1804). 
 
2.11 Analysis of CTCF binding using quantitative real time PCR 
The purified ChIP samples were analysed using qPCR. The reaction mix for qPCR (Table 15) 
was prepared using the QIAgility pipetting robot (Qiagen). All reactions were set up in 
duplicate and every run was repeated at 
least three times. The primer pairs used are 
given in Table 16. The master mix used was 
the SsoFast EvaGreen supermix from BioRad 
which contained a polymerase that 
amplified DNA at the melting temperature 
of the primers. Thus no separate amplification step was needed in the temperature cycles. 
The qPCR analysis was done using the Rotor Gene (Qiagen) with the following temperature 
cycles: 
 
- 5 minutes denaturing at 95°C 
- 60 s anneal/extend 60°C 
- 15 s melting 95°C 
- melting curve: gradual temperature increase from 60 °C to 99 °C in steps of 1 °C  
 
The melting curve of each primer pair was checked to ensure that a single target was 
amplified. The standard curves were generated in duplicates from 7 serial 1:5 dilutions of 
the wild type HPV18 input sample and their formulas were automatically calculated by the 
software of the qPCR machine. However the standard curves were checked manually for 
the hallmarks of a reliable qPCR which are a slope close to -3.33 and an R2 value close to 1. 
Standard curves for each primer pair were imported into each experimental run with the 
same experimental setup. Each imported standard curve was adjusted to each particular 
run with the help of a control sample that was run with every qPCR experiment, including 
the original experiment to generate the standard curve. All qPCR experiments used the 
45 cycles 
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same cycle threshold, so the Ct value of the control sample could be used to adjust the 
imported standard curve to each particular run. 
Importing standard curves and primer efficiencies this way is common practice in many 
modern qPCR systems like the systems from Qiagen, Biorad and Applied Biosystems. This 
can be looked up in the manuals of these systems. The manual for the qPCR system used 
here can be found at http://www.qiagen.com/knowledge-and-support/resource-
center/resource-download.aspx?id=bf47fa7f-6994-45af-b3bb-6e25b3ea7b17&lang=en.  
The amount of template present in each ChIP sample could be quantified based on its Ct 
value. For normalisation the quantification of each fragment was expressed as a percentage 
of the input sample. A range of primer pairs across the whole genome was used to analyse 
the ChIP samples. If a local peak in the samples precipitated with anti-CTCF antibody 
appeared that was not seen in the FLAG samples a CTCF binding site was confirmed. 
 
Fragment 
start 
Fragment 
end 
Fragment 
length 
Primer 
name 
Predicted binding sites 
on fragment 
Tm 
[°C] 
Sequence 5' to 3' 
789 890 102 844 FW 5.PWM 844 score 9.98 59,5 AGTGTGAAGCCAGAATTGAGC 
789 890 102 844 RV 5.PWM 844 score 9.98 60,0 ACCACGGACACACAAAGGA 
1165 1256 92 1205 FW E+1 1205 59,8 TTTAAAACGAAAGTTTGCAGGAG 
1165 1256 92 1205 RV E+1 1205 59,3 
CTTGTAACCGTGGACTTAACTCT
G 
2167 2251 85 2200 FW none 59,2 TTATAGGCGAGCCCAAAAAC 
2167 2251 85 2200 RV none 59,3 CCAATCTCCCCCTTCATCTAT 
2968 3069 102 2990 FW 6.PWM 2990 score 23.4 59,4 GGGAACATGGCATACAGACA 
2968 3069 102 2990 RV 6.PWM 2990 score 23.4 60,1 CTTGTAGGGCCATTTGCAGT 
3519 3620 102 3550 FW 
E-2 3488 and 6.PWM 3621 
score 14.2 
59,3 GGCACCGCAAAGACCTAC 
3519 3620 102 3550 RV 
E-2 3488 and 6.PWM 3621 
score 14.2 
60,2 ACCGAGAAGTGGGTTGACAG 
4442 4536 95 4505 FW 
1.PWM 4505 score 12.2 
and 5.PWM 4538 score 
10.5  
59,7 GGTCGTACAGGGTACATTCCA 
4442 4536 95 4505 RV 
1.PWM 4505 score 12.2 
and 5.PWM 4538 score 
10.5  
59,3 GGGCCCACAGGTTCAATA 
5405 5506 102 5475 FW E-1 5475 59,4 ACGGTCCCTTTAACCTCCTC 
5405 5506 102 5475 RV E-1 5475 59,2 GGCCGTGGGTGATACAAT 
5712 5811 100 5768 FW 1.PWM 5768 score 12.9 59,0 TTTTATCATGCTGGCAGCTC 
5712 5811 100 5768 RV 1.PWM 5768 score 12.9 59,2 
CAGAAACCTTAGGAATATCCTGC
T 
6371 6462 92 6400 FW none 59,6 GCAGCTTTTTGCTAGGCATT 
6371 6462 92 6400 RV none 59,8 CACGCATACCTGTGCCTTTA 
7746 7845 100 7800 FW none 59,1 ACTTTCATGTCCAACATTCTGTCT 
7746 7845 100 7800 RV none 59,5 ATGTGCTGCCCAACCTATTT 
Table 16) Primers used for qPCR 
The templates were ChIP samples containing the DNA of HPV18, accession number 
AY262282.1.  
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Formular for primer efficiency: 
Primer efficiency (as factor) =   
  
      
2.12 Quantification of viral episomes 
Viral episomes were quantified using qPCR. The qPCR procedure is identical with the one 
described in the previous section. Modified versions of two mathematical methods were 
used for this quantification, the Pfaffl method and the Livak method (Pfaffl, 2001, Livak and 
Schmittgen, 2001). Those methods were originally designed for the quantification of cDNA 
from a test gene against a reference gene but they can also be used to determine the 
amount of viral genomes against the amount of a host allele. This is described in detailed in 
the results section and final formulas used are shown at the end of this section. Two primer 
pairs were needed, one targeting the viral episome and one targeting a single copy host 
locus, in this case the TLR2 locus (Gray et al., 2010). The primers chosen are shown in Table 
17. The templates used for the qPCR reaction with these primer pairs were extracted DNA 
from undifferentiated cells using the QIAamp DNA Mini Kit from Qiagen according to the 
manufacturer’s instructions, including all optional steps. 
 
Template Primer name Location Fragment 
length 
Sequence 5' to 3' Tm 
HPV18 AY262282.1 HPV18 Episome FW 2167-2251 85 TTATAGGCGAGCCCAAAAAC 59,2 
HPV18 AY262282.1 HPV18 Episome RV 2167-2251 85 CCAATCTCCCCCTTCATCTAT 59,3 
Human TLR2 locus Human TLR2 FW 1893-1957 65 GCCAGCAAATTACCTGTGTGA 61.08 
Human TLR2 locus Human TLR2 RV 1893-1957 65 GGCGGACATCCTGAACCT 61.05 
Table 17) Primers used for the determination of episome copy number  
A fragment of the single copy locus TLR2 as well as a fragment of the HPV18 episome is 
targeted. 
 
An important factor for calculating episome copy number is the primer efficiency of each 
primer pair used. The primer efficiency is the factor by which the amount of amplicon is 
increased with every cycle. Every sample was loaded in duplicate and every run was 
repeated at least three times. Standard curves for each primer pair were generated and 
imported as described in the previous section. 
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In the Livak method the primer efficiency from both primer pairs used is assumed to be 2, 
resulting in a simplified calculation. The Pfaffl method takes individual primer efficiencies 
into account. The primer efficiencies from both primer pairs used were calculated from the 
standard curve and happened to be 2 for both primer pairs. In this case Livak method and 
Pfaffl method yield the same result. Thus the Livak method was used as shown below. The 
relative copy numbers of host allele and the viral episome were calculated from the Ct 
values of the qPCR samples. These Ct values were determined using the same threshold for 
each primer pair. Note that the copy numbers calculated this way were given relative to the 
number of host alleles.  
 
Modified Livak method for the determination of the absolute episome copy number per 
host allele: 
 
                          
 
Modified Livak method for the determination of the ratio of C3 genomes to WT genomes: 
 
  ((                            ) (                          )) 
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2.13 Site directed mutagenesis of HPV18 
The site directed mutagenesis was carried out using the QuikChange II XL Site-Directed 
Mutagenesis Kit from Agilent Technologies. Small deviations from the manufacturer’s 
protocol were made. In brief, site directed mutagenesis primers were used that had three 
mismatches to the original sequence. These primers were very carefully designed to 
maintain a high melting temperature despite the mismatches while exhibiting a low degree 
of self-complementarity.  
The sequence of the primer used for mutating the CTCF binding site at nucleotide 2990 was 
5’-CAGACATTAAATCACCAGGTAGTGCCAGCCTATAACATCTCAAAAAGTAAAG-3’ and the 
sequence of the primer used for mutating the CTCF binding site at nucleotide 5475 was  
5’-CATTACCATCTACTACCGTTGTACGGCCCATTGTATCACCC-3’. The reverse primer for either 
reaction was the reverse complement of the mutagenesis primer.  
The mutagenesis reaction was done on the vector pGEM2 containing the HPV18 genome. 
This was a PCR reaction performed according to the instruction manual using the DNA 
polymerase PfuUltra HF which is suitable for amplification of large targets. This way the 
vector including the HPV18 genome could be amplified as a whole. Remaining template was 
digested using the methylation-specific nuclease DpnI, which digests the input template 
plasmid, but not plasmids that were amplified during the PCR reaction thus removing wild 
type plasmids from the PCR reaction. The mutated genomes were transformed into E.coli 
XL10-Gold ultracompetent cells and spread on an ampicillin-containing agar plate (100 
μg/ml). After incubation overnight at 37 °C single colonies were picked to inoculate 5 ml LB 
broth supplemented with 100 μg/ml ampicillin. After another incubation overnight at 37 °C 
with shaking (200 rpm), the plasmids from these samples were extracted using the QIAprep 
Spin Miniprep Kit from Qiagen. These plasmids were sent for sequencing and plasmids 
containing the correct mutations were used for re-ligation of the viral genome. 
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2.14 Re-ligation of HPV18 genomes 
Following site directed mutagenesis of the HPV18 genome cloned into pGEM2 vector, 
mutated plasmids were amplified in bacteria and purified using the QIAprep Spin Miniprep 
Kit (Qiagen). The purified plasmids were digested with EcoRI to separate the HPV18 DNA 
from the pGEM2 backbone. To facilitate this, the following components were combined in 
an Eppendorf tube: 10 µg of DNA of plasmid DNA, 2 µl of EcoRI (12 U/µl), 5 µl of Buffer H 
(Promega) and ddH2O up to 50 µl total volume. This reaction mix was incubated at 37°C 
overnight. The following day, 1 µl of this reaction mix was separated on an agarose gel to 
ensure complete digestion of the plasmid. A band of 8000 bp for the linearised HPV18 
genome was observed together with a band of approximately 2800 bp for the plasmid 
backbone pGEM2. The restriction enzyme was then heat inactivated by incubating the 
sample at 65°C for 20 minutes. Subsequently the sample was randomly ligated using T4 
ligase. The following components made up the ligation mix: 650 µl ddH2O, 180 µl 5x 
ligation buffer (Invitrogen) and 10 µl T4 DNA ligase (3 U/µl, Promega, M1801). This ligation 
mix was incubated overnight in the cold room in a water bath set to 16°C. Subsequently the 
ligation products were precipitated. To do this the ligation samples were split into two 
Eppendorf tubes and the following reagents were added: 600 µl isopropyl alcohol and 180 
µl of 5 M NaCl. The samples were then incubated at -80°C overnight. The next morning the 
ligation samples were spun down at 20,000 RCF for 30 minutes at 4°C and the supernatant 
was removed. The pellet was washed with 70 % ethanol followed by centrifugation at 
20,000 RCF for 15 minutes. The supernatant was discarded and the pellet was air dried 
before suspending it in in 12 µl Tris-EDTA buffer (10 mM Tris-HCl pH 8 and 1 mM EDTA). 
The ligation product was analysed by separating 1 µl of the sample on an agarose gel. The 
presence of many random ligation products was confirmed, one of which was the re-ligated 
circular HPV18 genome. The ligation products were stored at -80°C. 
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2.15 Immunohistochemistry 
Histological, paraffin-embedded slices of raft cultures were immersed in Histoclear for 10 
minutes to remove the paraffin. This was followed by a bath in 100 % industrial methylated 
spirits (IMS) for 5 minutes, 3 washes in tap water and a bath in 0.3 % H2O2 for 15 minutes 
followed by another 3 washes with tap water. Subsequently the slides were immersed in 1 
litre of antigen retrieval buffer (1 mM EDTA-NaOH pH 8.0 and 0.1 % Tween) and incubated 
overnight at 65 °C while stirring with a magnetic stirrer at 600 rpm. The next morning the 
slides were removed from the beaker and washed with tap water before blocking them 
with blocking buffer (20 % heat-inactivated goat serum (HINGS), 0.1 % BSA in PBS) for 1 
hour at room temperature. Slides were then incubated with primary antibody (in blocking 
buffer) at 4 °C overnight (Table 18). The rafts were washed three times with PBS and 
incubated with secondary antibody (in blocking buffer) at 37 °C for 1 hour. Subsequently 
the slides were washed three times in PBS and incubated with 0.1 µg/ml Hoescht stain 
diluted in PBS for 10 minutes at room temperature. Following the incubation the slides 
were then mounted with three drops of Fluoroshield (Sigma) and a 40x20 mm coverslip and 
dried overnight at 4 °C. Imaging was done using a Nikon E600 microscope fitted with a 20x 
objective and pictures were captured using a Nikon DXM1200F digital camera.  
 
Antibody Supplier Dilution 
factor 
Secondary 
antibody 
Colour 
E1^E4 IDII (Roberts Lab) 1:5 mouse 
red A594, green 
A488 
E1^E4 r424 (Roberts Lab) 1:2000 rabbit red A594 
Cyclin B1 H-433 Santa Cruz 1:100 rabbit red A594 
BrdU 
347580 Becton 
Dickinson 
1:1000 mouse green A488 
Loricrin PRB-145P Covance 1:1000 rabbit red A594 
Secondary AB 
green 488 
A11029, Invitrogen, 
Alexa 488 
1:1000 N/A green A488 
Secondary AB red 
594 
A11037, Invitrogen, 
Alexa 594 
1:1000 N/A red A594 
Table 18) Antibodies used for immunohistochemistry 
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3 Results 
3.1 Aim 
This study aims to map CTCF binding sites to the papillomavirus genome, validate them and 
determine the function of CTCF for the papillomavirus life cycle. 
3.2 Overview 
CTCF binding sites in the BPV1 DNA sequence were predicted using 3 different in silico 
prediction tools. The binding sites found were experimentally confirmed by electrophoretic 
mobility shift assays (EMSA) using in vitro translated CTCF and fluorescein amidite (FAM) 
labelled DNA fragments of 200bp containing the CTCF binding site of interest. After 
confirmation or refute of predicted sites, additional fragments covering regulatory 
sequences such as promoters and the LCR were tested alongside DNA fragments of the 
BPV1 genome that were predicted to not bind CTCF. A CTCF binding site map for BPV1 was 
then created. Having mapped the sites in the BPV1 genome, predictions were made for 8 
different HPV types. The binding sites found were tested by EMSA, giving rise to the 
creation of CTCF binding maps for all HPV types tested. Based on these binding maps a 
common binding pattern among HPV types was revealed. It was decided to mutate a 
particularly well conserved binding site in HPV18 at nucleotide 2990. This mutant was 
generated using site directed mutagenesis and the abrogation of CTCF binding was 
confirmed by EMSA. Mutant and wild type HPV18 were transfected into primary human 
foreskin keratinocytes (HFK) resulting in continuous cell lines. The binding of CTCF to the 
conserved CTCF binding site in these cell lines was confirmed using chromatin 
immunoprecipitation (ChIP) and the episome copy number over a time course was 
determined using quantitative real time PCR. Wild type and mutant HFK lines were 
differentiated in methylcellulose and viral gene expression upon differentiation was 
analysed by western blotting. Additionally Organotypic raft cultures grown from the HPV 
genome maintaining HFK lines were analysed and potential differences in morphology, 
gene expression and virus life cycle were monitored using immunohistochemistry and light 
microscopy.  
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3.3 Computer predictions of CTCF binding sites on 9 different PV 
types 
3.3.1 Predictions using version 1.0 of the CTCFBSDB tool and the Essex tool 
Predicting CTCF binding sites in various PV sequences was done using three different tools. 
The first tool was provided by the University of Essex and is based on EMSA-confirmed CTCF 
binding sites (link: http://bsproteomics.essex.ac.uk:8080/bioinformatics/ctcfbind.htm). It 
screens a target sequence against a database of known in vitro confirmed CTCF binding 
sites with a length of 10 nt. This programme works in two steps. The first step is to screen 
the sense strand of the input sequence for the motifs in the database. The second step is to 
search the antisense sequence of the input sequence for binding sites. The locations of the 
binding sites found in this second step are given in 5’ to 3’ direction of the antisense sense 
strand. This can be confusing due to the fact that all other predicted binding sites are given 
in 5’ to 3’ direction of the sense strand. Thus the results from this second step were 
corrected to unify the way of giving the location of predicted binding sites in 5’ to 3’ 
direction of the sense strand.  
The second tool was provided by the CTCF binding site database (CTCFBSDB, version 1.0 – 
current version available at http://insulatordb.uthsc.edu/) and utilises 4 different position 
weight matrices (PWM) for CTCF binding site prediction (Xie et al., 2007, Kim et al., 2007, 
Bao et al., 2008). During the course of this project there was a major update to the 
CTCFBSDB tool from version 1.0 to 2.0 which increased the number of PWM used to 6 
(Figure 14) (Ziebarth et al., 2013, Schmidt et al., 2012). Shortly after the update an 
important bug fix was also released. However, the early predictions were carried out using 
version 1.0 of the CTCFBSDB tool and there was no update or bug fix applied at that time. 
The inherent flaws of version 1.0 of the CTCFBSDB prediction tool were not known at the 
time. Hence the first half of this chapter only covers predictions with the Essex tool and 
version 1.0 of the CTCFBSDB tool which are later complemented and corrected with 
CTCFBSTDB tool 2.0 and the third prediction tool, Storm.  
The CTCFBSDB tool 1.0 screened for position weight matrices of 19-20bp in size (Kim et al., 
2007, Xie et al., 2007). Every predicted binding site was rated with a score. A high score 
indicates a good fit to the PWM. Version 1.0 of the CTCFBSDB prediction tool contained a 
bug that made it count line breaks in an input sequence as spacers and therefore gave 
incorrect binding site locations and occasionally false predictions. 
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Despite not being aware of 
this bug at the time, it was 
realised that the location of a 
motif given by the 
programme did not exactly 
match up with the actual 
location of the motif. A 
correction step was therefore 
performed to give the correct 
location of each motif found. 
In Table 19 the location given 
by the tool is shown as the 
“native” position. The column 
labelled “corrected position” 
shows the real position of the 
motif recognised by the tool. 
During the course of this 
project it was also discovered 
that the CTCFBSDB tool had 
an even more serious flaw 
than the inability of handling 
line breaks. It gave 
incomplete results. However 
it is important to show the 
results given by the early, 
flawed version of the tool because these results led to constructive criticism which in turn 
led to a workaround of the tool.  
Throughout this thesis, the naming of predicted binding sites found with either the 
CTCFBSDB or Essex tool follows a nomenclature system. The first character of the name 
always is a C or E, referring to the tool by which the binding site was predicted, so either C 
for the CTCFBSDB tool or E for the Essex tool, respectively. The second character is either a 
plus or a minus sign depending on whether the predicted binding site is on the sense (+) or 
antisense (-) strand. The third character is a number indicating the order of the binding site 
1st and 2nd PWM, names in tool: AC  EMBL_M1 and M2 
 
 
3rd PWM, name in tool: AC  REN_20 
 
 
4th PWM, name in tool: AC  MIT_LM2 
 
 
5th PWM, name in tool: AC  MIT_LM7 
 
 
6th PWM, name in tool: AC  MIT_LM23 
 
LM23 
AGCACCACCTGGTGGTA 
 
Figure 14) Position weight matrices of CTCF 
These PWM were used for predictions with the 
CTCFBSDB tool and Storm. Version 1.0 of the CTCFBSDB 
tool uses PWM 3-6 whereas version 2.0 and Storm use 
all PWM shown. There is no graphical representation of 
LM23 publicly available. The figures of each PWM were 
acquired with permission from the copyright holders 
(Schmidt et al., 2012, Kim et al., 2007, Xie et al., 2007). 
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on this particular strand. For example, the binding site E+2 is the second binding site on the 
sense strand that was found by the Essex tool. If binding sites are compared among 
different PV types, the virus type number is put in front of the name of the binding site, e.g. 
18C-1 for the first binding site on the antisense strand found with the CTCFBSDB tool in the 
HPV18 sequence.  
The results of predictions with the Essex tool and CTCFBFSDB 1.0 are summarised in Table 
19 and Table 20. All 9 PV sequences screened are about 8kb in size and contain up to 12 
predicted CTCF binding sites per sequence. The CTCFBSDB tool and the Essex tool rarely 
agree on particular binding sites, indicating the complexity and difficulty of predicting CTCF 
binding sites in silico. The CTCFBSDB tool frequently found overlapping motifs. If this was 
the case only the highest scoring motif is shown in the tables. Table 19 shows predicted 
binding sites in BPV1 before and after the correction process. Two motifs were found by 
the CTCFBSDB 1.0 tool compared to 9 motifs found by the Essex tool. All of these predicted 
binding sites were found in an area from nucleotide 2427 to 6682. This leaves a large area 
of about 3700bp including the whole LCR of BPV1 devoid of predicted motifs. Table 20 
shows the results from screening 8 different HPV types with already corrected locations of 
the motifs. Almost all other PV types tested exhibited no predicted binding motifs in the 
LCR with the only exception of HPV38. Furthermore 3 out of 4 important high risk viruses 
harboured a very high scoring motif in the vicinity of nucleotide 3000. The low risk viruses 
HPV6b and HPV11 had a motif with similar score predicted in the vicinity of nucleotide 
5400. Most of the other PV tested also had a predicted binding site in this area. However 
the binding sites in this area on PV other than HPV6b and HPV11 were mostly predicted by 
the Essex tool which does not give a score, making them difficult to compare without 
experimental data. Predicting CTCF binding sites in beta-HPV types revealed an 
accumulation of binding motifs in the vicinity of nucleotide 3600. Overall the Essex tool 
found substantially more motifs than the CTCFBSDB tool. The amount of motifs identified 
by both tools independently was low. 
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Name of 
binding site 
Prediction 
tool 
Orientation 
"Native" 
start 
position 
"Native" 
end 
position 
Correct 
start 
position 
Correct 
end 
position 
Motif identified by tool 
Reverse complement motif 
(only if BS was found on 
negative strand) 
Score (only 
CTCFBSDB) 
C-1 CTCFBSDB antisense strand 3722 3741 3671 3690 TGAACCAGGTGGTGGTGCAG CTGCACCACCACCTGGTTCA 10,29 
C+1 CTCFBSDB sense strand 6682 6700 6589 6607 TTAACAGTGGGGGACAATA N/A 5,86 
E+1 Essex sense strand 3025 3034 3025 3034 CGCACAGAGG N/A N/A 
E+2 Essex sense strand 2427 2436 2427 2436 CAGGCAGAGG N/A N/A 
E+3 Essex sense strand 4535 4544 4534 4543 CGTCCAGGGG N/A N/A 
E-1 Essex antisense strand 7275 7284 663 672 CCGGGAGAGG CCTCTCCCGG N/A 
E-2 Essex antisense strand 5541 5550 2397 2406 CCAGGAGGGG CCCCTCCTGG N/A 
E-3 Essex antisense strand 6711 6720 1227 1236 CCTGGAGGGG CCCCTCCAGG N/A 
E-4 Essex antisense strand 2747 2756 5190 5199 TGTGTAGGGG CCCCTACACA N/A 
E-5 Essex antisense strand 3162 3171 4775 4784 TGCAGAGGGG CCCCTCTGCA N/A 
E-6 Essex antisense strand 3793 3802 4144 4153 TGAGCAGGGG CCCCTGCTCA N/A 
Table 19) CTCF binding site predictions in the BPV1 reference sequence 
The accession number of the BPV1 sequence screened is AB626705.1. Two binding sites were found using the CTCFBSDB tool 1.0. Native locations of 
the motifs found by the CTCFBSDB tool do not match up with the actual locations of the motifs in the sequence and therefore need to be corrected. 
The corrected locations are given in the columns next to the native locations. The Essex tool predicted 9 binding sites in this sequence and none of 
them matched up with the binding sites found with the other tool. Locations of binding sites found on the antisense strand with the Essex tool also 
needed to be corrected to unify the way of giving the location of a motif in 5’ to 3’ direction of the sense strand. The column next to the native 
locations shows the locations of the binding sites relative to the sense strand. 
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Class PV 
Corrected motif 
location 
Prediction 
tool 
Name Motif identified by tool 
Score (only 
CTCFBSDB) 
High risk 
HPV18 
2990 CTCFBSDB 18C+1 AAACCACCAGGTGGTGCCAG 23,44 
1205 Essex 18E+1 CCATTAGGGG N/A 
5474 Essex 18E-1 CATACAGAGG N/A 
3488 Essex 18E-2 CGGTGAGGGG N/A 
HPV16 
2916 CTCFBSDB 16C+1 TAACCACCAAGTGGTGCCAA 20,05 
1283 CTCFBSDB 16C+2 AACTCAGCAGATGTTACAGG 10,18 
6512 CTCFBSDB 16C-1 GAACCACTAGGTGTAGGAA 8,61 
6127 Essex 16E+1 CCTATAGGGG N/A 
5119 Essex 16E-1 CGCCTAGAGG N/A 
HPV16 
114/K 
2917 CTCFBSDB 114kC+1 TAACCACCAGGTGGTGCCAA 27,63 
6128 Essex 114kE+1 CCTATAGGGG N/A 
5120 Essex 114kE-1 CGCCTAGAGG N/A 
HPV31 
2413 CTCFBSDB 31C+1 AATGCACTAGATGGCAACC 14,68 
1278 CTCFBSDB 31C+2/E+3 AACGCAGCAGATGGTACAGG 13,98 
2332 CTCFBSDB 31C+3 CAACCACTGGCTGATGCTAA 8,34 
5179 Essex 31E+1 CCTTTAGGGG N/A 
1093 Essex 31E+2 CATGCAGAGG N/A 
1294 Essex 31C+2/E+3 CAGGTAGAGG N/A 
885 Essex 31E+4 TGGGGAGGGG N/A 
Low risk 
HPV6b 
5425 CTCFBSDB 6bC-1/E-1 GCAGCCACAAGAGGGTGCAT 17,03 
5018 CTCFBSDB 6bC-2/E+1 CTATCACTAGATGATACCA 7,53 
4987 Essex 6bC-2/E+1 CCTATAGAGG N/A 
1357 Essex 6bE+2 CATACAGAGG N/A 
6099 Essex 6bE+3 TGGGCAGGGG N/A 
5431 Essex 6bC-1/E-1 CCACAAGAGG N/A 
6264 Essex 6bE-2 CCCAAAGGGG N/A 
7206 Essex 6bE-3/E-4 CGAATAGAGG N/A 
7257 Essex 6bE-3/E-4 CGTTTAGGGG N/A 
4790 Essex 6bE-5 TGTGCAGGGG N/A 
HPV11 
5416 CTCFBSDB 11C-1/E-1 GCAGCCACTAGAGGGTGCAG 20,46 
6311 CTCFBSDB 11C-2 GTTCCAACGGGGGGCAGTC 13,21 
1357 Essex 11E+1 CATAGAGAGG N/A 
5422 Essex 11C-1/E-1 CCACTAGAGG N/A 
4781 Essex 11E-2 TGTGTAGGGG N/A 
4058 Essex 11E-3 TGCAAAGGGG N/A 
Beta HPV 
HPV38 
3540 CTCFBSDB 38C+1/E+5 TCCCCCACCAGGGGAAGGAG 3,67 
3571 CTCFBSDB 38C+2 GGGACAGCAGAAGGCGGGG 5,77 
1331 CTCFBSDB 38C+3 CCGGCAGCAGAGGGTGATAT 15,57 
117 CTCFBSDB 38C-1 CTACCACAAGCGGTTGCTTG 10,87 
254 Essex 38E+1 CCTGTAGAGG N/A 
3520 Essex 38E+2 CCTCCAGAGG N/A 
4454 Essex 38E+3 CCTGGAGAGG N/A 
3487 Essex 38E+4 CCAACAGGGG N/A 
3544 Essex 38C+1/E+5 CCACCAGGGG N/A 
HPV8 
3642 CTCFBSDB 8C-1/E-2/E-4 TTCGCCTAGAGGTGGCTGTA 12.60 
2383 CTCFBSDB 8C-2/E-1 CAGCCAGCAGGGGTCTGTCA 12.65 
4037 CTCFBSDB 3C-3 CCATGACCACGTGGTGCTAA 6.50 
7361 Essex 8E+1 CCGTCAGGGG N/A 
2390 Essex 8C-2/E-1 CCAGCAGGGG N/A 
3650 Essex 8C-1/E-2/E-4 CGCCTAGAGG N/A 
2346 Essex 8E-3 CACCAAGAGG N/A 
3644 Essex 8C-1/E-2/E-4 CCTAGAGGTGGCTG N/A 
Table 20) Prediction of CTCF binding sites for various HPV types 
The first three HPV types in this list have a binding site with a high score in the vicinity of nucleotide 
3000. Both low risk HPV types tested harbour a binding site with a particularly high score around 
nucleotide 5400. The beta viruses have many CTCF binding sites predicted around nucleotide 3600. 
The accession numbers of sequences screened are: HPV18: NC_001357.1 (identical sites found in 
AY262282.1), HPV16: NC_001526.2, HPV16-114/k: EU118173.1, HPV31: J04353.1, HPV6b: 
NC_001355.1, HPV11: FR872717.1, HPV38: U31787.1 and HPV8: M12737.1. 
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3.3.2 The CTCFBSDB tool: Update, bug fix and remaining flaws 
During the experimental confirmation of previously predicted binding motifs, a major 
update to the CTCFBSDB tool from version 1.0 to 2.0 was released. However the bug of 
including line breaks as spacers found in version 1.0 still persisted in version 2.0. Therefore, 
I reported the bug to Dr. Jesse Dylan Ziebarth from the University of Tennessee Health 
Science Centre, USA, who currently works on the tool (Ziebarth et al., 2013). When the bug 
was discussed with Dr. Ziebarth, a more serious flaw of the tool became apparent. The tool 
only gave the best match of an input sequence to every single PWM and ignored all lesser 
matches. Hence it was giving incomplete results, especially when screening large sequences 
containing several CTCF binding motifs. This neglect of lesser binding sites had not been 
indicated anywhere on the CTCFBSDB website. Also a new flaw was introduced in version 
2.0 of the CTCFBSDB tool 
through the implementation 
of two more PWM published 
by Schmidt et al. (Schmidt et 
al., 2012). These PWM are 
used as if they 
independently determine 
CTCF binding motifs. 
However Schmidt et al. 
showed that those two 
PWM work together to 
define single CTCF binding sites as illustrated in Figure 15. Motifs matching the primary 
PWM can define a binding site on their own but the presence of the secondary binding 
motif a few nucleotides downstream of the first motif enhances the probability of CTCF 
binding. On the other hand the binding sites identified by the secondary PWM alone are 
meaningless without a binding site of the first PWM close by. This fact is not taken into 
account by the tool. Since the CTCFBSDB tool only showed the best match for each PWM it 
only gave one single match to the secondary PWM. Matches to this PWM are very common 
due to its small size of 9 nt which makes a single hit for this PWM not helpful. Considering 
the remaining flaws of the tool it was decided to predict CTCF binding sites with an 
independent method using the programme Storm.  
 
 
Figure 15) PWM of CTCF published by Schmidt et al. 
This recently published position weight matrix consists of 
two separate motifs, both contributing to a single CTCF 
binding site. The distance between the mid-points of 
each motif is 20-21 base pairs in humans. Additionally 
Motif is able to define a CTCF site even in the absence of 
motif 1. Figure from Schmidt et al., reproduced with 
permission (Schmidt et al., 2012). 
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3.3.3 Predictions using the programme Storm and 6 different PWM 
Predicting CTCF binding sites with 6 different PWM on all 9 PV types using Storm was 
completed in collaboration with Dr. Jesse Ziebarth from Professor Yan Cue’s research group 
at the University of Tennessee, Health Science Center, USA. Matches to the PWM are given 
a score but it is not known which score threshold indicates a true CTCF binding site. In this 
experiment we decided to choose the 10 best matches to each PWM for each individual PV 
type. This resulted in the identification of 540 potential CTCF binding sites. To reduce the 
work load a score threshold was needed to define the cut-off point from which a predicted 
binding site was tested for CTCF binding experimentally. It was decided to base the 
calculation for a threshold on the scores of the best 6 matches for each PWM from each of 
the 9 PV types, resulting in 54 different scores. The threshold was defined as the arithmetic 
mean of these 54 scores for every single PWM.  
Table 21 shows the 6 best scores for each PWM and each virus and scores above threshold 
are highlighted in red. Predictions using the first and second PWM need to be addressed in 
particular. Those are the PWM published by Schmidt et al (Schmidt et al., 2012). The 1st 
PWM downloaded (source: http://www.ebi.ac.uk/~schwalie/CTCFCell2012/) only covers 
the 14 bases whereas the PWM published in the paper consists of 19 bases. In a query with 
the authors it was stated that some of the nucleotides within the PWM described in 
Schmidt et al. did not have significant information content and were therefore left out of 
the PWM used for screening purposes. Hence the most important bases of the first PWM 
are covered by the 14 bases in the PWM used for screening, making this prediction valid. 
The secondary PWM published by Schmidt et al. was used as a whole. However due to its 
small size of 9 bases there were numerous hits across the whole input sequence and these 
hits are only significant if they are in close proximity to a motif identified by the first PWM. 
Having only the 10 best hits available made it difficult to set these motifs in relation to 
motifs matching the first PWM. It is likely that important hits were left out since they may 
not be among the 10 best matches. This fact, combined with the limited ability of the 
second PWM to predict CTCF binding sites by itself, led to the decision to exclude the 
matches to secondary PWM from further experiments. Based on the thresholds chosen it 
was decided to experimentally test the predicted CTCF binding sites shown in Table 22 by 
electrophoretic mobility shift assay (EMSA). Many of the motifs found by Storm were 
identified by multiple PWM. This reduced the overall number of fragments to be tested 
experimentally. Among many potential new binding sites found with Storm, a high scoring 
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binding site in the vicinity of nucleotide 3000 in HPV31 was found. Thus all high risk viruses 
tested had a conserved, high scoring CTCF binding motif predicted in this region. Many of 
the additional binding sites found with Storm were located in the L1 and L2 ORFs.  
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PWM No. HPV18 HPV16 
HPV16 
114/k 
HPV31 HPV6b HPV11 HPV38 HPV8 BPV1 
Threshold 
(mean) 
1.PWM  
 
(AC 
EMBL_M1) 
 
1 18,41 13,90 19,27 19,16 16,92 18,44 15,27 14,29 9,35 
10,72 
 
2 12,87 12,11 13,89 14,42 10,00 9,94 14,92 13,69 8,87 
3 12,21 10,65 12,09 13,46 9,20 9,47 13,29 11,41 7,68 
4 10,51 10,18 10,63 10,09 8,92 9,05 10,25 11,14 7,50 
5 6,35 5,41 6,89 9,86 8,22 8,97 8,82 9,16 7,36 
6 5,71 5,14 5,38 8,64 6,36 8,74 8,59 8,55 7,26 
2.PWM  
 
(AC 
EMBL_M2) 
 
1 14,57 13,71 13,71 13,61 14,55 13,32 14,50 13,16 13,21 
11,60 
 
2 14,57 13,42 13,42 13,01 11,67 13,32 11,46 10,33 12,39 
3 12,19 11,31 11,31 11,26 11,37 11,50 11,03 10,31 12,29 
4 12,19 11,20 11,20 10,48 11,09 10,70 10,59 10,17 12,14 
5 11,90 11,11 11,10 8,97 10,68 10,61 10,02 9,74 11,48 
6 11,90 10,69 10,67 7,87 10,34 10,30 9,85 8,49 10,40 
3.PWM  
 
(AC 
REN_20) 
 
1 13,16 12,17 22,39 22,34 17,03 20,45 6,36 12,60 5,06 
6,45 (mean 
of scores 
above 0 
only) 
 
2 9,71 8,95 8,93 7,21 4,00 4,70 3,77 12,14 2,90 
3 8,27 6,48 6,48 2,99 2,91 3,91 3,67 2,70 0,69 
4 2,15 -0,30 -0,31 1,75 2,24 2,93 3,65 0,32 -1,50 
5 0,56 -0,93 -0,94 -2,93 2,04 2,11 2,29 -0,33 -1,53 
6 -0,14 -2,15 -2,17 -3,38 1,90 2,09 1,86 -1,64 -2,40 
4.PWM  
 
(AC 
MIT_LM2) 
 
1 13,28 8,61 16,03 16,00 7,53 13,21 5,77 11,65 7,06 
6,54 
 
2 7,27 7,68 8,60 14,68 6,89 11,50 4,07 6,55 6,46 
3 7,26 6,18 7,67 9,01 3,78 7,33 4,03 6,34 5,86 
4 4,97 5,44 6,18 8,23 3,55 7,29 3,79 4,82 5,47 
5 4,90 4,22 5,71 6,38 2,29 4,85 3,44 4,22 1,70 
6 4,22 4,21 5,43 6,25 2,16 4,77 3,10 3,91 1,24 
5.PWM  
 
(AC 
MIT_LM7) 
 
1 16,65 10,18 18,21 18,93 12,90 18,61 15,56 12,65 10,28 
8,71 
 
2 13,99 9,81 10,18 13,98 10,01 10,14 9,12 11,32 8,22 
3 10,46 6,32 6,31 9,01 5,69 6,81 8,21 9,40 7,12 
4 10,06 5,66 5,65 8,37 5,16 6,33 8,19 9,12 6,31 
5 9,98 5,48 5,46 6,28 4,67 3,83 8,05 7,96 5,93 
6 6,61 5,28 5,27 5,48 4,42 3,25 6,91 4,84 5,49 
6.PWM  
 
(AC 
MIT_LM23) 
1 23,44 20,05 27,63 27,48 12,22 15,82 10,87 6,50 10,61 
8,51 
2 14,25 9,32 9,31 8,34 8,06 9,30 9,15 6,35 8,52 
3 12,19 9,08 9,07 7,48 6,80 5,42 8,49 5,58 7,99 
4 7,71 5,96 8,20 7,01 6,50 5,16 5,38 5,55 7,58 
5 7,19 4,89 5,93 5,56 4,73 4,76 5,07 4,61 5,62 
6 7,15 3,66 5,64 4,53 4,59 3,35 4,75 4,54 4,69 
Table 21) Storm-scores of the 6 best matches of each PWM for each PV 
The arithmetic mean of the scores for each PWM was determined and served as a threshold 
from which binding sites were experimentally tested. The second PWM (2.PWM) taken from 
Schmidt et al. has a large number of matches, all of which have a similar score. Matches to 
this PWM are only significant for CTCF binding if they are in close proximity to a match to the 
primary PWM defined by Schmidt et al. (1.PWM). However the secondary PWM was used 
independently of the primary PWM in this bioinformatics analysis. Hence it was decided to 
leave out results given by the secondary PWM for future experiments. The third PWM had 
negative scores among the 6 best matches. Those were considered not to be scores of real 
matches to the PWM and were left out of the calculation for the threshold. The name of each 
PWM as it was used in the prediction tools is given in brackets in the first column. 
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Class Type 
Start of 
predicted motif 
PWM that identified this motif with a score 
above threshold [score] 
Motif identified by highest 
scoring PWM 
High 
risk 
HPV18 
844 5.PWM [10.0] ATTCCAGCAGCTGTTTCTGA 
2990 
1.PWM [18.4], 3.PWM [13.2], 4.PWM [13.3], 
4.PWM [7.3], 5.PWM [16.6], 6.PWM [23.4] 
AAACCACCAGGTGGTGCCAG 
3621 3.PWM [8.2], 5.PWM [14.0], 6.PWM [14.2] TTGCCTGTAGGTGTAGCTGC 
4505 1.PWM [12.2] CGTCCCCCAGTGGT 
4538 5.PWM [10.5] GTAACAATAGATGGGTCTGT 
5768 
1.PWM [12.9], 3.PWM [9.7], 4.PWM [7.3], 
5.PWM [10.1], 6.PWM [12.2] 
CACCACCTGCAGGA 
HPV16 
1283 5.PWM [10.2] AACTCAGCAGATGTTACAGG 
2916 3.PWM [12.2], 5.PWM [9.8], 6.PWM [20.1] TAACCACCAAGTGGTGCCAA 
6515 
1.PWM [13.9], 3.PWM [6.5], 4.PWM [8.6], 
6.PWM [9.3] 
CTACACCTAGTGGT 
6860 
1.PWM [12.1], 3.PWM [9.0], 4.PWM [7.7], 
6.PWM [9.1] 
CTCCCCCAGGAGGC 
HPV16 
114/K 
1284 5.PWM [10.2] AACTCAGCAGATGTTACAGG 
2917 
1.PWM [19.3], 3.PWM [22.4], 4.PWM [16.0], 
5.PWM [18.2], 6.PWM [27.6] 
TAACCACCAGGTGGTGCCAA 
6516 1.PWM [13.9], 3.PWM [6.5], 4.PWM [8.6] CTACACCTAGTGGT 
6861 
1.PWM [12.1], 3.PWM [8.9], 4.PWM [7.7], 
6.PWM [9.1] 
CTCCCCCAGGAGGC 
HPV31 
616 4.PWM [8.2] ATAACAGTGGAGGTCAGTT 
1278 5.PWM [14.0] AACGCAGCAGATGGTACAGG 
2413 1.PWM [14.4], 4.PWM [14.7] AATGCACTAGATGGCAACC 
2854 
1.PWM [19.2], 3.PWM [22.3], 4.PWM [16.0], 
4.PWM [9.0], 5.PWM [18.9], 6.PWM [27.5] 
TAACCACCAGGTGGTGCCAG 
6432 1.PWM [13.5], 3.PWM [7.2] CTACACCTAGCGGC 
Low risk 
HPV6b 
5018 4.PWM [7.5] CTATCACTAGATGATACCA 
5425 
1.PWM [16.9], 3.PWM [17.0], 4.PWM [6.9], 
5.PWM [12.9], 6.PWM [12.2] 
GCAGCCACAAGAGGGTGCAT 
6110 5.PWM [10.0] CAGCCATTAGGTGTGGGTGT 
HPV11 
4921 4.PWM [7.3] CCACCTGTGGAGGCCAGTG 
5416 
1.PWM [18.4], 3.PWM [20.5], 4.PWM [11.5], 
5.PWM [18.6], 6.PWM [15.8] 
GCAGCCACTAGAGGGTGCAG 
6311 4.PWM [13.2] GTTCCAACGGGGGGCAGTC 
6636 4.PWM [7.3] GAGCCACTAGGTGTATGTA 
6980 5.PWM [10.1], 6.PWM [9.3] CCTCCACCAAATGGTACACT 
Beta PV 
HPV38 
117 6.PWM [10.9] CTACCACAAGCGGTTGCTTG 
690 6.PWM [9.2] TTGCCACGAGGAGTTGCCTG 
1331 1.PWM [14.9], 5.PWM [15.6], 6.PWM [8.5] CCGGCAGCAGAGGGTGATAT 
3543 1.PWM [13.3] CTTCCCCTGGTGGG 
3573 1.PWM [15.3], 5.PWM [9.2] CGCCTTCTGCTGTC 
HPV8 
1959 5.PWM[9.1] GCCCCAGAAGATGCTAATGC 
2387 
1.PWM [13.7], 3.PWM [12.1], 4.PWM [11.7], 
5.PWM [12.7] 
AGACCCCTGCTGGC 
3642 3.PWM [12.6] TTCGCCTAGAGGTGGCTGTA 
3769 1.PWM [14.3] CTCCCCCTACTGCC 
5090 1.PWM [11.1], 4.PWM [6.5], 5.PWM [11.3] GATACAGCAGGTGGCTGTTG 
5280 5.PWM [9.4 ACTACACCAGCTGGCTATGT 
6172 1.PWM [11.4 TGTCCCCTACTGAT 
Bovine 
PV 
BPV1 
3670 5.PWM [10.3], 6.PWM [8.5] GAACCAGGTGGTGGTGCAGT 
4258 4.PWM [7.1] TGTCCACCAGATGTGATAC 
5317 6.PWM [10.6] CTACCAACAGGTGTAGAAGA 
Table 22) Storm-predicted CTCF binding sites with scores above threshold 
Matches to 5 different PWM were taken into account and 9 PV were screened. All binding 
sites shown are analysed in subsequent experiments. Many motifs were recognised by 
multiple PWM.  
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Figure 16) Generation of FAM-labelled DNA fragments 
using a labelled secondary primer 
A) Amplification of DNA fragment from template DNA 
using an overhang primer. B) PCR with secondary, labelled 
primer targeting the overhang of the previous primer. C) 
Complete, labelled fragment ready to be used in gel shifts. 
Figure from Schuelke, reproduced with permission 
(Schuelke, 2000). 
3.4 EMSA validation of CTCF binding sites predicted with the 
CTCFBSDB tool 1.0 and the Essex tool 
3.4.1 Testing predicted binding sites within BPV1 for CTCF binding 
EMSA were performed to experimentally validate all predicted binding sites. In these assays 
a FAM-labelled DNA fragment (probe) of approximately 200 bp containing the binding site 
of interest was amplified by PCR and incubated in a binding buffer together with in vitro 
translated CTCF protein. This reaction mix was run on a native polyacrylamide gel and FAM 
fluorescence was detected at a wavelength 520 nm. On native polyacrylamide gels DNA 
fragments do not solely migrate according to their size, also the GC content plays a role. 
The higher the GC content 
the faster is the migration 
speed through the gel, so 
fragments of the same size 
can migrate differently. 
Free labelled DNA is seen 
as a single band on the gel. 
However if CTCF binds to 
the fragment, there will 
also be complexes of 
fragment and CTCF 
present in addition to the 
free probe. These 
complexes are considerably larger than the free probe resulting in a shifted, secondary 
band above the band of the free probe. This additional band is referred to as the band shift.  
The generation of a fragment containing the predicted CTCF binding site was done in two 
steps. The first step was a standard PCR-amplification of the fragment using a primer pair 
specific to the region of interest. Each forward primer used in the first step had an M13 5’ 
overhang of 19 nucleotides to be used in the secondary PCR reaction (overhang: 5’-
TGTAAAACGACGGCCAGT-3’). Fragments generated in the first PCR reaction acted as a 
template for a secondary PCR reaction. In this secondary reaction a FAM-labelled primer 
complementary to the overhang of the forward primer was used together with the same 
reverse primer used in the first PCR reaction. The sequence of the FAM primer was  
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FAM-5’-TGTAAAACGACGGCCAGT-3’. As a result, all fragments generated this way were 
FAM-labelled using the same labelled primer in the secondary PCR reaction. The generation 
of labelled DNA fragments is illustrated in Figure 16. 
Another crucial component of the binding reaction was CTCF protein. Two expression 
constructs for full length human CTCF with a 10x histidine tag (his-tag) at the N-terminus 
were kindly provided by Dr. Dawn Farrar from the University of Essex, UK (Farrar et al., 
2010). Both of these constructs contained the CTCF cDNA under control of either a T7 
transcription initiation site or an SP6 promoter and could therefore act as a template for in 
vitro translation of CTCF using various kits from Promega that combine transcription and 
translation from template DNA in a single reaction. The kits used in this experiment were 
the TnT® T7 Coupled Reticulocyte Lysate System, the TnT® T7 Coupled Wheat Germ Extract 
System and the TnT® SP6 High-Yield Wheat Germ Protein Expression System.  
Starting with CTCF translation using the reticulocyte lysate (RRL) kit, reticulocyte lysate-
containing CTCF protein was combined with a labelled DNA fragment in the gel shift 
reaction. The presence of CTCF was confirmed by western blotting as seen in Figure 18. 
However it was discovered that the intensely coloured reticulocyte lysate interfered with 
the detection of FAM fluorescence and the band shift itself, resulting in a smear (Figure 17).  
 
 
Figure 17) Western blot and EMSA of CTCF protein generated in RRL 
Both images are representative of two independent experimental repeats. 
A) Western blot for CTCF protein translated in RRL. The positive control is lysate of the 
mouse cell line ID13. The negative control is luciferase translated in RRL. The in vitro 
translated CTCF migrates slightly faster than the control CTCF. This may be due to the 
lack of post-translational modifications or a change in charge dues to the HIS tag. B) 
EMSA of the positive control fragment using CTCF and luciferase translated in RRL. 
Whole RRL containing luciferase or CTCF was incubated with the FAM labelled DNA and 
the complexes formed were separated by PAGE. Both lanes containing RRL with either 
protein show a smear whereas the lane containing fragment only shows a single band. 
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Figure 18) Western blot of CTCF protein 
generated in WGE  
This image is representative of two 
independent experimental repeats. The 
positive control is cell lysate of mouse 
fibroblasts of the cell line ID13. The CTCF 
band from wheat germ extract migrated 
faster than the band from the positive 
control. This may be due to the lack of 
posttranslational modifications. 
Using purified CTCF protein would have 
solved this problem. However, attempts 
to purify CTCF protein using a nickel 
column failed, most likely due to the 11 
zinc fingers in CTCF protein that can bind 
to nickel, preventing efficient elution of 
the protein off nickel affinity resin used 
to purify histidine tagged proteins. Hence 
it was decided to in vitro translate CTCF 
in wheat germ extract (WGE) instead of 
reticulocyte lysate using another kit from 
Promega; the TnT® T7 Coupled Wheat 
Germ Extract System. WGE does not 
interfere with the detection of FAM 
fluorescence and CTCF-containing WGE could therefore be applied directly to the gel shift 
reactions without prior purification of CTCF protein. Successful expression of CTCF WGE 
was confirmed by western blotting (Figure 18). Whole cell lysate of the mouse fibroblast 
cell line ID13 was used as a positive control for CTCF western blots since this cell line was 
previously shown to express high levels of CTCF that cross-react with the human CTCF 
antibody used. The CTCF protein in WGE and RRL runs as a slightly higher band on Western 
blot than CTCF protein from ID13 cells. Nevertheless the DNA binding capacity was still 
confirmed as seen in the gel shifts (Figure 20). The addition of a histidine tag should rather 
decrease the migration speed instead of increasing it due to the added molecular mass. 
However the CTCF protein from the ID13 cell line migrates closer to 140 kDa than the 
expected 130 kDa. This may be due to the addition of potential posttranslational 
modifications. The SDS in the resolving gel should equalise the mass-to-charge ratio of the 
protein, but in the case of CTCF it has been shown that its charge can still influence its 
migration on a denaturing gel (Klenova et al., 1997). A change in charge due to the histidine 
tag should not have occurred since histidine (pKa 6) is de-protonated at the pH of the 
resolving gel (pH 8.8) and therefore not charged.  
During a set of gel shift experiments, a drop in sensitivity occurred. This led to a large series 
of trouble shooting experiments targeting the composition of the binding buffer, its single 
components as well as every component of the in vitro expression kit. Low CTCF-protein 
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Figure 19) The CTCF binding motif in the human C-myc 
promoter  
The positive control fragments used in EMSA contains this 
motif Figure from Schmidt et al., reproduced with 
permission (Schmidt et al., 2012). 
expression in T7 wheat germ extract kit was found to be the cause of the decline in EMSA 
sensitivity. Since all components of the WGE T7 kit were already replaced without any 
improvement of CTCF expression it was decided to use a different expression system based 
on the SP6 promoter; the TnT® SP6 High-Yield Wheat Germ Protein Expression System. 
Using protein generated with the SP6 system in combination with the best binding buffer 
found in the troubleshooting process for the T7 WGE generated CTCF protein, the overall 
quality of EMSA was increased. Due to the switch to another experimental setup, there are 
two separate methods with which the EMSA results were achieved. However, many of the 
fragments were tested with both methods and were found to give the same result.  
The first method utilised 2 µl CTCF protein expressed in T7 WGE incubated with 2 µl of 
FAM-labelled DNA fragment in the EMSA buffer defined by Sambrook et al. given in Table 9 
(materials and methods) (Sambrook and Russell, 2006). Incubation of WGE with the 
labelled DNA fragment was carried out at 4 °C for 1 hour followed by separation of the 
samples on a 4.5 % native polyacrylamide gel on ice. In the second method, CTCF protein 
was expressed in SP6 high yield WGE. From this 1 µl of WGE was incubated with 2 µl of 
FAM-labelled DNA fragment in the modified version of the buffer described by Zielke et al. 
shown in Table 9 (materials and methods) (Zielke et al., 2012). The incubation was carried 
out at room temperature for 1 hour followed by separation of the samples on a 4.5 % 
native polyacrylamide gel run at room temperature. Both buffers contained Poly 
(deoxyinosinic-deoxycytidylic) acid sodium salt, an unlabelled nucleotide polymer that was 
added in excess to the DNA fragment in order to reduce non-specific binding of proteins to 
DNA. Experimental controls used in all EMSA included a fragment of the c-Myc promoter 
which is known to bind CTCF in vivo and had been used in EMSA before (Vetchinova et al., 
2006, Filippova et al., 
1996). The CTCF binding 
site of the positive control 
fragment is shown in 
Figure 19. The negative 
control was a fragment of 
BPV1 that contained no 
predicted CTCF binding 
sites at all.  
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Since CTCF-containing WGE was used in gel shift assays, the possibility that other 
components of the WGE could cause a band shift needed to be addressed. To do this, 
luciferase protein was expressed in WGE and incubated with the fragment of interest as a 
secondary control. Thus it was possible to distinguish between background binding from 
WGE and binding that was specific to CTCF protein.  
Some publications suggest pre-running gels before use to remove remaining ammonium 
persulfate and EDTA as well as bringing the gel to a constant temperature and equilibrating 
possible binding factors in the running buffer (Kothinti et al., 2011, Mills and Marletta, 
2005). However for both experimental setups used here pre-running decreased the overall 
EMSA quality rather than increasing it. Hence it was decided to use gels that were not pre-
run.  
Since not all predictions were carried out at the same time, the confirmation experiments 
for each prediction were also not all performed at the same time either. Instead, they were 
split into sections which are presented in chronological order to follow the train of thought 
and to justify why certain experiments were done. Starting with BPV1, fragments 
containing motifs predicted by either the Essex tool or the CTCFBSDB tool 1.0 were 
amplified from the BPV1 genome and labelled in a secondary PCR reaction. All these 
fragments were used for EMSA analysis and, at the very least, each experiment was carried 
out in duplicate. The summarised results are given in Table 23 of the following section. 
Figure 20 shows an example of an EMSA. In addition to the positive and negative control, 3 
fragments each of which contains a predicted binding motif from the Essex tool are shown. 
Fragment Essex-3 is the only fragment that shows two weak band shifts so it is suggested 
that either two CTCF proteins can bind this fragment simultaneously or that a single CTCF 
protein can bind the fragment at two different and mutually exclusive locations leading to a 
distinct spatial conformation of the complex and therefore a distinct band shift for each 
possible binding location. Essex-4 shows no band shift. Fragment Essex-5 shows a shift that 
is stronger than the shifts of fragment Essex -3 but not as strong as the shift seen in the 
positive control. Therefore this shift is classified as medium strength. In some experiments 
a second band was seen in the lane containing free DNA only. Several fragments showed 
this secondary band occasionally but not consistently and the band always disappeared as 
soon as any WGE was added to the fragment no matter if the WGE contained luciferase or 
CTCF (Figure 21). When the same fragment that gave a secondary band on the gel shift was 
run on an agarose gel and stained with ethidium bromide, only a single band was seen.  
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Figure 21) Typical nonspecific band in EMSA 
A few samples showed a non-specific bands as seen in 
the well with Essex+1 DNA fragment only. This band 
disappeared upon addition of any WGE. A strong shift is 
seen with the Essex +1 fragment. The Essex +2 fragment 
shows a very weak shift. 
 
Hence it is suggested that the additional band was a complex of DNA fragments, most likely 
a homodimer consisting of 
two labelled DNA fragments. 
This complex may have 
formed in the reaction buffer 
but was disrupted when 
incubated with WGE.  
As shown in Figure 21, 
fragment Essex+2 contains 
two predicted binding sites, 
which are in close proximity; 
E+2 and E-2. However, only a 
single weak band is seen on 
the EMSA with a DNA 
fragment that contains both 
of these predicted binding 
sites. From this data it was 
 
Figure 20) Example EMSA for testing predicted CTCF binding sites in BPV1 
This image is representative of two independent experimental repeats. Fragment Essex-
3 shows two weak band shifts whereas fragment Essex -5 shows a single but stronger 
shift. All remaining gels for testing BPV1 binding sites can be found in the appendix. 
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not possible to distinguish CTCF binding to the E+2 motif or the E-2 motif. Fragment 
Essex+1 shows a single, strong band. Interestingly this fragment covers nucleotide 3000 
which is the area where all of the high risk viruses have a predicted CTCF binding site with a 
high score. Among all the other BPV1 fragments with predicted binding motifs only C-1 
showed a weak shift. The remaining fragments were all tested negative for CTCF binding. A 
complete collection of all gel shifts in duplicate can be found in the appendix. 
 
3.4.2 Testing CTCF binding to additional BPV1 fragments covering the LCR and 
viral promoters  
The findings from the previous EMSA revealed that many of the predicted CTCF binding 
sites were false positives. However, EMSA experiments may not always correctly resemble 
in vivo conditions, considering that these experiments are done on purely un-methylated 
DNA and that no other cellular factors are present. Nonetheless, they are good indicators 
for putative in vivo binding sites. As expected, predicting CTCF binding sites worked to a 
certain degree but it had its limitations. Hence it was decided to look for unpredicted CTCF 
binding sites in functionally important regions of the BPV1 genome. The whole LCR of BPV1 
was screened for CTCF binding using overlapping fragments of 200bp. Each fragment was 
overlapping with the next by at least 30bp. A weak band shift was seen with fragment 6 of 
the LCR even though no binding site was predicted here (Figure 22).  
BPV1 has three promoters outside the LCR of which two already have a gel shift confirmed 
binding site in their close vicinity. The only promoter outside the LCR that had not been 
tested for CTCF binding due to the lack of a predicted binding site is P890. Thus a fragment 
containing P890 was tested for CTCF binding resulting in a shift of weak strength as seen in 
Figure 22. Therefore every fragment containing a promoter sequence from outside the LCR 
was shown to have a band shift of weak strength. Also 7 random fragments and a fragment 
covering an E2 binding site outside the LCR were tested for CTCF binding. The fragment 
containing the E2 binding site does not show a shift. However one out of the 7 random 
fragments resulted in a weak shift as seen in Figure 22. Table 23 summarises all gel shift 
data of BPV1 up to this section. The EMSA from which this table is generated can be found 
in the appendix. 
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Fragment Predicted motifs on 
fragment 
Tool Fragment name CTCF band shift 
from to 
Predicted 
binding sites 
6519 6693 6589 CTCFBSDB C+1 6589 none 
3576 3775 3671 CTCFBSDB C-1 3671 weak 
2917 3096 3025 Essex Essex+1 3025 strong 
2327 2488 2427, 2397 Essex Essex+2 2427, Essex-2 2397 weak 
4442 4611 4534 Essex Essex+3 4534 none 
580 745 663 Essex Essex-1 663 none 
1137 1309 1227 Essex Essex-3 1227 two bands, weak 
5105 5263 5190 Essex Essex-4 5190 none 
4689 4863 4775 Essex Essex-5 4775 strong 
4049 4226 4144 Essex Essex-6 4144 none 
Fragments 
covering regulatory  
elements 
CTCF 
6968 7154 none N/A LCR P1 none 
7061 7263 none N/A LCR P2 none 
7205 7391 none N/A LCR P3 none 
7325 7520 none N/A LCR P4 none 
7486 7656 none N/A LCR P5 none 
7598 7794 none N/A LCR P6 weak 
7734 7904 none N/A LCR P7 none 
7857 81 none N/A LCR P8 none 
55 223 none N/A LCR P9 none 
772 950 none N/A P890 region weak 
1031 1201 none N/A E2 binding site at 1125 none 
Random 
fragments 
7205 7354 none N/A Random Frag 1 none 
5475 5639 none N/A Random Frag 2 weak 
6638 6790 none N/A Random Frag 3 none 
2650 2819 none N/A Random Frag 4 none 
3072 3238 none N/A Random Frag 5 none 
5856 6010 none N/A Random Frag 6 none 
843 983 none N/A Random Frag 7 none 
Table 23) Results of EMSA tested BPV1 fragments. 
Band shifts were classified as strong, medium or weak based on the band shift intensity 
compared to the positive control on each gel.   
 
Figure 22) EMSA of functional elements and a random fragment 
This image is representative of two independent repeats. The fragment 
containing promoter P890 shows a gel shift of weak strength. Also random 
fragment 2 and LCR fragment 6 show a weak gel shift. 
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Figure 23) Investigation of the exact position 
of the CTCF binding site around nucleotide 
3000 in BPV1 
Only the fragments shown in dark teal bound 
CTCF in EMSA. Hence the nucleotides those 
fragments have in common must contain the 
real CTCF binding site. Note that one of these 
fragments only contains two out of the 9 
nucleotides that make up the predicted 
binding site E+1 which is shown in yellow. This 
indicates that motif E+1 is not the correct 
binding motif of the strong CTCF binding site 
around nucleotide 3000. Instead the motif 
must be within the red bar that covers 
nucleotide 2917 to 3027. 
3.4.3 Determination of the exact position of the strong CTCF binding site found 
around nucleotide 3000 
With the intention to determine how the position of the CTCF binding site on the fragment 
influences the gel shift, fragments were designed with the predicted CTCF binding site at 
either the edge or in the middle of the fragment (Figure 23). EMSA results using these 
fragments unexpectedly revealed that the predicted binding motif around nucleotide 3000 
(E+1) was a false positive. Only the 
fragment containing E+1 at the 3’ edge 
was able to bind CTCF. Testing 
additional overlapping fragments 
revealed that one of the fragments 
tested resulted in a strong shift even 
though it did not contain the whole 
predicted binding motif of E+1. 
Although the predicted binding site 
was false, a real binding site must be 
present in close proximity to the 
predicted binding site.  
Using several overlapping fragments to 
determine the exact position of this 
unpredicted binding site revealed that 
the size of this site was very large. 
Despite very long overlaps of the 
fragment used, only two fragments 
were able to bind CTCF. These two 
fragments share 111 base pairs which 
must contain the real CTCF binding site 
(nucleotides 2917-3027). There is no match to any of the PWM within this shared 
sequence. Another study has shown that about 30 % of CTCF binding sites do not fit the 
consensus 20-mer binding motif of CTCF which might be the case for this particular binding 
site (Chen et al., 2012a). The shared base pairs of the CTCF binding fragments are indicated 
by a red bar in Figure 23. The gel shift results of all fragment tested for this experiment are 
summarised in Table 24 and the primary data can be found in the appendix. 
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Fragment Predicted motifs 
 on fragment 
Predicted 
by 
Fragment name 
CTCF band 
shift from to 
Overlapping 
 fragments around 
 nucleotide 3000 
2704 2915 none N/A No CTCF none 
2785 2984 none N/A Frag CTCF?A none 
2831 3027 none N/A Frag CTCF?B strong 
2917 3096 3025 Essex E+1 3025 (at 5’ edge) strong 
2947 3120 3025 Essex E+1 3025 (in middle) none 
2995 3174 3025 Essex E+1 3025 (at 3’ edge) none 
Table 24) EMSA results of fragments tested for CTCF binding around nucleotide 3000 in 
BPV1 
Only two fragments bind CTCF, one of which does not contain the entire predicted binding 
motif of E+1. 
 
 
3.4.4 Generation of a CTCF binding map of BPV1  
Based on the results from the EMSA it was possible to create a CTCF binding map of the 
whole BPV1 genome using the programme DNAman (Figure 24). The outermost, checked 
elements of the figure indicate the fragments tested. If a fragment tested positive for CTCF 
binding it is shown as a blue block on the genome. All predicted binding motifs are shown in 
yellow and labelled with the tool by which they were predicted and the score of the 
prediction. If a CTCF binding motif is located within a blue bar it is likely that this is the 
location where CTCF is binding to the fragment. However since unpredicted binding sites 
were discovered and many false predictions were revealed it is possible that CTCF binds at 
a location within the blue bar that is different from the predicted binding site. All promoter 
sequences are given in teal. The sequence that must contain the CTCF binding site at 
nucleotide 3000 is shown in red with the yellow prediction of E+1 next to it. The fragments 
shown in dark teal bind CTCF. The fragment of the LCR that was shown to contain a CTCF 
binding site also contains a predicted CTCF binding site. However this predicted site is 
below threshold and therefore coloured purple.  
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Figure 24) Complete CTCF binding map of the BPV1 genome based on EMSA 
Testing coverage is shown as checked fragments in an outer ring around the genome. 
Fragments tested positive for CTCF binding are shown in blue. Predicted binding sites are 
indicated with a yellow mark. The unpredicted binding site around nucleotide 3000 is 
shown in red and the overlapping fragments that bind CTCF are shown in teal. 
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3.4.5 In vitro confirmation of CTCF binding within 7 HPV types based on 
predictions with CTCFBSDB tool 1.0 and Essex tool 
After the confirmation of many CTCF binding sites in the BPV1 genome, it was decided to 
test the predicted binding sites of the HPV types 18, 16, 16 114/K, 31, 6b, 11, 38 and 8. 
Many predicted binding sites could be confirmed and some predicted binding sites were 
tested negative. The high risk types HPV18, 16 and 16 114/K showed a strong shift with the 
fragment covering the high scoring binding motif around nucleotide 3000. Accordingly, the 
low risk specific high scoring binding site at nucleotide 5400 tested positive for CTCF 
binding with a strong shift on the gel. Also every high risk type had a CTCF binding site 
confirmed in the area around nucleotide 5400; however the shift was weaker and the 
position of the binding site was not as conserved as in low risk types. In HPV16 and 31 this 
binding site is located around nucleotide 5200 and in HPV18 it is located at nucleotide 
5475. 
The beta virus HPV38 did not show a high degree of similarity to high risk or low risk alpha 
viruses. Only two CTCF binding sites were confirmed on HPV38, one of which is in the LCR. 
The predicted CTCF binding cluster in beta viruses at nucleotide 3600 did not result in a 
shift in the EMSA.  
Fragments from the HPV8 template DNA did not amplify. The template DNA was digested 
and the product was run on an agarose gel, resulting in a different banding pattern than 
expected for the HPV8 construct. Hence HPV8 could not be tested for CTCF binding. All 
EMSA results are summarised in Table 25. The primary gel shift data used to produce this 
table can be found in the appendix. 
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Class Template 
Fragment Predicted motifs 
on fragment 
Predicted 
by 
Fragment name 
CTCF band 
shift from to 
High 
risk 
HPV18 
2926 3117 2990 CTCFBSDB HPV18 C+1 2990 strong 
1102 1297 1205 Essex HPV18 E+1 1205 none 
5381 5577 5475 Essex HPV18 E-1 5475 medium 
3381 3575 3487 Essex HPV18 E-2 3487 none 
HPV16 
2852 3049 2916 CTCFBSDB HPV16 C+1 2916 strong 
1212 1405 1283 CTCFBSDB HPV16 C+2 1283 none 
6426 6600 6512 CTCFBSDB HPV16 C-1 6512 weak 
6051 6278 6127 Essex HPV16 E+1 6127 weak 
5000 5207 5119 Essex cor. HPV16 E-1 5120 weak 
HPV16 114/K 
2852 3049 2917 CTCFBSDB HPV16 C+1 2917 strong 
6051 6278 6128 Essex HPV16 E+1 6128 weak 
5000 5207 5120 Essex cor. HPV16 E-1 5120 weak 
HPV31 
2357 2531 2413 CTCFBSDB HPV31 C+1 2413 strong 
1182 1374 1278, 1294 
CTCFBSDB, 
Essex 
HPV31 C+2/E+3 1278 none 
2230 2406 2332 CTCFBSDB HPV31 C+3 2332 none 
5077 5273 5179 Essex HPV31 E+1 5179 strong 
1029 1200 1093 Essex HPV31 E+2 1093 none 
804 1008 885 Essex HPV31 E+4 885 none 
Low 
risk 
HPV6b 
5317 5515 5425, 5431 
CTCFBSDB, 
Essex 
HPV6b C-1 5425 E-1 5431 strong 
4913 5102 5018, 4987 
CTCFBSDB, 
Essex 
HPV6b C-2 5018 E+1 4987 none 
1251 1460 1357 Essex HPV6b E+2 1357 none 
5995 6199 6099 Essex HPV6b E+3 6099 none 
6179 6382 6264 Essex HPV6b E-2 6264 medium 
7155 7380 7206, 7257 Essex HPV6b E-3 7206 E-4 7257 none 
4715 4913 4790 Essex HPV6b E-5 4790 none 
HPV11 
5330 5501 5416, 5422 
CTCFBSDB, 
Essex 
HPV11 C-1 5416 E-1 5422 strong 
6243 6428 6311 CTCFBSDB HPV11 C-2 6311 weak 
1295 1494 1357 Essex HPV11 E+1 1357 none 
4709 4898 4781 Essex HPV11 E-2 4781 none 
3930 4153 4058 Essex HPV11 E-3 4058 medium 
Beta 
PV 
 
HPV38 
3436 3666 
3571, 3540, 
3520, 3487, 3544 
CTCFBSDB, 
Essex 
HPV38 C+1/2 and E+2/4/5 3540 none 
1243 1431 1331 CTCFBSDB HPV38 C+3 1331 medium 
35 219 117 CTCFBSDB HPV38 C-1 117 medium 
176 363 254 Essex HPV38 E+1 254 none 
4357 4545 4454 Essex HPV38 E+3 4454 none 
HPV8 
3553 3742 3642, 3650 
CTCFBSDB, 
Essex 
HPV8 C-1 /E-2/E-4 3642 N/A 
2262 2481 2383, 2390 
CTCFBSDB, 
Essex 
HPV8 C-2 /E-1/E-3 2383 
N/A 
3946 4130 4037 Essex HPV8 C-3 4037 N/A 
7260 7459 7361 Essex HPV8 E+1 7361 N/A 
Table 25) EMSA results of all predictions made with the Essex tool and the CTCFBSDB 
tool 1.0 
This screening revealed many false positives but also showed similarities among many HPV. 
All high risk types with a predicted, high scoring binding site around nucleotide 3000 
showed a strong band shift with the according fragment. HPV31 has no binding site 
predicted in this region. Additionally fragments around nucleotide 5400 of the low risk 
viruses tested showed a strong band shift, too.  
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Figure 25) Testing HPV31 fragments for an unpredicted 
binding site around nucleotide 3000 
This image is representative of two independent repeats. One of 
the fragments shows a strong band shift and confirms the 
presence of an unpredicted binding site. 
3.4.6 Testing additional fragments of several HPV types for CTCF binding 
around nucleotides 3000 and 5200 
On the basis of the EMSA data obtained so far it was decided to test for additional 
fragments on certain viruses. HPV31 was the only high risk virus that did not have a CTCF 
binding motif predicted around nucleotide 3000. All the other high risk viruses had a CTCF 
binding site predicted at this position and all fragments containing this binding site resulted 
in a strong band shift in EMSA. Hence it was decided to design two overlapping fragments 
for HPV31 that cover the region around nucleotide 3000. Based on the information from 
overlapping fragments used previously for testing BPV1 binding site E+1, the fragments for 
HPV31 were 
designed with a 
large overlap of 100 
nucleotides to make 
sure that a large 
binding site would 
not be disturbed by 
the possibility of a 
too short overlap. 
Also fragments of 
this region from 
both low risk viruses 
were tested for an 
unpredicted CTCF 
binding site.  
Since HPV18 was the only high risk virus that did not have a confirmed CTCF binding site 
around nucleotide 5200, fragments were designed to test this area for CTCF binding, too. A 
binding site for nucleotide 5200 at HPV18 could not be confirmed. From all the fragments 
tested only one of the HPV31 fragments bound CTCF in EMSA as seen in Table 26 and 
Figure 25. The gel shift observed for this fragment was strong. This shift confirmed the 
presence of a strong CTCF binding site around nucleotide 3000 in HPV31, revealing that this 
binding site is present across all high risk viruses tested.  
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Template 
Fragment Predicted motifs 
on fragment 
Predicted by Fragment name CTCF band shift 
from to 
HPV18 
4947 5155 None N/A HPV18 CTCF?A none 
5045 5253 None N/A HPV18 CTCF?B none 
HPV31 
2801 3015 None N/A HPV31 CTCF?A strong 
2894 3093 None N/A HPV31 CTCF?B none 
HPV6b 
2801 3007 None N/A HPV6b CTCF?A none 
2887 3101 None N/A HPV6b CTCF?B none 
HPV11 
2801 3003 None N/A HPV11 CTCF?A none 
2900 3104 None N/A HPV11 CTCF?B none 
Table 26) EMSA testing of areas in which many other PV have predicted CTCF binding 
sites 
HPV31 shows a strong shift with one of the fragments tested. Hence all high risk viruses 
have a confirmed CTCF binding site around nucleotide 3000 that produces a strong shift in 
EMSA. 
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3.4.7 In vitro confirmation of CTCF binding sites predicted by Storm  
After extensive testing of binding sites predicted with CTCFBSDB 1.0 and the Essex tool an 
update of the CTCFBSDB tool to version 2.0 was released. This version of the tool was 
improved but still flawed as described earlier. Instead of using the new version of the 
CTCFBSDB tool it was decided to manually predict binding sites using Storm and all 6 PWM 
for CTCF binding that version 2.0 of the CTCFBSDB tool would use. Predictions using Storm 
were carried out by Dr. Jesse Ziebarth (University of Tennessee Health Science Center, 
USA). Table 27 shows the new fragments used for testing Storm-predicted motifs that were 
not located on fragments tested earlier. Some of the fragments tested showed medium to 
weak strength shifts. HPV8 was again not tested because no functional template for 
fragment generation was available. Many newly predicted binding sites were confirmed, 
most of them showing weak or medium shifts. One fragment covering nucleotides 4440 to 
4638 of HPV18 showed two band shifts (Figure 26). 
 
Template 
Fragment 
Predicted 
motifs 
on 
fragment 
Predicted by  
[score] 
Fragment name CTCF band shift 
from to 
HPV18 
754 943 844 5.PWM [10.0] HPV18 pred. 844 none 
3527 3718 3621 
3.PWM [8.2], 5.PWM [14.0], 
6.PWM [14.2] 
HPV18 pred. 3621 medium 
4440 4638 4505, 4538 1.PWM [12.2], 5.PWM [10.5] HPV18 pred. 4505 two bands, medium 
5655 5850 5768 
1.PWM [12.9], 3.PWM [9.7], 
4.PWM [7.3], 5.PWM [10.1], 
6.PWM [12.2] 
HPV18 pred. 5768 medium 
HPV16 6772 6957 6860 
1.PWM [12.1], 3.PWM [9.0], 
4.PWM [7.7], 6.PWM [9.1] 
HPV16 pred. 6860 
 
weak 
HPV16 
114/K 
1216 1405 1284 5.PWM [10.2] 114K pred. 1284 none 
6421 6621 6517 
1.PWM [13.9], 3.PWM [6.5], 
4.PWM [8.6] 
114K pred. 6517 weak 
6783 6945 6861 
1.PWM [12.1], 3.PWM [8.9], 
4.PWM [7.7], 6.PWM [9.1] 
114K pred. 6861 weak 
HPV31 
534 713 616 4.PWM [8.2] HPV31 pred. 616 none 
6354 6540 6432 1.PWM [13.5], 3.PWM [7.2] HPV31 pred. 6432 medium 
HPV11 
4844 5041 4921 4.PWM [7.3] HPV11 pred. 4921 weak 
6544 6738 6636 4.PWM [7.3] HPV11 pred. 6636 weak plus smear 
6872 7074 6980 5.PWM [10.1], 6.PWM [9.3] HPV11 pred. 6980 none 
HPV38 584 791 690 6.PWM [9.2] HPV38 pred. 690 none 
BPV1 
4145 4354 4258 4.PWM [7.1] BPV1 pred. 4258 none 
5232 5422 5317 6.PWM [10.6] BPV1 pred. 5317 none 
Table 27) Gel shift results of the fragments used for testing CTCF binding sites predicted 
by Storm 
Only binding sites with a score above threshold are tested. If a Storm predicted binding site 
was located on a fragment tested earlier this fragment is not listed here. A complete 
summary of all fragments tested and the prediction sites they contain can be found in Table 
28 and Table 29.  
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Figure 26) Storm-predicted fragments of HPV18 tested for CTCF 
binding by EMSA 
This image is representative of two independent repeats The 
fragment containing prediction 844 does not bind CTCF. The 
fragment with prediction 3621 does show a single band of medium 
strength. Two band where seen with the fragment containing two 
predicted CTCF binding sites.  
On this fragment 
two independent 
binding sites were 
predicted and 
binding of CTCF to 
either one of 
these sites could 
result in two 
shifted bands if 
CTCF binding leads 
to a distinct 
migration pattern 
for each particular 
site. If this is the 
case it would 
imply that the binding of one CTCF protein prevents binding of a second protein on the 
same fragment because a third band would have been visible on the gel which would be 
the result of two fragments binding simultaneously to the fragment. However if the binding 
of CTCF to either one of the predicted binding sites results in an identical migration pattern 
only one band would be seen for binding to either predicted binding site. In this case the 
second band would be the result of CTCF proteins binding to each of the two predicted 
binding sites on the fragment.  
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3.4.8 Complete summary of all predictions and EMSA results combined 
All Fragments tested are summarised in Table 28 and Table 29, it is also indicated whether a 
fragment contains one or more predicted binding sites and which programme or PWM 
identified these binding sites. The fragment of HPV31 around nucleotide 3000 that tested 
positive for CTCF binding now contains a newly predicted binding site. This binding site was 
found by Storm and achieved a high score with multiple PWM. HPV31 is unique in that it 
contains 3 strong CTCF binding sites. All other HPV tested have only one CTCF binding site 
that is classified as strong.  
The results for the most thoroughly tested papillomavirus, BPV1, are summarised in Table 
28. One can see that fragments containing a predicted binding motif were much more often 
proven to bind CTCF than random fragments or fragments covering important regulatory 
elements of the PV genome. Hence the prediction tools were helpful in the search for novel 
CTCF binding sites. However they were not without flaw. Even the approach using Storm 
did not reveal the binding site at nucleotide 3000 of BPV1, despite the fact that the 
fragment of this region showed a strong shift. Additionally some other fragments that 
produced medium to weak strength shifts contained no predicted binding motif. However, 
considering that the EMSA were done in vitro in non-physiological binding buffer these 
results may not fully resemble in vivo conditions.  
A common CTCF binding pattern among high risk and low risk HPV could be defined. Strong 
binding sites were only present between nucleotide 2300 and 5500. Binding sites resulting 
in a weaker shift were more common than binding sites with strong shifts and they 
accumulated within the ORFs of both late genes. Whereas the biggest difference between 
high and low risk viruses was the presence of a conserved and strong binding site at 
nucleotide 3000 or 5400, the binding pattern in the beta virus tested was completely 
different. Here the only confirmed binding sites were found at nucleotides 116 and 1330, 
both resulting in a medium band shift. No strong binding sites were found and also 
accumulation of weaker binding sites in the open reading frames of the late genes was not 
seen. All primer data and EMSA images can be found in the appendix. 
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Fragment Predicted 
motifs on 
fragment 
Predicted by  
[score] 
Fragment name CTCF band shift 
from to 
Fragments of  
motifs predicted  
by Storm  
4145 4354 4258 4.PWM [7.1] BPV1 pred. 4258 none 
5232 5422 5317 6.PWM [10.6] BPV1 pred. 5317 none 
Fragments of  
motifs predicted by 
by CTCFBSDB 1.0  
and Essex tool 
580 745 663 Essex Essex-1 663 none 
1137 1309 1227 Essex Essex-3 1227 two bands, weak 
2327 2488 
2427,  
2397 
Essex Essex+2 2427, Essex-2 2397 weak 
2917 3096 3025 Essex Essex+1 3025 strong 
3576 3775 
S 3670,  
C 3671 
5.PWM [10.3], 
6.PWM [8.5], 
CTCFBSDB [10,3] 
C-1 3671 weak 
4049 4226 4144 Essex Essex-6 4144 none 
4442 4611 4534 Essex Essex+3 4534 none 
4689 4863 4775 Essex Essex-5 4775 medium 
5105 5263 5190 Essex Essex-4 5190 none 
6519 6693 6589 CTCFBSDB [5.9] C+1 6589 none 
Fragments 
covering regulatory 
elements 
55 223 none N/A LCR P9 none 
772 950 none N/A P890 region medium 
1031 1201 none N/A E2 binding site at 1125 none 
6968 7154 none N/A LCR P1 none 
7061 7263 none N/A LCR P2 none 
7205 7391 none N/A LCR P3 none 
7325 7520 none N/A LCR P4 none 
7486 7656 none N/A LCR P5 none 
7598 7794 none N/A LCR P6 weak 
7734 7904 none N/A LCR P7 none 
7857 81 none N/A LCR P8 none 
Random 
fragments 
843 983 none N/A Random Frag 7 none 
2650 2819 none N/A Random Frag 4 none 
3072 3238 none N/A Random Frag 5 none 
5475 5639 none N/A Random Frag 2 weak 
5856 6010 none N/A Random Frag 6 none 
6638 6790 none N/A Random Frag 3 none 
7205 7354 none N/A Random Frag 1 none 
Overlapping 
fragments at  
nucleotide 3025 
2704 2915 none N/A No CTCF none 
2785 2984 none N/A Frag CTCF?A none 
2831 3027 none N/A Frag CTCF?B strong 
2917 3096 3025 Essex E+1 3025 (at 5’ edge) strong 
2947 3120 3025 Essex E+1 3025 (in middle) none 
2995 3174 3025 Essex E+1 3025 (at 3’ edge) none 
Table 28) Complete summary of all EMSA-tested fragments of BPV1 
In the case of overlapping motifs found by Storm only the positions of the motif with the 
highest score is shown. If motifs of several tools are located on one fragment, the locations 
are labelled with S for Storm, C for CTCFBSDB tool and E for the Essex tool. 
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Class Type 
Fragment 
Predicted 
motifs 
on 
fragment 
Predicted by  
[score] 
Fragment name CTCF band shift 
from to 
High 
risk 
HPV18 
754 943 844 5.PWM [10.0] HPV18 pred. 844 none 
1102 1297 1205 Essex HPV18 E+1 1205 none 
2926 3117 
S 2990,  
C 2990 
1.PWM [18.4], 3.PWM 
[13.2], 4.PWM [13.3], 
4.PWM [7.3], 5.PWM [16.6], 
6.PWM [23.4], CTCFBSDB 
HPV18 C+1 2990 strong 
3381 3575 3487 Essex HPV18 E-2 3487 none 
3527 3718 3621 
3.PWM [8.2], 5.PWM [14.0], 
6.PWM [14.2] 
HPV18 pred. 3621 medium 
4440 4638 
S 4505,  
S 4538 
1.PWM [12.2], 5.PWM [10.5] HPV18 pred. 4505 two medium bands 
4947 5155 none N/A HPV18 CTCF?A none 
5045 5253 none N/A HPV18 CTCF?B none 
5381 5577 5475 Essex HPV18 E-1 5475 medium 
5655 5850 5768 
1.PWM [12.9], 3.PWM [9.7], 
4.PWM [7.3], 5.PWM [10.1], 
6.PWM [12.2] 
HPV18 pred. 5768 medium 
HPV16 
1212 1405 
S 1283, 
C 1283 
5.PWM [10.2], CTCFBSDB HPV16 C+2 1283 none 
2852 3049 
S 2916, 
C 2916 
3.PWM [12.2], 5.PWM [9.8], 
6.PWM [20.1], CTCFBSDB 
HPV16 C+1 2916 strong 
4999 5206 5119 Essex HPV16 E-1 5119 weak 
6051 6278 6127 Essex HPV16 E+1 6127 weak 
6426 6600 
S 6515, 
C 6512 
1.PWM [13.9], 3.PWM [6.5], 
4.PWM [8.6], 6.PWM [9.3], 
CTCFBSDB 
HPV16 C-1 6512 weak 
6772 6957 6860 
1.PWM [12.1], 3.PWM [9.0], 
4.PWM [7.7], 6.PWM [9.1] 
HPV16 pred. 6860 weak 
HPV16 
114/K 
1216 1405 1284 5.PWM [10.2] 114K pred. 1284 none 
2852 3049 
S 2917, 
C 2917 
1.PWM [19.3], 3.PWM 
[22.4], 4.PWM [16.0], 
5.PWM [18.2], 6.PWM 
[27.6], CTCFBSDB 
114K C+1 2917 strong 
5000 5207 5120 Essex 114K E-1 5120 weak 
6052 6279 6128 Essex 114K E+1 6128 weak 
6421 6621 6516 
1.PWM [13.9], 3.PWM [6.5], 
4.PWM [8.6] 
114K pred. 6516 weak 
6783 6945 6861 
1.PWM [12.1], 3.PWM [8.9], 
4.PWM [7.7], 6.PWM [9.1] 
114K pred. 6861 weak 
HPV31 
534 713 616 4.PWM [8.2] HPV31 pred. 616 none 
804 1008 885 Essex HPV31 E+4 885 none 
1029 1200 1093 Essex HPV31 E+2 1093 none 
1182 1374 
S 1278, 
C 1278, 
E 1294 
5.PWM [14.0], CTCFBSDB, 
Essex 
HPV31 C+2/E+3 1278 none 
2230 2406 2332 CTCFBSDB HPV31 C+3 2332 none 
2357 2531 
S 2413, 
C 2413 
1.PWM [14.4], 4.PWM 
[14.7], CTCFBSDB 
HPV31 C+1 2413 strong 
2801 3015 2854 
1.PWM [19.2], 3.PWM 
[22.3], 4.PWM [16.0], 
4.PWM [9.0], 5.PWM [18.9], 
6.PWM [27.5] 
HPV31 CTCF?A strong 
2894 3093 none N/A HPV31 CTCF?B none 
5077 5273 5179 Essex HPV31 E+1 5179 strong 
6354 6540 6432 1.PWM [13.5], 3.PWM [7.2] HPV31 pred. 6432 medium 
Table 29) Complete summary of all EMSA-tested fragments of high risk papillomaviruses 
In the case of overlapping motifs found by Storm only the positions of the motif with the 
highest score is shown. If motifs of several tools are located on one fragment, the locations 
are labelled with S for Storm, C for CTCFBSDB tool and E for the Essex tool.  
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Class Type 
Fragment Predicted 
motifs 
on fragment 
Predicted by  
[score] 
Fragment name 
CTCF band 
shift 
from to 
Low 
risk 
HPV6b 
1251 1460 1357 Essex HPV6b E+2 1357 none 
2801 3007 none N/A HPV 6b CTCF?A none 
2887 3101 none N/A HPV 6b CTCF?B none 
4715 4913 4790 Essex HPV6b E-5 4790 none 
4913 5102 
S 5018, 
C 5018, 
E 4987 
4.PWM [7.5], CTCFBSDB, Essex 
HPV6b C-2 5018 
E+1 4987 
none 
5317 5515 
S 5425,  
C 5425,  
E 5431 
1.PWM [16.9], 3.PWM [17.0], 
4.PWM [6.9], 5.PWM [12.9], 
6.PWM [12.2], CTCFBSDB, Essex 
HPV6b C-1 5425 E-
1 5431 
strong 
5995 6199 
S 6110, 
E 6099 
5.PWM [10.0], Essex HPV6b E+3 6099 none 
6179 6382 6264 Essex HPV6b E-2 6264 medium 
7155 7380 
E 7206,  
E 7257 
Essex 
HPV6b E-3 7206 E-4 
7257 
none 
HPV11 
1295 1494 1357 Essex HPV11 E+1 1357 none 
2801 3003 none N/A HPV 11 CTCF?A none 
2900 3104 none N/A HPV 11 CTCF?B none 
3930 4153 4058 Essex HPV11 E-3 4058 medium 
4709 4898 4781 Essex HPV11 E-2 4781 none 
4844 5041 4921 4.PWM [7.3] HPV11 pred. 4921 weak 
5330 5501 
S 5416, 
C 5416,  
E 5422 
1.PWM [18.4], 3.PWM [20.5], 
4.PWM [11.5], 5.PWM [18.6], 
6.PWM [15.8], CTCFBSDB, Essex 
HPV11 C-1 5416 E-1 
5422 
strong 
6243 6428 
S 6311,  
C 6311 
4.PWM [13.2], CTCFBSDB HPV11 C-2 6311 weak 
6544 6738 6636 4.PWM [7.3] HPV11 pred. 6636 
weak, 
smear 
6872 7074 6980 5.PWM [10.1], 6.PWM [9.3] HPV11 pred. 6980 none 
Beta 
PV 
HPV38 
35 219 S 117, C 117 6.PWM [10.9], CTCFBSDB HPV38 C-1 117 medium 
176 363 254 Essex HPV38 E+1 254 none 
584 791 690 6.PWM [9.2] HPV38 pred. 690 none 
1243 1431 
S 1331,  
C 1331 
1.PWM [14.9], 5.PWM [15.6], 
6.PWM [8.5], CTCFBSDB 
HPV38 C+3 1331 medium 
3436 3666 
S 3543, S 
3573,  
C 3540, 
C 3571, E 
3520, E 3544 
E 3487 
1.PWM [13.3], 1.PWM [15.3], 
5.PWM [9.2], CTCFBSDB, Essex 
HPV38 C+1/2 and 
E+2/4/5 3540 
none 
4357 4545 4454 Essex HPV38 E+3 4454 none 
HPV8 
N/A N/A 1959 5.PWM [9.1] N/A N/A 
2262 2481 
S 2387,  
C 2383,  
E 2390,  
E 2346 
1.PWM [13.7], 3.PWM [12.1], 
4.PWM [11.7], 5.PWM [12.7] 
CTCFBSDB [12.7], Essex 
HPV8 C-2 /E-1/E-3 
2380 
N/A 
3553 3742 
S 3642,  
C 3642,  
E 3644 E 3650 
3.PWM [12.6]. CTCFBSDB, Essex 
HPV8 C-1 /E-2/E-4 
3642 
N/A 
N/A N/A 3769 1.PWM [14.3] N/A N/A 
3946 4130 4037 CTCFBSDB [6.5] HPV8 C-3 4037 N/A 
N/A N/A 5090 
1.PWM [11.1], 4.PWM [6.5], 
5.PWM [11.3] 
N/A N/A 
N/A N/A 5280 5.PWM [9.4 N/A N/A 
N/A N/A 6172 1.PWM [11.4 N/A N/A 
7260 7459 7361 Essex HPV8 E+1 7361 N/A 
Table 30) Complete summary of all EMSA-tested fragments of low risk and beta PV 
Low risk viruses showed a strong and conserved CTCF binding site around nucleotide 5400. 
The CTCF binding cluster of beta viruses at nucleotide 3600 was not confirmed. If motifs of 
several tools are located on one fragment, the locations are labelled with S for Storm, C for 
CTCFBSDB tool and E for the Essex tool.  
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3.4.9 Creation of EMSA based CTCF binding maps of all HPV tested 
All data generated so far have been combined to create CTCF binding maps for all PV types 
tested using the DNAman software. The data shown in the maps on the following pages 
includes predicted binding sites, testing coverage and EMSA results (Figure 27 to Figure 30). 
Predicted binding sites are shown as yellow marks on the genome whereas the EMSA 
testing coverage is shown as checked fragments situated in an outer ring around the 
genome. If one of those fragments resulted in a shift on the gel this fragment is shown as a 
blue bar on the genome. Accordingly, if a yellow prediction mark is found on top of a blue 
bar it is likely that the CTCF protein binds the fragment at the predicted site. However this 
does not always need to be the case as seen with the overlapping fragments used to test 
binding site E+1 of BPV1. All prediction marks are labelled with the tool or PWM with which 
they were predicted. The score of the prediction and its location are also shown. 
Additionally functional elements like promoters and polyadenylation sites are indicated in 
the maps if the data was available (source: National Institute of Allergy and Infectious 
Disease, USA at http://pave.niaid.nih.gov/index.html#transcript) (reviewed by Van 
Doorslaer et al., 2013). The predicted CTCF binding sites in HPV8 could not be tested by 
EMSA due to the lack of functional template DNA. Therefore no testing coverage is shown.  
Looking at the high risk HPV types only, a common pattern is revealed. In addition to the 
strong and conserved binding site around nucleotide 3000, every high risk virus contains 
several more binding sites within the L1 and L2 reading frames. The majority of these 
binding sites showed a weak or medium strength gel shift. No binding sites were revealed 
in other regions of high risk papillomaviruses, including the LCR and the first 2000bp of the 
viral genome. The binding patterns of HPV16 and HPV16 114/K are virtually identical, which 
is likely to be the result of the high degree of similarity between these viruses. Even most of 
the predicted binding motifs have an identical sequence as seen in Table 22. Despite the 
fact that several CTCF binding sites were predicted between nucleotides 500 and 1500 
across all high risk and low risk viruses, none of those predicted sites showed a shift in the 
EMSA experiments, indicating that CTCF does not bind in this region of the HPV genome. 
On the other hand BPV1 has a confirmed CTCF binding site in this region. In fact, the 
binding sites across BPV1 are much more distributed across the genome compared HPV 
types. However BPV1 has a similarity to the high risk HPV types tested which is the strong 
CTCF binding site around nucleotide 3000. 
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Figure 27) Complete CTCF binding map of the HPV18 and HPV31 genome 
Fragments tested are checked and situated in an outer ring around the genome. CTCF binding fragments are shown in blue and predicted binding 
sites are indicated with a yellow bar. Promoters are shown in teal. 
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Figure 28) Complete CTCF binding map of the HPV16 and HPV16 114/K genome 
Fragments tested are checked and situated in an outer ring around the genome. CTCF binding fragments are shown in blue and predicted binding 
sites are indicated with a yellow bar. Promoters are shown in teal. No promoter locations for HPV16 114/K were available. 
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Figure 29) Complete CTCF binding map of the HPV6b and HPV11 genome 
Fragments tested are checked and situated in an outer ring around the genome. CTCF binding fragments are shown in blue and predicted binding 
sites are indicated with a yellow bar. Promoters are shown in teal. No promoter locations for HPV6b were available. 
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Figure 30) Complete CTCF binding map of the HPV38 genome and predicted CTCF binding sites on HPV8 
Fragments tested are checked and situated in an outer ring around the genome. CTCF binding fragments are shown in blue and predicted binding 
sites are indicated with a yellow bar. Promoters are shown in teal. None of the predicted binding sites of HPV8 have been tested via EMSA since no 
functional template DNA was available. The promoters of HPV8 were the only functional elements available for these viruses. 
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3.4.10 Analysis of CTCF binding site prediction tools  
With the number of fragments tested it was possible to evaluate the tools used for in silico 
screening of CTCF binding motifs. Table 31 summarises the EMSA results of the fragments 
designed to test predicted binding site from every tool. Fragments without predicted 
binding sites are also shown. The table indicates how many of those fragments showed a 
shift with CTCF protein. Additionally the percentages of fragments showing a gel shift were 
calculated for each category. The Essex tool predicted 33 binding sites in all the sequences 
tested, out of which 14 showed a shift on the gel with CTCF protein. This resulted in a ratio 
of confirmed to predicted CTCF binding sites of 42.4 %. Even though binding site E+1 in 
BPV1 has been shown not to be the real CTCF binding site on this fragment it was still 
counted as a confirmed binding site in the table since the other binding sites were not as 
thoroughly investigated as E+1 to confirm the true location of the binding site. Thus it 
would have introduced a bias if this fragment was removed from the calculation since the 
other fragments were not double checked in the same way.  
 
 
Number of fragments 
with predicted binding 
sites 
Fragments binding 
CTCF in vitro 
Percentage of 
confirmed binding 
sites 
Essex tool 33 14 42,4 % 
CTCFBSDB tool 1.0 17 11 64,7 % 
Storm 33 21 63,6 % 
Fragments without a 
predicted binding site 
25 3 12.0 % 
Table 31) Comparison of in silico prediction tools for CTCF binding motifs 
This table does not include the predicted binding sites of HPV8 since this virus was not 
tested experimentally.  
 
In contrast to the other two tools used, the Essex tool screened for short sequences of  
10 bp and since the primary CTCF binding motif is longer than that, the Essex tool was 
expected to find more false positives than the other tools. The Essex tool has a ratio of 
confirmed binding sites to predicted binding sites (hit ratio) of 42.4 %. The CTCFBSDB tool 
1.0 screened for 4 different PWM and only gave the best match to each PWM while 
ignoring all lesser matches. This led to a comparably small number of 17 predictions in all 
sequences screened. However the hit ratio was the highest with 64.7 %. Using Storm for 
screening with 5 different PWM revealed 33 putative binding sites, of which 21 showed a 
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shift on the gel. This results in a hit ratio of 63.6 % and is therefore only marginally less 
accurate than the CTCFBSDB tool 1.0 with 64.7 %. The fact that the Storm software 
revealed more total binding sites than the CTCFBSDB tool 1.0, while maintaining a high hit 
ratio makes this prediction tool superior to the other two prediction tools.  
Fragments that were not predicted to bind CTCF with any of the tools used showed gel 
shifts in 12.0 % of cases. This number is relatively high and may due to the in vitro testing of 
CTCF binding which may be prone to giving false positive results. Alternatively, many 
binding sites may exist that are not recognized by any of the tools. Since the Essex tool is 
completely based on in vitro EMSA data, it may be possible that the database it uses for 
screening may also contain many false positive results. If this is the case it would be likely 
that a lower percentage of EMSA confirmed binding sites of the Essex tool bind CTCF in vivo 
compared to confirmed binding sites predicted with the tools that are based on ChIP data.  
Binding sites predicted by Storm were split up into predictions for each of the single PWM 
used by the tool. Table 32 shows how many binding sites above threshold were found with 
each PWM and how many of the fragments containing these binding sites actually bound 
CTCF in EMSA. For example, 12 binding sites out of the 33 binding sites found by storm 
were identified by the 3rd PWM. All 12 fragments bound CTCF, resulting in a hit ratio of 100 
%. This is the highest hit ratio of all PWM used even though the third PWM has the lowest 
score threshold. The 1st PWM has a very similar hit-ratio. Only one out of the 14 fragments 
containing predicted binding sites from this PWM did not bind CTCF, resulting in a hit ratio 
of 92.9 %. PWM no. 4 and 6 both predicted 17 binding sites each while also having exactly 
the same hit ratios at 82.4 %. The fifth PWM exhibits the lowest overall hit ratio with only 
64.7 %, even though it has the second highest score threshold.  
 
 
Score 
threshold 
Number of 
fragments 
Fragments binding CTCF 
in vitro 
Percentage of confirmed 
binding sites 
1.PWM 10,72 14 13 92.9 % 
3.PWM 6,45 12 12 100,0 % 
4.PWM 6,54 17 14 82,4 % 
5.PWM 8,71 17 11 64,7 % 
6.PWM 8,51 17 14 82,4 % 
Table 32) Comparison of PWM used for Storm screening based on EMSA results 
PWM 1 and 3 are showing the best hit-ratio at the score threshold used. 
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Table 33 shows the hit ratio of fragments containing binding motifs predicted by several 
different PWM. All binding sites recognised by 3 to 5 different PWM showed a shift in 
EMSA. The ratio of confirmed to predicted binding sites drops down to 66.7 % with motifs 
predicted by only two PWM and it further drops to 28.6 % for binding sites that were 
predicted by only one single PWM. Hence the identification of a particular binding motif by 
several PWM is an important factor that determines the likelihood of this motif for being 
tested positive for CTCF binding in EMSA. 
 
Number of PWM that 
identified this site 
Number of 
fragments 
Fragments binding 
CTCF in vitro 
Percentage of confirmed 
binding sites 
5 6 6 100,0 % 
4 3 3 100,0 % 
3 4 4 100,0 % 
2 6 4 66,7 % 
1 14 4 28,6 % 
Table 33) Identification of CTCF binding motifs by multiple PWM increases the chance of 
EMSA confirmation  
 
However the sample size for this analysis was low. This leaves room for criticism. Also a 
slight bias may have been introduced because fragments from HPV16 and HPV16 114K 
were very similar and often had identical binding motifs, yet they were still treated as 
independent fragments in this analysis. Only very few binding sites were predicted by the 
Essex tool that were also found by either CTCFBSDB 1.0 or Storm. Hence binding sites 
predicted by the Essex tool were not included in Table 33. 
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3.5 Mutation of a CTCF binding site in the HPV18 genome and in 
vivo confirmation of binding abrogation  
3.5.1 Investigating mutations that have the potential to abrogate CTCF binding 
in EMSA 
With the intention to abrogate CTCF binding around nucleotide 3000 and 5400 in HPV18, 
mutations were investigated that could be introduced into the HPV18 genome. Small FAM-
labelled probes were synthesised that contained the CTCF binding site of interest either 
with or without mutations. It was shown previously that fragments of 60 base pairs are 
large enough to bind CTCF (Bell et al., 1999). A probe of 60bp containing the HPV18 CTCF 
binding site at nucleotide 3000 was designed and tested for CTCF binding by EMSA. Another 
60bp probe that contained a previously characterised CTCF binding site was used as a 
positive control for these experiments (Bell et al., 1999). The sequences of these probes can 
be found in Figure 31 and the gel shifts are shown in Figure 32. In contrast to the positive 
control probe the HPV18 probe did not bind CTCF in this in vitro reaction. Thus gel shifts 
with probes containing mutated versions of the binding site were futile. 
 
A possible reason for not seeing a band shift with the intact CTCF binding site could be that 
the predicted binding motif was wrong. However the conserved nature of this motif did not 
support this hypothesis. Furthermore, the fragment screening for the CTCF binding site 
around nucleotide 3000 in BPV1 revealed that at least some CTCF binding sites need a large 
stretch of DNA to be able to bind to the fragment. A 60bp probe may not have been 
enough for CTCF to bind to this particular motif or the CTCF binding site was not positioned 
optimally within the probe. Based on these possible explanations, it was decided to 
HPV18 probe: 
5’-GGCATACAGACATTAAACCACCAGGTGGTGCCAGCCTATAACATTTCAAAAAGTAAAGCA-3’ 
Pos. control: 
5’-AGGCGCGCCCCCAGGGATGTAATTACGTCCCTCCCCCGCTAGGGGGCAGCGGCGCGCCT-3’ 
Figure 31) Sequences of pos. control probe and the HPV18 probe containing binding 
site 3000 
In the positive control probe the bases which are crucial for CTCF binding are shown in 
yellow. The predicted binding site in the HPV18 probe is marked in yellow. This binding 
site was found on the sense strand by the CTCFBSDB tool 1.0. Considering that it was 
recently published that a secondary motif downstream of the primary motif can 
contribute to CTCF binding, the probe was designed to cover 26 base pairs downstream of 
the predicted binding site to include a potential secondary motif (Schmidt et al., 2012). 
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continue with site directed mutagenesis of the HPV18 genome and to use fragments 
amplified from the mutated HPV18 genome to screen for loss of CTCF binding.  
 
Further analysis of the predicted CTCF binding site gave another indication as to why a shift 
was not seen with the 60bp probe. The HPV18 probe was designed to include a binding 
motif found by CTCFBSDB 1.0 with the sequence AAACCACCAGGTGGTGCCAG. This motif 
was found on the sense strand. Schmidt et al. have shown that a secondary motif a few 
nucleotides downstream of the primary motif can be important for CTCF binding. 
Therefore, 26 nucleotides downstream of the motif found were included in the probe. At a 
later date, screening for CTCF binding sites with the PWM defined by Schmidt et al. became 
available using Storm or CTCFBSDB 2.0. It was revealed that the primary PWM recognises a 
CTCF binding site at the same position as CTCFBSDB 1.0 but on the antisense strand instead 
of the sense strand (motif: CACCACCTGGTGGT). Hence, the secondary motif would be 
present upstream instead of downstream of this primary motif. In the probe used for EMSA 
only 10 nucleotides upstream of the primary binding motif were included which means that 
the secondary binding motif was at the outer edge of the probe what may have resulted in 
 
Figure 32) EMSA of 60bp probe for HPV18 binding site 3000 
This image is representative of two independent experimental repeats. The control 
fragments used in previous EMSA are shown in addition to the positive control for the 
60bp probe shift. The 60bp positive control probe shows a strong band shift. However 
the HPV18 probe containing the predicted binding site does not show a shift. 
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abrogation of CTCF binding. Figure 33 shows a comparison of the position of primary and 
secondary binding motifs on the positive control probe and the HPV18 probe.  
  
 
Positive control sense strand: 
5’-AGGCGCGCCCCCAGGGATGTAATTACGTCCCTCCCCCGCTAGGGGGCAGCGGCGCGCCT-3’ 
 
Positive control antisense strand: 
5’-AGGCGCGCCGCTGCCCCCTAGCGGGGGAGGGACGTAATTACATCCCTGGGGGCGCGCCT-3’ 
 
 
HPV18 probe sense strand: 
5’-GGCATACAGACATTAAACCACCAGGTGGTGCCAGCCTATAACATTTCAAAAAGTAAAGCA-3’ 
 
HPV18 probe antisense strand: 
5’-TGCTTTACTTTTTGAAATGTTATAGGCTGGCACCACCTGGTGGTTTAATGTCTGTATGCC-3’ 
 
Figure 33) Probe sequence with binding motifs for the PWM defined by Schmidt et al.  
The primary motif is shown in yellow and the secondary motif is shown in teal. The positive 
control probe contains both matches to the PWM in the middle of the probe whereas the 
HPV18 probe has the secondary binding motif on the edge of the sequence. This is likely to 
be the reason why CTCF did not bind to the probe in EMSA. The PWM was reproduced 
from Schmidt et al. with permission from the copyright holder (Schmidt et al., 2012). 
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3.5.2 Site directed mutagenesis of HPV18 binding sites at nucleotide 3000 and 
5400 
The gel shift using a 60bp probe containing the HPV18 CTCF binding site at nucleotide 3000 
did not show a shift in EMSA experiments. This could either be due to the predicted motif 
being a false positive, the short length of the probe or the fact that the secondary motif is 
at the very edge of the probe. The conserved nature of the binding site at nucleotide 3000 
among all high risk HPV combined with the EMSA data from larger fragments led to the 
decision to mutate this binding site in HPV18 regardless the failed gel shift experiments 
with the 60bp probe. It was decided to look for the binding motifs that fit the PWM defined 
by Schmidt et al. PWM around nucleotide 3000 manually because the expertise for 
computer based screening for this PWM was not available at the time these experiments 
were carried out.  
The mutations for the abrogation of CTCF binding were designed in a way that the most 
important bases of the motifs found were altered. In addition to the PWM defined by 
Schmidt et al. the binding site at this position that was identified by CTCFBSDB 1.0 was 
taken into account. 
 
       
 
Wild type sequence around nucleotide 3000: 
 
5’-GGCATACAGACATTAAACCACCAGGTGGTGCCAGCCTATAACATTTCAAAAAGTAAAGCA-3’ 
    G  I  Q  T  L  N  H  Q  V  V  P  A  Y  N  I  S  K  S  K  A  
 
Mutant sequence around nucleotide 3000: 
 
5’-GGCATACAGACATTAAATCACCAGGTAGTGCCAGCCTATAACATCTCAAAAAGTAAAGCA-3’ 
    G  I  Q  T  L  N  H  Q  V  V  P  A  Y  N  I  S  K  S  K  A  
 
 
Figure 34) Mutations to abrogate CTCF binding at nucleotide 3000 of HPV18 
Bold letters mark the binding motif identified by CCFBSDB 1.0. The motifs of Schmidt et 
al. are shown in yellow and teal. Three important bases for the Schmidt motifs were 
mutated, two of which also disturbed the binding site identified by CTCFBSDB 1.0. None 
of the mutations shown changed the amino acid sequence of the E2 protein which is 
encoded in this region. The PWM was reproduced from Schmidt et al. with permission 
from the copyright holder (Schmidt et al., 2012). 
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Both motifs were found on the sense strand. Thus it was decided to proceed by mutating 
the predicted CTCF binding site at nucleotide 3000 on the sense strand of the HPV18 
genome by site directed mutagenesis in a way that disturbs both overlaying motifs at once. 
Figure 34 shows the motif found by CTCFBSDB 1.0 in bold and the motifs matching the 
PWM defined by Schmidt et al. are shown in yellow and teal. The nucleotides to be 
mutated are marked in purple. All mutations were chosen in a way that did not alter the 
amino acid sequence of the underlying gene of E2 which is encoded in this region. 
The CTCF binding site identified around nucleotide 5400 is highly conserved in low risk 
viruses and showed a medium shift in HPV18. Therefore this binding site was also mutated. 
However the binding site around nucleotide 5400 was identified by the Essex tool which 
does not rate the single bases of the motif by their importance for CTCF binding. Thus the 
motif defined by Schmidt et al. was overlaid to identify important base. Three of these 
bases were mutated without disturbing the amino acid sequence of the protein encoded in 
this region. The details about mutating binding site 5400 can be found in Figure 35.  
 
  
            
 
Wild type sequence around nucleotide 5400: 
 
5’-ATTACATTACCATCTACTACCTCTGTATGGCCCATTGTATCACCCACGGCCCCTG-
3’ 
     L  H  Y  H  L  L  P  L  Y  G  P  L  Y  H  P  R  P  L 
 
 
Mutant sequence around nucleotide 5400: 
 
5’-ATTACATTACCATCTACTACCGTTGTACGGCCCATTGTATCACCCACGGCCCCTG-
3’ 
     L  H  Y  H  L  L  P  L  Y  G  P  L  Y  H  P  R  P  L 
 
 
Figure 35) Mutations to abrogate CTCF binding at nucleotide 5400 of HPV18 
Three important bases were mutated. None of these mutations changed the amino acid 
sequence of the underlying protein L2. The PWM was reproduced from Schmidt et al. 
with permission from the copyright holder (Schmidt et al., 2012). 
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The template used for site directed mutagenesis is the cloning vector pGEM2 containing 
the complete HPV18 genome (obtained from Frank Stubenrauch, University Hospital 
Tuebingen, Germany). This construct can be easily amplified in bacteria, which simplifies 
the procedure of site directed mutagenesis. The HPV18 genome can be excised from the 
plasmid and re-ligated to re-establish the complete HPV18 genome including the 
mutations. However pGEM2 combined with the HPV18 genome results in a large plasmid of 
about 10,700bp which can cause problems with many site directed mutagenesis methods. 
A specialised kit was used to overcome this issue; the QuikChange II XL Site-Directed 
Mutagenesis Kit from Agilent Technologies.  
The primers used for this technique were carefully designed to fit the requirements of the 
kit (Figure 36). Mutations had to be located towards the middle of the primer, leaving at 
least 10 nucleotides at either end that were complementary to the template sequence. 
Since it was planned to introduce three disparate mutations per CTCF binding site, the 
mutagenesis primer needed to be long enough to cover all of the mutation sites while still 
having the 10 complementary nucleotides at either end. The introduction of three 
mutations at once lowered the melting temperature of the primer but a melting 
temperature of at least 78°C was suggested by the manufacturers of the site-directed 
mutagenesis kit. Thus, further elongation of the primer was required to prevent the melting 
temperature from dropping below 78°C.  
 
Primer for mutating the CTCF binding site at nucleotide 3000  
5’-CAGACATTAAATCACCAGGTAGTGCCAGCCTATAACATCTCAAAAAGTAAAG-3’ 
 
Primer for mutating the CTCF binding site at nucleotide 5400 
5400: 5’-CATTACCATCTACTACCGTTGTACGGCCCATTGTATCACCC-3’ 
 
 Binding site 3000 Binding site 5400 
Length 52nt 41nt 
Tm 78.1°C 78.1°C 
Nucleotides before first mutation    11nt 17nt 
Nucleotides after first mutation 12nt 17nt 
Potential for hairpin formation none none 
3’ complementarity none none 
 
Figure 36) Primers used for mutating the CTCF binding sites around nucleotide 3000 
and 5400 in HPV18 
The reverse primers used for site directed mutagenesis were the reverse complement of 
the forward primers shown here. 
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However using a long primer increased the chance of secondary structure formation and 
could potentially impair the mutagenesis reaction. Hence each primer was checked for its 
potential for hairpin formation, 3’ complementarity and self-annealing capacity. The 
forward primers used for the site-directed mutagenesis and their properties are shown in. 
The reverse primer used in the mutagenesis PCR was the exact reverse complement of the 
primer containing the mutations. A specialised DNA polymerase suitable for the 
amplification of large targets was used to synthesise the entire plasmid starting from the 
mutation primer.  
When the expertise for in silico screening for the motifs defined by Schmidt et al. became 
available, HPV genome sequences were re-screened and it was revealed that the CTCF 
binding site at nucleotide 3000 had a second match to the PWM defined by Schmidt et al. 
and this match was located on the antisense strand (Figure 37).  
 
Since the match on the antisense strand was an even better fit to the PWM than the one on 
the sense strand, it was likely that the motif on the antisense strand was the real binding 
motif for CTCF. Figure 37 shows the antisense sequence of the mutation site and the 
location of the newly discovered match to the PWM defined by Schmidt et al. It is also 
shown how the mutations introduced affect this second match to the PWM. The mutations 
                     
 
Antisense wild type sequence at nucleotide 3000: 
 
5’-TGCTTTACTTTTTGAAATGTTATAGGCTGGCACCACCTGGTGGTTTAATGTCTGTATGCC-
3’ 
 
Antisense mutant sequence at nucleotide 3000: 
 
5’-TGCTTTACTTTTTGAGATGTTATAGGCTGGCACTACCTGGTGATTTAATGTCTGTATGCC-
3’ 
 
 
 
Figure 37) Second CTCF binding motif found on the antisense strand of the mutation 
site at nucleotide 3000 
Computer screening for CTCF binding sites revealed a second match the PWM defined 
by Schmidt et al., located on the antisense strand that fits even better to the PWM than 
the motifs on the sense sequence. The mutations introduced in the mutant sequence 
also impair 2 important bases in the motif found on the antisense strand. Thus either 
binding site is disturbed by the mutations. 
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disturbed two important bases of the motif on the antisense strand. Therefore it was likely 
that CTCF binding to the motif on the antisense strand was also abrogated. The mutation 
site at nucleotide 5400 was also screened for the PWM defined by Schmidt et al. and no 
additional binding site was found here.  
In silico screening for potential transcription factor binding sites covering both mutation 
sites was done to account for any possible loss or gain of transcription factor binding other 
than CTCF. This screening was performed using MATCHTM from Biobase (available at 
http://www.gene-regulation.com/cgi-bin/pub/programs/match/bin/match.cgi) (Kel et al., 
2003). A balanced setting was used for screening that reduced false positive results and 
false negative results at once. The sequences screened are the ones shown in the figures 
for mutating both CTCF binding sites (Figure 34 and Figure 35). Every potential transcription 
factor binding site is given a score that shows how well the potential binding site matches 
to the core motif of the PWM used for a particular transcription factor. These scores are 
calculated with a different method than the one used for determining the scores of CTCF 
binding sites. Thus, these scores are not comparable with one another. The maximum score 
that can be given my MATCHTM is 1.000. All potential transcription factor binding sites 
across the mutation sites that were found by MATCHTM are summarised in Table 34.  
 
Transcription 
factor 
Wild type 3000 
[core score] 
Mutated 3000 
[core score] 
Wild type 5400 
[core score] 
Mutated 5400 
[core score] 
MyoD 1.000 - - - 
Oct1 0.964 0.982 - - 
GATA3 - 0.955 - - 
SOX9 - - 1.000 1.000 
Myb - - - 1.000 
Table 34) Screening for transcription factor binding sites across the mutation sites 
The mutation of the CTCF binding site around nucleotide 3000 disrupts the potential 
binding site for MyoD, increases the affinity for Oct1 and creates a binding site for GATA3. 
The mutation of the CTCF binding site around nucleotide 5400 does not change the affinity 
for SOX1, but a new binding site for Myb is created. 
 
The wild type CTCF binding site around nucleotide 3000 binds Myogenic Differentiation 1 
(MyoD) with a score of 1.000 and Octamer Transcription Factor 1 (Oct1) with a score of 
0.964. In the mutant of CTCF binding site 3000, the binding site for MyoD is disturbed and 
the score for Oct1 is slightly increased to 0.982. MyoD is not expressed in the HPV model 
cell line Human Foreskin Keratinocytes (HFK), so the loss of the binding site for MyoD may 
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have no effect on HPV gene expression (Woodman, University of Birmingham, personal 
communication). Also a putative new binding site for GATA binding protein 3 (GATA3) with 
a score of 0.955 is created in the mutant. This transcription factor is expressed in HFK, so 
potential GATA3 binding and the slightly increased affinity of the Oct1 binding site could 
account for functional differences in the mutant in addition to the potential loss of CTCF.  
The mutations of CTCF binding site 5400 do not change the affinity for SRY-box 9 (SOX9) 
which still scores 1.000 in the mutant. However a new potential binding site for 
myeloblastosis viral oncogene homolog (Myb) with a score of 1.000 is formed. Myb can 
activate or repress gene transcription and may have an influence on viral gene expression 
(Vargova et al., 2011).  
Having all the mutagenesis primers available for mutating both CTCF binding sites, three 
different mutants were planned; first, a mutant of binding site 3000; second, a mutant of 
binding site 5400 and; third, a double mutant of both binding sites. From here on these 
mutants are referred to as C3 for mutant 3000, C5 for mutant 5400 and C3C5 for the 
double mutant. Following the PCR-based site directed mutagenesis reaction, the remaining 
template DNA was degraded using the methylation specific nuclease Dpnl. The PCR product 
was then transformed into E.coli XL10-Gold ultracompetent cells, spread on an agar plate 
and single colonies were picked to grow overnight cultures. Plasmids from these overnight 
cultures were isolated using a Qiagen mini prep kit. The regions around the mutation sites 
of the isolated plasmids were sequenced and many clones were shown to contain the 
desired mutations. From each of the three mutants a particular clone was chosen to be 
sequenced in full. Only the clone for C5 showed a single point mutation at nucleotide 4360 
(GA). However this mutation is silent and was shown to occur naturally in other HPV18 
isolates like CU11 (accession number GenBank: GQ180787.1). Therefore the plasmid with 
this mutation was still used for future experiments.  
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3.5.3 Confirmation of CTCF binding abrogation at mutated sites within the 
HPV18 genome and re-construction of the viral episome 
Before transfecting the mutated genomes into cells, the CTCF binding abrogation in the 
mutant genomes needed to be confirmed in vitro using EMSA. The same primer pair was 
used to amplify the binding site-containing fragment from wild type (WT), C3 and C3C5 
genomes. Those fragments were tested by EMSA as described previously and the results 
are shown in Figure 38 and Figure 39. The C3 mutations resulted in a near complete 
abrogation of CTCF binding. Quantification of the band shifts revealed that the C3 mutant 
only showed 2.6 % of the CTCF binding of the wild type. This mutant was therefore used for 
further experiments. However the fragment containing the mutated C5 binding site still 
bound CTCF as efficiently as the WT fragment (Figure 38 and Figure 39).  
Either the mutations introduced did not affect CTCF binding or the actual CTCF binding site 
on this fragment was not situated at the predicted binding motif and was therefore not 
altered by the mutations. Hence the C5 and the C3C5 mutants were not used for 
transfection into primary human foreskin keratinocytes.  
 
 
Figure 38) Testing mutations at nucleotide 3000 and 5400 for CTCF binding abrogation 
The EMSA image shown here is representative of three independent experimental repeats. 
The wild type shows a strong band with fragment 2990 whereas the shift in the C3 mutant 
is almost completely gone. Binding site 5475 does not show a change in band shift with the 
mutant fragment. The mutations introduced here did not affect CTCF binding. 
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Figure 39) Quantification of CTCF band shifts for wild type and mutants 
The bands of all three independent repeat experiments were quantified and normalised 
against the positive control. The p values were calculated using the double sided t-test 
against the null hypothesis that the CTCF binding in the mutant was the same as in the wild 
type. The difference in CTCF binding at 2990 is significant. The C3 mutant only shows 2.6 % 
of the CTCF binding seen in the wild type. No significant difference in CTCF binding was 
found when comparing wild type and C5 mutant. 
 
 
Before the C3 mutant and wild type HPV18 genomes could be transfected into primary 
cells, the viral genome needed to be excised from the plasmid backbone using EcoRI 
followed by re-ligation to re-establish an uninterrupted HPV18 episome. The ligation was 
performed using T4 ligase overnight at 16 °C. The DNA from each of the single steps for 
reconstruction was run on an agarose gel to check the banding pattern of digested and 
ligated DNA as seen in Figure 40. The sample digested with EcoRI showed two bands as 
expected. The vector pGEM2 is 2869 bp and the HPV18 genome is 7857 bp. Re-ligation 
resulted in random ligation products of these two fragments, including the ligation product 
that was a re-constructed ring of the HPV18 DNA only. In this form the viral episome could 
be transfected into primary human foreskin keratinocytes (HFK). No purification of the 
ligation products was necessary since only re-ligated, complete HPV18 episomes can be 
stably maintained by the host cell. 
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CTCF binding in the mutant relative to CTCF 
binding in the wild type 
p= 0.006 
p= 0.689 
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3.5.4 Creation of cell lines of human foreskin keratinocytes that stably express 
wild type or mutant HPV18 
In collaboration with Dr. Sally Roberts at the University of Birmingham, UK, re-ligated viral 
episomes were transfected by Dr. Jo Parish into primary human foreskin keratinocytes from 
two different donors. Cells from two donors were chosen to reduce donor-specific bias. 
From the samples of each donor two cell lines were created out of which one contained the 
wild type virus (WT) and the other one the C3 mutant, resulting in overall 4 cells lines. Viral 
episomes were co-transfected together with a neomycin marker plasmid into sub-confluent 
primary HFK with subsequent selection using G418. Viral oncogenes transcribed from these 
HPV18 episomes immortalised the host cells. Continuous culturing led to senescence in 
cells without viral episome, leaving a continuous cell line of viral genome-containing cells 
(Hubert and Laimins, 2002, Wilson and Laimins, 2005).  
A fragment across the mutation site was amplified by PCR from whole DNA extracted from 
each cell line and sent for sequencing. It was shown that all cell lines contained the virus 
 
Figure 40) Digestion and re-ligation of plasmids containing WT and C3 mutant HPV18 
DNA 
Both images are representative of two independent technical repeats. 
A) Wild type and mutant plasmid were digested with EcoRl overnight. The linearised viral 
episome is found at 7857bp and the linearised pGEM2 is localised at 2869bp. B) Random 
ligation of all fragments present resulted in multiple bands. Also the viral genome was re-
ligated to from the circularised episome.  
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Figure 41) Southern blot of WT and 
C3 genomes isolated from Georgie 
HFK cells 
This image is representative of two 
independent experimental repeats 
(cropped section of Figure 42). EcoRI 
cuts the HPV18 genome once, 
resulting in a single band of 
approximately 8kb. BglII does not 
cut the HPV18 genome but cuts the 
host genome. The bands seen 
following BglII digestion resemble 
HPV18 episomes in supercoiled and 
open circle form. This confirms that 
the HPV genomes are episomally 
maintained. This data has been 
kindly provided by Dr. Jo Parish, 
University of Birmingham. 
intended, i.e. there was no cross contamination 
found in any of the cell lines (the alignment is 
shown in the appendix, page 209). The cell lines 
from the first donor were named Georgie WT 
(GWT) and Georgie C3 (GC3). Accordingly the cell 
lines of the second donor were Clonetics WT 
(CWT) and Clonetics C3 (CC3).  
Since PV episomes can, by chance, integrate into 
host DNA it was vital to check that the episomes 
introduced were maintained episomally instead 
of being integrated. To do so a southern blot was 
prepared by Dr. Jo Parish. Whole cell DNA from 
each cell line was sheared and then digested 
with two different restriction enzymes. EcoRI 
cuts the viral episome once, resulting in 
linearised DNA of 8kb as seen in Figure 41 and 
Figure 42. The enzyme BglII does not cut the viral 
episome but it frequently cuts host DNA. If the 
viral episome is maintained episomally two 
bands are seen on the southern blot, one for the 
open circle episome and one for the supercoiled 
episome.  
Digestion of episomal DNA with EcoRI results in linearised DNA shown as a single band of 8 
kb on the southern blot. Also digestion with BglII resulted in the expected banding pattern 
of supercoiled episomal DNA. Thus the presence of episomal HPV DNA was confirmed. If 
the viral episome is integrated, digestion with either EcoRI or BglII cuts the viral genomes 
out of the host DNA, resulting in linearised viral episomes with host DNA attached to either 
end of it, theoretically resulting in a different banding pattern (Dall et al., 2008). However 
single integrants would be below the detection limit of this experiment and could possibly 
co-exist with episomal HPV DNA.  
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Figure 42) Southern blot for HPV18 DNA from each of the cell lines created 
The images are representative of two independent experimental repeats. Some cell 
lines have been transfected in duplicate and also these duplicates are tested. The single 
cutter EcoRI linearises the viral episome so that it migrates at 8kb. All cell lines show 
episomal HPV18 DNA. Digestion with BglII only cuts host DNA and leaves the viral 
episome intact. Here open circle and supercoiled episome DNA can be seen. This data 
has been kindly provided by Dr. Jo Parish, University of Birmingham. 
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3.6 Analysis of cell lines maintaining wild type or mutant HPV18 
3.6.1 Collaboration project 
The data presented in this chapter was generated in collaboration with the University of 
Birmingham and the University of Cambridge. The exchange of expertise was essential for 
the success of this project and collaboration with the University of Birmingham made it 
possible to work on HPV infected human cells despite the lack of ethical approval for such 
work at St. Andrews University. 
 
3.6.2 ChIP testing of the viral CTCF binding pattern in cell lines maintaining 
wild type and C3 mutant HPV18 
All experiments presented in the previous sections confirmed CTCF binding sites in vitro. 
However the CTCF binding pattern based on in vitro results may not fully resemble in vivo 
conditions, especially considering the unexpected abundance of CTCF binding sites found 
using EMSA. Thus it was decided to test all predicted CTCF binding sites again using 
chromatin immunoprecipitation (ChIP) on the cell lines maintaining wild type and C3 
mutant HPV18. The ChIP experiments were carried out using the ChIP-IT® Express Enzymatic 
Kit from Active Motif. Since viral gene expression changes upon differentiation of the host 
cell the CTCF binding pattern in the viral genome may change as well. However it was 
decided to exclusively use undifferentiated cells for ChIP since differentiated and therefore 
keratinous cells were expected to cause major problems with the sample preparation. 
Undifferentiated cells were formaldehyde fixed, harvested by scraping and dounced with a 
dounce homogenizer to generate a nuclear preparation. Figure 43 shows HPV18 
maintaining HFK cells before and after douncing. These nuclear preparations were treated 
with a cocktail of restriction enzymes that enter the nuclei through nuclear pores and cut 
the DNA into fragments. Since the DNA is maintained in nucleosomes, enzymatic digestion 
with this cocktail of randomly cutting enzymes was only possible in-between nucleosomes. 
This resulted in shearing of the DNA into fragments that are multiples of 150bp. The 
enzymatic digestion was timed and stopped after the desired degree of fragmentation was 
reached. A fragmentation pattern was chosen of which the majority of fragments were 
between 150 and 450 base pairs in size as seen in Figure 44. 
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Figure 44) Enzymatic fragmentation of 
crosslinked DNA-protein complexes 
This image is representative of three 
independent experimental repeats. The 
fragmentation reaction was stopped at 
different time points. Digesting the DNA 
for 10 minutes resulted in a 
fragmentation pattern appropriate for 
ChIP. 
 
Immunoprecipitation was performed by incubating these fragments with antibodies 
targeting either CTCF or FLAG (negative control) followed by precipitation of protein-DNA 
complexes bound to these antibodies using 
protein A coated magnetic beads. Precipitated 
fragments were then eluted, crosslinks were 
reversed and the sample was Proteinase K 
digested before purifying it using a PCR clean-
up kit. Subsequently, the samples were 
analysed by qPCR. Primers used to check 
predicted CTCF binding sites amplified a 
region that either contained the predicted 
binding site or had a predicted binding site in 
its close vicinity. Also fragments that did not 
have a predicted CTCF binding site in their 
vicinity were tested to act as negative control 
and to give a more complete coverage of the 
HPV18 genome. All fragments used to test 
various predicted binding sites are shown in 
Figure 45 and Table 35. 
  
 
Figure 43) Sample preparation of crosslinked HFK cells maintaining HPV18 
Both images are representative of three independent experimental repeats. 
A) Crosslinked cells harvested by scraping. B) Same cells after 270 dounces. The cell 
membrane is disrupted and the nuclei are released. 
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Fragment 
name 
Fragment 
start 
Fragment 
end 
Predicted binding sites tested 
844 789 890 5.PWM 844 [9.98] 
1205 1165 1256 E+1 1205 
2200 2167 2251 None 
2990 2968 3069 6.PWM 2990 [23.4] 
3550 3519 3620 E-2 3487 and 6.PWM 3621 [14.2] 
4505 4442 4536 1.PWM 4505 [12.2] and 5.PWM 4538 [10.5]  
5475 5405 5506 E-1 5475 
5768 5712 5811 1.PWM 5768 [12.9] 
6400 6371 6462 none 
7800 7746 7845 none 
Table 35) Fragments used for qPCR analysis of ChIP samples 
Fragments across the whole genome are tested.  
 
 
 
Figure 45) Fragments used for qPCR analysis of ChIP samples 
The teal blocks show the fragments for testing predicted CTCF binding sites. Fragments 
indicated by black blocks have no CTCF binding site in their vicinity and were used as 
negative controls. Predicted CTCF binding sites are shown in yellow and fragments that 
showed a shift in EMSA are shown in blue. 
1
HPV18
7857bp
E6
E7
E1
E2
E4
E5
L2
L1
C+1 2990 score 23.4
E-1 5475
1.PWM, EMBL_M1 - scores above 10.71
2.PWM, EMBL_M2 - left out completly
3.PWM, AC REN20 - scores above 6.45
1.PWM 2992 score 18.4
1.PWM 5768 score 12.9
1.PWM 4505 score 12.2
3.PWM 2989 score 13.2
3.PWM 5765 score 9.7
3.PWM 3622 score 8.2
4.PWM, AC MIT_LM2 - scores above 6.54
4.PWM 2990 score 13.3
4.PWM 2993 score 7.3
4.PWM 5766 score 7.3
5.PWM, AC MIT_LM7 - scores above 8.71
5.PWM 2990 score 16.6
5.PWM 3621 score 14.0
5.PWM 4538 score 10.5 
5. PWM 5766 score 10.1
5.PWM 844 score 9.98
6.PWM, AC IT_LM23 - scores above 8.51
6.PWM 2990 score 23.4
6.PWM 3621 score 14.2
6.PWM 5766 score 12.2
 two bands, medium
medium
medium
 E+1 1205
medium
strong
E-2 3487
2990
Control 2200
Control 7800
Control 6400
844
1205
3550
4505
5475
5768
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A fragment of the c-Myc promoter that had been shown to bind CTCF was used as a 
positive control (Vetchinova et al., 2006). The negative control was a fragment of the TLR2 
gene that does not bind CTCF. Both of these fragments are amplified from host DNA. 
However, only the positive control gave a Ct value whereas the negative control remained 
below the Ct threshold after 45 PCR cycles. This was also experienced by a collaborator (Dr. 
Ian Groves from the Coleman laboratory, University of Cambridge, UK) who had 
independently encountered the same problem. Hence the fold enrichment of the positive 
control could not be determined. The normalisation of qPCR results was done against a 
1:100 dilution of the input WT sample so that a local peak of a particular fragment was 
accounted as a confirmed CTCF binding site. Furthermore it was made sure that this local 
peak was not present in the ChIP sample precipitated with FLAG antibody. 
The two ChIP experiments were performed on samples from undifferentiated Georgie cells 
and the results are shown in Figure 46 and the p values can be found in Table 36. The WT 
sample showed increased precipitation of fragment 3000 with CTCF antibody. This increase 
was not seen with the C3 mutant or with FLAG antibody. However other binding sites did 
not show a peak in the ChIP experiments despite the fact that these fragments showed 
weak or medium shifts in EMSA. Only the fragments adjacent to nucleotide 3000 show 
slightly increased precipitation with CTCF antibody which is most likely an artefact due to 
their close proximity to the confirmed CTCF binding site. Additionally, our collaborators at 
the University of Cambridge were able to confirm CTCF binding in the region of nucleotide 
3000 in HPV16 by using HPV16-maintaining, undifferentiated W12 cells for ChIP (personal, 
unpublished communication). However the ChIP experiments only captured the CTCF 
binding pattern of a particular stage of the HPV life cycle. The pattern may change when the 
life cycle progresses to a later stage and EMSA confirmed CTCF binding sites may be used at 
a later stage.  
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A) 
 
B) 
 
Figure 46) Results of two ChIP experiments 
A sample of undifferentiated Georgie cells maintaining WT or C3 HPV18 was used for two 
ChIP experiments. The qPCR analysis of each ChIP experiment was done in triplicate. 
Precipitation with CTCF and FLAG antibody is shown. A peak is seen around nucleotide 
3000 in the WT samples but not in the C3 mutant samples. All other fragments tested 
negative for CTCF binding even though some of them showed a medium or weak shift in 
EMSA. Only slightly increased precipitation with CTCF antibody is seen with fragments 
adjacent to nucleotide 3000 which is expected to be artefact caused by their close 
proximity to binding site 3000. All p-values can be found in Table 36. The samples 
analysed here are undifferentiated keratinocytes and the CTCF binding pattern may 
change upon differentiation. However reduced episomal copy number was seen in WT 
cells used for ChIP and this reduction was even stronger in C3 cells as shown in Figure 47. 
This experiment has been repeated by Dr. Jo Parish using cells of similar copy number and 
the results shown here were confirmed. Fragment 3000 in the WT binds CTCF and this 
binding is not seen in the C3 mutant. 
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
844 1205 2200 2990 3550 4505 5475 5768 6400 7800
Fo
ld
 o
f 
in
p
u
t 
sa
m
p
le
 
Fragment position [nt] 
First ChIP Experiment 
WT FLAG WT CTCF C3 FLAG C3 CTCF
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
844 1205 2200 2990 3550 4505 5475 5768 6400 7800
Fo
ld
 o
f 
in
p
u
t 
sa
m
p
le
 
Fragment position [nt] 
Second ChIP Experiment 
WT FLAG WT CTCF C3 FLAG C3 CTCF
p= 0.007 
p= 0.002 
p= 0.0001 
p= 0.0001 
Results  
112 
 
 844 1205 2990 3550 4505 5475 5768 
First ChIP 
experimen
t 
GWT 
CTCF 
0,911 0,924 0,007 0,000 0,301 0,776 0,814 
GC3 
CTCF 
0,414 0,397 0,828 0,417 0,311 0,353 0,073 
Second 
ChIP 
experimen
t 
GWT 
CTCF 
0,443 0,278 0,002 0,000 0,149 0,085 0,043 
GC3 
CTCF 
0,119 0,585 0,799 0,996 0,826 0,017 0,009 
Table 36) P-Values of the potential CTCF binding sites tested by ChIP 
These p values were calculated using Student’s double sided t-test against the null 
hypothesis that there is no difference in precipitation between the fragments tested and 
the 3 negative control fragments. In both experiments the fragments 2990 and 3550 of the 
WT show that this null hypothesis is not true for these two fragments. The spatial proximity 
of fragment 3550 to CTCF binding site 2990 is likely to have caused this outcome since the p 
value for this fragment is much higher in the C3 mutant. In the second ChIP experiment, the 
fragments 5475 and 5768 show evidence that the null hypothesis is false for these 
fragments. However fragment 5475 shows as much precipitation with CTCF antibody as 
with FLAG antibody. Thus it is likely that this is an experimental error. Fragment 5768 shows 
a very small standard deviation in the 3 measurements that skews the result into a low p-
value.  
 
 
In a later experiment the copy number of HPV18 episomes in the ChIP input samples was 
determined. By doing so it was discovered that a proportion of HPV18 episomes was lost in 
these samples. HPV episome loss is a known phenomenon that is not entirely understood 
(reviewed by Doorbar et al., 2012, Lace et al., 2008, Stubenrauch et al., 2000). However it is 
known to be an important step in cancer progression since the loss of episomal HPV 
genomes often abrogates the negative regulation over the viral oncogenes of HPV DNA that 
has randomly integrated into the host genome (Vinokurova et al., 2008). The C3 episomes 
were lost more quickly than the WT episomes as shown in Figure 47. Approximately half of 
the wild type episomes were lost at the time when the ChIP experiments were carried out. 
The number of C3 episomes present in the ChIP samples was about 5 fold less than the 
number of WT genomes. This has to be considered when interpreting the ChIP results since 
the lower amount of C3 genomes could have influenced the result. However the binding of 
CTCF in the area around nucleotide 3000 and the abrogation of this binding in the C3 
mutant in cells with high copy number has been confirmed in an independent ChIP 
experiment by Dr. Jo Parish (unpublished data). The loss of viral episomes observed in the 
ChIP sample gave rise to another set of experiment investigation this episome loss. 
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3.6.3 Determination of episome copy number in wild type and C3 mutant-
containing HFK lines  
Over the time course of an HPV infection it is known that the loss of viral episome can occur 
and the reasons for this are largely unknown (reviewed by Doorbar et al., 2012, Lace et al., 
2008, Stubenrauch et al., 2000). In most cervical tumours HPV genomes have integrated 
into the host DNA followed by loss of episomally maintained HPV genomes (Yu et al., 2005, 
Vinokurova et al., 2008). In other viruses, like herpes virus Saimiri and Kaposi’s sarcoma 
associated herpes virus, the abrogation of CTCF binding resulted in impaired maintenance 
of the viral genome (Stedman et al., 2008, Zielke et al., 2012). Thus episome copy number 
in the HPV infected cell lines was determined to check for potential episome loss due to a 
possible impairment in episomal maintenance caused by the lack of CTCF in the mutant cell 
lines. The copy number of a host locus and HPV18 episomes was quantified by qPCR using a 
sample of whole DNA extracted from the HPV18 maintaining cell lines with the QIAamp 
 
Figure 47) Episome copy number per host allele of cells used for ChIP 
The episome copy number of every sample was determined in three repeats of the 
qPCR analysis. Both cell lines lost episomes over time. The WT had lost about 60 % of its 
episomes in the cells used for the ChIP experiments. The loss in the C3 mutant is about 
90 %. The p values were determined using Student’s double sided t-test against the null 
hypothesis that the episome copy number stayed the same since the first measurement 
at low passage number. 
0
20
40
60
80
100
120
140
160
180
cells of low passage
number
cells used for 1st ChIP cells used for 2nd ChIP
Ep
is
o
m
e
s 
p
e
r 
h
o
st
 a
lle
l 
Episome copy number per host allele  
WT C3
P= 0.069 
P= 0.040 
P= 0.028 
P= 0.041 
Results  
114 
DNA Mini Kit. The WT and C3 mutant cell lines from Georgie and Clonetics cells of various 
passage numbers were harvested with the intention to determine the episome copy 
number of each of these cell lines over a time course. Since the cells were split once a 
week, the passage number is also the number of weeks the cells were growing in culture. 
For the repeat experiment, cells of low passage number were de-frosted and cultured over 
an extended period of time. Thus, cell samples of all four cell lines from two different 
batches were available for analysis. The qPCR analysis of each sample was done in three 
separate reactions. 
The episome copy number per host allele was determined mathematically by setting the Ct 
value of a fragment amplified from the viral episome in correlation to the Ct value of a 
fragment amplified from a single copy host locus. There are no large repetitive sequences in 
the HPV18 genome. Thus a primer pair targeting any location of the episome can be used 
for determining the number of episomes. The primers used for determining host locus copy 
number amplify a part of the TLR2 gene and have been previously used for episome copy 
number determination (Gray et al., 2010). However, any single copy host gene can serve 
this purpose. Single copy genes are present as two alleles in each cell in G1, which needs to 
be considered when determining the episome number per host cell rather than per allele. 
The primer pairs chosen for episome copy number determination can be found in Table 37.  
 
Template Primer name Location Amplicon 
length 
Sequence 5' to 3' Tm 
HPV18  HPV18 Episome FW 2167-2251 85 TTATAGGCGAGCCCAAAAAC 59,2 
HPV18  HPV18 Episome RV 2167-2251 85 CCAATCTCCCCCTTCATCTAT 59,3 
Human TLR2 locus Human TLR2 FW 1893-1957 65 GCCAGCAAATTACCTGTGTGA 61.1 
Human TLR2 locus  Human TLR2 RV 1893-1957 65 GGCGGACATCCTGAACCT 61.1 
Table 37 Primers used for the determination of episome copy number 
A fragment of the single copy locus TLR2 is targeted as well as a fragment of the HPV18 
episome, accession number AY262282.1. 
 
In a qPCR reaction these primer pairs were used together with whole DNA extracted from 
the HPV18 containing cell lines in combination with the SsoFast EvaGreen supermix from 
Bio-Rad. From the qPCR results a standard curve was generated for each primer pair and a 
common threshold for both primers pairs was chosen. Standard curves were checked for 
hallmarks of reliable qPCR like a slope close to -3.33 and a R2 value close to 1. It was also 
ensured that the Ct value for every sample was within the range of the standard curve. 
Additionally the melting curve for each amplicon was checked to ensure that each primer 
amplified a single target. According to the common threshold chosen a Ct value for each of 
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Livak Method: 
 
∆Ct(test) = Ct(target of test) – Ct(reference of test) 
 
∆Ct(calibrator) = Ct(target of calibrator) – Ct(reference of calibrator) 
 
∆∆Ct = ∆Ct(test) - ∆Ct(calibrator) 
 
Ratio = 2-∆∆Ct 
 
 
Pfaffl Method: 
 
 
Figure 48) Original Livak and Pfaffl method 
In the Livak method primer efficiency is assumed 
to be 2 whereas the Pfaffl method takes 
individual primer efficiencies into account. 
       
         
                           
            
                              
 
the DNA samples could be determined for each of the primer pairs. The Ct value in 
combination with the formula of the standard curve contained enough information for 
mathematical determination of episome copy number.  
Two different methods were used for qPCR-based episome quantification (Livak and 
Schmittgen, 2001, Pfaffl, 2001). These methods are called the Livak or 2-∆∆Ct method and the 
Pfaffl method. However, both methods needed to be modified because they are typically 
used to determine the change in mRNA expression as a ratio of two samples, for example a 
treated and an untreated sample. Accordingly the ratio of mutant episomes per cell to wild 
type episomes per cell could be determined with the original formulas (Figure 48). In this 
case the ratio of 1 would mean that 
an equal amount of episomes is 
present in cells maintaining either 
wild type or mutant HPV18. 
Originally these methods were 
applied to qPCR results from cDNA 
samples. Both methods depend on 
the comparison of the target gene 
against a constant reference gene.  
In the case of episome quantification 
the original formulas of both 
methods can be used but some of 
the variables have to be re-defined. 
TLR2 takes the place of the reference 
gene. Instead of determining mRNA 
levels, the number of host genomes is determined using the single copy locus TLR2. The 
“target gene” in the modified method is not a single gene but the entire viral episome. Also 
two other components in the original methods need to be addressed. The “calibrator” is an 
untreated sample in which reference gene and target gene are expressed in an amount that 
will serve as a reference to the treated sample. In the modified method this calibrator is 
replaced by the cell sample that contains wild type HPV18 DNA. The second component of 
the original method is the “test sample” which is a treated sample in which gene expression 
is expected to change. The test sample is replaced by the cell sample maintaining C3 
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mutant HPV18. Thus the modified formulas give the ratio of C3 to WT episomes per host 
allele of TLR2. All these conversions are summarised in Table 38.  
 
Component 
Original methods for 
cDNA quantification 
Episome 
quantification 
Genes and samples 
chosen 
Reference  
cDNA of gene with 
constant expression 
levels 
gDNA single copy 
host gene 
TLR2 
Target 
cDNA of gene of 
interest 
gDNA episome HPV18 Episome 
Calibrator Untreated sample 
Cell line containing 
wild type virus 
GWT or CWT 
Test Treated sample 
Cell line containing 
mutant virus 
GC3 or CC3 
Table 38) Factors used in the determination of either cDNA levels or episome copy 
number 
 
The absolute number of episomes per host allele can also be determined by altering the 
modified formula of either method. It is simple to alter the Livak method because the 
exponent needed for calculating the number of either episomes or host alleles is already 
determined in the first steps of the original Livak calculation and just needs to be applied to 
the basis 2 to yield the absolute copy number of either viral episomes or host alleles. 
Altering the Pfaffl method is more complex due to the fact that the term for calculating the 
exponents needs to be transformed into fractions. Subsequently, the formula can be 
converted into a form where the numerator is the number of episomes and the 
denominator the number of TLR2 alleles. In G1 cells, two copies of the host locus are 
present whereas cells in G2 contain this allele four times. Thus episome copy number per 
cell is either two times or four times the result of either one of the altered formulas 
depending on the phase of the cell cycle. 
The Livak and Pfaffl methods also differ in the way they incorporate primer efficiency. The 
primer efficiency is the factor by which the amount of amplicon is increased with every 
cycle. In theory, the optimal primer efficiency is 100 % (or 2 if given as a factor) which 
means that 100 % of the template present at the beginning of the cycle is amplified upon 
completion of the cycle. However, the primer efficiency is often not optimal. The 
acceptable range is between 90 % and 105 % (or factors 1.90 and 2.05). Primer efficiencies 
above 100 % are possible because the efficiency is calculated from the standard curve, 
which can be slightly inexact. Also nonlinear DNA amplification due to contamination can 
Results  
117 
influence the standard curve 
and therefore primer 
efficiency. The primer 
efficiency was calculated for 
each primer pair using the 
slope of the standard curve and 
the formula given in Figure 49. 
The Pfaffl method works with 
exact primer efficiencies 
whereas the Livak method 
assumes a primer efficiency of 
100 % for every primer pair used. Thus the Livak method is easy to use but slightly inexact 
whereas the Pfaffl method is more exact but requires more complex calculations. Also the 
Pfaffl method depends on an exact standard curve. Small inaccuracies can easily cause a 
bias in the result.  
 
  
Formula for primer efficiency: 
 
Primer efficiency =    
  
      
 
Example calculation: primer efficiency as factor: 
 
  
  
       = 2.01 
 
Example calculation: primer efficiency as percentage: 
 
  
  
         = 1.01 = 10 1 % 
 
Figure 49) Determination of primer efficiency 
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3.6.3.1 Using the Livak Method to compare wild type and C3 mutant episome 
copy numbers 
Step 1: Normalisation of WT and mutant sample. The difference between the episome Ct 
value and the host allele Ct value is calculated. 
 
∆Ct(WT) = Ct(episome of WT) – Ct(host gene of WT) 
∆Ct(mutant) = Ct(episome of mutant) – Ct(host gene of mutant) 
 
Step 2: The ∆Ct value of the mutant sample is normalised against ∆Ct of the WT sample. 
 
∆∆Ct = ∆Ct(mutant) - ∆Ct(WT) 
 
Step 3: calculating the ratio of C3 episomes per host allele relative to WT episomes per host 
allele. 
 
Ratio = 2-∆∆Ct 
 
The complete modified Livak method for the determination of the ratio of C3 genomes to 
WT genomes with all previous steps combines is therefore: 
 
  ((                            ) (                          )) 
 
The ratio of C3 episomes to WT episomes was calculated using the Livak method. Samples 
of all cell lines from two different batches across different passage numbers were analysed 
and the results are shown in Figure 50. The data shows that this ratio declines over time. At 
low passage number the ratio was close to being equal but over the course of about 10 
passages the ratio shifted towards a higher number of WT genomes than C3 genomes. This 
was observed in cells from two batches, each batch consisting of cells from two different 
donors. There are two possible reasons for this outcome. Either episome copy number in 
cells maintaining wild type episomes increased or episome copy number of C3 mutant 
episomes decreased. The absolute episome copy number was determined to find out which 
of the possible solutions is true. 
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Figure 50) The ratio of C3 episome to WT episomes in HFK from both donors 
Each batch is an independent experiment. The ratio of C3 to WT episomes was 
determined in three qPCR experiments. The p-values have been calculated using the two-
sided Student’s t-test with the null hypothesis that the ratio of C3 to WT episomes has 
remained the same as in the first measurement (passage number 5 and 8, respectively). 
A decline in the ratio of C3 episome to WT episomes in cells from both batches was seen. 
This decline was seen in samples from both donors but it is slightly faster in Georgie cells 
compared to Clonetics cells. The original Livak method was used to calculate the ratio of 
C3 mutant genomes per cell relative to wild type HPV18 containing HFK of the same 
passage number. Reasons for this outcome could either be an increase in WT episome or 
a decline in C3 episomes. To determine which of the possible solutions is true the 
absolute episome copy number was determined in a following experiment. These cell 
lines were split once a week so the passage number corresponds to the time of culturing 
in weeks. 
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Determination of the absolute episome number per host allele base on the Livak method: 
The absolute number of episomes per host allele could be calculated using the previously 
determined ∆Ct as the negative exponent to the primer efficiency, which is set to be 2 in 
the Livak method. Thus the formula of the absolute episome copy number per host allele is 
2-∆Ct. or 
                          
 
The results of the episome copy number determination in cells of various copy numbers per 
host allele are presented in Figure 51. The episome copy number of cells of low passage 
number is slightly higher than the expected range of about 100 to 200 copies per cell 
(Frattini et al., 1997). However a more recent review suggests the copy number to be more 
close to 200 copies (reviewed by Doorbar et al., 2012). All cell lines needed to be split about 
once a week so passage numbers and weeks of culturing are the same. The amount of viral 
episomes in the wild type cells of both batches showed little decline over the time course of 
12 and 7 passages, respectively. On the other hand the cells maintaining the C3 mutant 
showed a much steeper decline in episome copy number over time. Only the GC3 cells from 
the first batch show a near-stagnation of viral episomes between passage 5 and passage 9. 
However the decline seen in the cells from the third time point is very steep.  Only a small 
amount of C3 HPV18 DNA remained in GC3 cells of passage 17. A minimal amount of HPV 
DNA is thought to be essential for continuous cell growth due to the fact that 
immortalisation of the primary cells had been facilitated by the expression of the viral 
oncogene. If all viral DNA was lost only cells that acquired continuous cell growth through 
random mutations would be able to survive. However this viral DNA could be integrated 
rather than being episomal and that would prevent it from getting lost. The C3 mutant cell 
lines from both donor and both batches showed loss of episomes. However this loss is only 
statistically significant in Georgie cells. However the episome loss Clonetics cells containing 
C3 is close to being statistically significant with its p value of 0.053. Thus the reason for the 
shift in the ratio of C3 to WT episomes observed earlier is a faster decline of C3 mutant 
episome copies compared to the decline of WT episome copies. Donor specific traits may 
cause the different outcome in the Georgie and Clonetics cells containing the C3 mutant. 
The cell lines containing wild type HPV18 show a small decline in the average number of 
episomes, however this decline if far from being statistically significant.  
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Figure 51) Determination of the absolute copy number of viral episomes 
Each batch is an independent experiment. The episome copy number was determined 
in three qPCR repeats and the modified Livak method was used to determine the 
absolute copy number of viral episomes per host allele. The p-values were calculated 
using the two-sided Student’s t-test with the null hypothesis that the number of 
episomes has remained the same as in the earliest passage number (passage 5 and 8, 
respectively). The pattern seen in both batches is similar. The number of WT and C3 
episomes declines over time. However the decline in C3 genomes is stronger compared 
to WT genomes. This is seen in cells from both donors. Georgie cells loose C3 genomes 
slightly faster than Clonetics cells. Most WT samples show a stagnating number of 
episomes after about 10 passages. Only the GWT cells from the first patch show a 
further decline at passage 17. 
These cell lines were split once a week so the passage number corresponds to the time 
of culturing in weeks. 
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p= 0.150 
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3.6.3.2 Using the Pfaffl Method to compare wild type and C3 mutant episome 
copy numbers 
The Pfaffl method works similarly to the Livak method but takes empirically determined 
primer efficiencies into account. Accordingly the Ct values of episome and host fragments 
are used as exponents to their particular primer efficiency. The fact that the primer 
efficiencies are likely to be different for both of these primer pairs makes the calculation 
more complicated compared to the Livak method because exponents to different bases 
cannot simply be subtracted from one another. The primer efficiencies for the host gene 
primer and the episome primer can be calculated by using the slope of the standard curve 
as shown in Figure 49. For the Pfaffl method the ∆Ct values are calculated differently 
compared to the Livak method.  
 
Step 1: Calculation of ∆Ct values for host gene and episome. 
∆Ct(host gene) = Ct(host gene of WT) – Ct(host gene of mutant) 
∆Ct(episome) = Ct(episome of WT) – Ct(episome of mutant) 
 
Step 2: Calculation of the ratio of C3 episomes to wild type episomes  
       
                          
          
                            
           
 
 
The standard curves for the episome and TLR2 fragments have a slope of -3.314 and -3.330 
respectively, both resulting in a primer efficiency of 2 which is the value that is used by 
default in the Livak method. Thus Livak and Pfaffl method yield the same result in this 
particular case. Hence the results of the Pfaffl method are not shown because they are 
virtually identical with the results from the Livak method shown earlier.   
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Determination of the absolute episome number per host allele based on the Pfaffl 
method: 
Since the primer pairs targeting TLR2 and the HPV18 episome had different primer 
efficiencies, the Ct values cannot be simply subtracted from one another as is the case in 
the Livak method. Thus a more complex formula is needed. This formula can be derived 
from the original Pfaffl formula by converting the difference of the exponents into a 
fraction. 
 
Original Pfaffl formula: 
 
       
          
          
            
           
 
 
Conversion step 1: Substitution of ∆Ct with the formula for ∆Ct 
 
       
          
                              
            
                             
 
 
Conversion step 2: Converting exponents into fractions 
 
       
          
             
          
                
            
             
            
            
 
 
Conversion step 3: The formula converted so that the fraction in the numerator defines the 
number of mutant episomes per host allele and the fraction in the denominator defines the 
number wild type episomes per host allele. 
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Thus the formula for the absolute episome copy number can be derived as follows: 
 
Again, the fact that the primer efficiencies for both primer pairs were 2 led to virtually 
identical results of the Pfaffl method and the Livak method shown earlier. Hence these 
results are not shown again. However the modified Pfaffl method is still important if the 
episome copy number is determined using primer pairs for the episome and host locus that 
have different primer efficiencies. Primer efficiencies of each primer pair can also vary with 
changes in the qPCR setup like using a different master mix, primer concentration or 
temperature cycles. 
 
3.6.4 Comparison of viral gene expression in wild type and C3 mutant by 
western blotting 
Human foreskin keratinocytes can be differentiated by growing them in methylcellulose 
(Wilson and Laimins, 2005, Green, 1977). Viral gene expression is coupled to host cell 
differentiation and analysing cells in different stages of the differentiation process gives the 
opportunity to compare viral gene expression over the course of the viral life cycle 
(reviewed by Doorbar, 2005). Thus the expression of viral genes can be monitored on 
methylcellulose differentiated cells using western blotting. Dr. Jo Parish provided cell 
samples of differentiated cells from each cell line previously generated. Those samples 
were made from cells of intermediate passage number (passage 11) from the second batch. 
Thus the copy numbers of WT and C3 episomes are relatively high as shown in the previous 
section. In three experimental repeats these cells were differentiated for 0, 24 or 48 hours. 
Terminal keratinocyte differentiation was achieved after 48 hours, so the viral life cycle 
should be completed within this time course (Green, 1977). However L1 expression of 
HPV18 in methylcellulose differentiated cells is inefficient and only occurs after extended 
culturing in methylcellulose (personal communication with Dr. Sally Roberts from the 
University of Birmingham). Western blots from the samples of each time point were 
prepared using antibodies targeting Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
E2, E6, E7, E1^E4, loricrin, p53 and CTCF. Antibodies for E1 and E5 were either not available 
                                        
            
                                      
           
                           
Formula for calculating episome copy number: 
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or not functional with the experimental conditions used. All bands were quantified and 
GAPDH was used as a loading control. Figure 52 shows the western blots performed to 
ensure appropriate differentiation of the cells and the western blot for CTCF. When 
keratinocytes start to differentiate the viral protein E6 efficiently targets p53 for 
degradation (Sherman et al., 2002). This degradation of p53 was confirmed. However there 
were slight differences observed between WT and C3 (Figure 52). These differences are 
likely to be artefacts due to the background noise resulting from the quantification of very 
faint bands combined with the sometimes suboptimal quality of the western blot. Also the 
limited number of repeats influences the statistical significance of this result.  
The host gene loricrin is a keratin that is expressed at the terminal stages of keratinocyte 
differentiation and was therefore used as marker to confirm the complete differentiation of 
the keratinocyte (Hohl et al., 1991). A faint band of the expected size of 26 kDa in cells 
differentiated for 48h was seen (Gschwandtner et al., 2013). The presence of loricrin 
confirms the terminal differentiation of the cell samples differentiated for 48 hours. Also 
the amount of CTCF in the cell throughout the differentiation process was analysed. All cell 
lines showed a constant amount of CTCF throughout the differentiation process. The band 
for CTCF became smeary in differentiated cell samples, which might be due to the 
accumulation of keratin in differentiated cells.  
The western blots for E2, E1^E4, E6 and E7 are shown in Figure 53. Accumulation of E2 is 
expected at the intermediate and late stages of the differentiation process (reviewed by 
Doorbar et al., 2012). However the mutant cell lines show significantly increased E2 
expression after 24 hours of differentiation compared to the wild type. Interestingly the 
mutated CTCF binding site is located within the E2 reading frame. The expression of E1^E4 
is also altered in the mutant. E1^E4 is expected to be abundantly expressed at the late 
stages of the viral life cycle. Less E1^E4 expression is observed in the mutant cells lines after 
48 hours compared to the cells containing the WT. However this reduction in E1^E4 
expression is only significant in Georgie cells. In Clonetics cells the p value for the reduction 
of E1^E4 is 0.085. More experimental repeats are needed to double check the significance 
of the reduction in E1^E4 in Clonetics cells. It is possible that differential expression of 
E1^E4 in Georgie and Clonetics cells is a donor specific trait.  
There is no difference in the expression of the viral oncogenes E6 and E7 between wild type 
and C3 mutant as shown in Figure 54. The band for E6 is strongest in cells differentiated for 
24 hours. The expression of E7 is similar in all samples tested.  
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Figure 52) Differentiation controls and CTCF expression in Georgie and Clonetics cells 
In three independent experiments, western blots of methylcellulose differentiated HFK 
were carried out using antibodies for p53, loricrin and CTCF. A representative western blot 
for each protein is shown. The bands from each of the three repeats for each protein were 
quantified and protein expression in WT and C3 cells was compared using the double-sided 
t-test against the null hypothesis, that the gene expression in WT and C3 is the same. p-
values below 0.05 are indicated with a star in the graphs and with red background in the 
tables. The start of the differentiation process is confirmed by E6 mediated degradation of 
p53 after 24hours of differentiation. The C3 mutant shows slightly more efficient 
degradation of p53. However, this decrease is significant only for the 24 h sample of GC3 
and the 48 h sample of CC3. Terminal differentiation is confirmed by the presence of 
loricrin after 48 hours. CTCF expression remains constant throughout the differentiation 
process in all samples tested.   
0,0
0,4
0,8
1,2
1,6
0 h 24 h 48 h
Fo
ld
 o
f 
G
A
P
D
H
 
p53 
GWT CWT GC3 CC3
0,0
0,4
0,8
1,2
0 h 24 h 48 h
Fo
ld
 o
f 
G
A
P
D
H
 
Loricrin 
GWT CWT GC3 CC3
0,0
1,0
2,0
3,0
4,0
0 h 24 h 48 h
Fo
ld
 o
f 
G
A
P
D
H
 
CTCF 
GWT CWT GC3 CC3
 
p-values 
 
Georgie C3 Clonetics C3 
 
0 h 24 h 48 h 0 h 24 h 48 h 
P53 0,313 0,022 0,327 0,543 0,486 0,035 
 
p-values 
 
Georgie C3 Clonetics C3 
 
0 h 24 h 48 h 0 h 24 h 48 h 
Loricrin 0,237 0,902 0,070 0,901 0,739 0,413 
 
p-values 
 
Georgie C3 Clonetics C3 
 
0 h 24 h 48 h 0 h 24 h 48 h 
CTCF 0,733 0,599 0,346 0,910 0,510 0,963 
* * 
Results  
127 
 
 
Figure 53) Gene expression of E2 and E1^E4 in Georgie and Clonetics cells 
In three independent experiments, western blots of methylcellulose differentiated HFK 
were carried out using antibodies for E2 and E1^E4. A representative western blot for each 
protein is shown. The bands from each of the three repeats for each protein were 
quantified and the protein expression in WT and C3 cells was compared using the double-
sided t-test against the null hypothesis that the gene expression in WT and C3 is the same. 
p-values below 0.05 are indicated with a star in the graphs and with red background in the 
tables. The expression of E2 is significantly increased in the C3 mutant after 24 hours of 
incubation and normalises again after 48 h. The expression of E1^E4 is significantly 
decreased in the GC3 sample differentiated for 48 h. In CC3, the same sample has a p-value 
of 0.85. A higher sample size is needed to reveal if the decrease in E1^E4 is also significant 
for CC3 cells. 
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Figure 54) Gene expression of E6 and E7 in Georgie and Clonetics cells 
In three independent experiments, western blots of methylcellulose differentiated HFK 
were carried out using antibodies for E6 and E7. A representative western blot for each 
protein is shown. The bands were quantified and the protein expression in WT and C3 cells 
was compared using the double-sided t-test against the null hypothesis that the gene 
expression in WT and C3 is the same. p-values below 0.05 are indicated with a star in the 
diagrams and with red background in the tables. The expression of E6 peaks after 24 hours 
and all cell lines show the same expression pattern of this protein. The expression of E7 is 
the same in all cell lines across all stages of differentiation. 
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3.6.5 Monitoring organotypic raft culture morphology and gene expression 
using light microscopy and immunohistochemistry 
Human foreskin keratinocytes can be differentiated to form in vitro generated skin in 
organotypic raft culture. This was done by growing the cells on a collagen plug with a 
limited supply of nutrients diffusing through this plug (Wilson and Laimins, 2005). 
Differentiating cells in this way enables the virus to go through its entire life cycle. In this 
study, raft cultures provided by Dr. Jo Parish were stained to compare cellular morphology 
and viral gene expression of wild type HPV18 maintaining keratinocytes and keratinocytes 
maintaining C3 mutant genomes. Two separate sets of rafts were grown from cells of the 
second batch with early passage numbers (below passage 8), so the episomal copy numbers 
of wild type and mutant are assumed to be approximately equal. The amplification of 
episomally maintained HPV18 genomes in these raft slides was confirmed using in situ 
hybridisation and showed no difference between wild type and C3 mutant (unpublished 
data from Dr. Jo Parish). The rafts grown from Clonetics cells were of higher quality than 
the ones grown from Georgie cells. Hence this section focuses mostly on the Clonetics rafts.  
In HPV negative skin, only the basal cells actively divide. One of the daughter cells remains 
in the basal layer whereas the other daughter cell migrates towards the surface of the skin, 
differentiating on its way. The top layer of the skin consists of rigid, flat and keratinised cells 
which are eventually shed from the surface. Keratinocytes maintaining wild type HPV18 
genomes also actively divide in the suprabasal layer in addition to the basal layer so the raft 
is generally slightly thicker compared to a raft grown from HPV negative cells (Blanton et 
al., 1991). Figure 55 shows histological slices of raft cultures stained with eosin and 
hematoxylin. The raft grown from wild type maintaining cells showed the expected 
morphology (Frattini et al., 1997, Lace et al., 2009). However raft cultures grown from cells 
maintaining the C3 mutant showed even more cells in the basal, suprabasal and upper layer 
and the raft thickness was substantially increased in comparison to the wild type rafts. On 
the other hand the keratinous layer showed a decrease in thickness. Further investigation 
of this unusual raft morphology was done using immunohistochemistry to monitor viral 
gene expression in all layers of the raft. Prior to harvesting the rafts they were treated with 
bromodeoxyuridine (BrdU), which replaces thymidine during DNA replication and can be 
detected with a BrdU-specific antibody. Thus BrdU is used as a marker for cells that have 
actively replicated their DNA during the period BrdU was applied. 
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Fully grown raft cultures were embedded in paraffin before they were sliced with a 
microtome and mounted onto microscope slides. On every slide two primary antibodies 
were applied that were raised in different organisms so that two different secondary 
antibodies could be used to label each of the primary antibodies with a distinct 
fluorophore. In addition to the immunostaining, all slides were stained with Hoescht dye to 
visualise the nuclei by staining DNA. As a result each slide was stained for 3 targets of which 
each target was fluorescing at a distinct wavelength. In Figure 56 raft slides from all cell 
lines were stained with Hoescht stain and antibodies for BrdU and E1^E4. BrdU positive 
cells were seen in the suprabasal layer of cells maintaining either wild type or mutant 
HPV18. However the C3 mutant showed an increased number of BrdU positive cells in the 
upper layer. 
 
 
Figure 55) Histology of raft cultures grown from wild type and C3 maintaining HFK  
Organotypic raft cultures were stained with hematoxylin and eosin. The images shown 
here are representative of two independent rafts for each of the two cell lines. The top 
pictures show rafts grown from wild type Clonetics cells. The rafts show typical 
morphology. Actively diving cells are found in a thin, basal layer and the suprabasal layer. 
Cells differentiate and flatten out as they migrate upwards until they form a dense 
keratinous layer. The bottom pictures show rafts grown from Clonetics cells with C3 
mutant HPV18. Here the raft is substantially thicker. Differentiation and flattening of cells 
seems to be impaired and the keratinous layer on top of the raft is thinner compared to 
rafts grown with wild type maintaining cells. The rafts of the second donor (Georgie) 
showed the same morphological differences between WT and C3 mutant. 
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The cell counts of BrdU positive cells showed that there is a significantly higher percentage 
of BrdU positive cells in the upper layer of the C3 raft as shown in Figure 57. The counts also 
revealed that the percentage of BrdU positive cells in the basal layer of the C3 is reduced 
compared to the wild type. Only the percentage of BrdU positive cells in the suprabasal 
layer is similar in WT and C3. To confirm the changes in DNA replication and supposedly 
mitosis, rafts were stained with antibodies for the mitosis marker Cyclin B1 and stained 
cells were counted (Figure 57 and Figure 58).  
 
  
 
Figure 56) Raft slides stained for DNA, BrdU and E1^E4 
Raft slides from all cell lines stained for DNA, the DNA replication marker BrdU and 
E1^E4. These images are representative of two independent experimental repeats. The 
wild type rafts show the expected pattern of BrdU positive cells in the basal and 
suprabsal layers. BrdU positive cells in the C3 mutant show a different pattern, they are 
found throughout the entire raft, including the upper layer. E1^E4 expression occurs in 
upper layers as expected and there is no difference in E1^E4 positive cells between wild 
type and C3 mutant. 
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Figure 57) Quantification of BrdU and Cyclin B1 positive cells in CWT and CC3 rafts 
Two independently generated organotypic rafts of each of the two Clonetics cell lines, CWT 
and CC3, were generated and stained using antibodies against BrdU and Cyclin B1. From 
each staining three representative pictures were taken and the percentage of stained cell 
was determined. The percentage of stained cells in CWT and CC3 was compared using the 
double sided t-test against the null hypothesis that the percentage of stained cells was the 
same in WT and C3. p-values are given on top of the bars. 
There are significant differences in the staining of the DNA replication marker BrdU 
between WT and C3. In the basal layer of cells, significantly more DNA replication occurs in 
the WT. In suprabasal cells, the amount of DNA replication is about equal in WT and C3. In 
the upper layer of the raft significantly more DNA replication occurs in the mutant 
compared to the wild type.  
Quantification of cells stained for the mitosis marker Cyclin B1 reveals a similar pattern. The 
basal layer of cells contains more cells undergoing mitosis in the WT compared to the 
mutant. However this difference is only significant in the first of the two repeat 
experiments (p=0.046 and p=0.93, respectively). Similarly, the quantification of Cyclin B1 
positive cells in the suprabasal layer is also only significant in the first experiment. There are 
significantly more mitotic cells in the upper layer of the mutant rafts compared to the wild 
type rafts.  
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The pattern observed in the BrdU staining was confirmed with the Cyclin B1 staining. A 
lower percentage of Cyclin B1 positive cells was found in the basal layer of the raft in the C3 
mutant compared to the WT. However this difference was only significant in the first of the 
two repeat experiments (p=0.046 and p=0.93, respectively). Similarly, the quantification of 
Cyclin B1 positive cells in the suprabasal layer was also only significant in the first 
experiment (p=0.035 and p=0.618, respectively). More experimental repeats are needed to 
test if the difference in the percentage of mitotic cells observed in these layers consistently 
reaches statistical significantly. Considering the results of the BrdU staining and the p-
values achieved in the Cyclin B1 staining, reduced proliferation of C3 positive cells in the 
basal layer seems likely. Regarding the Cyclin B1 staining in the upper layer, both repeat 
experiments agree that only the rafts containing the C3 mutant showed Cyclin B1 positively 
cells. Despite the reduced percentage of mitotic cells in one layer and an increase in 
 
Figure 58) Raft slides stained for DNA, E1^E4 and the mitosis marker Cyclin B1 
These images are representative of two independent experimental repeats. The C3 
mutant slides show an increase in cell number. E1^E4 expression is very sporadic and 
counts of E1^E4 positive cells revealed no significant difference in E1^E4 positive cells 
between wild type and C3 mutant rafts Figure 60. Cyclin B1 expression in the wild type 
only occurs in the basal and suprabasal layer of the raft. In the mutant Cyclin B1 positive 
cells are found throughout the whole raft, including the upper layer.  
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another layer, the overall thickness of C3 mutant rafts was increased. Thus the cells in all 
layers of the rafts were counted as shown in Figure 59. An increased number of cells was 
found in all layers of the C3 mutant rafts. Only the increase in the upper layer of one of the 
two experiments fails to reach significance with a p-value of 0.099. Combining this result 
with the staining for DNA replication and mitotic cells reveals that there are more cells in 
the basal layer in the C3 rafts, but fewer of these cells do still replicate their DNA and 
undergo mitosis compared to the WT raft. 
 
   
Figure 59) Quantification of cells in CWT and CC3 rafts 
Two independently generated organotypic rafts of each of the two Clonetics cell lines were 
generated and stained using Hoescht stain to make the nuclei visible. From each staining 
three representative pictures were taken and the stained cells were counted. The number 
of cells in WT and C3 was compared using the double sided t-test against the null 
hypothesis that the number of cells was the same in WT and C3. p-values are given on top 
of the bars. Throughout all layers there are more cells in the C3 mutant raft than in the WT 
raft. Only the increase of cells seen in the upper layer of the first experiment did not reach 
significance (p= 0.099). 
 
For the suprabasal layer, the percentage of replicating cells was shown to be equal in WT 
and C3 rafts while the overall number of cells in this layer was increased (Figure 57 and 
Figure 59). Regarding the upper layer, the increase in proliferation seen in the BrdU and 
Cyclin B1 staining agrees with the increased number of cells in this layer. To test if the C3 
mutant generally accelerates the cell cycle, growth curves of undifferentiated cells in 
monolayer were generated by Dr. Jo Parish. These growth curves were very similar across 
all cell lines used (data not shown). Thus increased proliferation of cells infected with the C3 
mutant only occurs in the differentiating cells of organotypic raft cultures. 
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The name E1^E4 suggests that this gene belongs to the early genes. However it is expressed 
in the upper and keratinous layers of the skin where the virus is in the intermediate and 
late stages of its life cycle (Wilson et al., 2007). Staining for E1^E4 and quantification of 
E1^E4 positive cells revealed that those cells were seen in similar amounts in CWT and CC3 
cell lines (Figure 60). The expression of this protein was rather sporadic and was not seen in 
every single cell. This is the typical expression pattern of E1^E4 (Griffin et al., 2012). Even 
though western blots of methylcellulose differentiated cells showed a decrease in E1^E4 in 
CC3 cells, the rafts did not confirm this observation.  
 
   
Figure 60) Quantification of E1^E4 positive cells in CWT and CC3 rafts 
Two independently generated organotypic rafts of each of the two Clonetics cell lines were 
generated and stained using antibodies against E1^E4. From each staining three 
representative pictures were taken and the percentage of stained cells was quantified. The 
percentage of stained cells in WT and C3 was compared using the double sided t-test 
against the null hypothesis that the percentage of stained cells was the same in WT and C3. 
p-values are given on top of the bars. E1^E4 expression is about equal in WT and C3 and 
occurs in the upper layer of the raft. 
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Figure 61 shows raft slides stained for the keratin loricrin and E1^E4. The wild type showed 
fully flattened and differentiated keratinous cells that form a tight layer on top on the raft 
as it naturally occurs in skin (Nagarajan et al., 2010, Barcelos and Sotto, 2009). Cells 
maintaining the C3 mutant however did not flatten out and the keratinous layer was spotty 
instead of tight. This combined with the increase of cell proliferation in C3 infected rafts 
implies that the morphological differentiation process of the host cell was impaired. The 
amount of cells stained for loricrin was not quantified since the cells maintaining the WT 
were fused together. 
 
 
 
Figure 61) Raft slides stained for DNA, E1^E4 and the keratin loricrin 
These images are representative of two independent experimental repeats  
The C3 mutant slides show a significant increase in cell number. Loricrin expression 
occurs in the uppermost layer of the raft. In the wild type rafts, loricrin positive cells are 
flat and form a rigid surface on top of the raft. However loricrin positive cells maintaining 
the C3 mutant do not form this tight layer. Instead, loricrin positive cells have a round 
shape and the keratinous layer has gaps. 
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4 Discussion and Implications 
4.1 In silico screening and optimisation of future predictions 
The results presented in this study reveal that all three prediction tools used can provide a 
solid foundation for CTCF research. However the manual predictions using Storm gave the 
best results and the statistical analysis indicated how to optimise in silico prediction of CTCF 
binding sites further. 
The Essex tool is based on EMSA confirmed CTCF binding sites. Therefore, the influence of 
host factors or DNA methylation is not taken into account in predictions with this tool. 
Thus, solely the potential of a CTCF binding site to bind CTCF without any cellular factors 
determines if a potential binding site is recognised by this tool. Approaching an in silico 
prediction like this has advantages as well as drawbacks compared to the other tools. For 
example, 30 % of CTCF binding site are suggested to not contain the 20mer consensus 
binding motif of CTCF and can therefore not be recognised by PWM based tools (Chen et 
al., 2012a). However, an EMSA based tool does not neglect these binding sites. In many 
cases the CTCF binding pattern was shown to be subject to change upon cellular 
differentiation or imprinting (Bell and Felsenfeld, 2000, Hark et al., 2000). Therefore, an 
EMSA based tool can find binding sites that may not be currently occupied by CTCF but 
have the potential of being used in response to a stimulus or during differentiation of the 
cell. In contrast to this, ChIP based tools are limited towards the CTCF binding pattern of 
the particular cells used to generate the ChIP data. A potential change in CTCF binding 
pattern that occurs in cells from other tissues, or in response to a stimulus, is not taken into 
account by ChIP based tools. On the other hand the ChIP tools take the cellular factors that 
influence CTCF binding in the particular cell type into account. These factors may be more 
or less abundant in different cell types and could therefore influence the CTCF binding 
pattern. This is an advantage of the ChIP based tools CTCFBSDB and Storm over the Essex 
tool. Using different tools based on EMSA and ChIP in parallel gives the opportunity to 
benefit from the advantages of each tool and compensate their flaws to some extent. Thus 
using EMSA and ChIP based tools for each new CTCF prediction is recommended. 
By taking the statistical analysis into account it is possible to optimise the interpretation of 
results given by all three tools. Out of all the tools used, the Essex tool had the lowest ratio 
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of confirmed binding sites to predicted CTCF binding sites. However this hit ratio of 42.4 % 
was still higher than the hit ratio achieved with fragments that do not contain a predicted 
binding site (12.0 %). The CTCFBSDB tool 1.0 has a high hit ratio (64.5 %) but also a high 
chance of neglecting important binding motifs. The patched version 2.0 of the CTCFBSDB 
tool is an improvement over 1.0 but still neglects many important sites because only the 
best match to each PWM is shown. Unless this issue is resolved, predictions using Storm are 
the most reliable ones.  
The identification of many binding sites combined with a high hit ratio (63.6 %) are a clear 
advantage of Storm over the other two tools because those either find a large number of 
binding sites (Essex) or have a high hit ratio (CTCFBSDB). Statistical analysis of the results 
from Storm can be used to improve future predictions. Out of the six different PWM, PWM 
1 and 3 had nearly all their predictions above threshold confirmed in vitro, therefore, it 
would be sensible to decrease the threshold for these PWM in future experiments. For 
example the binding site below threshold found in the LCR of BPV1 was identified by PWM1 
and has a score of 9.35 while the score threshold is 10.72. Based on the high hit ratio of 
motifs predicted by this PWM (92.9 %), a binding site with a score of 9.35 still has a high 
probability of being EMSA confirmed. On the other hand, an increase of the threshold for 
PWM number 5 would be sensible since this PWM had the comparably low hit ratio of 64.7 
% at the threshold chosen.  
However the best indicator for the EMSA confirmation of a predicted binding site is the 
number of different PWM by which this binding site was identified. All 13 fragments 
containing binding motifs that were recognized by 3 or more different PWM were shown to 
bind CTCF in vitro. In addition, the strength of the shift correlated with the number of PWM 
that identified a particular binding site and the score it was given by each PWM. The 
strongest shifts were mostly seen with binding sites receiving high scores from many PWM. 
I recommend using Storm in combination with the Essex tool for new CTCF binding site 
predictions. However the CTCFBSDB tool could be on par with Storm if it is updated so that 
thresholds can be chosen manually and the neglect of binding sites is resolved. In this case 
the CTCFBSDB tool would give the same results as Storm since it uses the same PWM. 
Additionally it is widely available and easy to use. If the developers should decide to 
improve their tool this way it would benefit future CTCF research greatly. 
However this study has already led to significant improvements of the CTCFBSDB tool by 
fixing the line break bug and the bug of giving incorrect location of putative CTCF binding 
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sites. The fixed tool now identifies the strong and conserved binding site around nucleotide 
3000 in HPV31, which was neglected prior to the bug fix. It is thought that this particular 
motif had been disturbed by a line break and could only be discovered after the bug had 
been fixed. Since the CTCFBSDB tool is one of the most widely used tools for CTCF binding 
site prediction, fixing the bug will positively affect future research on CTCF. 
Nevertheless using the prediction tools does not supersede experimental confirmation. 
Some binding sites found by EMSA, including the strong binding site for BPV1 at nucleotide 
3000, were not predicted by any of the tools used. Considering the fact that all high risk 
HPV types have a confirmed strong, conserved binding site at this position makes it likely 
that the binding site in BPV1 in this position is also bound by CTCF in vivo. However more 
research is needed to confirm this.  
 
4.2 The CTCF binding pattern of HPV 
EMSA testing of predicted CTCF binding sites led to the generation of CTCF binding maps for 
each papillomavirus tested. The comparison of these binding maps revealed particular 
conserved CTCF binding sites. All high risk HPV screened have a high scoring CTCF binding 
motif around nucleotide 3000 that shows a strong shift in EMSA. Interestingly, no binding 
motifs were predicted in this area in low risk or beta HPV and EMSA testing for unpredicted 
binding sites in this region confirmed the absence of a CTCF binding site at this position in 
the low risk and beta types tested. However, both low risk HPV types tested had another 
high scoring motif predicted around nucleotide 5400 which showed a strong shift in EMSA. 
Most of the other viruses screened also had CTCF binding sites predicted in the wider area 
around nucleotide 5400 but the scores of these motifs were lower. EMSA testing of these 
binding sites showed shifts of either weak or medium strength. This, together with the 
lesser positional conservation of this binding site in high risk types, indicates that the CTCF 
binding sites around nucleotide 5400 may be more important to low risk types than to high 
risk types. The binding site around 5400 in low risk types may, in fact, replace the 
conserved binding site around nucleotide 3000 of high risk HPV types.  
It has been found that CTCF binding sites of high occupancy are conserved in most types of 
tissue whereas sites of low occupancy are more likely to be tissue specific (Essien et al., 
2009). Assuming the strength of a gel shift is a measure of occupancy, the strong binding 
sites may be used throughout the differentiation process of the host cell whereas the sites 
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showing a weaker shift may be bound by CTCF in a particular stage of the differentiation 
process. Furthermore It has been shown that the degree of occupancy of a transcription 
factor binding site can have a specific function in gene regulation (Tanay, 2006). For CTCF 
there may be a distinct functional difference between binding sites of low and high 
occupancy (Essien et al., 2009). The high occupancy binding sites of CTCF were shown to be 
more often associated with repressive histone marks whereas low occupancy sites were 
associated with transcriptionally active chromatin (Essien et al., 2009). 
The ChIP data presented in this study confirmed that the site in HPV18 at nucleotide 2990, 
which resulted in the strongest shift in vitro, bound CTCF in undifferentiated HFK. All CTCF 
binding sites that resulted in a weaker shift in EMSA were not confirmed by ChIP using 
undifferentiated HFK cells. Again assuming that shift strength is a measure of occupancy, 
this data supports the hypothesis made by Essien et al. that binding sites of high affinity are 
occupied regardless of tissue or stage of differentiation (Essien et al., 2009).  
The EMSA data produced in this study does not fully resemble in vivo conditions. CTCF is 
present in the gel shift reactions at high concentration and the binding reaction takes place 
in a binding buffer which is obviously different from in vivo conditions. Furthermore, the 
lack of co-factors and post-translational modifications in the in vitro binding reactions may 
play a role. The diversity in different binding motifs provided by the 11 zinc fingers could 
make CTCF inherently sticky to DNA which in turn may have led to some false positive 
results. I suggest that these false positive sites are more likely to show a weak shift in EMSA 
since the affinity to sub-optimal binding motifs should be low. Thus the strength of a shift 
may also be an indicator of how likely it is that an EMSA confirmed CTCF binding site 
actually binds CTCF in vivo; however this is speculation. Also the results achieved using ChIP 
have their limitations. EMSA confirmed binding sites with a medium or weak shift could 
potentially be below the detection limit of this technique and that could be another 
explanation as to why those weaker sites were not ChIP-confirmed. 
Nevertheless, all EMSA data of high risk and low risk viruses combined led to the creation of 
a common pattern of CTCF binding for the viruses tested (Figure 62).  
The area from nucleotide 7000 to 2400 was found to be completely devoid of CTCF binding 
sites in all HPV types tested. All of the binding sites predicted in this region were shown to 
be negative for CTCF binding in EMSA experiments. This is especially interesting since this 
region contains the whole LCR. 
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However many functions of CTCF are long range so CTCF binding sites influencing the LCR 
may not necessarily be located within in the LCR (Zlatanova and Caiafa, 2009a). The 
sequence from nucleotide 2400 to 5500 was the only part of the genome where strong 
CTCF binding sites were found. Interestingly, this area spans the border between the early 
and the late genes so CTCF could potentially be involved in the separation of active from 
inactive chromatin. Also, CTCF binding sites that are highly conserved in high risk and low 
risk viruses are located in this region. CTCF binds strongly in the region of nucleotide 3000 
in high risk viruses or nucleotide 5400 in low risk viruses. In EMSA, fragments containing 
these binding sites all showed a strong shift and the binding site around nucleotide 3000 
 
Figure 62) CTCF binding pattern of high and low risk HPV types 
Out of 4 high risk HPV types and 2 low risk HPV types, none had a binding site confirmed 
within the area shown in green (nucleotide 7000 to 2400). CTCF binding sites showing a 
strong shift have exclusively been found within the blue area which is located from 
nucleotide 2400 to 5500. The red bar on the right marks the area where all high risk HPV 
have a conserved CTCF binding site that showed a strong band shift. Accordingly the red 
area on the left marks the area where both low risk viruses tested have a conserved and 
strong CTCF binding site. In the yellow area (nucleotide 3500 to 7000) CTCF binding sites 
showing a weak or medium shift are common. Many of these weaker sites accumulate 
here. However ChIP testing of HPV maintaining, undifferentiated keratinocytes did not 
confirm CTCF binding in this region.  
1
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was ChIP confirmed in undifferentiated cells maintaining HPV18 (Figure 46) and HPV16 
(unpublished data from Dr. Ian Groves, University of Cambridge). The potential function of 
this binding site is discussed in detail in the following sections. 
From nucleotide 3500 to 7000, the CTCF binding sites showed weaker shifts but binding 
motifs were abundant in this region and clustered in particular in the ORFs of the late 
genes. However ChIP experiments of undifferentiated cells maintaining HPV18 (Figure 46) 
or HPV16 (Dr. Ian Groves, University of Cambridge, personal communication) did not show 
CTCF binding to these sites. Thus CTCF may bind to these binding sites later in the viral life 
cycle or they may be false positives.  
 
4.3 The CTCF binding pattern of BPV1 
BPV1 was the most thoroughly tested PV in this study. This virus has served as a model for 
HPV gene regulation for the past 5 decades and is still widely used in research (Boiron et al., 
1964, Black et al., 1963).  
The CTCF binding pattern of BPV1 has some similarities to that of HPV but distinct 
differences have also been found. The most notable similarity to high risk HPV is the 
presence of the high risk specific, strong CTCF binding site around nucleotide 3000. 
However this binding site was not predicted by any of the tools used. The Essex tool 
predicted a binding site very close to the EMSA confirmed binding site, but this region was 
found to be a false positive in EMSA since fragment containing only parts of the predicted 
motif bound CTCF. Therefore, the true binding site seems to be located in the vicinity of the 
predicted site. The strong shift and the conserved location of this binding site make it likely 
that the EMSA result is not an artefact.  
The remaining CTCF binding pattern within the BPV genome is distinct from that of all the 
HPV types tested. For example there are binding sites located within the area from 
nucleotide 7000 to 2400 and even in the LCR whereas this region appears devoid of CTCF 
binding sites in HPV.  
Another interesting trait of BPV1 is the CTCF binding in the vicinity of promoters outside of 
the LCR. Each promoter outside of the LCR was shown to have a CTCF binding site in close 
proximity, most often located shortly upstream of the promoter judging from the 
predictions and the coverage of fragment P890. In KSHV it was shown that CTCF is 
necessary for recruiting RNA polymerase II to a specific promoter (Kang et al., 2013). The 
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CTCF binding sites in BPV1 may have the same function. Also other functions of CTCF could 
influence the transcription of BPV1 genes, for example by blocking enhancers, forming 
loops or preventing de novo methylation.  
The strong CTCF binding site around nucleotide 3000 may have a distinct role regarding the 
expression of different variants of the E2 protein. In BPV1, three E2 variants exist: Full 
length E2, E2-TR and E8^E2 (Hubbert et al., 1988). The isoforms are expressed in a ratio of 
1:10:3, respectively (Hubbert et al., 1988). Full length E2 can activate or inhibit transcription 
from promoters in a dose dependent manner (Dostatni et al., 1991, Steger and Corbach, 
1997, Thierry and Howley, 1991). E2-TR is transcribed from its own promoter at 3080 and 
mostly functions as a repressor through competition with full length E2 for binding site (Lim 
et al., 1998, Vaillancourt et al., 1990). This variant of E2 is lacking the transactivator 
domain; however it was recently suggested to be able to still activate some promoters 
upstream of its binding site (McBride et al., 1989, Lace et al., 2012). Elimination of E2-TR 
resulted in an increase in viral copy number as well as increased transformation potential 
(Riese et al., 1990, Lambert et al., 1990). The expression of E2-TR is unique to BPV and the 
strong CTCF binding site is located between nucleotide 2917 and 3027 which is very close to 
the E2-TR specific promoter at nucleotide 3080 (Vaillancourt et al., 1990). Thus this 
promoter may be regulated by CTCF. If this is the case CTCF would regulate transcription of 
the most prevalent variant of the viral transcription factor E2, indicating that CTCF binding 
in this region may be vital for the global regulation of viral gene transcription. However the 
western blots show that this is not the case for methylcellulose differentiated HFKs. A 
downregulation of E2-TR should result in increased viral copy number and increased 
transformation potential whereas upregulation of E2-TR is likely to have the opposite effect 
and may even repress viral gene expression to an extent that is insufficient for viral 
maintenance (Riese et al., 1990, Lambert et al., 1990).  
The E2 variant E8^E2 is a clear repressor of E2 function similar to the ones found in HPV. 
The transcript encoding this variant is transcribed from promoter P890 (Vaillancourt et al., 
1990, Lace et al., 2008). E8^E2 can repress transcription as well as replication of viral DNA 
(Lace et al., 2008). CTCF may play a role in the regulation of E8^E2 expression considering 
that a CTCF binding site in the P890 promoter region was confirmed by EMSA.  
Data from HPV18 and HPV11 showed that increased expression of E8^E2C resulted in 
maintenance defects by over-abundance of heterodimers of E8^E2C and E2 which are not 
sufficient for long term maintenance of the viral episome (Kurg et al., 2010). However, 
Discussion and Implications 
144 
disruption of the E8^E2 protein in BPV did only show little effects on viral gene expression 
so the mechanisms from HPV16 and HPV31 may not apply to BPV1 (Lambert et al., 1990).  
Another feature of the CTCF binding pattern in BPV1 is the distribution of CTCF binding sites 
across the entire BPV1 genome. Considering that CTCF was found to protect an area of at 
least 2kbp around its binding site from de novo methylation, the distribution of CTCF 
binding sites in BPV1 has the potential to protect the majority BPV1 genome from de novo 
methylation (Zampieri et al., 2012, Davalos-Salas et al., 2011, reviewed by Klenova and 
Ohlsson, 2005, Fedoriw et al., 2004, Szabo et al., 2004). On the other hand the potential of 
CTCF to form DNA loops and bridges opens up the possibility that CTCF may be involved in 
packaging of the DNA into the viral particle by folding the episome in a particular way.  
BPV1 was the only papillomavirus of which the whole LCR was tested for CTCF binding 
experimentally. The fragments used for screening the BPV1 LCR mostly had an overlap of 
60bp but a few had a shorter overlap of about 30bp. Considering that the overlapping 
fragments for testing the binding site at nucleotide 3000 revealed that a CTCF binding motif 
can be very large, it is possible that a CTCF binding sites have been missed out due too 
short overlaps.  
 
4.4 Generation of HFK cell lines maintaining an HPV18 mutant 
deficient in CTCF binding 
The generation of a HPV18 mutant that was deficient in CTCF binding around nucleotide 
3000 was successful. A near complete abrogation of CTCF was confirmed in EMSA 
experiments. Subsequent ChIP experiments suggested the abrogation of CTCF binding in C3 
mutant maintaining HFK. However the low episome copy number of the C3 samples used 
for the ChIP could have influenced this result. Hence the ChIP experiments shown in this 
study have been repeated by Dr. Jo Parish with cells of normal episome copy number and 
the loss of CTCF binding in the C3 has been confirmed.  
It is important to note that the fragment used in EMSA to test the binding site around 
nucleotide 3000 was 200 bp in size and may have contained a CTCF binding site other than 
the predicted one as it was the case for the fragments used for mutating binding site 5400 
or testing binding site 3000 in BPV1. The fact that CTCF binding was abrogated in the 
mutant confirmed that the predicted binding site within the 200bp fragment tested by 
EMSA was the true binding site of CTCF. However, the confirmed binding site at nucleotide 
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3000 in HPV18 was also present on the 60bp probe, which did not bind CTCF in EMSA 
experiments. This could be explained by the motif being at the very edge of the probe what 
prevented CTCF binding to the motif. This is in agreement with the conclusion of Nakahashi 
et al. who suggested that some zinc fingers of CTCF bind nonspecific sequences at either 
side of the binding motif (Nakahashi et al., 2013). Thus the absence of such a nonspecific 
sequence at one edge of the probe rendered CTCF unable to bind to the motif. 
The mutation introduced at binding site 5400 of HPV18 failed to abrogate CTCF binding. 
This binding site was predicted by the Essex tool which had the lowest hit-ratio of all tools 
used and the fit to the PWM defined by Schmidt et al. was not optimal. Therefore it is 
possible that this binding site was a false positive prediction and that the true CTCF binding 
site exists elsewhere on the 200bp fragment used for testing the binding site around 
nucleotide 5400. However the ChIP data showed that this binding site is not occupied by 
CTCF in undifferentiated keratinocytes. Another incorrect prediction of a CTCF binding site 
was revealed in BPV1 for the binding site around nucleotide 3000. A putative binding site in 
the close vicinity of the real binding site was predicted by Essex tool. The actual location of 
the real CTCF binding site was shown to be not exactly at the predicted motif. The reasons 
for this could be mere chance or an inaccuracy of the Essex tool itself. However more data 
is needed to investigate this further. 
Nevertheless, it was shown experimentally that unpredicted CTCF binding motifs exist on 
the fragments used for testing binding site 5400 in HPV18 and binding site 3000 in BPV1. 
With the thresholds used for Storm, no putative CTCF binding sites on these fragments 
were revealed. A new prediction with Storm could be performed to screen for binding sites 
using lower thresholds than the ones previously chosen. Considering the fact that binding 
sites above threshold predicted with PWM 1 and 3 were almost always confirmed, even 
binding sites below threshold recognised by these PWM have a good chance of revealing 
the real binding site on these fragments.  
In this project only the mutation for CTCF binding abrogation around nucleotide 3000 in 
HPV18 was successful and could be used for further experiments. However three potential 
binding sites of other transcription factors at the mutation site were changed when the 
mutations were introduced as seen in Table 34. The binding site for MyoD was disrupted 
with the introduction of the mutations. MyoD is not expressed in HFK, so an effect on viral 
gene expression due to the disruption of this binding site is unlikely (unpublished data from 
Professor Ciaran Woodman, University of Birmingham). The change in the affinity of the 
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binding site for Oct1 is minor, resulting in a score increase from 0.964 to 0.982. However an 
effect on the viral gene expression cannot be excluded. A new potential binding site for 
GATA3 was created at the mutation site. This transcription factor is expressed in HFK and 
could therefore influence future experiments (unpublished data from Professor Ciaran 
Woodman, University of Birmingham). To investigate this further a ChIP experiment could 
be carried out to determine if GATA3 binding to the newly generated potential binding site 
occurs. 
Creating a continuous, viral episome maintaining cell line from primary keratinocytes was a 
very labour intensive process which was done by Dr. Jo Parish from the University of 
Birmingham. Primary foreskin keratinocytes from two donors (Georgie and Clonetics) were 
chosen to reduce bias from donor specific genetics and to keep the workload to a 
manageable amount. Using primary cells of two donors has been shown to be beneficial for 
this project since a difference between the cell lines from different donors have been 
observed (Figure 50). The maintenance of the C3 mutant episome appeared to be worse in 
Georgie cells compared to Clonetics cells. 
Before the creation of the cell lines it was not known if the mutated CTCF binding site at 
nucleotide 2990 of HPV18 performs a vital function to the virus. The successful creation of 
the C3 mutant cell line proves for the first time that the CTCF binding site around 
nucleotide 3000 in HPV18 is not vital for episome maintenance in the first weeks of 
culturing. However long term maintenance was affected as cells maintaining the mutant 
lost viral episome quicker compared to cells maintaining wild type HPV18. Sequencing of 
the mutation site from DNA isolated from all wild type and mutant cell lines confirmed the 
desired sequence in each of the samples. Thus there was no carryover of wild type HPV18 
genomes in the C3 mutant sample.  
Southern blot analysis of DNA from the cell lines which was digested with the single cutter 
EcoRI showed one clear band of the expected size for the linearised full length HPV18 
genome. No background bands were seen. The samples were also digested with BglII and 
analysed by Southern blotting. This enzyme does not have a restriction site within the 
HPV18 genome and resulted in the typical banding pattern of circular DNA in open circle 
and supercoiled form on a Southern blot. A few very faint bands were seen in the 
background in addition to the two expected bands. If these bands were due to integrants 
such bands would also be seen in the EcoRI sample since EcoRI also cuts the host genome. 
However the Southern blot with EcoRI showed a clear background. Additionally the pattern 
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of these background bands was identical in all cell lines. Every integration event would take 
place at semi-random sites resulting in a different banding pattern after digestion (Thorland 
et al., 2003, Dall et al., 2008). Hence the faint bands seen in the BglII digests were 
considered to be background noise. Thus the presence of episomal HPV18 genomes in all 
cell lines was confirmed. 
 
4.5 The role of CTCF in genome maintenance  
The C3 mutant maintaining HFK have been shown to lose episomes over time. In other 
studies episome loss has been observed in response to various different alterations in HPV 
gene expression and the putative causes of episome loss can give indications to the 
function of the CTCF binding site around nucleotide 3000 in HPV18. The regulation of the 
episome copy number in HPV maintaining cells is complex and not fully understood. Viral 
gene expression, methylation, tethering and host cell traits contribute to this mechanism 
(Hoffmann et al., 2006, Parish et al., 2006, Kurg et al., 2010, Penrose and McBride, 2000, 
De-Castro Arce et al., 2012).  
At the early passages 5 and 6 the samples of C3 Georgie and C3 Clonectics cells have been 
shown to have a similar copy number to their wild type counterparts. These cell lines 
needed to be split once a week so the cells of passage numbers 5 and 6 were already 
growing for over a month without significant episome loss. However C3 maintaining cell 
lines above 10 passages showed a decline in episome copy number (Figure 51).  
The replication of the viral episome can be divided into three phases and the regulation of 
viral copy number is likely to be different in each of these phases (reviewed by McBride, 
2008). Firstly the initial amplification upon infection of the cell, secondly the maintenance 
replication that keeps viral copy number in basal cells constant and thirdly the amplification 
of viral genome for the assembly of viral particles (reviewed by McBride, 2008). There is 
also some evidence for HPV latency at low episomal copy number which may involve a 
fourth phase of replication but HPV latency is not well understood at the current state of 
research (reviewed by Doorbar, 2013). The low copy number that remained in the C3 cells 
after extended culture could be an indicator for such a latency phase. However the immune 
system is suggested to be an important factor in HPV latency and this factor was not 
present when genome loss occurred in this study (reviewed by Doorbar, 2013). 
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The two major regulators of episome copy number in HPV are E1 and E2. Additionally the 
viral oncogenes E6 and E7 contribute indirectly to viral genome replication by the 
promotion of proliferation and the degradation of inhibitory factors such as TBP, CDP, YY1 
and p53 (Hartley and Alexander, 2002, Ilves et al., 2003, Narahari et al., 2006). The 
regulation of episome copy number immediately after infection and later in the life cycle 
for the assembly of viral particles is dependent on E1 since this protein is suggested to 
facilitate episome replication independently of host DNA (Egawa et al., 2012, Bodily and 
Laimins, 2011, reviewed by Doorbar et al., 2012). E1 is recruited to the origin of replication 
by E2, also making E2 essential for the replication of viral genomes in these two phases 
(Sedman and Stenlund, 1995). However the maintenance phase, which is in-between the 
initial amplification and the mass production of episomes, has been shown to be 
independent of E1 expression since replication takes place together with the host 
chromosomes (Egawa et al., 2012, Kim and Lambert, 2002). HPV episomes in 
undifferentiated keratinocytes are in this maintenance phase so E1 protein is likely not 
essential for replication of viral episomes. Even the E1-mediated initial amplification of the 
HPV18 genome after transfection of the HFK may not have been necessary since many 
genomes were possibly transfected into the cell at once. However E1 has been shown to 
impair the tethering mechanism by interacting with E2, possibly leading to episome loss 
(Voitenleitner and Botchan, 2002). Thus induction of E1 expression has the potential to 
decrease viral copy number by impairing tethering of the viral genome to host 
chromosomes. The expression of E1 in the cell lines has not been tested due to the lack of 
functional antibody. However a putative change in transcription of E1 that is directly caused 
by the lack of CTCF would have taken place from the time the virus was transfected into the 
host cell but the episome loss observed started months after initial transfection. Only an 
indirect effect of the abrogation of CTCF binding could cause a change in E1 expression 
after a long period of time, for example the gradual accumulation of DNA methylation.  
In contrast to E1, the protein E2 is involved in all three phases of episome replication, 
including the maintenance replication of HPV18 which takes place in primary keratinocytes 
(reviewed by McBride, 2013). In the natural HPV life cycle, E2 is crucial for recruiting E1 to 
the origin of replication of the HPV episome in the initial and late amplification phases. E2 
binding sites in the LCR are needed for the recruitment of E1 and the number of binding 
sites necessary for stable episome maintenance differs between PV types (Piirsoo et al., 
1996, Li et al., 1989, reviewed by McBride, 2013). For HPV18 three out of the 4 binding sites 
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for E2 are essential for episome maintenance (unpublished data from van Doorslaer et al.; 
mentioned in a recent review (McBride, 2013)).  
In addition to its function in replication, E2 also mediates the maintenance of a stable 
episome copy number by tethering HPV genomes to mitotic host chromosomes (You et al., 
2004). E2 binds to its binding motif within the HPV genome and interacts with other 
proteins such as Brd4 and ChlRI. This interaction is needed to form a stable connection with 
a host chromosome similar to the one in sister chromatid cohesin (Parish et al., 2006, 
McPhillips et al., 2006, Kurg et al., 2006). Note that Brd4 is only essential for tethering in 
some papillomaviruses, including BPV1 and some beta papillomaviruses (McPhillips et al., 
2006). In all alpha papillomaviruses tested (HPV11, 16, 31, and 57), the interaction of Brd4 
and E2 is only relevant for gene regulation whereas the tethering mechanism is 
independent of Brd4 (McPhillips et al., 2006). Furthermore the tethering pattern seems to 
be different in alpha virus as the association of episomes with host chromosomes is only 
seen in telophase and the general physical connection is suggested to be weaker 
(McPhillips et al., 2006). So there is some degree of episomal co-localisation with host 
chromosomes in alpha papillomaviruses that is dependent on E2. Thus a change in E2 
expression could also impair tethering and therefore genome maintenance. Interestingly 
the amount of E2 was shown to correlate with episome copy number in BPV1 and an 
increase in E2 also increased the copy number of viral episomes (Penrose and McBride, 
2000).  
In methylcellulose differentiated cells it was discovered that E2 expression was slightly 
increased earlier in differentiation in the C3 mutant compared to the wild type (Figure 53). 
However the amount of E2 present in undifferentiated cells in which the episome loss 
occurred could not be measure with western blotting because E2 expression in these cells is 
below the level of sensitivity with the E2-specific antibody available. It is possible that the 
E2 expression level may have also been increased in these cells. However, increased 
expression of E2 should increase viral copy number instead of decreasing it.  
Several E2 binding sites within the LCR have been shown to be critical for the replication 
and maintenance of viral episomes (Li et al., 1989, Piirsoo et al., 1996, reviewed by 
McBride, 2013). The E2 binding motif ACCG(N)4CGGT contains a CpG motif that can be 
methylated and methylation of E2 binding sites results in abrogation of E2 binding (Kim et 
al., 2003, Thain et al., 1996). Therefore methylation of E2 binding sites can be linked to 
episome replication and maintenance. Interestingly, the viral proteins E2, E6 and E7 have 
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been shown to induce de novo methylation of the viral episome (De-Castro Arce et al., 
2012). In turn, this resulted in reduced expression of the methylation-promoting proteins 
E2, E6 and E7 and a reduction in episome copy number (De-Castro Arce et al., 2012). All 
three of these methylation-promoting proteins are essential to genome maintenance in 
HPV16 and 31 suggesting a mechanism in which self-regulation of viral copy number is due 
to an interplay of methylation-promoting viral proteins and the regulation of transcription 
and episome copy number by methylation (Park and Androphy, 2002, Thomas et al., 1999).  
The majority of this methylation dependent regulation of viral copy number originates from 
the LCR, which is located about 3000 nucleotides away from the CTCF binding site around 
nucleotide 3000. The methylation protection function of CTCF applies to at least 2kbp 
around its binding site so it could potentially extend to the LCR, especially if CTCF would 
form a loop to the LCR (Davalos-Salas et al., 2011, Zampieri et al., 2012, reviewed by 
Klenova and Ohlsson, 2005, Szabo et al., 2004, Fedoriw et al., 2004). However, methylation 
of the ORF of a gene can also result in epigenetic silencing. In conclusion a change in 
methylation caused by loss of CTCF binding could contribute to the episome loss observed. 
Methylation has recently been shown to be involved in splicing. Thus de novo methylation 
as a result of the abrogation of CTCF binding could result in altered mRNA processing of 
viral transcripts, leading to a loss of episomes (Maunakea et al., 2013). In addition, CTCF 
mediated stalling of RNA polymerase II was shown to promote the assembly of a splicing 
complex, favouring the inclusion of weak upstream exons (Shukla et al., 2011). The absence 
of CTCF would abrogate RNA polymerase II stalling which could result in alternative splicing 
and may change viral gene expression in a way that does not properly support episome 
maintenance. 
Considering the role of CTCF as a boundary factor, it is possible that CTCF at nucleotide 
3000 prevents the spread from the transcriptionally silent heterochromatin of the late 
genes into the early genes during maintenance phase (reviewed by Ohlsson et al., 2010, 
Probst et al., 2009). Downregulation of early genes via this mechanism could also cause 
episome loss.  
All papillomaviruses express at least one variant of E2 that can act as a repressor of full 
length E2 by forming heterodimers (reviewed by McBride, 2013). In alpha HPV this 
repressor is called E8^E2C since it contains a small part of the otherwise untranslated E8 
ORF attached to the DNA binding domain of E2 (Hubbert et al., 1988). E8^E2C does not 
contain the transactivator domain of full length E2. Mutation of the E8 ORF to prevent 
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E8^E2 expression in HPV16 and HPV31 revealed that long-term episome maintenance of 
HPV31 failed after an initial increase in viral copy number of 30-40 fold in HFK and SSC13 ( 
HPV-negative squamous cell carcinoma line) (Lace et al., 2008, Stubenrauch et al., 2000). 
Episome copy number of HPV16 in HFK was also increased when E8^E2 expression was 
prevented. However unlike the HPV31 genomes, long term maintenance of mutated HPV16 
genomes was supported in these cells (Lace et al., 2008). Interestingly heterodimers of 
HPV18 and HPV11 E2 and E8^E2C have been shown to be able to initiate replication but fail 
in the long term maintenance of the HPV18 and HPV11 genomes in SiHa (squamous cell 
carcinoma line) and HaCaT cells (cultured human keratinocytes) (Kurg et al., 2010). Thus 
both the depletion of E8^E2C and the overexpression of E8^E2C can lead to episome loss in 
some HPV types. Hence a putative over or underexpression of E8^E2C is one possible 
explanation for the accelerated loss of episomes observed in the C3 mutant.  
The different outcomes regarding E8^E2C-dependency of episome maintenance in different 
HPV types and cell lines may be connected to the mode of replication the virus acquires in 
these particular cell lines. HPV genomes in the maintenance phase can be replicated 
through two different modes (Hoffmann et al., 2006). The first mode is random choice 
episomal replication which means that the viral genomes replicate randomly to a certain 
final number during S-Phase (Hoffmann et al., 2006). The second mode is called licensed 
replication and refers to a mechanism in which each viral genome is replicated once during 
S phase, just like host chromosomes (Hoffmann et al., 2006). The mode of replication that 
HPV acquires was shown to be dependent on HPV type and the cell line used. HPV16 
genomes replicate once per cell cycle in W12 cells whereas HPV31 replicates via random 
choice in CIN612 cells (cervical intraepithelial neoplasm cell line) (Hoffmann et al., 2006). 
However, transfection of HPV16 or HPV31 into the spontaneously immortalised normal 
keratinocyte cells (NIKS) promotes random choice replication in both HPV types (Hoffmann 
et al., 2006). In addition to E8^E2 expression, the level of E1 expression may be the 
determining factor of the mode of replication because high expression of E1 has been 
shown to induce random choice replication in HPV16 maintaining W12 cells (Hoffmann et 
al., 2006). 
The mechanism of genome replication in HPV18 maintaining HFK has not yet been 
investigated. If replication in HFK is licensed, the virus may not be able to replace single 
genomes if they are lost. Hence a small chance of losing an episome during each cell 
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division would result in a slow decline in the number of viral episomes over time. The loss 
of CTCF binding may result in such a chance for genome loss during cell division. 
The varying effect of E8^E2C loss regarding maintenance in different cell lines may be 
connected to the mode of replication the virus acquires in these cell lines. Hence E8^E2C 
may only be essential to only one mode of replication, for example licenced replication. 
Unfortunately the study investigating the influence of E8^E2C on replication and the study 
investigating the mode of replication used different cell lines (Hoffmann et al., 2006, Lace et 
al., 2008). The mode of replication of the cells in which E8^E2C was depleted was not 
determined. Hence it is not known if the ambiguous effect of E8^E2C on episome 
maintenance is linked to the mode of replication. 
Interestingly, E8^E2C is transcribed from a particular promoter in HPV16, 18 and BPV1 
situated around nucleotide 1150 (Lace et al., 2008, Hubbert et al., 1988, reviewed by Van 
Doorslaer et al., 2013). The regulation of this promoter has not yet been researched and 
CTCF has the potential to affect transcription from this promoter remotely by blocking 
enhancers, protection from methylation, or looping. Hence abrogation of CTCF binding 
could potentially alter transcription of E8^E2C which could be the reason for the impaired 
episome maintenance seen in the C3 cell lines.  
The expression of some E2 transcripts is partly regulated by the use of suboptimal codons in 
the E2 coding region (Oliveira et al., 2006, Kurg et al., 2010). With the mutations introduced 
in the C3 mutant, three codons in the E2 ORF were changed which may have resulted in an 
optimisation of codons, thus increasing translation efficiency of E2. However E2 consists of 
more than 360 amino acids and changing only three of them probably has limited impact on 
translation efficiency. The mutations were situated in the transactivator domain of E2 
which is excised in the splice variant encoding E8^E2C. Hence the codon optimisation from 
the mutation of the CTCF binding site would not affect translation efficiency of E8^E2C 
through the optimisation of codons. Also, increased expression of E2 in the C3 mutant cells 
was only seen at a particular time point, after 24 hours of differentiation. 
Another putative cause for the aberrant maintenance of episomes in the CTCF binding 
defective HPV18 genomes can be hypothesised on the basis that CTCF has been shown to 
play a role in asynchronous replication of alleles (Bergstrom et al., 2007). The data 
published by Bergstrom et al. shows that the CTCF binding allele of the H19/Igf2 locus 
replicates late in S phase whereas the methylated allele that does not bind CTCF replicates 
early in S phase (Bergstrom et al., 2007). Assuming the HPV episomes follow the same 
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principle, the replication of the C3 mutant episomes would be shifted from late S phase to 
early S phase. Considering that genome amplification in suprabasal layers takes place in a 
pseudo S-phase in which the early proteins E6 and E7 promote proliferation while the 
E1^E4 protein inhibits proliferation, the shift of genome replication from a late to an early 
stage of the S phase may have an impact on vegetative genome replication (reviewed by 
Doorbar et al., 2012). However maintenance replication occurs in the typical S phase of 
basal keratinocytes and an effect of CTCF on the time of replication needs further 
investigation to draw conclusions on a possible role in episome replication during the 
maintenance phase. 
Episome loss upon the abrogation of CTCF binding was also seen in EBV (Tempera et al., 
2010). They found that the latency specific promoter Qp was no longer protected from de 
novo methylation in a CTCF binding deficient mutant (Tempera et al., 2010). This led to a 
slow and gradual DNA methylation that took 16 weeks until the promoter was completely 
silenced (Tempera et al., 2010). In the samples tested in this study a significant loss of 
episomes was observed in samples of passage 14/15 or older. This corresponds to about 15 
weeks of culturing and therefore correlates to the episome loss observed in EBV. However 
in HPV18 there are only two main promoters (early and late promoter) and one secondary 
promoter which is solely dedicated to the transcription of E8^E2C (Wang et al., 2011). The 
early promoter could be silenced by methylation which would result in a general reduction 
in the expression of early genes and an inability of maintaining the viral genome. Also the 
promoter that is only used for the transcription of E8^E2C could be silenced by methylation 
since any change in transcription from this promoter could potentially cause genome loss. 
In conclusion the known reasons of episome loss are changes in the expression levels of the 
proteins E2, E8^E2C, E6 and E7. There is a multitude of different mechanisms through 
which the abrogation of CTCF binding could have caused such changes. One of these 
mechanisms is the transcription regulation by interaction with the promoter either through 
targeting of enhancers and transcription factors or through recruiting of the RNA 
polymerase II to the promoter. CTCF could also alter the expression of these genes by 
altering methylation of the DNA, including the methylation of various E2 binding sites. This 
is interconnected with the third mechanism; the alteration of the splicing of viral 
transcripts. Alternative splicing could be achieved by CTCF-controlled methylation of splice 
sites or the stalling of the RNA polymerase II during transcription. 
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Considering the data presented in this study I suggest the interference with methylation to 
be the most likely solution to the episome loss. The slow accumulation of CpG methylation 
in response to abrogation of CTCF binding has already shown to be the cause of episome 
loss in EBV (Tempera et al., 2010). Also the timing of the episome loss observed in EBV was 
very similar to the one seen in the experiments presented in this study. In EBV, a promoter 
was methylated whereas the conserved CTCF binding site in high risk HPV is located 3000 
nucleotides away from the promoter for the early genes. It is uncertain if the protective 
function of CTCF can extend to the LCR but also methylation of the ORFs of the early genes 
could lead to epigenetic silencing of the early genes. 
 
4.6 CTCF could regulate splicing in HPV 
CTCF can influence splicing through two different mechanisms: the stalling of RNA 
polymerase II and the regulation of DNA methylation (Maunakea et al., 2013, Shukla et al., 
2011). The stalling of the RNA polymerase II takes place when the polymerase encounters a 
CTCF-cohesin complex bound to the template DNA. This favours the assembly of a splicing 
complex upstream of the CTCF binding site, leading to the inclusion of weak upstream 
exons (Shukla et al., 2011). The inclusion of weak upstream exons has been confirmed for 
the first 1000 nucleotides upstream of the CTCF binding site but it may extend further than 
that (Shukla et al., 2011). The interplay of CTCF and methylation is rather complex since 
CTCF can protect DNA from de novo methylation and CTCF binding itself is abrogated by 
methylation (Guastafierro et al., 2008, Zampieri et al., 2012). The protection from de novo 
methylation has been shown to depend on a post-translational modification of CTCF called 
poly(ADP)ribosylation or PARlation (Caiafa et al., 2009). PARlated CTCF can to protect an 
area of at least 2kb in the vicinity of its binding site from de novo methylation (Zampieri et 
al., 2012, Davalos-Salas et al., 2011, Fedoriw et al., 2004, Szabo et al., 2004).  
The CTCF binding maps of HPV can be combined with transcription maps to draw 
conclusions as to how CTCF could influence splicing of particular transcripts. Figure 64 to 
Figure 68 show the transcript maps for HPV16R, HPV18 and HPV31 with all EMSA confirmed 
binding sites indicated as red vertical bars (reviewed by Van Doorslaer et al., 2013). Not all 
HPV transcripts could be determined so these binding maps do not show the complete 
transcriptome of HPV. The transcript of the essential protein E1 is missing in some of the 
maps, most likely to the low abundance of this transcript.  
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The strong and conserved CTCF binding site around nucleotide 3000 is the only binding site 
that could be confirmed in ChIP experiments using either HPV18 maintaining HFK cells or 
HPV16 maintaining W12 cells. Exon inclusion upstream of the CTCF binding site caused by 
RNA polymerase II stalling may play a role in HPV16 because the transcripts I, J and K 
contain a complete exon just upstream of the CTCF binding site. These are the only 
transcripts that can encode a truncated form of the E1 helicase; E1C. Thus E1C expression 
may depend on CTCF binding. Expression of E1C in HPV infected cells has not been 
confirmed and there is no information available on E1C so the transcripts encoding E1C may 
just offer improved or impaired translation of the other proteins encoded on these 
transcripts. Thus the expression of E2, E5, E6 and E7 may be altered by increased 
transcription of the transcripts I, J and K. 
All high risk HPV genomes tested for CTCF binding have parts of the exon for the E1 
transcript within 1000 bp upstream of the CTCF binding site. Thus abrogation of CTCF 
binding could have decreased the inclusion of the exon for E1, leading to reduced E1 
expression. However only increased expression of E1 has been suggested to interfere with 
episome copy number by interference with tethering (Voitenleitner and Botchan, 2002). 
The dependency on E1 for maintenance replication may also be connected to the mode of 
replication in particular cell lines so there is the possibility that the reduction in E1 may 
have reduced episome copy if the episome replicated in a particular mode of replication, 
for example random choice replication. 
Furthermore, post translational modifications of CTCF upon cellular differentiation could 
trigger the inclusion of the E1 exon later in the viral life cycle to support vegetative 
replication. Unfortunately, the expression of E1 protein in methylcellulose differentiated 
cells could not be analysed due to lack of functional antibody. 
E1 expression in BPV1 could also be regulated by the strong CTCF binding site around 
nucleotide 3000 (Figure 68). However the widespread distribution of the other weak CTCF 
binding sites throughout the BPV1 genome could alter splicing in a multitude of ways which 
makes predicting particular mechanisms difficult.  
Assuming that RNA polymerase II stalling has an effect on the splicing of mRNA sequences 
further upstream than 1000 nucleotides of the CTCF binding site, the presence of CTCF 
around nucleotide 3000 may alter the splicing of all viral transcripts. There is also the 
possibility that CTCF acts as a roadblock during transcription and delays the transcription of 
every single viral transcript through the stalling of RNA polymerase II. This delay in 
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transcription could be a regulatory mechanism that reduces viral gene expression in 
primary keratinocytes in order to reduce proliferation and immunogenicity while 
maintaining a relatively high copy number of viral episomes. However, the low risk specific 
strong and conserved binding site at 5400 would only downregulate the late transcripts 
since it is situated downstream of the early polyadenylation signal (Figure 67). Considering 
that the low risk E2, E6 and E7 are less potent in their functions compared to their high risk 
equivalents, a possible downregulation of these early proteins by CTCF may not be essential 
for low risk HPV which could make a CTCF binding site in this region obsolete (Hou et al., 
2002, Kovelman et al., 1996, reviewed by Klingelhutz and Roman, 2012). 
Also there is an exon 1100 nucleotides upstream of the CTCF binding site in low risk HPV so 
there is a chance that CTCF may promote the inclusion of this exon, resulting in the only 
mRNA transcript that is able to encode for L2. Thus the conserved CTCF binding site of low 
risk HPV may be involved in the splicing of late gene transcripts. However, suggesting a 
function for the CTCF binding sites that were only confirmed by EMSA is difficult since the 
putative effects regarding splicing and methylation if all these binding sites were occupied 
by CTCF could affect nearly the entire genome. As of now it is not known which of the 
EMSA confirmed binding sites are occupied by CTCF in vivo during the viral life cycle.  
A potential function in protection from de novo methylation within a wide area around the 
strong and conserved CTCF binding sites would cover many HPV genes. The genes in an 
area of 2 kbp around the low risk specific binding site at nucleotide 5400 include L1 and L2. 
The strong and conserved binding site of high risk HPV around nucleotide 3000 could 
possibly protect E1, E2, E4 and E5 from de novo methylation. However these are just the 
proteins in the confirmed area of protection from de-novo methylation so the extension of 
protection to a wider area is possible (Szabo et al., 2004, Fedoriw et al., 2004).  
Interestingly, western blotting of methylcellulose differentiated cells showed differences in 
the expression of E2 and E1^E4 (Figure 53). The lack of CTCF could lead to a change in 
methylation of these genes in the C3 mutant which could have resulted in decreased 
transcription through epigenetic silencing of these genes. Only the amount of E1^E4 was 
reduced in the C3 mutant compared to the wild type in methylcellulose differentiated cells. 
This effect varied between donors and was only significant in Georgie cells (Figure 53). 
However the data from raft cultures showed the same percentage of E1^E4 expressing cells 
in WT and C3 mutant (Figure 60). The reason for this may be a possible reduction of the 
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amount of E1^E4 per cell rather than a reduction in the number of E1^E4 expressing cells. 
Thus a possible reduction of E1^E4 expression in rafts may have gone unnoticed.  
Nevertheless the increased and earlier expression of E2 in the C3 mutant upon 
differentiation contradicts the hypothesis of decreased gene expression due to methylation 
of the E2 gene. The intermediate passage number (passage 11) of the cells in which 
increased expression of E2 was observed leaves the option that accumulation of 
methylation may still downregulate E2 later in time. Instead, the lack of CTCF mediated 
enhancer blocking, looping or the lack of roadblock function could have increase E2 
expression without accumulation of methylation.  
Another interesting factor is the time frame in which de novo methylation takes place. In 
EBV it was shown that de novo methylation due to the lack of CTCF binding caused changes 
in gene expression only after 8 weeks of culturing, and complete silencing through 
increased methylation of particular sequences took 16 weeks (Tempera et al., 2010). 
Methylcellulose differentiated cells of passage 11 were used for western blotting. This 
corresponds to 11 weeks of culturing. 
The raft cells were generated from cells of passage numbers 6 and 10. This corresponds to 5 
and 10 weeks of culturing, respectively. Another two weeks of culturing were needed to 
generate the rafts. Some changes in methylation could have occurred in this time frame but 
it is possible that a stronger effect would have been seen with cells of higher passage 
number. However cells with mutant genomes of higher passage number started losing 
significant numbers of genomes which may have been a result of progressing de novo 
methylation. The comparison of raft cultures from wild type and C3 cells with considerably 
different viral copy numbers would have introduced a bias into the data.  
The weaker CTCF binding sites in HPV congregate in the ORFs for the late genes. If they are 
used in vivo it is likely that these binding sites could regulate the splicing of late gene 
transcripts. A protective function towards preventing de novo methylation is unlikely since 
it was already shown that none of these binding sites was occupied by CTCF in 
undifferentiated HFK or W12 cells maintaining HPV18 or 16, respectively. Thus these genes 
would not be protected against de novo methylation in the basal cells of the epithelium in 
which the virus can reside for decades. 
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Figure 63) The E2 ORF of HPV18 with the 
transcripts of E4^E2-S and E4^E2-L 
CTCF binding around nucleotide 3000 is 
indicated with a red line. It is located in-
between the splice sites and may regulate 
the ratio of both splice variants. Figure of Tan 
et al., modified with permission (Tan et al., 
2012). 
All binding sites within the late genes 
showed an either weak or medium band 
shift in EMSA. The observation made by 
Essien et al. that low occupancy CTCF 
binding sites are more likely to be tissue 
specific supports the hypothesis that 
these binding sites may be occupied 
later in the viral life cycle when the cell 
differentiates (Essien et al., 2009). 
Recently two novel E2^E4 splice 
transcripts of HPV18 were discovered in 
raft culture and CIN I-II biopsy (Tan et 
al., 2012). These transcripts are called 
E2^E4-S and E2^E4-L and were shown to be upregulated upon keratinocyte differentiation. 
Translation of the E2^E4-L protein has been confirmed by the presence of a 23kDa protein 
in raft culture and CIN biopsy (Tan et al., 2012). As yet their function remains unknown but 
the splicing pattern of the transcripts was analysed. The splice site used to generate the 
E2^E4-S transcript is situated at 2853, so just upstream of the CTCF binding site around 
nucleotide 3000. The splice site for E2^E4-L is situated just downstream of the CTCF binding 
site at nucleotide 3165 as seen in Figure 63 (Tan et al., 2012). Thus the presence or absence 
of CTCF may be involved in the regulation of these two transcripts. 
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Figure 64) Transcription map of HPV16R with the EMSA confirmed CTCF binding sites 
The strong and conserved CTCF binding site of high risk HPV  around nucleotide 3000 (thick red bar) has also been confirmed in ChIP using undifferentiated W12 cells 
(unpublished data from Dr. Ian Groves from the Coleman laboratory, University of Cambridge, UK). The only exon within 1000 bp upstream of the conserved CTCF 
binding site around nucleotide 3000(thick red bar) encodes for E1C. All other EMSA confirmed binding sites are indicated with thin red vertical bars. Figure of Van 
Doorslaer et al., modified with permission (Van Doorslaer et al., 2013).   
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Figure 65) Transcription map of HPV18 with the EMSA confirmed CTCF binding sites 
The strong and conserved CTCF binding site of high risk HPV at around nucleotide 3000 (thick red bar) was also confirmed in ChIP experiments with undifferentiated 
HFK cells. Only parts of the exon of E1 are within 1000 bp upstream of the conserved CTCF binding site around nucleotide 3000. All other EMSA confirmed binding 
sites are indicated with thin red vertical bars. Figure of Van Doorslaer et al., modified with permission (Van Doorslaer et al., 2013). 
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Figure 66) Transcription map of HPV31 with the EMSA confirmed CTCF binding sites 
Only parts of the exon of E1 are within 1000 bp upstream of the conserved CTCF binding site around nucleotide 3000 (thick red bar). All other EMSA confirmed 
binding sites are indicated with thin red vertical bars. Figure of Van Doorslaer et al., modified with permission (Van Doorslaer et al., 2013). 
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Figure 67) Transcription map of HPV11 with the EMSA confirmed CTCF binding sites 
The only exon within 1000 bp upstream of the conserved CTCF binding site around nucleotide 5400 (thick red bar) is the exon encoding L2. All other EMSA confirmed 
binding sites are indicated with thin red vertical bars. Figure of Van Doorslaer et al., modified with permission (Van Doorslaer et al., 2013). 
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Figure 68) Transcription map of BPV1R with the EMSA confirmed CTCF binding sites 
Only parts of the exon of E1 are within 1000 bp upstream of the CTCF binding site around nucleotide 300 (thick red bar). All other EMSA confirmed binding sites are 
indicated with thin red vertical bars. Figure of Van Doorslaer et al., modified with permission (Van Doorslaer et al., 2013). 
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Area 
E2 binding 
site no. 
Location 
CTCF binding 
fragment within 
100 bp 
LCR 
1 7203 no 
2 7365 no 
3 7408 no 
4 7459 no 
5 7510 yes 
6 7592 yes 
7 7621 yes 
8 7635 yes 
9 7761 yes 
10 7781 yes 
11 7896 yes 
12 16 no 
Coding 
region 
13 855 yes 
14 1125 yes 
15 2396 yes 
16 2921 yes 
17 3088 yes 
Table 39) Locations of E2 binding sites in BPV1 
Data from Li et al. reproduced with permission (Li et al., 
1989) 
4.7 The role of CTCF in enhancer blocking, targeting of 
transcription factors and recruiting of RNA polymerase II 
CTCF is able to regulate gene expression though a multitude of different mechanisms 
including the blocking of enhancers, the targeting of transcription factors and recruiting of 
the RNA polymerase II to promoters (Hark et al., 2000, Chernukhin et al., 2007).  
For the H19/Igf2 locus it was shown that CTCF needs to be located between a promoter and 
enhancer to block the enhancer from acting on the promoter (Banerjee et al., 2001, 
Kurukuti et al., 2006, Hark et al., 2000). This function was shown to depend on PARlation of 
CTCF (Farrar et al., 2010, Yu et al., 2004). The blocking of an enhancer often results in re-
targeting of the enhancer so that it acts on an alternative promoter (reviewed by Wallace 
and Felsenfeld, 2007, Ling et 
al., 2006, Kanduri et al., 
2000). Similarly, the 
formation of loops can result 
in re-targeting of 
transcription factors 
(reviewed by Holwerda and 
de Laat, 2013). The major 
transcription factor in HPV 
gene regulation is E2 which 
is known to preferably bind 
within the LCR (reviewed by 
McBride, 2013). The entire 
genome of BPV1 has been 
thoroughly screened for E2 
binding sites, resulting in the 
identification of 17 binding 
sites, most of which are 
situated within the LCR (Li et 
al., 1989). In the last two 
decades the majority research in HPV gene regulation has focused on the LCR while the E2 
binding sites outside the LCR have been neglected (reviewed by McBride, 2013). The results 
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presented in this study support the idea that E2 binding sites outside the LCR may still play 
important roles in PV gene regulation. As seen in Table 39 and Figure 69, all of the E2 
binding sites in BPV1 situated outside the LCR co-localise with EMSA confirmed CTCF 
binding sites. Also there are many CTCF binding sites that are situated in-between the LCR 
and E2 binding sites and. Thus the E2 proteins bound outside the LCR could be blocked 
from acting on the LCR by looping mediated by CTCF. Using this mechanism, CTCF could 
target E2 action on particular promoters.  
Also every promoter in BPV1 that is located outside of the LCR co-localises with CTCF and 
CTCF was shown to be able to recruit RNA polymerase II and induce transcription (Figure 
69) (Chernukhin et al., 2007).  
 
 
 
Figure 69) Co-localisation of CTCF with E2 and promoters in BPV1 
CTCF binding fragments are shown in blue, promoters are teal and E2 binding sites red. 
All E2 binding sites and promoters outside the LCR co-localise with CTCF binding sites.  
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Yet another function of CTCF may play a role in the co-localisation with E2. CTCF is known 
to recruit PARP1 and induce PARlation of proteins in its vicinity (Guastafierro et al., 2008). 
Via this mechanism CTCF inhibits de novo methylation by PARlating the DNA 
methyltransferase DNMT1, resulting in deactivation of this enzyme (Zampieri et al., 2012). 
In contrast to this, HPV18 E2 was shown to only be transcriptionally active if it is PARlated 
(Lee et al., 2002). Thus CTCF could ensure E2 PARlation to induce transcription. Since the 
protection from de-novo methylation through CTCF-induced PARlation of DNMT1 covers an 
area of at least 2 kbp around the CTCF binding site, also CTCF-induced PARlation of E2 could 
possibly extend over this area (Fedoriw et al., 2004, Szabo et al., 2004). Furthermore it is 
not known if there is an E2 binding around the CTCF binding site at nucleotide 3000 in high 
risk HPV as it is seen in BPV1, so there may be an E2-PARlation target in close vicinity to the 
strong and conserved CTCF binding site of high risk HPV. However the association of CTCF 
with E2 and promoters is only seen in BPV1 so this function may have a bigger impact on 
BPV1 than on HPV. The region where most of the promoters outside the LCR are located in 
BPV1 has been shown to be devoid of CTCF binding sites in HPV. Most HPV have either no 
or few promoters located outside the LCR and there is no CTCF binding site predicted in the 
LCR of these viruses. Nevertheless the CTCF binding site in BPV1 that is located within the 
LCR was not predicted either so there is the chance that CTCF could still be recruited to the 
LCR of HPV at some point during the viral live cycle. 
Another transcription factor, the estrogen receptor, has been shown to be located close to 
nucleotide 3000 in HPV16 (Kitasato et al., 1997). Its position has been defined to be 
between the nucleotides 3142 and 3255 (Kitasato et al., 1997). Thus CTCF is located in 
between this transcription factor and the LCR. Closer investigation of an isolated fragment 
containing this estrogen receptor binding site showed that it had no effect gene regulation 
(Kitasato et al., 1997). This isolated DNA fragment did not contain the CTCF binding site 
around nucleotide 3000 (Kitasato et al., 1997). CTCF is known to facilitate the regulatory 
function of the estrogen receptor when it is bound in close proximity. This may have been 
the reason why no effect was seen (Kitasato et al., 1997, Ross-Innes et al., 2011). There is 
an estrogen response element in the LCR which was shown to be involved in carcinogenesis 
(Arbeit et al., 1996, Gariglio et al., 2009). The location of CTCF between the oestrogen 
receptor binding site and this estrogen response element supports the hypothesis that 
CTCF could possibly block the estrogen receptor from acting on the estrogen response 
element. Thus a role for CTCF in HPV induced carcinogenesis is possible. This is supported 
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by the fact that the HPV18 positive HeLa cells that originated from a high grade cervical 
carcinoma were shown not to bind CTCF around nucleotide 3000 of integrated genomes 
(reviewed by Johannsen and Lambert, 2013). Since oestrogen promotes HPV induced 
carcinogenesis it is possible that the abrogation of CTCF exposes the estrogen receptor to 
the estrogen response element resulting in altered viral genome expression that promotes 
cancer. It would be interesting to see how the cell lines containing wild type and mutant 
HPV18 respond to stimulation by oestrogen. However the presence of the estrogen 
receptor binding site is so far only confirmed for HPV16. 
 
4.8 The viral life cycle is altered when CTCF binding is abrogated 
The comparison of raft cultures and western blots from cells maintaining wild type HPV18 
or C3 mutant revealed distinct differences between these two viruses. Rafts grown from 
mutant C3 maintaining cells were thicker compared to the rafts from wild type maintaining 
cells and they resembled pre-cancerous lesions. Immunohistochemical staining of the 
markers BrdU (S-phase) and Cyclin B1 (G2 entry) revealed that cells in the upper layer of the 
C3 raft were dividing more often compared to the wild type maintaining cells. This increase 
in proliferation was only seen in differentiating cells whereas the growth curves of 
undifferentiated cells maintaining wild type and mutant HPV18 looked identical 
(unpublished data from Dr. Jo Parish). Thus viral gene regulation in advanced stages of the 
viral life cycle was affected by the mutations that abrogated CTCF binding around 
nucleotide 3000. 
Analysis of E1^E4 using immunohistochemistry revealed the same pattern in wild type and 
mutant maintaining cells and therefore contradicted the result from methylcellulose 
differentiated cells which showed decreased E1^E4 expression in the C3 mutant. A reason 
for this may be a possible reduction of the amount of E1^E4 per cell rather than a reduction 
in the number of E1^E4 expressing cells. Thus a probable reduction of E1^E4 expression in 
rafts may have gone unnoticed. Another explanation is that the generally high level of 
E1^E4 expression per cell may have led to the inability to detect subtle changes in E1^E4 
expression due to limiting factors like the availability of antibody. On the other hand 
methylcellulose differentiated cells do not fully resemble the typical differentiation stages. 
Hence the different results of both differentiation methods could perhaps be artefacts. Also 
the possibility of episome loss in the C3 mutant could play a role. Since E1^E4 expression is 
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generally very strong, frequent transcription may occur and the reduction in template DNA 
may have decreased the overall expression of E1^E4. Cells of passage 11 were used for 
differentiating cells in methylcellulose. Those cells showed a reduction in C3 episome 
number of approximately 60 % which could explain the reduction in E1^E4. On the other 
hand cells of low passage number (passage 6), which showed no reduction in episomes, 
have been used for generating the rafts. The rafts did not show a difference in E1^E4 
expression between WT and mutant.  
However, decreased expression of E1^E4 protein provides some limited explanation for the 
phenotype of C3 mutant raft cultures because E1^E4 is one of the proteins involved in 
creating the pseudo S-phase by stopping cell cycle progression while E6 and E7 promote cell 
cycle progression (Knight et al., 2004, Knight et al., 2011, Knight et al., 2006, Davy et al., 
2002, Davy et al., 2006). A reduction in E1^E4 is likely to allow the viral oncoproteins to 
push the cells into mitosis which would explain the increased number of dividing cells in the 
C3 mutant compared to the wild type (reviewed by McBride, 2008, Davy et al., 2002).  
Staining for loricrin revealed another distinct difference between wild type and mutant 
rafts (Figure 61). In the wild type rafts, cells in the keratinous layer flattened out and 
formed a typical solid and keratinous layer that protects the skin. Cells maintaining the C3 
mutant did not flatten out and rather than forming a protective layer of keratin, round 
keratinous cells were seen that left gaps between them. Morphological differentiation in 
the C3 mutant appeared to be impaired whereas expression of the differentiation marker 
loricrin remained intact. Morphological abnormalities in HPV infected cells are often the 
result of E5 and E6 expression (Crusius et al., 2000, Crusius et al., 1998, Krawczyk et al., 
2008, Stoppler et al., 1996, Straight et al., 1993). Since the expression of E6 was shown to 
be constant throughout the differentiation in methylcellulose, the factor responsible for 
abnormal morphology in the C3 mutant cells is likely to be E5. Thus the expression of E5 
may be upregulated in the C3 mutant compared to the wild type.  
The growth pattern seen in the mutant rafts resembled pre-cancerous lesions that usually 
occur when the negative control over the early genes in HPV is lost (Lowy and Schiller, 
2006). However the expression of the viral oncogenes E6 and E7 was shown to be normal in 
methylcellulose differentiated cells (Figure 54).  
Instead the expression of E2 occurred earlier. At low expression levels E2 stimulates 
oncogene expression but at higher levels it is able to inhibit expression of the same 
oncogenes (Steger and Corbach, 1997). However the levels of E6 and E7 were normal in 
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methylcellulose differentiated cells (Figure 54). Thus the increase in proliferation seen in 
the C3 mutant is likely to be caused by a factor other than the overexpression of E6 and E7. 
The overexpression of E5 is a possible explanation since this protein can also stimulate 
proliferation and enhances the efficiency of immortalisation by E6 and E7 (Straight et al., 
1993, reviewed by Klingelhutz and Roman, 2012, Maufort et al., 2010, Stoppler et al., 
1996). 
In conclusion the abrogation of CTCF around nucleotide 3000 disrupts events in the mid- 
and late stages of the viral live cycle and promotes hyperplastic morphology of raft cultures 
despite typical expression of viral oncogenes E6 and E7 in methylcellulose differentiated 
cells. Thus CTCF has the potential to be an important regulatory factor in the HPV life cycle 
and cancer progression. 
 
4.9 A potential role of CTCF in genome integration, episome 
positioning and DNA looping 
CTCF has been shown to be involved in the general arrangement of DNA through 
mechanisms like the formation of loops, bridges and potentially the positioning of DNA 
inside the nucleus (reviewed by Zlatanova and Caiafa, 2009a). Since the nucleus is 
subdivided into transcriptionally active and inactive compartments, CTCF could potentially 
regulate viral transcription by positioning the episome in a location that favours or inhibits 
transcription (reviewed by Zlatanova and Caiafa, 2009a). It has been shown that small and 
gene rich chromosomes tend to be situated more centrally in the nucleus (Bolzer et al., 
2005, reviewed by Cremer and Cremer, 2001). Hence confirmation of a CTCF binding site in 
the HPV genome opens up the possibility that CTCF may facilitate positioning of the HPV 
genome to transcriptionally active regions of the nucleus. However more research is 
needed to investigate this hypothesis.  
DNA looping has already been confirmed in papillomaviruses; however this looping is 
presently attributed to E2 function. The E2 protein was shown to form loops in the viral 
episome by dimerisation through its N-terminal domain in HPV16, HPV11 and BPV1 
(Hernandez-Ramon et al., 2008, Sim et al., 2008, Knight et al., 1991, Antson et al., 2000). 
Shorter forms of E2 were shown to be unable to form DNA loops suggesting that 
competition with shorter forms of E2 for E2 binding sites regulates loop formation (Knight 
et al., 1991). 
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Interestingly, occupation of some E2 binding sites seems to depend on occupation of 
another E2 binding site which may be a result of looping. It was shown in BPV1 that 
mutation of E2 binding site 17 also resulted in abrogation of E2 binding at binding site 16 
(Knight et al., 1991). Both of these E2 binding sites are located outside the LCR. 
Unfortunately, the E2 binding sites outside the LCR in other HPV have not been published 
so it is hard to say if CTCF also co-localises with these E2 binding sites. It is worth noting 
that CTCF is not known among the direct interaction partners of E2, but there is at least one 
common interaction partner of CTCF and E2 which is the Poly [ADP-ribose] polymerase 1 
(PARP1) (reviewed by McBride, 2013, Zampieri et al., 2012). Furthermore the looping 
function of E2 in HPV16 was seen using affinity purified E2 protein, thus a contribution of 
CTCF to E2 dependent looping seems unlikely (Hernandez-Ramon et al., 2008).  
Nevertheless, the presence of CTCF binding sites in the HPV genome introduces the 
possibility of a second factor in HPV DNA looping. Potential loops from the high risk specific 
binding site at nucleotide 3000 to the LCR are especially interesting because of the 
presence of an estrogen receptor binding site in the vicinity of the CTCF binding site and an 
estrogen response element in the LCR (Kitasato et al., 1997). Thus CTCF could form a loop 
to the LCR to activate transcription via the estrogen response element. This is supported by 
the fact that the transcription inducing function of the estrogen receptor can depend on a 
CTCF binding site in its vicinity (Ross-Innes et al., 2011). Furthermore the presence of 
oestrogen and corticosteroids has been shown to promote HPV induced carcinogenesis 
(Arbeit et al., 1996, Gariglio et al., 2009). Thus it can be hypothesised that CTCF can possibly 
regulate viral gene transcription via the estrogen receptor through looping and could 
therefore be an important factor in carcinogenesis. However, while the oestrogen 
responsiveness of HPV-induced carcinogenesis is confirmed, the presence of a binding site 
for the estrogen receptor outside the LCR has only been confirmed in HPV16 so far (Arbeit 
et al., 1996, Kitasato et al., 1997). 
The integration of the viral genome into the host genome is an important factor for HPV-
induced carcinogenesis. Nearly all of HPV18 induced tumours of the cervix contain 
integrated viral DNA (Woodman et al., 2003). Also in HPV16 induced tumours the 
prevalence of integrated genomes is high since only 30 % of these tumours contain 
exclusively episomal DNA (Badaracco et al., 2002). The HPV genome was found to integrate 
semi-randomly into the host DNA, most often at common fragile sites (Ziegert et al., 2003, 
Thorland et al., 2003). 
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CTCF is known to form physical connection between distant DNA loci in trans (Zhao et al., 
2006, reviewed by Zlatanova and Caiafa, 2009a). These connections are called bridges and 
bring the otherwise distant loci in close proximity. Bringing viral and host DNA in close 
proximity could possibly contribute to the integration of the viral genome into host DNA. 
Also the looping function of E2 may play a role in this mechanism; however the function of 
E2 looping has so far only been shown in cis (Knight et al., 1991).  
The integration sites on the viral genome found in cervical tumours follow a loose pattern 
as seen in Figure 70. The most common carcinogenic integrants contain an intact LCR as 
well as the complete E6 and E7 ORFs (Cone et al., 1992, Schwarz et al., 1985). Also the open 
reading frame for E2 is commonly interrupted or inactivated (Pett and Coleman, 2007). 
 
However the most common integrations overall, independently of their potential to cause 
cancer, occur in the E1 and L1 ORFs (Dall et al., 2008, Wang et al., 2013). The data on this is 
partly contradictory since another study claims that most integrations were observed 
within the L2 region (Li et al., 2013). The integration sites determined by Dall et al. can be 
seen in Figure 71. Interestingly the integration sites discovered in this study are often 
situated within 1000 nucleotides of the strong and conserved CTCF binding site around 
nucleotide 3000. However more research is needed to determine if bridge formation by 
CTCF occurs in HPV and if bridge formation plays a role in integration of the viral genome. 
 
Figure 70) The integration pattern of HPV16 
The LCR as well as the ORFs for the viral oncoproteins are often intact in integrants while 
the E2 ORF is disturbed. Thus the negative regulator of the viral oncogenes is no longer 
transcribed as episomes are lost. On rare occasions fragments of multiple episomes were 
found to be integrated into the host genome and these often have intact E2 ORFs. 
However methylation of the LCR regulating these ORF can abrogate E2 transcription so 
that viral oncogenes can be overexpressed regardless. Figure of Pett et al., reproduced 
with permission (Pett and Coleman, 2007). 
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Also the CTCF mediated protection from de novo methylation can be a factor in the 
integration of viral genomes since it was shown that mutation of various E2 binding sites in 
HPV31 strongly promotes integration (Stubenrauch et al., 1998). The methylation of E2 
binding sites may have the same effect since methylation abrogates E2 binding 
(Chaiwongkot et al., 2013, Kim et al., 2003, Thain et al., 1996). The loss of CTCF may open 
up the viral genome to de novo methylation and could contribute to the integration process 
this way. It is interesting to note, that the HPV18 transformed HeLa cells no longer bind 
CTCF around nucleotide 3000 of their integrated HPV18 DNA (reviewed by Johannsen and 
Lambert, 2013). This is supported by the observation that integrated viral DNA is often 
methylated whereas actively replicating and transcribing viral DNA is generally 
unmethylated (Turan et al., 2006, Chaiwongkot et al., 2013). 
 
4.10 Clinical implications 
The data presented in this study gives rise to further research that has the potential to 
change diagnostic, prognosis and treatment of HPV infections.  
The abrogation of CTCF binding around nucleotide 3000 in HPV was shown to increase cell 
proliferation and is suggested to open up E2 binding sites for methylation. Methylation of 
E2 binding sites abrogates E2 binding and often results in overexpression of the viral 
oncogenes, thus promoting cancer (Cheung et al., 2013). The abrogation of E2 binding has 
 
Figure 71) Integration sites of the HPV16 genome determined by Dall et al 
The red bar marks the strong and conserved CTCF binding site. Most integrations (blue 
arrows) occurred within 1000 nucleotides of this binding site. Figure of Dall et al., 
modified with permission (Dall et al., 2008). 
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also been shown to promote integration of the viral genome which is an important factor 
that contributes to carcinogenesis (Stubenrauch et al., 1998). It is interesting to note that 
HPV18 transformed HeLa cells do not bind CTCF at nucleotide 3000 in their integrated 
copies of HPV18 (reviewed by Johannsen and Lambert, 2013). All these observations 
indicate that the binding of CTCF could have an important impact on HPV-induced 
carcinogenesis. Thus CTCF binding or the methylation of the CTCF binding sites has the 
potential to give information on the likelihood of progression to cancer. If the abrogation of 
CTCF binding results in a high chance of a cervical neoplasm to progress to cancer this 
information could help clinicians to decide a suitable treatment strategy. However further 
research is needed to more closely investigate the role of CTCF in methylation protection, 
bridging and general disease progression before a diagnostic potential for CTCF in HPV-
induced disease can be confirmed. Also it has to be made sure that effect seen upon 
abrogation of CTCF binding is not due the new potential binding site for GATA3 that was 
formed through the mutations introduced. 
HPV episome stability has been suggested to be a possible drug target and there are studies 
that aim to clear an HPV infection by interfering with episome maintenance (Edwards et al., 
2011). Since CTCF has been shown to be involved in episome maintenance it could be 
another factor that needs to be considered for these kinds of treatment. However using 
CTCF as a direct drug target may be problematic due to the major impact on host cell gene 
expression. Nevertheless, targeting an interacting protein of CTCF or the CTCF binding site 
itself using gene-targeting medicine opens up the possibility of treating an HPV infection by 
impairing episome maintenance or viral gene expression through interference with CTCF 
function. Possible risks like an increase in cell proliferation have to be considered but could 
possibly be outweighed by increased immunogenicity of the host cell due to altered viral 
gene expression.  
 
4.11 Comparison of HPV with other viruses that utilise CTCF 
The role of CTCF has been studied in EBV, HVS, HSV and KSHV (Kang et al., 2013, Tempera 
et al., 2010, Ertel et al., 2012, Zielke et al., 2012). These viruses have a number of 
similarities to HPV but also distinct differences. They are all episomally maintained DNA 
viruses with a circular genome and distinct stages in their life cycles. In the latent stage they 
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are maintained at a stable copy number, undergo licensed replication and attach to host 
chromosomes via a tethering mechanism.  
The maintenance of some of these viruses has been shown to depend on CTCF (Zielke et al., 
2012, Tempera et al., 2010). However the reason for episome loss in response to 
abrogation of CTCF binding was suggested to be the downregulation of latency associated 
transcripts instead of a direct interaction of CTCF with the tethering mechanism (Zielke et 
al., 2012, Tempera et al., 2010). In the case of EBV the downregulation of latency 
transcripts was a gradual process that took 16 weeks until the latency transcript were not 
detectable any more (Tempera et al., 2010). HPV genomes in the C3 mutants were lost 
within a similar time span making it possible, like in EBV, that slowly progressing de novo 
methylation of HPV DNA caused downregulation of the early genes and eventually the loss 
of viral episomes. 
Also a role for CTCF in maintaining virus latency was discovered in all other viruses (Kang et 
al., 2013, Tempera et al., 2010, Ertel et al., 2012, Zielke et al., 2012). There is some 
evidence that a latency phase of HPV may exist (reviewed by Doorbar, 2013). Most of this 
evidence is based on animal models but there are some observations of recurrent HPV-
related disease in immunosuppressed humans (Ozsaran et al., 1999, Paternoster et al., 
2008). According to animal models, this putative latency stage is suggested to involve a 
reduction in the copy number of viral episomes per cell (Maglennon et al., 2011, Nicholls et 
al., 1999, reviewed by Doorbar, 2013). The abrogation of CTCF binding in HPV18 caused a 
reduction in viral episomes and it is likely that each cell retained a minimal number of 
episomes since the viral oncoproteins are needed for the immortalisation and 
transformation of the primary keratinocytes used to generate the cell lines. Thus there is a 
chance that the abrogation of CTCF binding around nucleotide 3000 could possibly induce a 
slow transition of the HPV activity into the latent stage. 
One of the major differences between HPV and the other viruses is the size of the episome. 
The genomes of EBV, HVS, HSV and KSHV are about 20 times the size of the HPV genome. 
This indicates that long range interactions mediated by CTCF as well as the formation of 
chromatin borders may be more common to these viruses compared to HPV. Epigenetic 
roles of CTCF in these viruses have already been confirmed in terms of the maintenance of 
transcriptionally active or inactive domains as well as regulation of the methylation pattern 
(Ertel et al., 2012, Kubat et al., 2004b, Kubat et al., 2004a, Tempera et al., 2010). Despite 
the small size of the HPV genome, the regulation of methylation could have an important 
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impact on the HPV life cycle. The region on the HPV genome that encodes L1 and L2 is 
transcriptionally silent until the late stages of the viral life cycle. Thus epigenetic silencing of 
the late genes by histone modifications could potentially be maintained by the CTCF. The 
expression of late genes has not been tested in the C3 mutant. The high risk specific CTCF 
binding site within the E2 ORF upstream of the late genes is positioned in a similar fashion 
to the CTCF binding site of HSV that regulates the epigenetic silencing of the late genes 
which is situated within the ORF of the latency associated transcripts (Ertel et al., 2012).  
Furthermore, differences in the locations of the CTCF binding sites between HPV and the 
other DNA viruses studied have been observed. In HPV, CTCF binding sites were neither 
predicted nor confirmed in the LCR whereas CTCF binding sites of the other viruses 
accumulate within the LCR. However in BPV1 there is definite association of CTCF binding 
sites with promoters outside the LCR, and one weak binding site was found by EMSA within 
the LCR of BPV1. This indicates that the function of CTCF in BPV1 could be related to direct 
initiation of transcription by recruiting RNA pol II or by facilitating the PARlation of E2. For 
HPV it is more likely that the function of CTCF may be long ranged or related to enhancer 
blocking and epigenetics rather than a direct initiation of transcription. 
CTCF has been shown to block enhancers, form loops and regulate splicing in other viruses, 
which gives further insight into the potential roles of CTCF in the HPV life cycle (Amelio et 
al., 2006, Ertel et al., 2012).  
Accordingly, the estrogen receptor around nucleotide 3000 in HPV16 may be re-targeted 
through CTCF mediated looping so that it cannot act on the estrogen response element in 
the LCR (Arbeit et al., 1996). The CTCF binding site is situated between the estrogen-
receptor and the estrogen response element in the LCR, making it possible that CTCF 
binding to this site does indeed block transcriptional activation. A role of CTCF binding in 
viral mRNA splicing has been confirmed in KSHV (Kang et al., 2013). The abundance of 
differently spliced transcripts upstream of the CTCF binding site around nucleotide 3000 in 
HPV makes tight regulation of splicing necessary, which could be mediated by CTCF. On the 
other hand the CTCF binding site in this location could also downregulate the transcription 
of viral early genes through RNA polymerase II stalling to ensure viral persistence in basal 
cells. 
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4.12 Outlook on the future 
This study is the first analysis of the role of CTCF in the papillomavirus life cycle. However 
many questions remain due to the multitude of different functions CTCF can provide.  
So far, the binding pattern of CTCF in undifferentiated keratinocytes has been confirmed 
but it is uncertain how the binding pattern will change in differentiated cells. For HPV-
induced cancer tissue the only data available on CTCF binding to integrated HPV genomes 
shows absence of CTCF binding around nucleotide 3000. However this data is from HeLa 
cells which are known to have many genetic abnormalities (reviewed by Johannsen and 
Lambert, 2013). The determination of the CTCF binding pattern throughout the cell cycle in 
HPV positive cancer tissues and in latently infected tissue will give a deeper insight into the 
role of CTCF HPV gene regulation and cancer development.  
The function of CTCF regarding methylation of the HPV genome is another important 
question. Methylation is of vital importance in HPV gene regulation and studies of EBV 
show that CTCF has the potential to protect episomal viruses from de novo methylation 
(Tempera et al., 2010). Methylation was also shown to contribute to integration of the viral 
genome and the upregulation of viral oncogenes which raises questions regarding the role 
of CTCF in cancer development (Turan et al., 2006, Chaiwongkot et al., 2013, Stubenrauch 
et al., 1998, Thain et al., 1996). Thus unravelling how CTCF influences viral methylation has 
the potential to improve the understanding of HPV gene regulation considerably.  
The possible formation of DNA bridges between HPV genomes and host DNA is another 
topic to investigate since it may promote integration and could affect gene regulation. 
Loops in HPV DNA can also be formed by E2; however the regulatory nature of this 
mechanism is poorly understood and E2-looping has only been confirmed in cis 
(looping/bridging in trans may still occur) (Hernandez-Ramon et al., 2008, Sim et al., 2008, 
Knight et al., 1991, Antson et al., 2000). CTCF could be another player involved in the 
looping of HPV DNA and it could possibly form bridges between two HPV episomes or an 
episome and host DNA.  
The striking co-localisation of CTCF and E2 binding sites outside the LCR of BPV1 leads to 
the speculation as to whether such co-localisation also exists in HPV. Using computer 
prediction and EMSA it would be possible to determine E2 binding sites outside the LCR. 
This would reveal if the pattern revealed in BPV1 also applies to HPV.  
CTCF could be involved in blocking the estrogen receptor from acting on the estrogen 
response element what could explain how oestrogen promotes CIN progression. This 
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relationship is relatively easy to test with the cell lines generated in this study. The 
presence of an estrogen response element in HPV18 has to be confirmed and viral gene 
expression during oestrogen stimulation could be monitored in C3 mutant and wild type 
HPV18.  
The PARlation status of CTCF is another important feature because PARlation of CTCF is 
needed for enhancer blocking, the protection from de novo methylation and CTCF-
mediated PARlation of proteins in the vicinity of CTCF (Farrar et al., 2010, Zampieri et al., 
2012). This could be done by ChIP using PAR antibody on samples of the cell lines generated 
in this study. However E2 binding sites outside of the LCR need to be determined first since 
PARlated E2 would also precipitate parts of the HPV genome and could lead to a false 
interpretation of the ChIP result if un-PARlated CTCF and PARlated E2 should co-localise. 
Furthermore a possible function of CTCF in promoting PARlation of E2 can be investigated 
by ChIP using E2 antibody and PAR antibody. The precipitated samples with E2 antibody 
would need to be precipitated again with PAR antibody check if E2 is PARlated. Using PAR 
antibody directly could give false positive results in case PARlated CTCF binds in the vicinity 
of E2. If an E2 binding site can be precipitated this way in the WT but not in the mutant it 
would mean that PARlation of E2 only occurs if CTCF binds to the HPV genome.  
Also the expression of E1, E5, L1 and L2 in the C3 mutant is worth investigating. The viral 
helicase E1 can interfere with the tethering mechanism, so increased expression of E1 may 
be one possible reason for episome loss in the C3 mutant (Voitenleitner and Botchan, 
2002). Furthermore the morphological abnormalities as well as the increased cell 
proliferation in the upper layers of the C3 mutant raft could be the result of increased E5 
expression. This can be investigated by immunostaining or western blotting with functional 
E5 antibody. Also the expression of the late genes L1 and L2 may be altered in the C3 
mutant if CTCF is involved in silencing these late genes. Again, this could be investigated by 
western blotting and immunostaining. 
In conclusion, unravelling the details of how CTCF regulates HPV gene expression can 
improve our current understanding of HPV function and HPV-induced carcinogenesis. The 
enhanced understanding of the biological mechanisms in HPV-related disease has the 
potential to improve diagnostics as well as treatment and could eventually reduce the 
impact of this disease on the life of millions. 
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6 Appendix 
6.1 Expression constructs for human CTCF  
6.1.1 Amino acid sequence of expressed product 
Histidine tag 
CTCF protein 
 
MGHHHHHHHHHHSSGHIEGRHMEGDAVEAIVEESETFIKGKERKTYQRRREGGQEEDACH  60 
LPQNQTDGGEVVQDVNSSVQMVMMEQLDPTLLQMKTEVMEGTVAPEAEAAVDDTQIITLQ  120 
VVNMEEQPINIGELQLVQVPVPVTVPVATTSVEELQGAYENEVSKEGLAESEPMICHTLP  180 
LPEGFQVVKVGANGEVETLEQGELPPQEDPSWQKDPDYQPPAKKTKKTKKSKLRYTEEGK  240 
DVDVSVYDFEEEQQEGLLSEVNAEKVVGNMKPPKPTKIKKKGVKKTFQCELCSYTCPRRS  300 
NLDRHMKSHTDERPHKCHLCGRAFRTVTLLRNHLNTHTGTRPHKCPDCDMAFVTSGELVR  360 
HRRYKHTHEKPFKCSMCDYASVEVSKLKRHIRSHTGERPFQCSLCSYASRDTYKLKRHMR  420 
THSGEKPYECYICHARFTQSGTMKMHILQKHTENVAKFHCPHCDTVIARKSDLGVHLRKQ  480 
HSYIEQGKKCRYCDAVFHERYALIQHQKSHKNEKRFKCDQCDYACRQERHMIMHKRTHTG  540 
EKPYACSHCDKTFRQKQLLDMHFKRYHDPNFVPAAFVCSKCGKTFTRRNTMARHADNCAG  600 
PDGVEGENGGETKKSKRGRKRKMRSKKEDSSDSENAEPDLDDNEDEEEPAVEIEPEPEPQ  660 
PVTPAPPPAKKRRGRPPGRTNQPKQNQPTAIIQVEDQNTGAIENIIVEVKKEPDAEPAEG  720 
EEEEAQPAATDAPNGDLTPEMILSMMDR  748 
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6.1.2 pCi-T7-hCTCF-HIS-tag construct 
Restriction site 
Remaining sequence of previous vector from which the CTCF construct was excised 
CTCF protein sequence 
T7 promoter 
 
pCi sequence containing the insert for CTCF expression 
TCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTA 60 
TTGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCC 120 
AATATGACCGCCATGTTGGCATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGG 180 
GTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCC 240 
GCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCAT 300 
AGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGC 360 
CCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGA 420 
CGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTG 480 
GCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACAC 540 
CAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGT 600 
CAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATAACCC 660 
CGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGC 720 
TCGTTTAGTGAACCGTCAGATCACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAAT 780 
TGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGAAGTTGGTC 840 
GTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAA 900 
ACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTAC 960 
TGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCAATTACAGCTCTTA 1020 
AGGCTAGAGTACTTAATACGACTCACTATAGGCTAGAAATAATTTTGTTTAACTTTAAGA 1080 
AGGAGATATACCATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCAT 1140 
ATCGAAGGTCGTCATATGGAAGGTGATGCAGTCGAAGCCATTGTGGAGGAGTCCGAAACT 1200 
TTTATTAAAGGAAAGGAGAGAAAGACTTACCAGAGACGCCGGGAAGGGGGCCAGGAAGAA 1260 
GATGCCTGCCACTTACCCCAGAACCAGACGGATGGGGGTGAGGTGGTCCAGGATGTCAAC 1320 
AGCAGTGTACAGATGGTGATGATGGAACAGCTGGACCCCACCCTTCTTCAGATGAAGACT 1380 
GAAGTAATGGAGGGCACAGTGGCTCCAGAAGCAGAGGCTGCTGTGGACGATACCCAGATT 1440 
ATAACTTTACAGGTTGTAAATATGGAGGAACAGCCCATAAACATAGGAGAACTTCAGCTT 1500 
GTTCAAGTACCTGTTCCTGTGACTGTACCTGTTGCTACCACTTCAGTAGAAGAACTTCAG 1560 
GGGGCTTATGAAAATGAAGTGTCTAAAGAGGGCCTTGCGGAAAGTGAACCCATGATATGC 1620 
CACACCCTACCTTTGCCTGAAGGGTTTCAGGTGGTTAAAGTGGGGGCCAATGGAGAGGTG 1680 
GAGACACTAGAACAAGGGGAACTTCCACCCCAGGAAGATCCTAGTTGGCAAAAAGACCCA 1740 
GACTATCAGCCACCAGCCAAAAAAACAAAGAAAACCAAAAAGAGCAAACTGCGTTATACA 1800 
GAGGAGGGCAAAGATGTAGATGTGTCTGTCTACGATTTTGAGGAAGAACAGCAGGAGGGT 1860 
CTGCTATCAGAGGTTAATGCAGAGAAAGTGGTTGGTAATATGAAGCCTCCAAAGCCAACA 1920 
AAAATTAAAAAGAAAGGTGTAAAGAAGACATTCCAGTGTGAGCTTTGCAGTTACACGTGT 1980 
CCACGGCGTTCAAATTTGGATCGTCACATGAAAAGCCACACTGATGAGAGACCACACAAG 2040 
TGCCATCTCTGTGGCAGGGCATTCAGAACAGTCACCCTCCTGAGGAATCACCTTAACACA 2100 
CACACAGGTACTCGTCCTCACAAGTGCCCAGACTGCGACATGGCCTTTGTGACCAGTGGA 2160 
GAATTGGTTCGGCATCGTCGTTACAAACACACCCACGAGAAGCCATTCAAGTGTTCCATG 2220 
TGCGATTACGCCAGTGTAGAAGTCAGCAAATTAAAACGTCACATTCGCTCTCATACTGGA 2280 
GAGCGTCCGTTTCAGTGCAGTTTGTGCAGTTATGCCAGCAGGGACACATACAAGCTGAAA 2340 
AGGCACATGAGAACCCATTCAGGGGAAAAGCCTTATGAATGTTATATTTGTCATGCTCGG 2400 
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TTTACCCAAAGTGGTACCATGAAGATGCACATTTTACAGAAGCACACAGAAAATGTGGCC 2460 
AAATTTCACTGTCCCCACTGTGACACAGTCATAGCCCGAAAAAGTGATTTGGGTGTCCAC 2520 
TTGCGAAAGCAGCATTCCTATATTGAGCAAGGCAAGAAATGCCGTTACTGTGATGCTGTG 2580 
TTTCATGAGCGCTATGCCCTCATCCAGCATCAGAAGTCACACAAGAATGAGAAGCGCTTT 2640 
AAGTGTGACCAGTGTGATTACGCTTGTAGACAGGAGAGGCACATGATCATGCACAAGCGC 2700 
ACCCACACCGGGGAGAAGCCTTACGCCTGCAGCCACTGCGATAAGACCTTCCGCCAGAAG 2760 
CAGCTTCTCGACATGCACTTCAAGCGCTATCACGACCCCAACTTCGTCCCTGCGGCTTTT 2820 
GTCTGTTCTAAGTGTGGGAAAACATTTACACGTCGGAATACCATGGCAAGACATGCTGAT 2880 
AATTGTGCTGGCCCAGATGGCGTAGAGGGGGAAAATGGAGGAGAAACGAAGAAGAGTAAA 2940 
CGTGGAAGAAAAAGAAAGATGCGCTCTAAGAAAGAAGATTCCTCTGACAGTGAAAATGCT 3000 
GAACCAGATCTGGACGACAATGAGGATGAGGAGGAGCCTGCCGTAGAAATTGAACCTGAG 3060 
CCAGAGCCTCAGCCTGTGACCCCAGCCCCACCACCCGCCAAGAAGCGGAGAGGACGACCC 3120 
CCTGGCAGAACCAACCAGCCCAAACAGAACCAGCCAACAGCTATCATTCAGGTTGAAGAC 3180 
CAGAATACAGGTGCAATTGAGAACATTATAGTTGAAGTAAAAAAAGAGCCAGATGCTGAG 3240 
CCCGCAGAGGGAGAGGAAGAGGAGGCCCAGCCAGCTGCCACAGATGCCCCCAACGGAGAC 3300 
CTCACGCCCGAGATGATCCTCAGCATGATGGACCGGTGATGGCGGAGCCTTGTGCGTCGC 3360 
CAGGACTTCTCTGGGCTGTGTTTAAACGGCCCGCATCTTAATTTTTCTCCCTTCTTTCTT 3420 
TTTTTGGCTTTGGGAAAAGCATCATTTTACCAAACATACCGAGAACGAAAACTTCAAGGA 3480 
TGATGTTAGAAAAAAATGTGATTTAACTAGAACTTGCTGTCTGATGTTAGCAAATCATGG 3540 
AATGTTCTGAGTCCCTGAGGGTTTACTGTGAAGTGCTGAGGACAGTGTTGACAACTAACT 3600 
CGTTTTCCTAGATGGAAACGGAGACATTGACCCCTCCCTCCATGTGGTAAACCACTCCAG 3660 
AATGGCCGCACTCGAGAATTCACGCGTGGTACCTCTAGAGTCGACCCGGGCGGCCGCTTC 3720 
GAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAA 3780 
AAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCT 3840 
GCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGA 3900 
TGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAAAATCGATAAGGATC 3960 
CGGGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCC 4020 
TGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTAC 4080 
GCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCC 4140 
TTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTT 4200 
AGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGG 4260 
TTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCAC 4320 
GTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTA 4380 
TTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGAT 4440 
TTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGATGCGG 4500 
TATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATGGTGCACTCTCAGTACA 4560 
ATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCG 4620 
CCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGG 4680 
AGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTC 4740 
GTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGT 4800 
GGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCA 4860 
AATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGG 4920 
AAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGC 4980 
CTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTG 5040 
GGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTT 5100 
CGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTA 5160 
TTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAAT 5220 
GACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGA 5280 
GAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACA 5340 
ACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACT 5400 
CGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACC 5460 
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ACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACT 5520 
CTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTT 5580 
CTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGT 5640 
GGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTT 5700 
ATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATA 5760 
GGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAG 5820 
ATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAAT 5880 
CTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAA 5940 
AAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACA 6000 
AAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTT 6060 
CCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCG 6120 
TAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATC 6180 
CTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGA 6240 
CGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCC 6300 
AGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGC 6360 
GCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACA 6420 
GGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGG 6480 
TTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTA 6540 
TGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCT 6600 
CACATGGCTCGACAGATCT 
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6.1.3 pDrive-Sp6-hCTCF-HIS-tag construct 
Restriction site 
Remaining sequence of previous vector from which the CTCF construct was excised 
CTCF protein sequence 
SP6 promoter 
 
pDrive sequence containing the inverted insert for CTCF expression 
GCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCA 60 
CGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCT 120 
CACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAAT 180 
TGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTA 240 
ATACGACTCACTATAGGGAAAGCTCGGTACCACGCATGCTGCAGACGCGTTACGTATCGG 300 
ATCCAGAATTCTCGAGTGCGGCCATTCTGGAGTGGTTTACCACATGGAGGGAGGGGTCAA 360 
TGTCTCCGTTTCCATCTAGGAAAACGAGTTAGTTGTCAACACTGTCCTCAGCACTTCACA 420 
GTAAACCCTCAGGGACTCAGAACATTCCATGATTTGCTAACATCAGACAGCAAGTTCTAG 480 
TTAAATCACATTTTTTTCTAACATCATCCTTGAAGTTTTCGTTCTCGGTATGTTTGGTAA 540 
AATGATGCTTTTCCCAAAGCCAAAAAAAGAAAGAAGGGAGAAAAATTAAGATGCGGGCCG 600 
TTTAAACACAGCCCAGAGAAGTCCTGGCGACGCACAAGGCTCCGCCATCACCGGTCCATC 660 
ATGCTGAGGATCATCTCGGGCGTGAGGTCTCCGTTGGGGGCATCTGTGGCAGCTGGCTGG 720 
GCCTCCTCTTCCTCTCCCTCTGCGGGCTCAGCATCTGGCTCTTTTTTTACTTCAACTATA 780 
ATGTTCTCAATTGCACCTGTATTCTGGTCTTCAACCTGAATGATAGCTGTTGGCTGGTTC 840 
TGTTTGGGCTGGTTGGTTCTGCCAGGGGGTCGTCCTCTCCGCTTCTTGGCGGGTGGTGGG 900 
GCTGGGGTCACAGGCTGAGGCTCTGGCTCAGGTTCAATTTCTACGGCAGGCTCCTCCTCA 960 
TCCTCATTGTCGTCCAGATCTGGTTCAGCATTTTCACTGTCAGAGGAATCTTCTTTCTTA 1020 
GAGCGCATCTTTCTTTTTCTTCCACGTTTACTCTTCTTCGTTTCTCCTCCATTTTCCCCC 1080 
TCTACGCCATCTGGGCCAGCACAATTATCAGCATGTCTTGCCATGGTATTCCGACGTGTA 1140 
AATGTTTTCCCACACTTAGAACAGACAAAAGCCGCAGGGACGAAGTTGGGGTCGTGATAG 1200 
CGCTTGAAGTGCATGTCGAGAAGCTGCTTCTGGCGGAAGGTCTTATCGCAGTGGCTGCAG 1260 
GCGTAAGGCTTCTCCCCGGTGTGGGTGCGCTTGTGCATGATCATGTGCCTCTCCTGTCTA 1320 
CAAGCGTAATCACACTGGTCACACTTAAAGCGCTTCTCATTCTTGTGTGACTTCTGATGC 1380 
TGGATGAGGGCATAGCGCTCATGAAACACAGCATCACAGTAACGGCATTTCTTGCCTTGC 1440 
TCAATATAGGAATGCTGCTTTCGCAAGTGGACACCCAAATCACTTTTTCGGGCTATGACT 1500 
GTGTCACAGTGGGGACAGTGAAATTTGGCCACATTTTCTGTGTGCTTCTGTAAAATGTGC 1560 
ATCTTCATGGTACCACTTTGGGTAAACCGAGCATGACAAATATAACATTCATAAGGCTTT 1620 
TCCCCTGAATGGGTTCTCATGTGCCTTTTCAGCTTGTATGTGTCCCTGCTGGCATAACTG 1680 
CACAAACTGCACTGAAACGGACGCTCTCCAGTATGAGAGCGAATGTGACGTTTTAATTTG 1740 
CTGACTTCTACACTGGCGTAATCGCACATGGAACACTTGAATGGCTTCTCGTGGGTGTGT 1800 
TTGTAACGACGATGCCGAACCAATTCTCCACTGGTCACAAAGGCCATGTCGCAGTCTGGG 1860 
CACTTGTGAGGACGAGTACCTGTGTGTGTGTTAAGGTGATTCCTCAGGAGGGTGACTGTT 1920 
CTGAATGCCCTGCCACAGAGATGGCACTTGTGTGGTCTCTCATCAGTGTGGCTTTTCATG 1980 
TGACGATCCAAATTTGAACGCCGTGGACACGTGTAACTGCAAAGCTCACACTGGAATGTC 2040 
TTCTTTACACCTTTCTTTTTAATTTTTGTTGGCTTTGGAGGCTTCATATTACCAACCACT 2100 
TTCTCTGCATTAACCTCTGATAGCAGACCCTCCTGCTGTTCTTCCTCAAAATCGTAGACA 2160 
GACACATCTACATCTTTGCCCTCCTCTGTATAACGCAGTTTGCTCTTTTTGGTTTTCTTT 2220 
GTTTTTTTGGCTGGTGGCTGATAGTCTGGGTCTTTTTGCCAACTAGGATCTTCCTGGGGT 2280 
GGAAGTTCCCCTTGTTCTAGTGTCTCCACCTCTCCATTGGCCCCCACTTTAACCACCTGA 2340 
AACCCTTCAGGCAAAGGTAGGGTGTGGCATATCATGGGTTCACTTTCCGCAAGGCCCTCT 2400 
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TTAGACACTTCATTTTCATAAGCCCCCTGAAGTTCTTCTACTGAAGTGGTAGCAACAGGT 2460 
ACAGTCACAGGAACAGGTACTTGAACAAGCTGAAGTTCTCCTATGTTTATGGGCTGTTCC 2520 
TCCATATTTACAACCTGTAAAGTTATAATCTGGGTATCGTCCACAGCAGCCTCTGCTTCT 2580 
GGAGCCACTGTGCCCTCCATTACTTCAGTCTTCATCTGAAGAAGGGTGGGGTCCAGCTGT 2640 
TCCATCATCACCATCTGTACACTGCTGTTGACATCCTGGACCACCTCACCCCCATCCGTC 2700 
TGGTTCTGGGGTAAGTGGCAGGCATCTTCTTCCTGGCCCCCTTCCCGGCGTCTCTGGTAA 2760 
GTCTTTCTCTCCTTTCCTTTAATAAAAGTTTCGGACTCCTCCACAATGGCTTCGACTGCA 2820 
TCACCTTCCATATGACGACCTTCGATATGGCCGCTGCTGTGATGATGATGATGATGATGA 2880 
TGATGATGGCCCATGGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGCCTATA 2940 
GTGAGTCGTATTAAGTACTCTAGCCTTAAGAGCTGTAATTGAACTGGGAGTGGACACCTG 3000 
TGGAGAGAAAGGCAAAGTGGATGTCAGTAAGACCAATAGGTGCCTATCAGAAACGCAAGA 3060 
GTCTTCTCTGTCTCGACAAGCCCAGTTTCTATTGGTCTCCTTAAACCTGTCTTGTAACCT 3120 
TGATACTTACCTGCCCAGTGCCTCACGACCAACTTCTGCAGCTTAAGTTCGAGACTGTTG 3180 
TGTCAGAAGCACTGACTGCGTTAGCAATTTAACTGTGATAAACTACCGCAATAAAGCTTC 3240 
TAGTGATCTGACGGTTCACTAAACGAGCTCGCGGCCGCTGTATTCTATAGTGTCACCTAA 3300 
ATGGCCGCACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGT 3360 
TACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGA 3420 
GGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGAAATTGTA 3480 
AGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAAC 3540 
CAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTG 3600 
AGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAA 3660 
GGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGT 3720 
TTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTT 3780 
AGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA 3840 
GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCC 3900 
GCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGA 3960 
ACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAA 4020 
CCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGT 4080 
GTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACG 4140 
CTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTG 4200 
GATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATG 4260 
AGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAG 4320 
CAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACA 4380 
GAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATG 4440 
AGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACC 4500 
GCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTG 4560 
AATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACG 4620 
TTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGAC 4680 
TGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGG 4740 
TTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTG 4800 
GGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACT 4860 
ATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA 4920 
CTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTT 4980 
AAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGAACAATAAAACTGTCTGCTTA 5040 
CATAAACAGTAATACAAGGGGTGTTATGAGCCATATTCAACGGGAAACGTCTTGCTCTAG 5100 
GCCGCGATTAAATTCCAACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAA 5160 
TGTCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAGTT 5220 
GTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACT 5280 
AAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGA 5340 
TGATGCATGGTTACTCACCACTGCGATCCCCGGGAAAACAGCATTCCAGGTATTAGAAGA 5400 
ATATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCA 5460 
Appendix 
209 
TTCGATTCCTGTTTGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGC 5520 
GCAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACGAGCGTAATGG 5580 
CTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAACTTTTGCCATTCTCACCGGATTC 5640 
AGTCGTCACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAATTAAT 5700 
AGGTTGTATTGATGTTGGACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCT 5760 
ATGGAACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAATATGG 5820 
TATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTA 5880 
AGAATTAATTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACC 5940 
CCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCT 6000 
TGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAA 6060 
CTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAG 6120 
TGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTC 6180 
TGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGG 6240 
ACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCA 6300 
CACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTAT 6360 
GAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGG 6420 
TCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTC 6480 
CTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGC 6540 
GGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGC 6600 
CTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCG 6660 
CCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGA 6720 
GCGAGGAAGCGGAAGA 
 
 
6.2 Sequence alignment of PCR fragments across mutation site 
3000 from all four cell lines 
 
 
Georgie cells 
 
HPV 18 AY262282.1 CATACAGACATTAAACCACCAGGTGGTGCCAGCCTATAACATTTCAAAAAGTAA 
Georgie WT  CATACAGACATTAAACCACCAGGTGGTGCCAGCCTATAACATTTCAAAAAGTAA 
C3 mutant sequence CATACAGACATTAAATCACCAGGTAGTGCCAGCCTATAACATCTCAAAAAGTAA 
Georgie C3  CATACAGACATTAAATCACCAGGTAGTGCCAGCCTATAACATCTCAAAAAGTAA 
   *************** ******** ***************** *********** 
 
 
Clonetics cells 
 
HPV 18 AY262282.1 CATACAGACATTAAACCACCAGGTGGTGCCAGCCTATAACATTTCAAAAAGTAA 
Clonetics WT  CATACAGACATTAAACCACCAGGTGGTGCCAGCCTATAACATTTCAAAAAGTAA 
C3 mutant sequence CATACAGACATTAAATCACCAGGTAGTGCCAGCCTATAACATCTCAAAAAGTAA 
Clonetics C3  CATACAGACATTAAATCACCAGGTAGTGCCAGCCTATAACATCTCAAAAAGTAA 
   *************** ******** ***************** *********** 
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6.3 Primers for EMSA testing of CTCF binding sites 
 
Template Start End Fragment name 
Sequence FW 5' to 3' with M13 (-
21) tag at 5' 
Tm FW Sequence RV 5' to 3'  Tm RV  CTCF binding 
BPV1 55 223 LCR P9 M13-aactataaaaagctgctgacagacc 59,45 agccttcccgaattacaaca 59,57 none 
BPV1 580 745 Essex-1 663  M13-agcacctgatgcacctgatt 60,69 tcagctcttttccgcatttc 60,47 none 
BPV1 772 950 P890 region M13-gtccctgcttggatttgaac 59,53 cccgggttcctcattctc 60,41 weak 
BPV1 843 983 Random Frag 7 M13-agcgtcatggcaaacgat 60,23 ccgatcagattccacagaca 59,63 none 
BPV1 1031 1201 E2 BS no. 14 at 1125 M13-gggaaatcacctggaggtct 60,31 tcagcaaataatcttcgctttg 59,52 none 
BPV1 1137 1309 Essex-3 1227  M13-tccgaagcatctgaaactcc 60,34 acaagctgcagatgtagatgactaa 59,53 two weak bands 
BPV1 2327 2488 Essex+2 2427, Essex-2 2397 M13-aaatgcattggatggctacc 59,79 ggctgctcaaagcgaaag 59,82 weak 
BPV1 2650 2819 Random Frag 4 M13-caaatgcagttgattgagaaaagt 59,71 tgcttggctctctcttgaca 59,86 none 
BPV1 2704 2915 No CTCF 2704-2915 M13-tggactgctgttagaactgagaac 59,99 atatatcggtcccagcttgtgt 59,75 none 
BPV1 2785 2984 CTCF?A 2785 - 2984 M13-ccacactctgtagtttgtcaagaga 59,9 cttgcatttccatcaaactcc 59,56 none 
BPV1 2831 3027 CTCF?B 2840-3020 M13-tgcagttgtctttgcaggag 60,18 gcgcatgtacaaattgctgt 59,76 strong 
BPV1 2917 3096 E+1 3025 (at 5' edge) M13-tcagaacctaaacggtgcttt 58,89 ggccatggtgcagtagtagag 59,77 strong 
BPV1 2947 3120 E+1 3025 (in middle) M13-gccagggtggtagaggtg 59,05 agaatagtaaatgcgtccagcac 59,71 none 
BPV1 2995 3174 E+1 3025 (at 3' edge) M13-tggtacactgtctacagcaatttgt 60,04 tcttacagagtaatgccctgttgt 59,26 none 
BPV1 3072 3238 Random Frag 5 M13-tgggctctactactgcaccat 59,77 cgtctgggcgatctctaaaa 60,34 none 
BPV1 3576 3775 C-1 3671 M13-aggagggtcatgctttgct 59,82 gaaagtcttgcctttgacttgg 60,27 weak 
BPV1 4049 4226 Essex-6 4144 M13-tgttgtgtggatttgatttgttt 59,28 tcataggcactggcacgtt 60,28 none 
BPV1 4145 4354 pred.4257 M13-ccctgctcagattttatatggtt 58.60 ttcctagccctcctaagtagattg 59.36 none 
BPV1 4442 4611 Essex+3 4534 M13-catcaataggatccagagctgtaa 59,65 tgaatctgcaggaacagcat 59,4 none 
BPV1 4689 4863 Essex-5 4775 M13-ggacatagcggttcttgagc 59,84 tcctcctgtatcccctaaacc 59,29 medium 
BPV1 4910 5051 Neg. Contr.  M13-cccgcagtattgcctctaaa 60,22 agcacagctggttctgcttc 60,74 none 
Table 40) Primers for EMSA testing of BPV1 part I 
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Template Start End Fragment name 
Sequence FW 5' to 3' with  
M13 (-21) tag at 5' 
Tm FW Sequence RV 5' to 3'  Tm RV  CTCF binding 
BPV1 5105 5263 Essex-4 5190 M13-ttacaacacgtagcgggaca 60,17 cctcaaaacctgcttgctct 59,62 none 
BPV1 5232 5422 pred. 5316 M13-acccttgcatgaagagcaa  59.38 aagtgtcaggtgagccatagg 59.22 none 
BPV1 5475 5639 Random Frag 2 M13-cgatgacactactactacaccaatca 59,55 tacagcttctggccttgttg 59,07 yes 
BPV1 5856 6010 Random Frag 6 M13-caggactgttcacaacccaag 60,59 gggtggtgacttttctattcaca 60,27 none 
BPV1 6519 6693 C+1 6589 M13-ttaatcggccctactggcta 59,7 tggtatacattgaattttgagctatca 60,15 none 
BPV1 6638 6790 Random Frag 3 M13-cctcagatggaaccccacta 59,92 agggcataagtccttgcaga 59,84 none 
BPV1 6968 7154 LCR P1 M13-tggacttagatcaatttcccttg 59,49 aggtgcagttgacttaccttctg 59,86 none 
BPV1 7061 7263 LCR P2 M13-cttccagtaagcctgcaaaaa 59,52 gccagcacaataattcaatgc 60,48 none 
BPV1 7205 7354 Random Frag 1 M13-acacccggtacacatcctgt 60,16 gcgtcccattgatgcttagt 60,1 none 
BPV1 7205 7391 LCR P3 M13-acacccggtacacatcctgt 60,16 tacttaccccgcatctaccg 59,97 none 
BPV1 7325 7520 LCR P4 M13-ttggcaagaaactaagcatcaa 59,89 accagttctggttccgacag 60,15 none 
BPV1 7486 7656 LCR P5 M13-tctatttttgtctctctgtcggaac 60,17 gggagccccaaacctatatc 59,63 none 
BPV1 7598 7794 LCR P6 M13-atggtgcatagcggatgtct 60,51 agcaccgaagacggtttg 59,83 weak 
BPV1 7734 7904 LCR P7 M13-aagttgtaacctgatctccacaaag 59,98 cggtttcggtgagcttaaaa 60,24 none 
BPV1 7857 81 LCR P8 M13-cgggagccaatcaaaatg 60 ggggtctgtcagcagcttt 60,4 none 
Table 41) Primers for EMSA testing of BPV1 part II 
 
 
Template Start End Fragment name 
Sequence FW 5' to 3' with  
M13 (-21) tag at 5' 
Tm FW Sequence RV 5' to 3'  Tm RV  CTCF binding 
HPV18 754 943 HPV18 pred.844 M13-accacaacgtcacacaatgtt 58,82 ctccccgtctgtaccttctg 59,72 none 
HPV18 1102 1297 HPV18 E+1 1205 M13-agagacagcacaggcattgtt 59,93 ccgcctttttgccttttt 60,18 none 
HPV18 2926 3117 HPV18 cor. C+1 2990 M13-ggcaactaatacgttgggaaaa 60,23 tgtcttgcagtgtccaatcc 59,68 strong 
HPV18 3381 3575 HPV18 E-2 3487 M13-tgggaagtacattttgggaataa 59,61 tccacagtgtccaggtcgt 60,15 none 
HPV18 3527 3718 HPV18 pred.3621 M13-aaagacctacggccagacg 60.26 cattttaaactgtttctgtcaccttt 59.15 medium 
HPV18 4440 4638 HPV18 pred.4505 M13-ggggtcgtacagggtacatt 58.65 gatgttatatcaaacccagacgtg 59.67 
two medium 
bands 
HPV18 4947 5155 HPV18 CTCF?A 4947-5155 M13-cagtggctaaccctgagtttct 59,81 agttgcccgttgacctaatc 59,06 none 
HPV18 5045 5253 HPV18 CTCF?B 5045-5253 M13-cgtagtgatgttcctgattcagat 59,55 ggctgcagttcaatatattctgg 60 none 
HPV18 5381 5577 HPV18 E-1 5475 M13-tctgcctcttcctatagtaatgtaacg 60,41 ggaataaaataatataatggccacaaa 59,7 medium 
HPV18 5655 5850 HPV18 pred.5768 M13-cctccttctgtggcaagagt 59.45 ggtcaggtaactgcaccctaa 59.11 medium 
Table 42) Primers for EMSA testing of HPV18  
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Template Start End Fragment name 
Sequence FW 5' to 3' with  
M13 (-21) tag at 5' 
Tm FW Sequence RV 5' to 3'  Tm RV  CTCF binding 
HPV 16  1212 1405 HPV16 C+2 1283 M13-aaacaaagtagagctgcaaaaagg 60,32 ctaacaccctctcccccact 60,36 none 
HPV 16 2852 3049 HPV16 C+1 2916 M13-ggaaacacatgcgcctaga 59,81 ggctaacgtcttgtaatgtccac 59,95 strong 
HPV 16 4999 5206 HPV16 E-1 5119 M13-ctgcatatgaaggtatagatgtggat 59,71 accttagcacctatagattttccact 59,15 weak 
HPV 16 L1 plasmid 6051 6278 HPV16 E+1 6127 M13-tgcaggtgtggataatagagaatg 60,38 tgtaatgtagtaaagtccatagcacca 60,23 weak 
HPV 16  6426 6600 HPV16 C-1 6512 M13-ggctggtactgttggtgaaaa 60,02 attattgtggccctgtgctc 59,96 weak 
HPV 16  6772 6957 HPV16 pred.6860 M13-tgcaaaataaccttaactgcagac 59.74 gggatcatcttctttaggtgct 58.74 weak 
Table 43) Primers for EMSA testing of HPV16 
The HPV16 fragment HPV16 E+1 6127 needed to be amplified from a separate template plasmid since it includes the site were the other HPV16 
template plasmid was cut to be inserted into an amplification vector. 
 
 
Template Start End Fragment name 
Sequence FW 5' to 3' with  
M13 (-21) tag at 5' 
Tm FW Sequence RV 5' to 3'  Tm RV  CTCF binding 
HPV16 114/K 1216 1406 HPV16 114K pred.1284 M13-caaagtagagctgcaaaaagga 60,32 ctaacaccctctcccccact 60,36 none 
HPV16 114/K 2853 3050 HPV16 114K C+1 2917 M13-ggaaacacatgcgcctaga 59,81 ggctaacgtcttgtaatgtccac 59,95 strong 
HPV16 114/K 5000 5207 HPV16 114K E-1 5120 M13-ctgcatatgaaggtatagatgtggat 59,71 accttagcacctatagattttccact 59,15 weak 
HPV 16 L1 plasmid 6052 6279 HPV16 114K E+1 6128 M13-tgcaggtgtggataatagagaatg 60,38 tgtaatgtagtaaagtccatagcacca 60,23 weak 
HPV16 114/K 6421 6621 HPV16 114K pred.6516 M13-taatagggctggtgctgttg 58.80 taacaccctctcccccactt 60.74 weak 
HPV16 114/K 6773 6958 HPV16 114K pred.6861 M13-tgcaaaataaccttaactgcagac 59.74 gggatcatcttctttaggtgct 58.74 weak 
Table 44) Primers for EMSA testing of HPV16 114/K 
The HPV16 114/K fragment HPV16 114/K E+1 6127 needed to be amplified from a separate template plasmid since it includes the site were the other 
HPV16 114/K template plasmid was cut to be inserted into an amplification vector. The predicted binding on this fragment is identical with the one in 
HPV16. Thus the HPV16 L1 plasmid could be used as template. 
  
Appendix 
 
2
13
 
Template Start End Fragment name 
Sequence FW 5' to 3' with  
M13 (-21) tag at 5' 
Tm FW Sequence RV 5' to 3'  Tm RV  CTCF binding 
HPV31 534 713 HPV31 pred.616 M13-cctcgtactgaaacccaagtg 59.64 aattggatgtgtccggttct 59.26 none 
HPV31 804 1008 HPV31 E+4 885 M13-tgttaatgggctcatttggaa 60,31 gtcaaccatatcctccccagt 60,07 none 
HPV31 1029 1200 HPV31 E+2 1093 M13-atacaacaatcaggcagaagca 59,77 gcatatagcttttaaccgtggact 59,95 none 
HPV31 1182 1374 HPV31 C+2/E+3 1278 M13-acggttaaaagctatatgcatagaaaa 59,89 tgttggagtttcattctctcgtt 60,16 none 
HPV31 2230 2406 HPV31 second C+3 2332 M13-ggtgcacctaatacaggtaaatca 59,35 gtaattgtctatataatgccaacatgg 59,12 none 
HPV31 2357 2531 HPV31 second C+1 2413 M13-gcatgttagatgatgctacaacg 59,69 ggccatctgtcatccttacct 60,34 strong 
HPV31 2801 3015 HPV31 A? 2801-3015 M13-cgacttgaatgtgtattaatgtataaagc 59,73 cctgtaggtgcagttaaatacagttc 59,59 strong 
HPV31 2894 3093 HPV31 B? 2894-3093 M13-aaagccttacaagctattgaactaca 59,08 cagttagtataatgcatggtgttgtg 59,79 none 
HPV31 5077 5273 HPV31 E+1 5179 M13-caaactttgcgcactcgtag 59,67 gtggcaggtgtatccacagtaa 59,92 strong 
HPV31 6354 6540 HPV31 pred.6432 M13-ttggtgaatcggtccctact 59.41 aactgattgccccaacaaat 59.29 medium 
Table 45) Primers for EMSA testing of HPV31 
 
 
Template Start End Fragment name 
Sequence FW 5' to 3' with  
M13 (-21) tag at 5' 
Tm FW Sequence RV 5' to 3'  Tm RV  CTCF binding 
HPV6b 1251 1460 HPV6b E+2 1357 M13-tgaagtggaagctggaacg 59,97 ccaagtaatgctgcccgta 59,7 none 
HPV6b 2801 3007 HPV 6b A? 2801-3007 M13-cacaaacatgtattgcattgga 59,35 ttgtaatgtccacggttccat 60,1 none 
HPV6b 2887 3101 HPV 6b B? 2887-3101 M13-aatgcaagtagtgccaccatta 59,54 tgtttgcacagccatcaaat 60,12 none 
HPV6b 4715 4913 HPV6b E-5 4790 M13-ccccttcggatccatctatt 60,11 gaaggttctgtaaagacaggatttct 59,64 none 
HPV6b 4913 5102 HPV6b C-2 5018 E+1 4987 M13-ctgtaacacaaccccaaccac 60,18 cgactatataggcccacacga 59,99 none 
HPV6b 5317 5515 HPV6b C-1 5425 E-1 5431 M13-attggacaacgggggtctat 60,44 taacagggtgttgggtaggg 59,71 strong 
HPV6b 5995 6199 HPV6b E+3 6099 M13-atttaaggtggtgttaccagatcc 59,57 ctgtccagggttaccaccac 60,28 none 
HPV6b 6179 6382 HPV6b E-2 6264 M13-agtggtggtaaccctggaca 60,28 gtcaaccatatcgccatcct 59,78 medium 
HPV6b 7155 7380 HPV6b E-3 7206 E-4 7257 M13-agtatcctttgggacgcaag 59,19 caaataacttacattacacacagaacaca 59,78 none 
Table 46) Primers for EMSA testing of HPV6b 
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Template Start End Fragment name 
Sequence FW 5' to 3' with  
M13 (-21) tag at 5' 
Tm FW Sequence RV 5' to 3'  Tm RV  CTCF binding 
HPV11 1295 1494 HPV11 E+1 1357 M13-aaaatgggggagatggtca 60,12 aacaaatgacagcccaaagc 60,12 none 
HPV11 2801 3003 HPV 11 A? 2801-3003 M13-cacaaacacattatgcattgga 59,35 aatgtccaaggttccacacc 59,68 none 
HPV11 2900 3104 HPV 11 B? 2900-3104 M13-ccaccattaactgtgtcagagact 59,61 cattgtcttcacagccatcaa 59,71 none 
HPV11 3930 4158 HPV11 E-3 4058 M13-tgttattgcatttgcagtatgtttt 59,86 atcaccattattgttgcgtttg 59,76 medium 
HPV11 4709 4898 HPV11 E-2 4781 M13-cttccgatccctccattgt 59,87 tctgtaaacagtggattttgaaaca 59,96 none 
HPV11 4844 5041 HPV11 pred.4921 M13-tgtctgttaccaatcacactacca 59.47 tggatgtaggtccactatcactaga 59.10 weak 
HPV11 5330 5501 HPV11 C-1 5416 E-1 5422 M13-acacacgcagtggacaacat 60,08 gaatgttggacagggtcagg 60,36 strong 
HPV11 6243 6428 HPV11 C-2 6311 M13-gtgctccaccgttaggtga 59,69 caaggggaacatccgattta 59,76 weak 
HPV11 6544 6738 HPV11 pred.6636 M13-taatagggccggtactgtgg 59.84 ccccagcaaataccattgtt 59.69 weak, smear 
HPV11 6872 7074 HPV11 pred.6980 M13-ttacagtttatttttcaattgtgtagca 59.52 tcctgtttttctttttcaggtgt 59.21 none 
Table 47) Primers for EMSA testing of HPV11 
 
Template Start End Fragment name 
Sequence FW 5' to 3' with  
M13 (-21) tag at 5' 
Tm FW Sequence RV 5' to 3'  Tm RV  CTCF binding 
HPV38 35 219 HPV38 C-1 117 M13-agacttttctcttttaaccgtaggc 59,77 tgaggttttggtagttccatga 59,47 medium 
HPV38 176 363 HPV38 E+1 254 M13-ggcctgtaagcttgggatg 60,61 tcctcttgagtccagattaactgtaag 60,53 none 
HPV38 584 791 HPV38 pred.690 M13-aattggaaaggaaggtgcag 59.17 cccccacaaagaactatgattt 59.24 none 
HPV38 1243 1431 HPV38 C+3 1331 M13-tgtggagcaagacagtggac 59,87 ccaaacgagtctttaaatttgctt 60,06 medium 
HPV38 3436 3666 HPV38 C+1/2 and E+2/4/5 3540 M13-aaaccacaggcacccaaa 59,94 ccactttgtcaggcgatatg 59,15 none 
HPV38 4357 4545 HPV38 E+3 4454 M13-accaaccgaactgatacctattg 59,32 gtattgcggcctccactc 59,2 none 
Table 48) Primers for EMSA testing of HPV38 
 
Template Start End Fragment name 
Sequence FW 5' to 3' with  
M13 (-21) tag at 5' 
Tm FW Sequence RV 5' to 3'  Tm RV  CTCF binding 
BPV1 4910 5051 Neg. control  M13-CCCGCAGTATTGCCTCTAAA 60,22 AGCACAGCTGGTTCTGCTTC 60,74 none 
Human C-myc promoter 41894249 41894403 Pos. control  M13-GGGATCGCGCTGAGTATAAA 58,74 GGATCTCCCTTCCCAGGAC  59,24 strong 
All forward primers 41894249 41894403 FAM-M13(-21) FAM-TGTAAAACGACGGCCAGT 57,7 NA NA NA 
M13 tag NA NA 
M13 sequence preceding every FW 
primer 
TGTAAAACGACGGCCAGT NA NA NA NA 
Table 49) Primers for EMSA used to generate control fragments or label all fragments with FAM 
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6.4 Electrophoretic mobility shift assays of all fragments tested 
6.4.1 BPV1 
 
Fragment Predicted motifs on 
fragment 
Tool Fragment name CTCF band shift 
Start End 
Fragments of 
Storm predictions 
4145 4354 4258 4PWM [7.1] BPV1 pred.4258 none 
5232 5422 5317 6PWM [10.6] BPV1 pred.5317 none 
Fragments of CTCFBSDB 1.0 
and Essex tool predictions 
6519 6693 6589 CTCFBSDB [5.9] C+1 6589 none 
3576 3775 C 3671, S 3670 5PWM [10.3], 6PWM [8.5],CTCFBSDB [10,3] C-1 3671 weak 
2917 3096 3025 Essex Essex+1 3025 strong 
2327 2488 2427, 2397 Essex Essex+2 2427, Essex-2 2397 weak 
4442 4611 4534 Essex Essex+3 4534 none 
580 745 663 Essex Essex-1 663 none 
1137 1309 1227 Essex Essex-3 1227 two bands, weak 
5105 5263 5190 Essex Essex-4 5190 none 
4689 4863 4775 Essex Essex-5 4775 medium 
4049 4226 4144 Essex Essex-6 4144 none 
Fragments 
covering functional 
elements 
6968 7154 none N/A LCR P1 none 
7061 7263 none N/A LCR P2 none 
7205 7391 none N/A LCR P3 none 
7325 7520 none N/A LCR P4 none 
7486 7656 none N/A LCR P5 none 
7598 7794 none N/A LCR P6 weak 
7734 7904 none N/A LCR P7 none 
7857 81 none N/A LCR P8 none 
55 223 none N/A LCR P9 none 
772 950 none N/A P890 region weak 
1031 1201 none N/A E2 binding site at 1125 none 
Table 50) Part I of the BPV1 fragments of the EMSAs images below 
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Fragment Predicted motifs on 
fragment 
Tool Fragment name CTCF band shift 
Start End 
Random 
fragments 
7205 7354 none N/A Random Frag 1 none 
5475 5639 none N/A Random Frag 2 weak 
6638 6790 none N/A Random Frag 3 none 
2650 2819 none N/A Random Frag 4 none 
3072 3238 none N/A Random Frag 5 none 
5856 6010 none N/A Random Frag 6 none 
843 983 none N/A Random Frag 7 none 
Overlapping 
fragments at 3025 
2704 2915 none N/A No CTCF none 
2785 2984 none N/A Frag CTCF?A none 
2831 3027 none N/A Frag CTCF?B strong 
2917 3096 3025 Essex E+1 3025 (at 5’ edge) strong 
2947 3120 3025 Essex E+1 in middle none 
2995 3174 3025 Essex E+1 at 3’ edge none 
Table 51) Part II of the BPV1 fragments of the EMSAs images below 
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6.4.1.1 Fragments of Storm predictions 
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6.4.1.2 Fragments of CTCFBSDB 1.0 and Essex tool predictions 
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6.4.1.3 Fragments covering functional elements 
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6.4.1.4 Random fragments 
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6.4.2 High risk HPV types 
6.4.2.1 HPV18 
 
Template Fragment Predicted motifs 
on fragment 
Predicted by Fragment name CTCF band shift 
Start End 
HPV18 
2926 3117 
S 2990, 
C 2990 
1.PWM [18.4], 3.PWM [13.2], 4.PWM [13.3], 
4.PWM [7.3], 5.PWM [16.6], 6.PWM [23.4], 
CTCFBSDB 
HPV18 C+1 2990 strong 
1102 1297 1205 Essex HPV18 E+1 1205 none 
5381 5577 5475 Essex HPV18 E-1 5475 medium 
3381 3575 3487 Essex HPV18 E-2 3487 none 
754 943 844 5.PWM [10.0] HPV18 pred. 844 none 
3527 3718 3621 3.PWM [8.2], 5.PWM [14.0], 6.PWM [14.2] HPV18 pred. 3621 medium 
4440 4638 S 4505, S 4538 1.PWM [12.2], 5.PWM [10.5] HPV18 pred. 4505 and 4538 two bands, medium 
5655 5850 5768 
1.PWM [12.9], 3.PWM [9.7], 4.PWM [7.3], 
5.PWM [10.1], 6.PWM [12.2] 
HPV18 pred. 5768 medium 
4947 5155 None N/A HPV18 CTCF?A none 
5045 5253 None N/A HPV18 CTCF?B none 
Table 52) HPV18 fragments of the EMSAs images below 
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6.4.2.2 HPV16 
 
Template Fragment Predicted motifs 
on fragment 
Predicted by Fragment name CTCF band shift 
Start End 
HPV16 
2852 3049 
S 2916, 
C 2916 
3.PWM [12.2], 5.PWM [9.8], 6.PWM [20.1], 
CTCFBSDB 
HPV16 C+1 2916 strong 
1216 1405 
S 1283, 
C 1283 
5.PWM [10.2], CTCFBSDB HPV16 C+2 1283 none 
6426 6600 
C 6512, 
S 6515 
1.PWM [13.9], 3.PWM [6.5], 4.PWM [8.6], 
6.PWM [9.3], CTCFBSDB 
HPV16 C-1 6512 weak 
6051 6278 6127 Essex HPV16 E+1 6127 weak 
4999 5206 5119 Essex HPV16 E-1 5119 weak 
6772 6957 6860 
1.PWM [12.1], 3.PWM [9.0], 4.PWM [7.7], 
6.PWM [9.1] 
HPV16 pred. 6860 weak 
Table 53) HPV16 fragments of the EMSAs images below 
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6.4.2.3 HPV16 114/K 
 
Template Fragment Predicted motifs 
on fragment 
Predicted by Fragment name CTCF band shift 
Start End 
HPV16 114/K 
2852 3049 
S 2917, 
C 2917 
1.PWM [19.3], 3.PWM [22.4], 4.PWM [16.0], 
5.PWM [18.2], 6.PWM [27.6], CTCFBSDB 
114K C+1 2917 strong 
6051 6278 6128 Essex 114K E+1 6128 weak 
5000 5207 5120 Essex 114K E-1 5120 weak 
1216 1405 1284 5.PWM [10.2] 114K pred. 1284 none 
6421 6621 6516 1.PWM [13.9], 3.PWM [6.5], 4.PWM [8.6] 114K pred. 6516 weak 
6783 6945 6861 
1.PWM [12.1], 3.PWM [8.9], 4.PWM [7.7], 
6.PWM [9.1] 
114K pred. 6861 weak 
Table 54) HPV16 114/K fragments of the EMSAs images below 
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6.4.2.4 HPV31 
 
Template Fragment Predicted motifs 
on fragment 
Predicted by Fragment name CTCF band shift 
Start End 
HPV31 
2357 2531 
S 2413, 
C 2413 
1.PWM [14.4], 4.PWM [14.7], CTCFBSDB HPV31 C+1 2413 strong 
1182 1374 
C 1278 , S 1278, 
E 1294 
CTCFBSDB, Essex, 5.PWM [14.0] HPV31 C+2/E+3 1278 none 
2230 2406 2332 CTCFBSDB HPV31 C+3 2332 none 
5077 5273 5179 Essex HPV31 E+1 5179 strong 
1029 1200 1093 Essex HPV31 E+2 1093 none 
804 1008 885 Essex HPV31 E+4 885 none 
534 713 616 4.PWM [8.2] HPV31 pred. 616 none 
6354 6540 6432 1.PWM [13.5], 3.PWM [7.2] HPV31 pred. 6432 medium 
2801 3015 2854 
1.PWM [19.2], 3.PWM [22.3], 4.PWM [16.0], 
4.PWM [9.0], 5.PWM [18.9], 6.PWM [27.5] 
HPV31 CTCF?A strong 
2894 3093 None N/A HPV31 CTCF?B none 
Table 55) HPV31 fragments of the EMSAs images below 
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6.4.3 Low risk HPV types 
6.4.3.1 HPV6b 
 
Template 
Fragment Predicted motifs 
on fragment 
Predicted by Fragment name CTCF band shift 
Start End 
HPV6b 
5317 5515 
S 5425,  
C 5425,  
E 5431 
1.PWM [16.9], 3.PWM [17.0], 
4.PWM [6.9], 5.PWM [12.9], 
6.PWM [12.2], CTCFBSDB, Essex 
HPV6b C-1 5425 E-1 5431 strong 
4913 5102 
S 5018, 
C 5018, 
E 4987 
4.PWM [7.5], CTCFBSDB, Essex HPV6b C-2 5018 E+1 4987 none 
1251 1460 1357 Essex HPV6b E+2 1357 none 
5995 6199 
S 6110, 
E 6099 
5.PWM [10.0], Essex HPV6b E+3 6099 none 
6179 6382 6264 Essex HPV6b E-2 6264 medium 
7155 7380 
E 7206,  
E 7257 
Essex HPV6b E-3 7206 E-4 7257 none 
4715 4913 4790 Essex HPV6b E-5 4790 none 
2801 3007 none N/A HPV6b CTCF?A none 
2887 3101 none N/A HPV6b CTCF?B none 
Table 56) HPV6b fragments of the EMSAs images below 
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6.4.3.2 HPV11 
 
Template 
Fragment Predicted motifs 
on fragment 
Predicted by Fragment name CTCF band shift 
Start End 
HPV11 
5330 5501 
S 5416, 
C 5416,  
E 5422 
1.PWM [18.4], 3.PWM [20.5], 
4.PWM [11.5], 5.PWM [18.6], 
6.PWM [15.8], CTCFBSDB, Essex 
HPV11 C-1 5416 E-1 5422 strong 
6243 6428 
S 6311,  
C 6311 
4.PWM [13.2], CTCFBSDB HPV11 C-2 6311 weak 
1295 1494 1357 Essex HPV11 E+1 1357 none 
4709 4898 4781 Essex HPV11 E-2 4781 none 
3930 4153 4058 Essex HPV11 E-3 4058 medium 
4844 5041 4921 4.PWM [7.3] HPV11 pred. 4921 weak 
6544 6738 6636 4.PWM [7.3] HPV11 pred. 6636 weak, smear 
6872 7074 6980 5.PWM [10.1], 6.PWM [9.3] HPV11 pred. 6980 none 
2801 3003 None N/A HPV11 CTCF?A none 
2900 3104 None N/A HPV11 CTCF?B none 
Table 57) HPV11 fragments of the EMSAs images below 
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6.4.4 HPV38 
 
Template 
Fragment Predicted motifs 
on fragment 
Predicted by Fragment name CTCF band shift 
Start End 
HPV38 
3436 3666 
S 3543, S 3573, C 3540, 
C 3571, E 3520, E 3544 
E 3487 
1.PWM [13.3], 1.PWM [15.3], 
5.PWM [9.2], CTCFBSDB, Essex 
HPV38 C+1/2 and E+2/4/5 
3540 
none 
1243 1431 S 1331, C 1331 
1.PWM [14.9], 5.PWM [15.6], 
6.PWM [8.5], CTCFBSDB 
HPV38 C+3 1331 medium 
35 219 S 117, C 117 6.PWM [10.9], CTCFBSDB HPV38 C-1 117 medium 
176 363 254 Essex HPV38 E+1 254 none 
4357 4545 4454 Essex HPV38 E+3 4454 none 
584 791 690 6PWM [9.2] HPV38 pred. 690 none 
Table 58) HPV38 fragments of the EMSAs images below 
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